UN	10087562_D004280_2_569_579_dobutamine_D001145_2_629_640_arrhythmias	This report of torsade de pointes ventricular tachycardia during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances.
UN	10087562_D004280_0_72_82_dobutamine_D002311_0_111_133_dilated cardiomyopathy	Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure.
UN	10087562_D004280_0_72_82_dobutamine_D006333_0_138_162_congestive heart failure	Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure.
UN	10087562_D004280_1_479_489_dobutamine_D008133_1_353_368_QT prolongation	The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.
CID	10087562_D004280_2_569_579_dobutamine_D016171_2_506_524_torsade de pointes	This report of torsade de pointes ventricular tachycardia during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances.
CID	10087562_D004280_0_72_82_dobutamine_D016171_0_0_18_Torsade de pointes	Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure.
UN	10087562_D004280_2_569_579_dobutamine_D017180_2_525_548_ventricular tachycardia	This report of torsade de pointes ventricular tachycardia during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances.
UN	10087562_D004280_0_72_82_dobutamine_D017180_0_19_42_ventricular tachycardia	Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure.
UN	10327032_D000644_6_805_813_ammonium_D001424_6_890_910_bacterial infections	Higher plasma ammonium levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively).
UN	10327032_D000644_6_805_813_ammonium_D022124_6_845_859_hyperammonemia	Higher plasma ammonium levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively).
UN	10327032_D005472_6_1018_1022_5-FU_D001424_6_890_910_bacterial infections	Higher plasma ammonium levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively).
CID	10327032_D005472_8_1295_1299_5-FU_D001927_8_1210_1239_hyperammonemic encephalopathy	In conclusion, hyperammonemic encephalopathy can occur in patients receiving continuous infusion of 5-FU.
CID	10327032_D005472_1_305_319_5-fluorouracil_D001927_1_241_270_hyperammonemic encephalopathy	From 1986 to 1998, 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil (5-FU) were identified.
CID	10327032_D005472_0_103_117_5-fluorouracil_D001927_0_18_47_hyperammonemic encephalopathy	Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.
UN	10327032_D005472_0_103_117_5-fluorouracil_D003681_0_143_154_dehydration	Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.
UN	10327032_D005472_0_103_117_5-fluorouracil_D007239_0_159_168_infection	Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.
UN	10327032_D005472_0_103_117_5-fluorouracil_D009369_0_51_57_cancer	Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.
CID	10327032_D005472_0_103_117_5-fluorouracil_D022124_0_18_47_hyperammonemic encephalopathy	Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.
CID	10327032_D005472_1_305_319_5-fluorouracil_D022124_1_241_270_hyperammonemic encephalopathy	From 1986 to 1998, 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil (5-FU) were identified.
CID	10327032_D005472_8_1295_1299_5-FU_D022124_8_1210_1239_hyperammonemic encephalopathy	In conclusion, hyperammonemic encephalopathy can occur in patients receiving continuous infusion of 5-FU.
CID	10390729_D009020_4_866_874_morphine_D006948_4_893_906_hyperactivity	In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity. 3.
CID	10390729_D009020_6_1189_1197_morphine_D006948_6_1206_1219_hyperactivity	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.
UN	10390729_D009020_4_794_802_morphine_D009069_4_811_823_hypoactivity	In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity. 3.
UN	10390729_D009020_6_1189_1197_morphine_D009069_6_1168_1180_hypoactivity	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.
UN	10390729_D011188_4_834_835_K_D006948_4_893_906_hyperactivity	In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity. 3.
UN	10390729_D011188_6_1289_1290_K_D006948_6_1206_1219_hyperactivity	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.
UN	10390729_D011188_4_834_835_K_D009069_4_811_823_hypoactivity	In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity. 3.
UN	10390729_D011188_6_1080_1081_K_D009069_6_1168_1180_hypoactivity	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.
UN	10390729_D011803_6_1250_1257_quinine_D006948_6_1206_1219_hyperactivity	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.
UN	10390729_D011803_6_1250_1257_quinine_D009069_6_1168_1180_hypoactivity	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.
UN	10390729_D015761_6_1263_1278_4-aminopyridine_D006948_6_1206_1219_hyperactivity	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.
UN	10390729_D015761_6_1263_1278_4-aminopyridine_D009069_6_1168_1180_hypoactivity	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.
UN	10401555_C096012_2_395_405_nociceptin_D006930_2_414_423_allodynia	On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced allodynia and hyperalgesia. 2.
UN	10401555_C096012_4_712_723_orphanin FQ_D007859_4_754_787_impairment of learning and memory	The present study was designed to investigate whether nociceptin/orphanin FQ and nocistatin could modulate impairment of learning and memory induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice. 4.
UN	10401555_C096012_0_11_22_orphanin FQ_D007859_0_41_71_learning and memory impairment	Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice. 1.
UN	10401555_C096012_0_11_22_orphanin FQ_D008569_0_41_71_learning and memory impairment	Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice. 1.
UN	10401555_C096012_4_712_723_orphanin FQ_D008569_4_754_787_impairment of learning and memory	The present study was designed to investigate whether nociceptin/orphanin FQ and nocistatin could modulate impairment of learning and memory induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice. 4.
UN	10401555_C111148_2_314_324_nocistatin_D006930_2_414_423_allodynia	On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced allodynia and hyperalgesia. 2.
UN	10401555_C111148_0_27_37_nocistatin_D007859_0_41_71_learning and memory impairment	Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice. 1.
UN	10401555_C111148_4_728_738_nocistatin_D007859_4_754_787_impairment of learning and memory	The present study was designed to investigate whether nociceptin/orphanin FQ and nocistatin could modulate impairment of learning and memory induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice. 4.
UN	10401555_C111148_4_728_738_nocistatin_D008569_4_754_787_impairment of learning and memory	The present study was designed to investigate whether nociceptin/orphanin FQ and nocistatin could modulate impairment of learning and memory induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice. 4.
UN	10401555_C111148_0_27_37_nocistatin_D008569_0_41_71_learning and memory impairment	Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice. 1.
CID	10401555_D012601_0_83_94_scopolamine_D007859_0_41_71_learning and memory impairment	Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice. 1.
CID	10401555_D012601_4_799_810_scopolamine_D007859_4_754_787_impairment of learning and memory	The present study was designed to investigate whether nociceptin/orphanin FQ and nocistatin could modulate impairment of learning and memory induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice. 4.
CID	10401555_D012601_0_83_94_scopolamine_D008569_0_41_71_learning and memory impairment	Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice. 1.
CID	10401555_D012601_4_799_810_scopolamine_D008569_4_754_787_impairment of learning and memory	The present study was designed to investigate whether nociceptin/orphanin FQ and nocistatin could modulate impairment of learning and memory induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice. 4.
UN	10427794_C065757_1_146_155_meloxicam_D001172_1_78_98_rheumatoid arthritis	We report the case of a female patient with rheumatoid arthritis who developed acute cytolytic hepatitis due to meloxicam.
CID	10427794_C065757_3_365_374_meloxicam_D004342_3_469_485_hypersensitivity	The acute cytolytic hepatitis occurred rapidly after meloxicam administration and was associated with the development of antinuclear antibodies suggesting a hypersensitivity mechanism.
CID	10427794_C065757_0_0_9_Meloxicam_D056486_0_18_32_liver toxicity	Meloxicam-induced liver toxicity.
CID	10427794_C065757_1_146_155_meloxicam_D056486_1_129_138_hepatitis	We report the case of a female patient with rheumatoid arthritis who developed acute cytolytic hepatitis due to meloxicam.
CID	10427794_C065757_4_516_525_meloxicam_D056486_4_534_548_liver toxicity	This first case of meloxicam related liver toxicity demonstrates the potential of this drug to induce hepatic damage.
CID	10427794_C065757_3_365_374_meloxicam_D056486_3_332_341_hepatitis	The acute cytolytic hepatitis occurred rapidly after meloxicam administration and was associated with the development of antinuclear antibodies suggesting a hypersensitivity mechanism.
UN	10462057_C084325_11_1898_1904_NCQ436_D000741_11_1811_1826_aplastic anemia	We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.
UN	10462057_C084325_7_1271_1277_NCQ436_D009336_7_1227_1235_necrosis	No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations.
UN	10462057_C112341_11_1909_1915_NCQ344_D000741_11_1811_1826_aplastic anemia	We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.
UN	10462057_C112341_11_1909_1915_NCQ344_D000741_11_2002_2017_aplastic anemia	We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.
UN	10462057_C112341_7_1282_1288_NCQ344_D009336_7_1227_1235_necrosis	No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations.
CID	10462057_D001554_11_1792_1799_benzene_D000741_11_1811_1826_aplastic anemia	We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.
CID	10462057_D017330_11_1776_1787_remoxipride_D000741_11_1811_1826_aplastic anemia	We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.
CID	10462057_D017330_0_133_144_remoxipride_D000741_0_153_168_aplastic anemia	Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19- human bone marrow progenitor cells: potential relevance to remoxipride-induced aplastic anemia.
CID	10462057_D017330_1_208_282_(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide_D000741_1_318_333_aplastic anemia	The antipsychotic agent, remoxipride [(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide] has been associated with acquired aplastic anemia.
CID	10510854_D006220_3_830_841_haloperidol_D002375_3_809_818_catalepsy	Compound 7e, 5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy dro-1H- indol-2-one, from this series showed significant affinities at the 5-HT1A and 5-HT2A receptors and moderate affinity at the D2 receptor. 7e exhibits a high reversal of catalepsy induced by haloperidol indicating its atypical antipsychotic nature.
UN	10672628_D004298_4_516_524_dopamine_D002375_4_547_556_catalepsy	Neuroleptic drugs such as haloperidol, which block dopamine receptors, also cause catalepsy in rodents.
CID	10672628_D006220_0_58_69_haloperidol_D002375_0_78_87_catalepsy	Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice.
CID	10672628_D006220_5_643_654_haloperidol_D002375_5_663_672_catalepsy	OBJECTIVES: To investigate the effects of subchronic L-NOARG treatment in haloperidol-induced catalepsy and the number of NOS neurons in areas related to motor control.
CID	10672628_D006220_9_1241_1252_haloperidol_D002375_9_1261_1270_catalepsy	RESULTS: L-NOARG sub-chronic administration produced tolerance of L-NOARG and of haloperidol-induced catalepsy.
UN	10672628_D009249_0_106_111_NADPH_D002375_0_78_87_catalepsy	Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice.
UN	10672628_D009569_0_26_38_nitric-oxide_D002375_0_78_87_catalepsy	Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice.
UN	10672628_D019335_9_1226_1233_L-NOARG_D002375_9_1261_1270_catalepsy	RESULTS: L-NOARG sub-chronic administration produced tolerance of L-NOARG and of haloperidol-induced catalepsy.
UN	10672628_D019335_5_622_629_L-NOARG_D002375_5_663_672_catalepsy	OBJECTIVES: To investigate the effects of subchronic L-NOARG treatment in haloperidol-induced catalepsy and the number of NOS neurons in areas related to motor control.
UN	10677406_D004280_0_98_108_dobutamine_D003324_0_63_86_coronary artery disease	Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia.
UN	10677406_D004280_2_474_484_dobutamine_D007511_2_493_502_ischaemia	DESIGN: A randomised crossover study of recovery time of systolic and diastolic left ventricular function after exercise and dobutamine induced ischaemia.
UN	10677406_D004280_11_1726_1736_dobutamine_D007511_11_1745_1754_ischaemia	CONCLUSIONS: In patients with coronary artery disease, dobutamine induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be myocardial stunning, similar to that seen after exercise.
UN	10677406_D004280_12_1890_1900_Dobutamine_D007511_12_1909_1918_ischaemia	Dobutamine induced ischaemia could therefore be used to study the pathophysiology of this phenomenon further in patients with coronary artery disease.
UN	10677406_D004280_0_98_108_dobutamine_D017202_0_130_150_myocardial ischaemia	Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia.
CID	10677406_D004280_11_1726_1736_dobutamine_D017682_11_1832_1851_myocardial stunning	CONCLUSIONS: In patients with coronary artery disease, dobutamine induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be myocardial stunning, similar to that seen after exercise.
CID	10677406_D004280_11_1726_1736_dobutamine_D018487_11_1787_1815_left ventricular dysfunction	CONCLUSIONS: In patients with coronary artery disease, dobutamine induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be myocardial stunning, similar to that seen after exercise.
CID	10677406_D004280_0_98_108_dobutamine_D018487_0_10_38_left ventricular dysfunction	Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia.
CID	10713017_D005277_9_1219_1232_fenfluramines_D006976_9_1281_1284_PPH	However, of the medications surveyed, only the fenfluramines had a significant preferential association with PPH as compared with SPH (adjusted odds ratio for use > 6 months, 7.5; 95% confidence interval, 1.7 to 32.4).
CID	10713017_D005277_12_1837_1850_fenfluramines_D006976_12_1875_1878_PPH	CONCLUSION: The magnitude of the association with PPH, the increase of association with increasing duration of use, and the specificity for fenfluramines are consistent with previous studies indicating that fenfluramines are causally related to PPH.
CID	10726030_D006493_6_696_703_heparin_D000505_6_807_815_alopecia	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.
CID	10726030_D006493_6_696_703_heparin_D004342_6_759_777_allergic reactions	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.
CID	10726030_D006493_6_696_703_heparin_D004802_6_729_741_eosinophilia	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.
UN	10726030_D006493_5_571_578_heparin_D006470_5_518_526_bleeding	Major bleeding is of primary concern in patients receiving heparin therapy.
UN	10726030_D006493_4_503_510_heparin_D006470_4_460_468_Bleeding	Bleeding is the primary untoward effect of heparin.
CID	10726030_D006493_6_696_703_heparin_D006947_6_834_846_hyperkalemia	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.
CID	10726030_D006493_6_696_703_heparin_D006994_6_848_865_hypoaldosteronism	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.
CID	10726030_D006493_6_696_703_heparin_D010024_6_715_727_osteoporosis	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.
CID	10726030_D006493_6_696_703_heparin_D011317_6_871_879_priapism	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.
CID	10726030_D006493_6_696_703_heparin_D012871_6_743_757_skin reactions	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.
CID	10726030_D006493_6_662_669_heparin_D013921_6_678_694_thrombocytopenia	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.
CID	10726030_D006493_0_20_27_heparin_D013921_0_36_52_thrombocytopenia	Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy.
UN	10726030_D006493_0_20_27_heparin_D013927_0_57_67_thrombosis	Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy.
UN	10726030_D006493_2_304_311_heparin_D013927_2_363_373_thrombotic	Although several new anticoagulant drugs are in development, heparin remains the anticoagulant of choice to treat acute thrombotic episodes.
CID	10764869_D016559_6_727_737_Tacrolimus_D009901_6_796_816_optic nerve toxicity	CONCLUSION: Tacrolimus and other immunosuppressive agents may be associated with optic nerve toxicity.
CID	10764869_D016559_1_188_198_tacrolimus_D009901_1_148_164_optic neuropathy	PURPOSE: To report a case of bilateral optic neuropathy in a patient receiving tacrolimus (FK 506, Prograf; Fujisawa USA, Inc, Deerfield, Illinois) for immunosuppression after orthotropic liver transplantation.
CID	10764869_D016559_0_53_63_tacrolimus_D009901_0_20_36_optic neuropathy	A case of bilateral optic neuropathy in a patient on tacrolimus (FK506) therapy after liver transplantation.
UN	10764869_D016559_5_703_713_tacrolimus_D015354_5_639_662_Deterioration of vision	Deterioration of vision occurred despite discontinuation of the tacrolimus.
UN	10770468_D008094_1_258_265_lithium_D001714_1_236_243_bipolar	Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.
UN	10770468_D008094_5_915_922_lithium_D001714_5_931_938_bipolar	Thus, two control groups were generated: group C1, which included age- and sex-comparable lithium-treated bipolar normocalcemic patients, and group C2, which included bipolar normocalcemic patients treated with anticonvulsant mood stabilizers.
UN	10770468_D008094_8_1456_1463_lithium_D001714_8_1434_1441_bipolar	Patients with hypercalcemia resulting from medical diseases and bipolar patients with lithium-associated hypercalcemia had significantly higher frequencies of conduction defects.
UN	10770468_D008094_1_108_115_lithium_D001919_1_163_178_bradyarrhythmia	Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.
CID	10770468_D008094_8_1456_1463_lithium_D006934_8_1475_1488_hypercalcemia	Patients with hypercalcemia resulting from medical diseases and bipolar patients with lithium-associated hypercalcemia had significantly higher frequencies of conduction defects.
CID	10770468_D008094_3_632_639_lithium_D006934_3_651_664_hypercalcemia	After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).
CID	10770468_D008094_1_258_265_lithium_D006934_1_277_290_hypercalcemia	Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.
UN	10770468_D008094_3_503_510_lithium_D009369_3_559_571_malignancies	After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).
CID	10933650_C059765_5_905_910_D-AmB_D007683_5_885_901_tubular necrosis	Histopathological examination of the kidney showed tubular necrosis in D-AmB-treated rats but no change in NS-718-treated rats.
UN	10933650_D000666_7_1219_1233_amphotericin B_D007674_7_1201_1215_nephrotoxicity	Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the nephrotoxicity of amphotericin B.
CID	10939760_D013411_3_249_261_sulfadiazine_D007669_3_349_362_renal calculi	Under treatment with sulfadiazine they developed oliguria, abdominal pain, renal failure and showed multiple radiolucent renal calculi in echography.
UN	10939760_D013411_3_249_261_sulfadiazine_D009846_3_277_285_oliguria	Under treatment with sulfadiazine they developed oliguria, abdominal pain, renal failure and showed multiple radiolucent renal calculi in echography.
UN	10939760_D013411_1_47_59_Sulfadiazine_D014123_1_125_138_toxoplasmosis	Sulfadiazine acute nephrotoxicity is reviving specially because of its use in toxoplasmosis in HIV-positive patients.
UN	10939760_D013411_3_249_261_sulfadiazine_D015746_3_287_301_abdominal pain	Under treatment with sulfadiazine they developed oliguria, abdominal pain, renal failure and showed multiple radiolucent renal calculi in echography.
UN	10939760_D013411_3_249_261_sulfadiazine_D051437_3_303_316_renal failure	Under treatment with sulfadiazine they developed oliguria, abdominal pain, renal failure and showed multiple radiolucent renal calculi in echography.
CID	10939760_D013411_1_47_59_Sulfadiazine_D058186_1_60_80_acute nephrotoxicity	Sulfadiazine acute nephrotoxicity is reviving specially because of its use in toxoplasmosis in HIV-positive patients.
CID	10939760_D013411_0_12_24_sulfadiazine_D058186_0_25_45_acute nephrotoxicity	Patterns of sulfadiazine acute nephrotoxicity.
CID	10960401_D009020_1_264_272_morphine_D004244_1_152_161_dizziness	IMPLICATIONS: This case documents a patient who developed dizziness with downbeating nystagmus while receiving a relatively large dose of IV patient-controlled analgesia morphine.
CID	10960401_D009020_0_84_92_morphine_D009759_0_0_18_Downbeat nystagmus	Downbeat nystagmus associated with intravenous patient-controlled administration of morphine.
UN	10975596_C118667_7_1533_1544_dronedarone_D001145_7_1629_1640_arrhythmias	Consequently, dronedarone might be particularly suitable for the treatment and prevention of various clinical arrhythmias, without compromising the left ventricular function.
UN	10975596_C118667_0_42_53_dronedarone_D009203_0_94_115_myocardial infarction	Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction.
UN	10975596_C118667_5_1220_1231_dronedarone_D013610_5_1290_1301_tachycardia	Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced tachycardia.
UN	10975596_D000638_0_58_68_amiodarone_D009203_0_94_115_myocardial infarction	Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction.
UN	10975596_D000638_5_1236_1246_amiodarone_D013610_5_1290_1301_tachycardia	Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced tachycardia.
CID	10975596_D007545_5_1342_1355_isoproterenol_D013610_5_1364_1375_tachycardia	Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced tachycardia.
UN	10985896_D004317_0_27_38_doxorubicin_D005185_0_86_120_ovarian and fallopian tube cancers	Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
UN	10985896_D004317_3_959_970_doxorubicin_D005185_3_698_731_ovarian or fallopian tube cancers	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.
UN	10985896_D004317_0_27_38_doxorubicin_D010051_0_86_120_ovarian and fallopian tube cancers	Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
UN	10985896_D004317_1_218_229_doxorubicin_D010051_1_297_311_ovarian cancer	BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and stomatitis.
UN	10985896_D004317_3_959_970_doxorubicin_D010051_3_698_731_ovarian or fallopian tube cancers	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.
UN	10985896_D004317_3_959_970_doxorubicin_D010534_3_743_763_peritoneal carcinoma	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.
UN	10985896_D004317_0_27_38_doxorubicin_D010534_0_133_160_carcinoma of the peritoneum	Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
CID	10985896_D004317_11_1677_1688_doxorubicin_D013280_11_1723_1733_stomatitis	CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule.
CID	10985896_D004317_11_1677_1688_doxorubicin_D060831_11_1735_1753_hand-foot syndrome	CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule.
UN	10985896_D010984_0_55_63_platinum_D005185_0_86_120_ovarian and fallopian tube cancers	Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
UN	10985896_D010984_3_769_777_platinum_D005185_3_698_731_ovarian or fallopian tube cancers	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.
UN	10985896_D010984_12_1895_1903_platinum_D010051_12_1931_1945_ovarian cancer	Definite, although limited, antineoplastic activity is observed in patients with well-defined platinum- and paclitaxel-refractory ovarian cancer.
UN	10985896_D010984_3_769_777_platinum_D010051_3_698_731_ovarian or fallopian tube cancers	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.
UN	10985896_D010984_1_278_286_platinum_D010051_1_297_311_ovarian cancer	BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and stomatitis.
UN	10985896_D010984_0_55_63_platinum_D010051_0_86_120_ovarian and fallopian tube cancers	Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
UN	10985896_D010984_3_769_777_platinum_D010534_3_743_763_peritoneal carcinoma	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.
UN	10985896_D010984_1_278_286_platinum_D013280_1_454_464_stomatitis	BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and stomatitis.
UN	10985896_D010984_1_278_286_platinum_D060831_1_408_426_erythrodysesthesia	BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and stomatitis.
UN	10985896_D017239_0_64_74_paclitaxel_D005185_0_86_120_ovarian and fallopian tube cancers	Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
UN	10985896_D017239_3_778_788_paclitaxel_D005185_3_698_731_ovarian or fallopian tube cancers	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.
UN	10985896_D017239_12_1909_1919_paclitaxel_D010051_12_1931_1945_ovarian cancer	Definite, although limited, antineoplastic activity is observed in patients with well-defined platinum- and paclitaxel-refractory ovarian cancer.
UN	10985896_D017239_0_64_74_paclitaxel_D010051_0_86_120_ovarian and fallopian tube cancers	Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
UN	10985896_D017239_3_778_788_paclitaxel_D010051_3_698_731_ovarian or fallopian tube cancers	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.
UN	10985896_D017239_0_64_74_paclitaxel_D010534_0_133_160_carcinoma of the peritoneum	Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
UN	10985896_D017239_3_778_788_paclitaxel_D010534_3_743_763_peritoneal carcinoma	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.
UN	10986547_C076029_0_12_22_olanzapine_D001714_0_32_45_bipolar mania	Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study.
UN	10986547_C076029_2_173_183_olanzapine_D001714_2_222_235_bipolar mania	BACKGROUND: We compared the efficacy and safety of olanzapine vs placebo for the treatment of acute bipolar mania.
CID	10986547_C076029_11_1536_1546_olanzapine_D006970_11_1752_1762_somnolence	However, olanzapine-treated patients had a statistically significant greater mean (+/- SD) weight gain than placebo-treated patients (2.1 +/- 2.8 vs 0.45 +/- 2.3 kg, respectively) and also experienced more treatment-emergent somnolence (21 patients [38.2%] vs 5 [8.3% ], respectively).
CID	10986547_C076029_11_1536_1546_olanzapine_D015430_11_1618_1629_weight gain	However, olanzapine-treated patients had a statistically significant greater mean (+/- SD) weight gain than placebo-treated patients (2.1 +/- 2.8 vs 0.45 +/- 2.3 kg, respectively) and also experienced more treatment-emergent somnolence (21 patients [38.2%] vs 5 [8.3% ], respectively).
CID	11026989_D014331_0_34_45_tropicamide_D015878_0_14_28_pupil dilation	The effect of pupil dilation with tropicamide on vision and driving simulator performance.
CID	11026989_D014331_2_355_366_tropicamide_D015878_2_327_341_pupil dilation	METHODS: A series of tests on various parameters of visual function and driving simulator performance were performed on 12 healthy drivers, before and after pupil dilation using guttae tropicamide 1%.
CID	11105626_D015474_1_208_220_isotretinoin_D004310_1_162_187_Taussig-Bing malformation	We report a newborn infant with multiple congenital anomalies (anotia and Taussig-Bing malformation) due to exposure to isotretinoin within the first trimester.
CID	11105626_D015474_1_208_220_isotretinoin_D065817_1_151_157_anotia	We report a newborn infant with multiple congenital anomalies (anotia and Taussig-Bing malformation) due to exposure to isotretinoin within the first trimester.
CID	11135381_D008729_4_632_643_Methoxamine_D006973_4_724_769_a significant rise in systolic blood pressure	Methoxamine evoked non-significant increases in MUP and diastolic blood pressure but caused a significant rise in systolic blood pressure and significant fall in heart rate at maximum dosage.
UN	11135381_D008729_0_10_21_methoxamine_D014550_0_73_92_stress incontinence	Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence: a placebo-controlled, double-blind crossover study.
UN	1117341_C037652_1_175_183_caproate_D006030_1_266_276_glucosuria	The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, glucosuria.
UN	1117341_C037652_0_64_72_caproate_D006943_0_0_13_Hyperglycemic	Hyperglycemic effect of amino compounds structurally related to caproate in rats.
UN	1117341_C037652_1_175_183_caproate_D006943_1_196_209_hyperglycemia	The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, glucosuria.
UN	1117341_D005947_1_223_230_glucose_D006030_1_266_276_glucosuria	The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, glucosuria.
UN	1117341_D005947_1_223_230_glucose_D006943_1_196_209_hyperglycemia	The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, glucosuria.
UN	1117341_D015119_1_154_159_amino_D006030_1_266_276_glucosuria	The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, glucosuria.
CID	1117341_D015119_1_154_159_amino_D006943_1_196_209_hyperglycemia	The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, glucosuria.
CID	1117341_D015119_0_24_29_amino_D006943_0_0_13_Hyperglycemic	Hyperglycemic effect of amino compounds structurally related to caproate in rats.
UN	11176729_D000806_10_2046_2059_ACE inhibitor_D003920_10_2194_2202_diabetes	Subgroups presumed to be at higher risk for ACE inhibitor intolerance (blood pressure, <120 mm Hg; creatinine, > or =132.6 micromol/L [> or =1.5 mg/dL]; age, > or =70 years; and patients with diabetes) generally tolerated the high-dose strategy.
UN	11176729_D000806_2_224_270_angiotensin-converting enzyme (ACE) inhibitors_D006333_2_328_341_heart failure	BACKGROUND: Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients are not receiving these agents or are being treated with doses lower than those found to be efficacious in trials, primarily because of concerns about the safety and tolerability of these agents, especially at the recommended doses.
UN	11176729_D000806_11_2293_2306_ACE inhibitor_D006333_11_2337_2340_CHF	CONCLUSIONS: These findings demonstrate that ACE inhibitor therapy in most patients with CHF can be successfully titrated to and maintained at high doses, and that more aggressive use of these agents is warranted.
UN	11176729_D000806_0_28_68_angiotensin-converting enzyme inhibitors_D006333_0_94_107_heart failure	Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial.
UN	11176729_D000806_7_1493_1506_ACE inhibitor_D006947_7_1690_1702_hyperkalemia	RESULTS: Of 405 patients not previously receiving an ACE inhibitor, doses in only 4.2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension (2.0%) or because of renal dysfunction or hyperkalemia (2.3%).
UN	11176729_D000806_7_1493_1506_ACE inhibitor_D007022_7_1636_1647_hypotension	RESULTS: Of 405 patients not previously receiving an ACE inhibitor, doses in only 4.2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension (2.0%) or because of renal dysfunction or hyperkalemia (2.3%).
UN	11176729_D000806_7_1493_1506_ACE inhibitor_D007674_7_1669_1686_renal dysfunction	RESULTS: Of 405 patients not previously receiving an ACE inhibitor, doses in only 4.2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension (2.0%) or because of renal dysfunction or hyperkalemia (2.3%).
UN	11176729_D003404_10_2101_2111_creatinine_D003920_10_2194_2202_diabetes	Subgroups presumed to be at higher risk for ACE inhibitor intolerance (blood pressure, <120 mm Hg; creatinine, > or =132.6 micromol/L [> or =1.5 mg/dL]; age, > or =70 years; and patients with diabetes) generally tolerated the high-dose strategy.
UN	11176729_D017706_3_696_706_lisinopril_D006333_3_710_713_CHF	The present study examines the safety and tolerability of high- compared with low-dose lisinopril in CHF.
UN	11229942_C066444_0_22_34_cocaethylene_D000437_0_70_95_cocaine and ethanol abuse	Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse.
CID	11229942_C066444_9_1334_1336_CE_D002303_9_1405_1431_decrease in cardiac output	Peak CE levels were associated with a 45% (SD +/- 22%, 95% CI = 22% to 69%) decrease in cardiac output (p < 0.05), a 56% (SD +/- 23%, 95% CI = 32% to 80%) decrease in dP/dt(max) (p <.006), and a 23% (SD +/- 15%, 95% CI = 7% to 49%) decrease in SVO(2) (p < 0.025).
UN	11229942_C066444_13_1910_1922_cocaethylene_D009202_13_1969_1990_myocardial depression	Peak serum cocaethylene concentrations were associated with prolonged myocardial depression.
UN	11229942_C066444_0_22_34_cocaethylene_D019970_0_70_95_cocaine and ethanol abuse	Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse.
UN	11229942_C066444_4_524_526_CE_D066126_4_543_557_cardiotoxicity	The purpose of this study was to delineate the role of CE in the combined cardiotoxicity of cocaine and ethanol in a model simulating their abuse.
UN	11229942_C066444_0_22_34_cocaethylene_D066126_0_35_47_cardiotoxity	Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse.
UN	11229942_D000431_0_9_16_ethanol_D000437_0_70_95_cocaine and ethanol abuse	Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse.
UN	11229942_D000431_0_9_16_ethanol_D019970_0_70_95_cocaine and ethanol abuse	Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse.
UN	11229942_D000431_4_573_580_ethanol_D066126_4_543_557_cardiotoxicity	The purpose of this study was to delineate the role of CE in the combined cardiotoxicity of cocaine and ethanol in a model simulating their abuse.
UN	11229942_D003042_0_0_7_Cocaine_D000437_0_70_95_cocaine and ethanol abuse	Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse.
UN	11229942_D003042_0_0_7_Cocaine_D019970_0_70_95_cocaine and ethanol abuse	Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse.
UN	11229942_D003042_4_561_568_cocaine_D066126_4_543_557_cardiotoxicity	The purpose of this study was to delineate the role of CE in the combined cardiotoxicity of cocaine and ethanol in a model simulating their abuse.
CID	11299446_C027429_0_43_54_veralipride_D010302_0_13_25_Parkinsonism	Worsening of Parkinsonism after the use of veralipride for treatment of menopause: case report.
UN	11366874_D019888_0_0_8_Viracept_D001145_0_13_32_irregular heartbeat	Viracept and irregular heartbeat warning.
UN	11366874_D019888_1_104_112_Viracept_D001145_1_126_146_irregular heart beat	A group of doctors in Boston warn that the protease inhibitor Viracept may cause an irregular heart beat, known as bradycardia, in people with HIV.
CID	11366874_D019888_1_104_112_Viracept_D001919_1_157_168_bradycardia	A group of doctors in Boston warn that the protease inhibitor Viracept may cause an irregular heart beat, known as bradycardia, in people with HIV.
CID	11366874_D019888_2_249_257_Viracept_D001919_2_190_201_Bradycardia	Bradycardia occurred in a 45-year-old male patient who was Viracept in combination with other anti-HIV drugs.
CID	11380496_D011441_13_2058_2061_PTU_D005334_13_1970_1975_fever	In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.
UN	11380496_D011441_0_131_147_propylthiouracil_D006111_0_93_108_Graves' disease	Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations.
UN	11380496_D011441_1_382_398_propylthiouracil_D006111_1_344_359_Graves' disease	OBJECTIVE: Myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-positive vasculitis has been reported in patients with Graves' disease who were treated with propylthiouracil (PTU).
UN	11380496_D011441_5_1016_1019_PTU_D006980_5_897_912_hyperthyroidism	PATIENTS: We investigated 102 untreated patients with hyperthyroidism due to Graves' disease for the presence of MPO-ANCA, and for the development vasculitis after starting PTU therapy.
UN	11380496_D011441_12_1828_1831_PTU_D014652_12_1848_1868_vasculitic disorders	In two of them, the MPO-ANCA titres transiently increased to 12.8 and 15.0 U/ml, respectively, despite continued PTU therapy, but no vasculitic disorders developed.
UN	11380496_D011441_5_1016_1019_PTU_D014657_5_990_1000_vasculitis	PATIENTS: We investigated 102 untreated patients with hyperthyroidism due to Graves' disease for the presence of MPO-ANCA, and for the development vasculitis after starting PTU therapy.
UN	11380496_D011441_3_676_679_PTU_D014657_3_658_668_vasculitis	Nevertheless, there have been no studies on the temporal relationship between the appearance of MPO-ANCA and vasculitis during PTU therapy, or on the incidence of MPO-ANCA in untreated Graves' disease patients.
CID	11380496_D011441_13_2058_2061_PTU_D018771_13_1993_2007_polyarthralgia	In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.
CID	11380496_D011441_13_2058_2061_PTU_D019226_13_1977_1988_oral ulcers	In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.
CID	11385188_D003042_5_835_842_cocaine_D003324_5_751_788_coronary artery or myocardial disease	We conclude that coronary artery or myocardial disease is common (38%) in young asymptomatic chronic cocaine users.
UN	11385188_D003042_1_153_160_cocaine_D006331_1_98_111_heart disease	To determine the prevalence of heart disease in outpatient young asymptomatic chronic cocaine users, 35 cocaine users and 32 age-matched controls underwent resting and exercise electrocardiography (ECG) and Doppler echocardiography.
UN	11385188_D003042_0_52_59_cocaine_D006331_0_14_27_heart disease	Prevalence of heart disease in asymptomatic chronic cocaine users.
CID	11385188_D003042_5_835_842_cocaine_D009202_5_751_788_coronary artery or myocardial disease	We conclude that coronary artery or myocardial disease is common (38%) in young asymptomatic chronic cocaine users.
UN	11395263_D000431_1_139_146_ethanol_D009203_1_226_247_myocardial infarction	The cardioprotective effect of the ethanol extract of Picrorrhiza kurroa rhizomes and roots (PK) on isoproterenol-induced myocardial infarction in rats with respect to lipid metabolism in serum and heart tissue has been investigated.
CID	11395263_D007545_2_428_441_isoproterenol_D009203_2_450_471_myocardial infarction	Oral pre-treatment with PK (80 mg kg(-1) day(-1) for 15 days) significantly prevented the isoproterenol-induced myocardial infarction and maintained the rats at near normal status.
CID	11395263_D007545_1_204_217_isoproterenol_D009203_1_226_247_myocardial infarction	The cardioprotective effect of the ethanol extract of Picrorrhiza kurroa rhizomes and roots (PK) on isoproterenol-induced myocardial infarction in rats with respect to lipid metabolism in serum and heart tissue has been investigated.
UN	11401944_C086123_1_391_400_azimilide_D008133_1_349_364_QT prolongation	BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and azimilide.
UN	11401944_C086123_1_391_400_azimilide_D016171_1_319_337_torsade de pointes	BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and azimilide.
CID	11401944_D013015_1_379_386_sotalol_D008133_1_349_364_QT prolongation	BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and azimilide.
CID	11401944_D013015_1_379_386_sotalol_D016171_1_339_342_TdP	BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and azimilide.
CID	11423811_D003042_1_192_199_cocaine_D002637_1_163_173_Chest pain	STUDY OBJECTIVE: Chest pain in the setting of cocaine use poses a diagnostic dilemma.
CID	11423811_D003042_3_545_552_cocaine_D002637_3_564_574_chest pain	Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain.
CID	11423811_D003042_13_1921_1928_cocaine_D002637_13_1937_1947_chest pain	CONCLUSION: No exaggerated adrenergic response was detected when dobutamine was administered to patients with cocaine-related chest pain.
CID	11423811_D003042_5_775_782_cocaine_D002637_5_822_832_chest pain	Patients were eligible for DSE if they had used cocaine within 24 hours preceding the onset of chest pain and had a normal ECG and tropinin I level.
CID	11423811_D003042_0_115_122_cocaine_D002637_0_134_144_chest pain	A pilot study to assess the safety of dobutamine stress echocardiography in the emergency department evaluation of cocaine-associated chest pain.
UN	11423811_D004280_13_1876_1886_dobutamine_D002637_13_1937_1947_chest pain	CONCLUSION: No exaggerated adrenergic response was detected when dobutamine was administered to patients with cocaine-related chest pain.
UN	11423811_D004280_2_232_242_Dobutamine_D007511_2_337_345_ischemia	Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia.
CID	11425091_D003042_2_289_296_cocaine_D001927_2_333_351_subependymal cysts	We sought to determine if prenatal cocaine exposure increases the incidence of subependymal cysts in preterm infants.
CID	11425091_D003042_9_1319_1326_cocaine_D001927_9_1252_1269_subependymal cyst	CONCLUSIONS: We found an increased incidence of subependymal cyst formation in preterm infants who were exposed to cocaine prenatally.
CID	11425091_D003042_8_1105_1112_cocaine_D001927_8_1064_1082_subependymal cysts	The incidence of subependymal cysts in infants exposed to cocaine prenatally was 44% (8 of 18) compared with 8% (8 of 99) in the unexposed group (p < 0.01).
CID	11425091_D003042_9_1319_1326_cocaine_D003560_9_1252_1269_subependymal cyst	CONCLUSIONS: We found an increased incidence of subependymal cyst formation in preterm infants who were exposed to cocaine prenatally.
CID	11425091_D003042_8_1105_1112_cocaine_D003560_8_1064_1082_subependymal cysts	The incidence of subependymal cysts in infants exposed to cocaine prenatally was 44% (8 of 18) compared with 8% (8 of 99) in the unexposed group (p < 0.01).
CID	11425091_D003042_2_289_296_cocaine_D003560_2_333_351_subependymal cysts	We sought to determine if prenatal cocaine exposure increases the incidence of subependymal cysts in preterm infants.
UN	11425091_D003042_1_97_104_cocaine_D006470_1_148_158_hemorrhage	PURPOSE: Prenatal cocaine exposure has been linked with subependymal hemorrhage and the formation of cysts that are detectable on cranial sonography in neonates born at term.
CID	11425091_D003042_0_9_16_cocaine_D007235_0_62_77_preterm infants	Prenatal cocaine exposure and cranial sonographic findings in preterm infants.
CID	11425091_D003042_2_289_296_cocaine_D007235_2_355_370_preterm infants	We sought to determine if prenatal cocaine exposure increases the incidence of subependymal cysts in preterm infants.
CID	11425091_D003042_9_1319_1326_cocaine_D007235_9_1283_1298_preterm infants	CONCLUSIONS: We found an increased incidence of subependymal cyst formation in preterm infants who were exposed to cocaine prenatally.
UN	11425091_D003042_5_668_675_cocaine_D019970_5_725_738_cocaine abuse	Infants were assigned to the cocaine-exposed group if there was a maternal history of cocaine abuse during pregnancy or if maternal or neonatal urine toxicology results were positive at the time of delivery.
UN	11439380_D000728_2_198_206_androgen_D011471_2_219_234_prostate cancer	Sixty-seven men with metastatic androgen-independent prostate cancer in an open-label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies (NCS) prior to and at 3-month intervals during treatment.
UN	11439380_D013792_11_1143_1154_thalidomide_D009422_11_1095_1105_Neuropathy	Neuropathy may thus be a common complication of thalidomide in older patients.
UN	11439380_D013792_0_0_11_Thalidomide_D009422_0_12_22_neuropathy	Thalidomide neuropathy in patients treated for metastatic prostate cancer.
UN	11439380_D013792_1_102_113_thalidomide_D009422_1_122_132_neuropathy	We prospectively evaluated thalidomide-induced neuropathy using electrodiagnostic studies.
UN	11439380_D013792_2_266_277_thalidomide_D011471_2_219_234_prostate cancer	Sixty-seven men with metastatic androgen-independent prostate cancer in an open-label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies (NCS) prior to and at 3-month intervals during treatment.
UN	11439380_D013792_0_0_11_Thalidomide_D011471_0_58_73_prostate cancer	Thalidomide neuropathy in patients treated for metastatic prostate cancer.
UN	11474137_D000617_1_145_159_aminoglycoside_D006311_1_168_179_ototoxicity	The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.
UN	11474137_D000617_9_1235_1249_aminoglycoside_D006311_9_1258_1269_ototoxicity	The protection by overexpression of superoxide dismutase supports the hypothesis that oxidant stress plays a significant role in aminoglycoside-induced ototoxicity.
UN	11474137_D003300_2_407_409_Cu_D006311_2_479_490_ototoxicity	We therefore hypothesized that overexpression of Cu/Zn-superoxide dismutase (h-SOD1) should protect transgenic mice from ototoxicity.
UN	11474137_D003300_0_18_24_copper_D034381_0_83_95_hearing loss	Overexpression of copper/zinc-superoxide dismutase protects from kanamycin-induced hearing loss.
UN	11474137_D007501_1_235_239_iron_D006311_1_168_179_ototoxicity	The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.
CID	11474137_D007612_0_65_74_kanamycin_D034381_0_83_95_hearing loss	Overexpression of copper/zinc-superoxide dismutase protects from kanamycin-induced hearing loss.
UN	11474137_D010100_1_127_133_oxygen_D006311_1_168_179_ototoxicity	The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.
UN	11474137_D013481_1_276_286_superoxide_D006311_1_337_348_ototoxicity	The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.
UN	11474137_D013481_0_30_40_superoxide_D034381_0_83_95_hearing loss	Overexpression of copper/zinc-superoxide dismutase protects from kanamycin-induced hearing loss.
UN	11474137_D015032_2_410_412_Zn_D006311_2_479_490_ototoxicity	We therefore hypothesized that overexpression of Cu/Zn-superoxide dismutase (h-SOD1) should protect transgenic mice from ototoxicity.
UN	11474137_D015032_0_25_29_zinc_D034381_0_83_95_hearing loss	Overexpression of copper/zinc-superoxide dismutase protects from kanamycin-induced hearing loss.
UN	1158089_D013752_4_585_597_tetracycline_D003866_4_653_663_depression	With provision of adequate oleic acid as a substrate for the isolated perfused liver, a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and depression of output of triglyceride by livers from male and female rats.
UN	1158089_D013752_7_1191_1203_tetracycline_D003866_7_1207_1217_depression	However, livers from female, and especially pregnant female rats, were strikingly resistant to the effects of tetracycline on depression of output of triglyceride under these experimental conditions.
CID	1158089_D013752_0_23_35_tetracycline_D005234_0_0_11_Fatty liver	Fatty liver induced by tetracycline in the rat.
CID	1158089_D013752_9_1645_1657_tetracycline_D005234_9_1618_1629_fatty liver	Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich fatty liver in response to tetracycline.
CID	1158089_D013752_2_211_223_tetracycline_D005234_2_188_199_fatty liver	Dose-response relationships, biochemical mechanisms, and sex differences in the experimental fatty liver induced by tetracycline were studied in the intact rat and with the isolated perfused rat liver in vitro.
UN	1158089_D014280_7_1231_1243_triglyceride_D003866_7_1207_1217_depression	However, livers from female, and especially pregnant female rats, were strikingly resistant to the effects of tetracycline on depression of output of triglyceride under these experimental conditions.
UN	1158089_D014280_4_677_689_triglyceride_D003866_4_653_663_depression	With provision of adequate oleic acid as a substrate for the isolated perfused liver, a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and depression of output of triglyceride by livers from male and female rats.
UN	1158089_D014280_9_1600_1612_triglyceride_D005234_9_1618_1629_fatty liver	Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich fatty liver in response to tetracycline.
UN	1158089_D019301_4_475_485_oleic acid_D003866_4_653_663_depression	With provision of adequate oleic acid as a substrate for the isolated perfused liver, a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and depression of output of triglyceride by livers from male and female rats.
CID	11708428_D011241_1_104_107_PDN_D001008_1_118_125_anxiety	OBJECTIVE: To assess whether prednisone (PDN) produces anxiety and/or cerebral glial changes in rats.
CID	11708428_D011241_0_0_10_Prednisone_D001008_0_19_26_anxiety	Prednisone induces anxiety and glial cerebral changes in rats.
CID	11708428_D011241_8_728_731_PDN_D001008_8_687_694_Anxiety	RESULTS: Anxiety was documented in both groups of PDN treated rats compared with controls.
CID	11708428_D011241_12_1479_1482_PDN_D001008_12_1491_1498_anxiety	CONCLUSION: Subacute exposure to PDN induced anxiety and reactivity of microglia.
UN	11745287_D004317_0_44_55_doxorubicin_D002294_0_83_120_squamous cell carcinoma of the cervix	Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix.
UN	11745287_D004317_0_44_55_doxorubicin_D002583_0_83_120_squamous cell carcinoma of the cervix	Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix.
UN	11745287_D004317_8_1538_1549_doxorubicin_D002583_8_1597_1615_cervical carcinoma	CONCLUSIONS: The combination of carboplatin and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma.
UN	11745287_D016190_0_18_29_carboplatin_D002294_0_83_120_squamous cell carcinoma of the cervix	Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix.
UN	11745287_D016190_0_18_29_carboplatin_D002583_0_83_120_squamous cell carcinoma of the cervix	Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix.
CID	11799346_D002939_8_864_877_ciprofloxacin_D001714_8_939_944_mania	Cases reported by the FDA showed clarithromycin and ciprofloxacin to be the most frequently associated with the development of mania.
CID	11799346_D004917_7_754_766_erythromycin_D001714_7_796_801_manic	Cotrimoxazole, metronidazole, and erythromycin were involved in 15 reported manic episodes.
CID	11799346_D008795_7_735_748_metronidazole_D001714_7_796_801_manic	Cotrimoxazole, metronidazole, and erythromycin were involved in 15 reported manic episodes.
CID	11799346_D015662_7_720_733_Cotrimoxazole_D001714_7_796_801_manic	Cotrimoxazole, metronidazole, and erythromycin were involved in 15 reported manic episodes.
CID	11799346_D017291_8_845_859_clarithromycin_D001714_8_939_944_mania	Cases reported by the FDA showed clarithromycin and ciprofloxacin to be the most frequently associated with the development of mania.
UN	11835460_D007980_0_0_8_Levodopa_D010300_0_39_58_Parkinson's disease	Levodopa-induced ocular dyskinesias in Parkinson's disease.
CID	11835460_D007980_1_60_68_Levodopa_D015835_1_77_95_ocular dyskinesias	Levodopa-induced ocular dyskinesias are very uncommon.
CID	11835460_D007980_0_0_8_Levodopa_D015835_0_17_35_ocular dyskinesias	Levodopa-induced ocular dyskinesias in Parkinson's disease.
CID	11835460_D007980_3_411_419_levodopa_D015835_3_427_445_ocular dyskinesias	We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa, and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa-induce ocular dyskinesias.
UN	11915580_D004008_0_41_51_diclofenac_D004412_0_81_93_dysmenorrhea	A comparison of glyceryl trinitrate with diclofenac for the treatment of primary dysmenorrhea: an open, randomized, cross-over trial.
UN	11915580_D004008_3_656_666_diclofenac_D004412_3_624_636_dysmenorrhea	The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an NO donor, in the resolution of primary dysmenorrhea in comparison with diclofenac (DCF).
UN	11915580_D004008_15_2165_2168_DCF_D004412_15_2197_2209_dysmenorrhea	These findings indicate that GTN has a reduced efficacy and tolerability by comparison with DCF in the treatment of primary dysmenorrhea.
UN	11915580_D004008_13_1974_1977_DCF_D006261_13_1919_1927_Headache	Headache was significantly increased by GTN but not by DCF.
UN	11915580_D004008_11_1564_1567_DCF_D017699_11_1606_1617_pelvic pain	However, DCF continued to be effective in reducing pelvic pain for two hours, whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12.8 +/- 17.9; DFC, -18.9 +/- 16.6 and after two hours: GTN, -23.7 +/- 20.5; DFC, -59.7 +/- 17.9, p = 0.0001).
UN	11915580_D005996_0_16_35_glyceryl trinitrate_D004412_0_81_93_dysmenorrhea	A comparison of glyceryl trinitrate with diclofenac for the treatment of primary dysmenorrhea: an open, randomized, cross-over trial.
CID	11915580_D005996_13_1959_1962_GTN_D006261_13_1919_1927_Headache	Headache was significantly increased by GTN but not by DCF.
CID	11915580_D005996_14_2008_2011_GTN_D006261_14_2020_2028_headache	Eight patients stopped using GTN because headache--attributed to its use--became intolerable.
UN	11915580_D005996_11_1641_1644_GTN_D017699_11_1606_1617_pelvic pain	However, DCF continued to be effective in reducing pelvic pain for two hours, whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12.8 +/- 17.9; DFC, -18.9 +/- 16.6 and after two hours: GTN, -23.7 +/- 20.5; DFC, -59.7 +/- 17.9, p = 0.0001).
UN	11915580_D009569_3_585_587_NO_D004412_3_624_636_dysmenorrhea	The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an NO donor, in the resolution of primary dysmenorrhea in comparison with diclofenac (DCF).
UN	11915580_D011453_1_258_272_prostaglandins_D004412_1_142_154_dysmenorrhea	Primary dysmenorrhea is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial prostaglandins; non-steroidal anti-inflammatory drugs are the first choice for its treatment.
UN	11936424_C055603_1_240_250_temocapril_D005921_1_394_412_glomerulosclerosis	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.
UN	11936424_C055603_1_240_250_temocapril_D006984_1_368_379_hypertrophy	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.
UN	11936424_C055603_0_0_10_Temocapril_D007674_0_90_107_glomerular injury	Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
UN	11936424_C055603_0_0_10_Temocapril_D009401_0_145_154_nephrosis	Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
UN	11936424_C055603_12_1786_1796_temocapril_D009401_12_1878_1886_neprotic	It appears that temocapril was effective in retarding renal progression and protected renal function in PAN neprotic rats.
UN	11936424_C055603_1_240_250_temocapril_D009404_1_466_475_nephrotic	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.
UN	11936424_C055603_8_1254_1264_Temocapril_D011507_8_1283_1294_proteinuria	Temocapril did not attenuate proteinuria at 8 days, but it did markedly lower it from weeks 4 to 20.
UN	11936424_D000809_1_279_290_angiotensin_D005921_1_394_412_glomerulosclerosis	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.
UN	11936424_D000809_1_279_290_angiotensin_D006984_1_368_379_hypertrophy	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.
UN	11936424_D000809_0_39_50_angiotensin_D007674_0_90_107_glomerular injury	Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
UN	11936424_D000809_0_39_50_angiotensin_D009401_0_145_154_nephrosis	Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
UN	11936424_D000809_1_279_290_angiotensin_D009404_1_466_475_nephrotic	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.
UN	11936424_D000809_1_279_290_angiotensin_D011507_1_334_345_proteinuria	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.
UN	11936424_D011692_1_424_449_puromycin aminonucleoside_D005921_1_394_412_glomerulosclerosis	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.
UN	11936424_D011692_1_424_449_puromycin aminonucleoside_D006984_1_368_379_hypertrophy	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.
UN	11936424_D011692_0_119_144_puromycin aminonucleoside_D007674_0_90_107_glomerular injury	Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
CID	11936424_D011692_12_1874_1877_PAN_D009401_12_1878_1886_neprotic	It appears that temocapril was effective in retarding renal progression and protected renal function in PAN neprotic rats.
CID	11936424_D011692_2_520_523_PAN_D009401_2_482_491_Nephrosis	Nephrosis was induced by injection of PAN (15mg/100g body weight) in male Sprague-Dawley (SD) rats.
CID	11936424_D011692_0_119_144_puromycin aminonucleoside_D009401_0_145_154_nephrosis	Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
UN	11936424_D011692_1_451_454_PAN_D009404_1_466_475_nephrotic	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.
CID	11936424_D011692_1_424_449_puromycin aminonucleoside_D011507_1_334_345_proteinuria	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.
CID	11988250_D007052_1_125_134_ibuprofen_D000860_1_108_118_hypoxaemia	We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation.
CID	11988250_D007052_4_601_610_ibuprofen_D000860_4_546_556_hypoxaemia	We suggest that investigators involved in similar trials pay close attention to pulmonary pressure if hypoxaemia occurs after prophylactic administration of ibuprofen.
UN	11988250_D007052_1_246_255_ibuprofen_D004374_1_216_240_patent ductus arteriosus	We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation.
CID	11988250_D007052_0_29_38_ibuprofen_D006976_0_0_22_Pulmonary hypertension	Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants.
UN	11988250_D009569_3_422_434_nitric oxide_D000860_3_383_393_Hypoxaemia	Hypoxaemia resolved quickly on inhaled nitric oxide therapy.
CID	12051122_D014750_3_735_746_vincristine_D007010_3_693_705_hyponatremia	RESULTS: A total of 76 cases of hyponatremia and/or SIADH associated with vincristine use were identified.
CID	12051122_D014750_8_1243_1254_vincristine_D007010_8_1201_1213_hyponatremia	CONCLUSION: Our data suggest that Asian patients may be at increased risk of hyponatremia and/or SIADH associated with vincristine use.
CID	12051122_D014750_3_735_746_vincristine_D007177_3_713_718_SIADH	RESULTS: A total of 76 cases of hyponatremia and/or SIADH associated with vincristine use were identified.
CID	12051122_D014750_1_356_367_vincristine_D007177_1_343_348_SIADH	PURPOSE: This retrospective study used a pharmaceutical company's global safety database to determine the reporting rate of hyponatremia and/or syndrome of inappropriate secretion of anti-diuretic hormone (SIADH) among vincristine-treated patients and to explore the possibility of at-risk population subgroups.
CID	12051122_D014750_0_90_101_Vincristine_D007177_0_17_64_syndrome of inappropriate anti-diuretic hormone	Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of Vincristine: an over-representation of Asians?
CID	12051122_D014750_9_1320_1331_vincristine_D007177_9_1298_1303_SIADH	Although the overall reported rate of SIADH associated with vincristine is very low, physicians caring for Asian oncology patients should be aware of this potential serious but reversible adverse event.
CID	12051122_D014750_8_1243_1254_vincristine_D007177_8_1221_1226_SIADH	CONCLUSION: Our data suggest that Asian patients may be at increased risk of hyponatremia and/or SIADH associated with vincristine use.
CID	12059909_D003520_3_576_578_CY_D003556_3_618_626_cystitis	Early CY toxicity caused a typical haemorrhagic cystitis in both strains that was completely repaired in about 7-10 days.
CID	12059909_D003520_4_709_711_CY_D003556_4_765_773_cystitis	After 30 days of CY injection ulcerous and non-ulcerous forms of chronic cystitis appeared in 86% of DBA/2 mice but only in 4% of C57BL/6 mice.
CID	12059909_D003520_3_576_578_CY_D006470_3_605_617_haemorrhagic	Early CY toxicity caused a typical haemorrhagic cystitis in both strains that was completely repaired in about 7-10 days.
UN	12119460_D002945_15_2116_2125_cisplatin_D006463_15_2194_2197_HUS	It may serve as an alternative to cisplatin-containing regimens; however, it has to be considered that possibly HUS may occur.
UN	12119460_D002955_5_885_887_FA_D013274_5_817_820_AGC	PATIENTS AND METHODS: From February, 1998 to September, 2000 we recruited 33 patients with AGC to receive weekly 24-hour 5-FU 2,600 mg/m(2) preceded by 2-hour FA 500 mg/m(2) for 6 weeks, followed by a 2-week rest period.
UN	12119460_D002955_14_1980_1982_FA_D013274_14_2045_2048_AGC	CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%).
UN	12119460_D002955_0_27_39_folinic acid_D013274_0_114_128_gastric cancer	High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer.
UN	12119460_D002955_2_221_233_folinic acid_D013274_2_306_320_gastric cancer	BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low toxicity.
UN	12119460_D005472_5_847_851_5-FU_D013274_5_817_820_AGC	PATIENTS AND METHODS: From February, 1998 to September, 2000 we recruited 33 patients with AGC to receive weekly 24-hour 5-FU 2,600 mg/m(2) preceded by 2-hour FA 500 mg/m(2) for 6 weeks, followed by a 2-week rest period.
UN	12119460_D016685_0_73_84_mitomycin C_D013274_0_114_128_gastric cancer	High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer.
UN	12165618_D003404_8_1148_1158_creatinine_D006417_8_1184_1193_hematuria	Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin/creatinine ratio and by microscopic hematuria.
CID	12165618_D019469_3_432_441_indinavir_D007674_3_450_464_nephrotoxicity	DESIGN: A prospective study to monitor indinavir-related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1-infected children treated with indinavir.
CID	12165618_D019469_13_1765_1774_indinavir_D007674_13_1803_1817_nephrotoxicity	In 4 children, indinavir was discontinued because of nephrotoxicity.
CID	12165618_D019469_19_2403_2412_Indinavir_D007674_19_2424_2438_nephrotoxicity	Indinavir-associated nephrotoxicity must be monitored closely, especially in children with risk factors such as persistent sterile leukocyturia, age <5.6 years, an area under the curve of indinavir >19 mg/L x h, and a C(max) >12 mg/L.
UN	12165618_D019469_0_145_154_indinavir_D015658_0_78_122_human immunodeficiency virus type 1-infected	Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir.
UN	12165618_D019469_3_550_559_indinavir_D015658_3_483_527_human immunodeficiency virus type 1-infected	DESIGN: A prospective study to monitor indinavir-related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1-infected children treated with indinavir.
UN	12359538_D003042_3_435_442_cocaine_D002637_3_443_453_chest pain	OBJECTIVE: To assess outcomes based on troponin positivity in patients with cocaine chest pain admitted for exclusion of MI.
UN	12359538_D003042_12_1737_1744_cocaine_D002637_12_1756_1766_chest pain	Troponin appears to have an equivalent diagnostic accuracy compared with CK-MB for diagnosing necrosis in patients with cocaine-associated chest pain and suspected MI.
UN	12359538_D003042_1_254_261_cocaine_D002637_1_273_283_chest pain	Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction (MI) difficult in patients with cocaine-associated chest pain.
UN	12359538_D003042_0_39_46_cocaine_D002637_0_58_68_chest pain	Utility of troponin I in patients with cocaine-associated chest pain.
UN	12359538_D003042_1_254_261_cocaine_D009202_1_153_172_myocardial necrosis	Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction (MI) difficult in patients with cocaine-associated chest pain.
CID	12359538_D003042_1_254_261_cocaine_D009203_1_223_225_MI	Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction (MI) difficult in patients with cocaine-associated chest pain.
CID	12359538_D003042_3_435_442_cocaine_D009203_3_480_482_MI	OBJECTIVE: To assess outcomes based on troponin positivity in patients with cocaine chest pain admitted for exclusion of MI.
CID	12359538_D003042_4_559_566_cocaine_D009203_4_550_552_MI	METHODS: Outcomes were examined in patients admitted for possible MI after cocaine use.
CID	12359538_D003042_12_1737_1744_cocaine_D009203_12_1781_1783_MI	Troponin appears to have an equivalent diagnostic accuracy compared with CK-MB for diagnosing necrosis in patients with cocaine-associated chest pain and suspected MI.
UN	12359538_D003042_12_1737_1744_cocaine_D009336_12_1711_1719_necrosis	Troponin appears to have an equivalent diagnostic accuracy compared with CK-MB for diagnosing necrosis in patients with cocaine-associated chest pain and suspected MI.
UN	12372954_C036067_3_279_294_bendazac lysine_D012170_3_302_324_retinal vein occlusion	Before admission, he had been taking nicergoline and bendazac lysine due to retinal vein occlusion at ophthalmologic department.
CID	12372954_D009530_0_36_47_nicergoline_D009395_0_6_28_interstitial nephritis	Acute interstitial nephritis due to nicergoline (Sermion).
CID	12372954_D009530_1_121_132_nicergoline_D009395_1_109_112_AIN	We report a case of acute interstitial nephritis (AIN) due to nicergoline (Sermion).
CID	12372954_D009530_8_886_897_nicergoline_D009395_8_909_912_AIN	To our knowledge, this is the first report of nicergoline-associated AIN.
UN	12372954_D009530_3_263_274_nicergoline_D012170_3_302_324_retinal vein occlusion	Before admission, he had been taking nicergoline and bendazac lysine due to retinal vein occlusion at ophthalmologic department.
UN	12452552_D008728_1_245_260_levomepromazine_D007676_1_130_151_chronic renal failure	A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.
CID	12452552_D008728_1_245_260_levomepromazine_D009459_1_200_203_NMS	A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.
UN	12452552_D018967_1_229_240_risperidone_D007676_1_130_151_chronic renal failure	A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.
CID	12452552_D018967_1_229_240_risperidone_D009459_1_200_203_NMS	A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.
UN	12487093_C009591_3_320_340_triphenyltetrazolium_D006973_3_252_264_hypertension	Adrenaline-induced hypertension was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving adrenaline for 30 s.
CID	12487093_D004837_3_233_243_Adrenaline_D006973_3_252_264_hypertension	Adrenaline-induced hypertension was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving adrenaline for 30 s.
UN	12498738_C043211_0_0_10_Carvedilol_D009202_0_62_76_cardiomyopathy	Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.
UN	12498738_C043211_11_1975_1985_carvedilol_D009369_11_2220_2226_cancer	It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.
UN	12498738_C043211_11_1975_1985_carvedilol_D028361_11_2125_2150_mitochondrial dysfunction	It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.
CID	12498738_D004317_11_2197_2208_doxorubicin_D009202_11_2155_2169_cardiomyopathy	It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.
CID	12498738_D004317_1_210_221_doxorubicin_D009202_1_185_199_cardiomyopathy	Several cytopathic mechanisms have been suggested to mediate the dose-limiting cumulative and irreversible cardiomyopathy caused by doxorubicin.
CID	12498738_D004317_0_28_39_doxorubicin_D009202_0_62_76_cardiomyopathy	Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.
UN	12498738_D004317_11_2197_2208_doxorubicin_D009369_11_2220_2226_cancer	It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.
UN	12498738_D004317_11_2197_2208_doxorubicin_D028361_11_2125_2150_mitochondrial dysfunction	It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.
UN	12523489_D000241_2_256_265_adenosine_D004409_2_298_330_decreased the locomotor activity	All adenosine receptor agonists significantly decreased the locomotor activity in mice, and the effects were dose-dependent.
UN	12523489_D000241_0_52_61_adenosine_D006948_0_16_29_hyperactivity	Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity.
UN	12523489_D000241_12_2081_2090_adenosine_D006948_12_2045_2058_hyperactivity	Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.
UN	12523489_D000241_10_1521_1530_adenosine_D006948_10_1579_1592_hyperactivity	Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced hyperactivity.
UN	12523489_D000661_1_196_207_amphetamine_D006948_1_216_229_hyperactivity	The influence of adenosine receptor agonists and antagonists on cocaine-and amphetamine-induced hyperactivity was examined in mice.
UN	12523489_D000661_0_85_96_amphetamine_D006948_0_105_118_hyperactivity	Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity.
UN	12523489_D000661_10_1559_1570_amphetamine_D006948_10_1579_1592_hyperactivity	Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced hyperactivity.
UN	12523489_D000661_12_2142_2153_amphetamine_D006948_12_2162_2175_hyperactivity	Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.
UN	12523489_D003042_1_184_191_cocaine_D006948_1_216_229_hyperactivity	The influence of adenosine receptor agonists and antagonists on cocaine-and amphetamine-induced hyperactivity was examined in mice.
UN	12523489_D003042_12_2029_2036_cocaine_D006948_12_2045_2058_hyperactivity	Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.
UN	12523489_D003042_10_1650_1657_cocaine_D006948_10_1666_1679_hyperactivity	Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced hyperactivity.
UN	12523489_D003042_0_0_7_Cocaine_D006948_0_16_29_hyperactivity	Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity.
UN	12535818_D000638_2_398_408_amiodarone_D001145_2_518_541_ventricular arrhythmias	BACKGROUND: Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ventricular arrhythmias.
UN	12535818_D000638_9_1629_1639_amiodarone_D001281_9_1665_1667_AF	CONCLUSIONS: This study suggests that the use of amiodarone in elderly patients with AF and a previous MI increases the risk of bradyarrhythmia requiring a permanent pacemaker.
UN	12535818_D000638_1_221_231_amiodarone_D001281_1_249_268_atrial fibrillation	OBJECTIVES: The aim of this study was to determine whether the use of amiodarone in patients with atrial fibrillation (AF) increases the risk of bradyarrhythmia requiring a permanent pacemaker.
CID	12535818_D000638_0_0_10_Amiodarone_D001919_0_27_42_bradyarrhythmia	Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction.
CID	12535818_D000638_2_398_408_amiodarone_D001919_2_375_390_bradyarrhythmia	BACKGROUND: Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ventricular arrhythmias.
UN	12535818_D000638_9_1629_1639_amiodarone_D009203_9_1683_1685_MI	CONCLUSIONS: This study suggests that the use of amiodarone in elderly patients with AF and a previous MI increases the risk of bradyarrhythmia requiring a permanent pacemaker.
CID	12559315_D007213_9_1276_1288_Indomethacin_D008415_9_1405_1417_mastocytosis	CONCLUSIONS: Indomethacin resulted in histopathologic findings typical of interstitial cystitis, such as leaky bladder epithelium and mucosal mastocytosis.
CID	12559315_D007213_9_1276_1288_Indomethacin_D018856_9_1337_1358_interstitial cystitis	CONCLUSIONS: Indomethacin resulted in histopathologic findings typical of interstitial cystitis, such as leaky bladder epithelium and mucosal mastocytosis.
UN	12644816_D000728_0_56_64_androgen_D011471_0_77_92_prostate cancer	An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.
UN	12644816_D000728_3_425_433_androgen_D011471_3_446_461_prostate cancer	We undertook an open-label study using thalidomide 100 mg once daily for up to 6 months in 20 men with androgen-independent prostate cancer.
CID	12644816_D013792_11_1376_1387_thalidomide_D010523_11_1413_1434_peripheral neuropathy	In the seven men who completed six months on thalidomide, subclinical evidence of peripheral neuropathy was found in four before treatment, but in all seven at repeat testing.
UN	12644816_D013792_0_41_52_thalidomide_D011471_0_77_92_prostate cancer	An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.
UN	12644816_D013792_1_124_135_thalidomide_D019337_1_209_236_haematological malignancies	The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and haematological malignancies.
CID	12677626_C476513_3_518_533_levobupivacaine_D004830_3_451_469_grand mal seizures	We describe 2 cases of grand mal seizures following accidental intravascular injection of levobupivacaine.
UN	12677626_C476513_9_1449_1464_levobupivacaine_D012640_9_1506_1517_convulsions	CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions.
UN	12677626_C476513_0_64_79_levobupivacaine_D020258_0_0_31_Central nervous system toxicity	Central nervous system toxicity following the administration of levobupivacaine for lumbar plexus block: A report of two cases.
UN	12677626_C476513_9_1342_1357_levobupivacaine_D066126_9_1375_1391_cardiac toxicity	CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions.
UN	12677626_D002045_9_1413_1424_bupivacaine_D012640_9_1506_1517_convulsions	CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions.
UN	12677626_D002045_9_1413_1424_bupivacaine_D066126_9_1375_1391_cardiac toxicity	CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions.
UN	12677626_D004837_5_756_767_epinephrine_D004830_5_809_827_grand mal seizures	Immediately after the administration of levobupivacaine 0.5% with epinephrine 2.5 microgram/mL, the patients developed grand mal seizures, despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration.
UN	12677626_D013390_6_1009_1024_succinylcholine_D012640_6_936_944_seizures	The seizures were successfully treated with sodium thiopental in addition to succinylcholine in 1 patient.
UN	12677626_D013874_6_976_993_sodium thiopental_D012640_6_936_944_seizures	The seizures were successfully treated with sodium thiopental in addition to succinylcholine in 1 patient.
UN	12678199_D000638_6_730_740_amiodarone_C537153_6_821_835_hypomagnesemia	In the absence of amiodarone therapy, a second bladder irrigation did not induce TdP despite hypokalemia and hypomagnesemia.
UN	12678199_D000638_6_730_740_amiodarone_D007008_6_805_816_hypokalemia	In the absence of amiodarone therapy, a second bladder irrigation did not induce TdP despite hypokalemia and hypomagnesemia.
CID	12678199_D000638_1_218_228_amiodarone_D016171_1_192_195_TdP	The authors present a case of early (within 4 days) development of torsade de pointes (TdP) associated with oral amiodarone therapy.
CID	12678199_D000638_0_0_10_Amiodarone_D016171_0_19_37_torsade de pointes	Amiodarone-induced torsade de pointes during bladder irrigation: an unusual presentation--a case report.
UN	12678199_D004077_2_368_375_digoxin_D007008_2_352_363_hypokalemia	Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including hypokalemia and digoxin excess.
UN	12678199_D004077_2_368_375_digoxin_D016171_2_281_284_TdP	Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including hypokalemia and digoxin excess.
UN	12699527_D002712_1_188_196_chloride_D009224_1_119_137_Myotonia congenita	Myotonia congenita (MC) is caused by a defect in the skeletal muscle chloride channel function, which may cause sustained membrane depolarisation.
CID	12699527_D013390_2_440_453_suxamethonium_D013035_2_350_362_muscle spasm	We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of suxamethonium.
CID	12752472_D010862_3_347_358_pilocarpine_D004827_3_367_375_epilepsy	Here we sought to generate information with regard to the interictal period in animals with pilocarpine-induced epilepsy.
UN	12752472_D010862_7_1084_1095_pilocarpine_D006985_7_1010_1026_hyperventilation	RESULTS: The hyperventilation maneuver caused a decrease in spontaneous ventilation in pilocarpine-treated and control rats.
CID	1280054_D014750_0_45_56_vincristine_D001927_0_6_25_myeloencephalopathy	Fatal myeloencephalopathy due to intrathecal vincristine administration.
CID	1280054_D014750_1_73_84_Vincristine_D007049_1_159_188_sensory and motor dysfunction	Vincristine was accidentally given intrathecally to a child with leukaemia, producing sensory and motor dysfunction followed by encephalopathy and death.
UN	1280054_D014750_1_73_84_Vincristine_D007938_1_138_147_leukaemia	Vincristine was accidentally given intrathecally to a child with leukaemia, producing sensory and motor dysfunction followed by encephalopathy and death.
CID	1280707_D002045_9_1421_1432_bupivacaine_D001145_9_1433_1443_arrhythmia	Potentiation of bupivacaine arrhythmia in myocyte cultures suggests that this effect is at least partly mediated at the myocyte level.
UN	1280707_D006851_2_484_487_HCl_D001145_2_423_433_arrhythmic	After determining the bupivacaine AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become arrhythmic), we determined the effect of 1-hour progesterone HCl exposure on myocyte contractile rhythm.
CID	1280707_D011374_2_471_483_progesterone_D001145_2_423_433_arrhythmic	After determining the bupivacaine AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become arrhythmic), we determined the effect of 1-hour progesterone HCl exposure on myocyte contractile rhythm.
CID	12828076_D000082_6_904_915_paracetamol_D017114_6_877_896_acute liver failure	Levels were significantly greater in patients with acute liver failure due to paracetamol overdose (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E hepatitis (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01).
CID	12828076_D000082_0_72_83_paracetamol_D017114_0_45_64_acute liver failure	Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose.
UN	12828076_D000082_6_904_915_paracetamol_D056486_6_1005_1014_hepatitis	Levels were significantly greater in patients with acute liver failure due to paracetamol overdose (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E hepatitis (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01).
UN	12828076_D000082_0_72_83_paracetamol_D062787_0_84_92_overdose	Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose.
UN	12828076_D000082_6_904_915_paracetamol_D062787_6_916_924_overdose	Levels were significantly greater in patients with acute liver failure due to paracetamol overdose (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E hepatitis (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01).
CID	12865514_D007980_12_1616_1624_levodopa_D004409_12_1655_1679_drug-induced dyskinesias	The reduction in the levodopa dose is useful in controlling drug-induced dyskinesias.
CID	12865514_D007980_3_440_448_levodopa_D004409_3_457_468_dyskinesias	METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and levodopa-induced dyskinesias underwent bilateral implantation of electrodes in the STN.
UN	12865514_D007980_3_440_448_levodopa_D009127_3_426_434_rigidity	METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and levodopa-induced dyskinesias underwent bilateral implantation of electrodes in the STN.
UN	12865514_D007980_3_440_448_levodopa_D010300_3_335_354_Parkinson's disease	METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and levodopa-induced dyskinesias underwent bilateral implantation of electrodes in the STN.
UN	12865514_D007980_3_440_448_levodopa_D018476_3_412_424_bradykinesia	METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and levodopa-induced dyskinesias underwent bilateral implantation of electrodes in the STN.
UN	1289188_D003676_1_185_200_desferrioxamine_D013789_1_141_152_thalassemia	A patient with transfusion-dependent thalassemia was undergoing home intravenous desferrioxamine (DFX) treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy.
UN	1289188_D003676_4_877_892_desferrioxamine_D058186_4_847_866_acute renal failure	From the results obtained, haemodialysis can therefore be suggested as a useful therapy in rare cases of progressive acute renal failure caused by desferrioxamine.
UN	1289188_D003676_0_49_64_desferrioxamine_D058186_0_0_19_Acute renal failure	Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis.
CID	12912689_D016190_9_1360_1371_carboplatin_D005355_9_1416_1424_fibrosis	CONCLUSIONS: Subtenon carboplatin chemotherapy is associated with significant fibrosis of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult.
UN	12912689_D016190_6_953_964_carboplatin_D012175_6_903_917_retinoblastoma	RESULTS: Limitation of ocular motility was detected in all 12 eyes of 10 patients treated for intraocular retinoblastoma with 1 to 6 injections of subtenon carboplatin as part of multimodality therapy.
UN	12912689_D016190_3_504_515_carboplatin_D012175_3_463_477_retinoblastoma	METHODS: We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin.
UN	12912689_D016190_0_39_50_carboplatin_D012175_0_68_82_retinoblastoma	Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma.
CID	12912689_D016190_2_362_373_carboplatin_D015835_2_303_327_abnormal ocular motility	OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy.
CID	12948256_D004977_7_915_925_ethambutol_D009901_7_860_876_optic neuropathy	CONCLUSION: Early recognition of optic neuropathy should be considered in patients with ethambutol therapy.
CID	12948256_D004977_2_196_206_ethambutol_D009901_2_154_170_optic neuropathy	METHOD: Thirteen patients who developed optic neuropathy after being treated with ethambutol for tuberculosis of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed.
CID	12948256_D004977_0_0_10_Ethambutol_D009901_0_15_31_optic neuropathy	Ethambutol and optic neuropathy.
CID	12948256_D004977_1_81_91_ethambutol_D009901_1_96_112_optic neuropathy	PURPOSE: To demonstrate the association between ethambutol and optic neuropathy.
UN	12948256_D004977_2_196_206_ethambutol_D014388_2_211_249_tuberculosis of the lung or lymph node	METHOD: Thirteen patients who developed optic neuropathy after being treated with ethambutol for tuberculosis of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed.
UN	12948256_D004977_2_196_206_ethambutol_D014397_2_211_249_tuberculosis of the lung or lymph node	METHOD: Thirteen patients who developed optic neuropathy after being treated with ethambutol for tuberculosis of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed.
CID	12950111_D006024_7_1068_1082_glycopyrrolate_D006261_7_1040_1048_headache	Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1.5% glycopyrrolate).
CID	12950111_D006024_7_1015_1029_glycopyrrolate_D010612_7_985_996_sore throat	Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1.5% glycopyrrolate).
UN	12950111_D006024_0_63_77_glycopyrrolate_D013547_0_26_49_gustatory hyperhidrosis	Treatment of compensatory gustatory hyperhidrosis with topical glycopyrrolate.
UN	12950111_D006024_7_1015_1029_glycopyrrolate_D014987_7_969_978_dry mouth	Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1.5% glycopyrrolate).
UN	1359137_D001971_2_234_247_bromocriptine_D000568_2_144_154_amenorrhea	Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.
UN	1359137_D001971_6_598_611_bromocriptine_D000568_6_711_721_amenorrhea	This suggests that bromocriptine should be further evaluated as potential therapy for neuroleptic-associated hyperprolactinemia and amenorrhea/galactorrhea.
UN	1359137_D001971_6_598_611_bromocriptine_D005687_6_722_734_galactorrhea	This suggests that bromocriptine should be further evaluated as potential therapy for neuroleptic-associated hyperprolactinemia and amenorrhea/galactorrhea.
UN	1359137_D001971_2_234_247_bromocriptine_D006966_2_121_139_hyperprolactinemia	Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.
UN	1359137_D001971_6_598_611_bromocriptine_D006966_6_688_706_hyperprolactinemia	This suggests that bromocriptine should be further evaluated as potential therapy for neuroleptic-associated hyperprolactinemia and amenorrhea/galactorrhea.
UN	1359137_D001971_2_234_247_bromocriptine_D009839_2_155_169_oligomenorrhea	Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.
CID	1359137_D001971_4_435_448_bromocriptine_D011618_4_401_421_psychiatric symptoms	One woman, however, developed worsened psychiatric symptoms while taking bromocriptine, and it was discontinued.
CID	1359137_D014150_6_665_676_neuroleptic_D000568_6_711_721_amenorrhea	This suggests that bromocriptine should be further evaluated as potential therapy for neuroleptic-associated hyperprolactinemia and amenorrhea/galactorrhea.
CID	1359137_D014150_2_192_215_neuroleptic medications_D000568_2_144_154_amenorrhea	Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.
UN	1359137_D014150_6_665_676_neuroleptic_D005687_6_722_734_galactorrhea	This suggests that bromocriptine should be further evaluated as potential therapy for neuroleptic-associated hyperprolactinemia and amenorrhea/galactorrhea.
CID	1359137_D014150_2_192_215_neuroleptic medications_D006966_2_121_139_hyperprolactinemia	Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.
CID	1359137_D014150_0_0_11_Neuroleptic_D006966_0_23_41_hyperprolactinemia	Neuroleptic-associated hyperprolactinemia.
CID	1359137_D014150_6_665_676_neuroleptic_D006966_6_688_706_hyperprolactinemia	This suggests that bromocriptine should be further evaluated as potential therapy for neuroleptic-associated hyperprolactinemia and amenorrhea/galactorrhea.
CID	1359137_D014150_2_192_215_neuroleptic medications_D009839_2_155_169_oligomenorrhea	Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.
UN	1360900_D000109_1_294_307_acetylcholine_D012640_1_131_141_convulsive	Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.
CID	1360900_D004976_3_463_478_ethacrynic acid_D012640_3_487_498_convulsions	In ethacrynic acid-induced convulsions, these neurotransmitter systems may be differentially modulated, probably through activation of glutaminergic neurons in the brain.
CID	1360900_D004976_1_110_125_ethacrynic acid_D012640_1_131_141_convulsive	Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.
CID	1360900_D004976_0_0_15_Ethacrynic acid_D012640_0_24_35_convulsions	Ethacrynic acid-induced convulsions and brain neurotransmitters in mice.
UN	1360900_D005680_1_266_289_gamma-aminobutyric acid_D012640_1_131_141_convulsive	Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.
UN	1360900_D012701_1_207_226_5-hydroxytryptamine_D012640_1_131_141_convulsive	Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.
UN	1361574_C037476_8_1883_1892_[35S]TBPS_D012640_8_1909_1920_convulsions	Moreover, 0.05 mg/kg of this beta-carboline reduced markedly the increase of [35S]TBPS binding and the convulsions induced by isoniazid (200 mg/kg s.c.).(ABSTRACT TRUNCATED AT 250 WORDS)
UN	1361574_D002243_8_1835_1849_beta-carboline_D012640_8_1909_1920_convulsions	Moreover, 0.05 mg/kg of this beta-carboline reduced markedly the increase of [35S]TBPS binding and the convulsions induced by isoniazid (200 mg/kg s.c.).(ABSTRACT TRUNCATED AT 250 WORDS)
CID	1361574_D007538_8_1932_1941_isoniazid_D012640_8_1909_1920_convulsions	Moreover, 0.05 mg/kg of this beta-carboline reduced markedly the increase of [35S]TBPS binding and the convulsions induced by isoniazid (200 mg/kg s.c.).(ABSTRACT TRUNCATED AT 250 WORDS)
CID	1395192_D001971_3_216_229_Bromocriptine_D009203_3_286_307_myocardial infarction	Bromocriptine has been implicated in several previous case reports of myocardial infarction in the puerperium.
CID	1395192_D001971_0_66_79_bromocriptine_D009203_0_10_31_myocardial infarction	Recurrent myocardial infarction in a postpartum patient receiving bromocriptine.
UN	1420650_D002220_4_632_635_CBZ_D020258_4_492_505_neurotoxicity	We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.
UN	1420650_D002220_0_21_34_carbamazepine_D020820_0_0_9_Asterixis	Asterixis induced by carbamazepine therapy.
UN	1420650_D002220_2_299_312_carbamazepine_D020820_2_258_267_asterixis	In this report we present four patients treated with a combination of different psychotropic drugs, in whom asterixis was triggered either by adding carbamazepine (CBZ) to a treatment regimen, or by increasing its dosage.
UN	1420650_D003024_4_593_602_clozapine_D020258_4_492_505_neurotoxicity	We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.
CID	1420650_D003024_4_593_602_clozapine_D020820_4_447_456_asterixis	We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.
UN	1420650_D008094_4_582_589_lithium_D020258_4_492_505_neurotoxicity	We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.
CID	1420650_D008094_4_582_589_lithium_D020820_4_447_456_asterixis	We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.
UN	1423336_D000596_6_667_677_amino acid_D007022_6_767_778_hypotensive	Phenylalanine, a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa.
CID	1423336_D007980_7_838_846_levodopa_D007022_7_861_872_hypotensive	We conclude that levodopa has a central hypotensive action that parallels the motor effects in fluctuating patients.
CID	1423336_D007980_6_811_819_levodopa_D007022_6_767_778_hypotensive	Phenylalanine, a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa.
CID	1423336_D007980_2_254_262_levodopa_D007022_2_232_243_hypotensive	The magnitude of the hypotensive effect of levodopa was concentration dependent and was fit to an Emax model in fluctuating responders.
CID	1423336_D007980_0_46_54_levodopa_D007022_0_24_35_hypotensive	Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients.
UN	1423336_D007980_1_112_120_levodopa_D010300_1_138_150_parkinsonian	Blood pressure effects of i.v. levodopa were examined in parkinsonian patients with stable and fluctuating responses to levodopa.
UN	1423336_D007980_0_46_54_levodopa_D010300_0_58_70_parkinsonian	Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients.
UN	1423336_D010649_6_636_649_Phenylalanine_D007022_6_767_778_hypotensive	Phenylalanine, a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa.
UN	1424076_D003907_1_250_263_dexamethasone_D009101_1_126_142_multiple myeloma	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone.
UN	1424076_D004317_1_219_230_doxorubicin_D009101_1_126_142_multiple myeloma	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone.
CID	1424076_D014750_0_77_88_vincristine_D007177_0_0_59_Syndrome of inappropriate secretion of antidiuretic hormone	Syndrome of inappropriate secretion of antidiuretic hormone after infusional vincristine.
UN	1424076_D014750_1_203_214_vincristine_D009101_1_126_142_multiple myeloma	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone.
CID	1449452_D004077_6_410_417_digoxin_D001145_6_519_530_arrhythmias	Also, digoxin has undesirable effects such as increasing peripheral resistance and myocardial demands, and causing arrhythmias.
UN	1449452_D004077_3_177_184_digoxin_D001281_3_157_176_atrial fibrillation	In patients with atrial fibrillation digoxin is beneficial for ventricular rate control.
UN	1449452_D004077_11_990_997_digoxin_D009203_11_1027_1048_myocardial infarction	Pooled analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that digoxin may increase mortality after myocardial infarction (MI).
CID	1451544_D017275_3_499_509_isradipine_D004244_3_394_403_dizziness	The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with isradipine or with placebo.
CID	1451544_D017275_3_499_509_isradipine_D005483_3_421_429_flushing	The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with isradipine or with placebo.
CID	1451544_D017275_3_499_509_isradipine_D006261_3_384_392_headache	The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with isradipine or with placebo.
UN	1451544_D017275_0_0_10_Isradipine_D006973_0_25_37_hypertension	Isradipine treatment for hypertension in general practice in Hong Kong.
CID	14616590_D015742_8_1346_1356_Disoprivan_D010146_8_1211_1215_Pain	Pain on injection (80 vs. 20%, p < 0.01) and thrombophlebitis (93.3 vs. 6.6%, p < 0.001) occurred more frequently with AM149 than with Disoprivan.
CID	14616590_D015742_8_1346_1356_Disoprivan_D013924_8_1256_1272_thrombophlebitis	Pain on injection (80 vs. 20%, p < 0.01) and thrombophlebitis (93.3 vs. 6.6%, p < 0.001) occurred more frequently with AM149 than with Disoprivan.
CID	146391_D010672_0_80_97_diphenylhydantoin_D003875_0_23_39_toxic dermatitis	Pure red cell aplasia, toxic dermatitis and lymphadenopathy in a patient taking diphenylhydantoin.
UN	146391_D010672_1_116_133_diphenylhydantoin_D005076_1_170_179_skin rash	A patient taking diphenylhydantoin for 3 weeks developed a generalized skin rash, lymphadenopathy and pure red cell aplasia.
UN	146391_D010672_6_657_674_diphenylhydantoin_D005076_6_701_710_skin rash	In this patient the time relation between the ingestion of diphenylhydantoin and the occurrence of the skin rash, lymphadenopathy and pure red cell aplasia is very suggestive of a direct connection.
UN	146391_D010672_3_340_357_diphenylhydantoin_D005076_3_298_307_Skin rash	Skin rash is a well-known complication of diphenylhydantoin treatment as is benign and malignant lymphadenopathy.
CID	146391_D010672_3_340_357_diphenylhydantoin_D008206_3_395_410_lymphadenopathy	Skin rash is a well-known complication of diphenylhydantoin treatment as is benign and malignant lymphadenopathy.
CID	146391_D010672_0_80_97_diphenylhydantoin_D008206_0_44_59_lymphadenopathy	Pure red cell aplasia, toxic dermatitis and lymphadenopathy in a patient taking diphenylhydantoin.
CID	146391_D010672_4_450_467_diphenylhydantoin_D012010_4_412_433_Pure red cell aplasia	Pure red cell aplasia associated with diphenylhydantoin medication has been reported in 3 patients.
UN	14748761_C030852_2_311_314_VNR_D009369_2_378_390_malignancies	In order to quantify the incidence of these cardiac events, we performed a meta-analysis of clinical trials comparing VNR with other chemotherapeutic agents in the treatment of various malignancies.
UN	14748761_C030852_3_429_432_VNR_D009369_3_470_476_cancer	Randomized clinical trials comparing VNR with other drugs in the treatment of cancer were searched in Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library from 1987 to 2002.
CID	14748761_C030852_8_1039_1042_VNR_D066126_8_1099_1110_cardiotoxic	The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].
UN	14748761_C056507_8_1148_1159_gemcitabine_D066126_8_1099_1110_cardiotoxic	The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].
UN	14748761_D005472_8_1118_1130_fluorouracil_D066126_8_1099_1110_cardiotoxic	The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].
UN	14748761_D014751_8_1084_1087_VDS_D066126_8_1099_1110_cardiotoxic	The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].
UN	14748761_D018943_8_1132_1146_anthracyclines_D066126_8_1099_1110_cardiotoxic	The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].
CID	15018178_D015662_1_223_252_trimethoprim-sulfomethoxazole_D000743_1_188_204_hemolytic anemia	We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing hemolytic anemia crisis induced by trimethoprim-sulfomethoxazole, resulting in cerebral anoxia leading to permanent damage.
UN	15018178_D015662_1_223_252_trimethoprim-sulfomethoxazole_D002534_1_267_282_cerebral anoxia	We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing hemolytic anemia crisis induced by trimethoprim-sulfomethoxazole, resulting in cerebral anoxia leading to permanent damage.
UN	15094729_D020888_1_220_230_Vigabatrin_D012640_1_305_312_seizure	PURPOSE: To determine the natural history of visual field defects in a group of patients known to have Vigabatrin-associated changes who elected to continue the medication because of good seizure control.
CID	15094729_D020888_9_1461_1471_Vigabatrin_D014786_9_1483_1503_visual field defects	These data give support to the hypothesis that the pathogenesis of Vigabatrin-associated visual field defects may be an idiosyncratic adverse drug reaction rather than dose-dependent toxicity.
CID	15094729_D020888_8_1304_1314_Vigabatrin_D014786_8_1261_1281_visual field defects	CONCLUSION: Established visual field defects presumed to be due to Vigabatrin therapy did not usually progress in spite of continuing use of the medication.
CID	15094729_D020888_1_220_230_Vigabatrin_D014786_1_162_182_visual field defects	PURPOSE: To determine the natural history of visual field defects in a group of patients known to have Vigabatrin-associated changes who elected to continue the medication because of good seizure control.
CID	15094729_D020888_0_23_33_Vigabatrin_D014786_0_45_65_visual field defects	The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication.
UN	15096374_D013256_1_303_310_steroid_D012393_1_322_329_rosacea	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral dermatitis.
UN	15096374_D013256_1_303_310_steroid_D019557_1_334_353_perioral dermatitis	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral dermatitis.
UN	15096374_D016559_8_1237_1247_tacrolimus_D003872_8_1190_1200_dermatitis	CONCLUSIONS: Our observations suggest that the spectrum of rosaceiform dermatitis as a complication of treatment with tacrolimus ointment is heterogeneous.
UN	15096374_D016559_2_427_437_tacrolimus_D003872_2_380_390_dermatitis	We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment.
UN	15096374_D016559_0_92_102_tacrolimus_D003872_0_25_35_dermatitis	Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment.
UN	15096374_D016559_0_92_102_tacrolimus_D005148_0_56_86_facial inflammatory dermatoses	Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment.
UN	15096374_D016559_3_535_545_tacrolimus_D005148_3_486_516_inflammatory facial dermatoses	OBSERVATIONS: Six adult patients with inflammatory facial dermatoses were treated with tacrolimus ointment because of the ineffectiveness of standard treatments.
CID	15096374_D016559_1_125_135_Tacrolimus_D012393_1_322_329_rosacea	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral dermatitis.
UN	15096374_D016559_1_125_135_Tacrolimus_D019557_1_334_353_perioral dermatitis	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral dermatitis.
CID	1522360_D012293_2_228_236_rifampin_D006461_2_177_186_hemolysis	Intravascular hemolysis leading to acute renal failure following rifampin therapy is extremely rare.
CID	1522360_D012293_3_348_356_rifampin_D006461_3_304_313_hemolysis	Two patients with leprosy who developed hemolysis and acute renal failure following rifampin are reported.
CID	1522360_D012293_0_71_79_rifampin_D006461_0_14_23_hemolysis	Intravascular hemolysis and acute renal failure following intermittent rifampin therapy.
UN	1522360_D012293_3_348_356_rifampin_D007918_3_282_289_leprosy	Two patients with leprosy who developed hemolysis and acute renal failure following rifampin are reported.
UN	1522360_D012293_1_153_161_rifampin_D051437_1_89_102_Renal failure	Renal failure is a rare complication associated with the use of rifampin.
CID	1522360_D012293_3_348_356_rifampin_D058186_3_318_337_acute renal failure	Two patients with leprosy who developed hemolysis and acute renal failure following rifampin are reported.
CID	1522360_D012293_2_228_236_rifampin_D058186_2_198_217_acute renal failure	Intravascular hemolysis leading to acute renal failure following rifampin therapy is extremely rare.
CID	1522360_D012293_0_71_79_rifampin_D058186_0_28_47_acute renal failure	Intravascular hemolysis and acute renal failure following intermittent rifampin therapy.
CID	15229250_D008694_4_819_821_MA_D001930_4_718_788_abnormalities in the cortex, hippocampus, white matter, and ventricles	We used high-resolution MRI and surface-based computational image analyses to map regional abnormalities in the cortex, hippocampus, white matter, and ventricles in 22 human subjects who used MA and 21 age-matched, healthy controls.
CID	15229250_D008694_1_194_209_methamphetamine_D001930_1_131_169_structural deficits in the human brain	We visualize, for the first time, the profile of structural deficits in the human brain associated with chronic methamphetamine (MA) abuse.
UN	15229250_D008694_3_548_550_MA_D003072_3_605_625_cognitive impairment	Using magnetic resonance imaging (MRI) and new computational brain-mapping techniques, we determined the pattern of structural brain alterations associated with chronic MA abuse in human subjects and related these deficits to cognitive impairment.
UN	15229250_D008694_6_1030_1032_MA_D006984_6_1173_1184_hypertrophy	On average, MA abusers had 7.8% smaller hippocampal volumes than control subjects (p < 0.01; left, p = 0.01; right, p < 0.05) and significant white-matter hypertrophy (7.0%; p < 0.01).
CID	15229250_D008694_8_1345_1360_methamphetamine_D008569_8_1440_1467_impaired memory performance	MRI-based maps suggest that chronic methamphetamine abuse causes a selective pattern of cerebral deterioration that contributes to impaired memory performance.
UN	15229250_D008694_2_262_264_MA_D008659_2_354_377_metabolic abnormalities	Studies of human subjects who have used MA chronically have revealed deficits in dopaminergic and serotonergic systems and cerebral metabolic abnormalities.
UN	15265979_D000638_8_1489_1499_amiodarone_D006528_8_1444_1452_hepatoma	The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 hepatoma cells indicates that the effects of amiodarone on the function of this receptor were indirect.
CID	15265979_D000638_3_470_480_Amiodarone_D006529_3_489_501_hepatomegaly	Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose.
UN	15265979_D000638_7_1247_1257_amiodarone_D015431_7_1313_1324_weight loss	Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body weight loss.
CID	15265979_D000638_10_1829_1839_amiodarone_D056486_10_1806_1817_hepatotoxic	These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against amiodarone-induced hepatotoxicity.
CID	15265979_D000638_10_1885_1895_amiodarone_D056486_10_1904_1918_hepatotoxicity	These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against amiodarone-induced hepatotoxicity.
UN	15265979_D005947_3_603_610_glucose_D006529_3_489_501_hepatomegaly	Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose.
UN	15265979_D014280_3_585_598_triglycerides_D006529_3_489_501_hepatomegaly	Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose.
UN	15276093_C451780_1_181_215_Niacin extended-release/lovastatin_D006937_1_279_299_hypercholesterolemia	Niacin extended-release/lovastatin is a new combination product approved for treatment of primary hypercholesterolemia and mixed dyslipidemia.
UN	15276093_C451780_5_945_979_niacin extended-release/lovastatin_D050171_5_928_940_dyslipidemia	Patients also received dietary counseling, educational materials, and reminders to call a toll-free number that provided further education about dyslipidemia and niacin extended-release/lovastatin.
UN	15276093_D003401_12_1654_1662_creatine_D009135_12_1775_1783_myopathy	An increase of creatine phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of drug-induced myopathy were observed.
CID	15282950_D007545_1_215_228_isoproterenol_D009202_1_257_274_myocardial damage	Cardioprotective effect of ethanolic extract of Terminalia chebula fruits (500 mg/kg body wt) was examined in isoproterenol (200 mg/kg body wt) induced myocardial damage in rats.
CID	15282950_D007545_0_90_103_isoproterenol_D009202_0_61_78_myocardial injury	Protective effect of Terminalia chebula against experimental myocardial injury induced by isoproterenol.
UN	15282950_D010936_0_21_39_Terminalia chebula_D009202_0_61_78_myocardial injury	Protective effect of Terminalia chebula against experimental myocardial injury induced by isoproterenol.
CID	15321332_D004329_4_440_450_droperidol_D001008_4_459_484_psychological disturbance	The diagnosis of droperidol-induced psychological disturbance was not made straight away although on subsequent close questioning the patient gave a very clear history.
CID	15321332_D004329_0_48_58_droperidol_D001008_0_24_31_anxiety	A case of postoperative anxiety due to low dose droperidol used with patient-controlled analgesia.
UN	15366550_D008094_5_852_859_lithium_D001930_5_924_936_brain trauma	By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his lithium-induced nephrogenic DI and developed neurogenic DI secondary to brain trauma.
CID	15366550_D008094_5_852_859_lithium_D018500_5_868_882_nephrogenic DI	By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his lithium-induced nephrogenic DI and developed neurogenic DI secondary to brain trauma.
CID	15366550_D008094_4_465_472_Lithium_D018500_4_503_517_nephrogenic DI	Lithium is implicated in drug-induced nephrogenic DI, and because the patient had not received lithium since being admitted to the hospital, his treatment changed to focus on nephrogenic DI.
UN	15366550_D008094_3_452_459_lithium_D059606_3_423_433_polydipsia	The nursing staff, by reviewing the patient's health history with his family, discovered a history of polydipsia and long-standing lithium use.
UN	15482540_D012254_5_602_611_Ribavirin_D000740_5_620_626_anemia	RESULTS: Ribavirin-induced anemia occurred in 18 (20.5%) patients during treatment.
UN	15482540_D012254_0_24_33_ribavirin_D000740_0_42_48_anemia	Factors contributing to ribavirin-induced anemia.
UN	15482540_D012254_2_231_240_ribavirin_D000740_2_249_255_anemia	This study was conducted to identify the factors contributing to ribavirin-induced anemia.
UN	15482540_D012254_4_567_576_ribavirin_D000740_4_585_591_anemia	A hemoglobin concentration of <10 g/dL was defined as ribavirin-induced anemia.
CID	15482540_D012254_1_85_94_ribavirin_D000743_1_148_164_hemolytic anemia	BACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.
UN	15482540_D012254_1_85_94_ribavirin_D019698_1_119_138_chronic hepatitis C	BACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.
CID	15482540_D016898_1_70_80_Interferon_D000743_1_148_164_hemolytic anemia	BACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.
UN	15482540_D016898_3_326_345_interferon-alpha-2b_D019698_3_293_312_chronic hepatitis C	METHODS: Eighty-eight patients with chronic hepatitis C who received interferon-alpha-2b at a dose of 6 MU administered intramuscularly for 24 weeks in combination with ribavirin administered orally at a dose of 600 mg or 800 mg participated in the study.
UN	15482540_D016898_1_70_80_Interferon_D019698_1_119_138_chronic hepatitis C	BACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.
UN	1556529_D015215_1_67_77_zidovudine_D000163_1_108_112_AIDS	A case of acute hepatitis induced by zidovudine in a 38-year-old patient with AIDS is presented.
CID	1556529_D015215_1_67_77_zidovudine_D056486_1_46_55_hepatitis	A case of acute hepatitis induced by zidovudine in a 38-year-old patient with AIDS is presented.
CID	1556529_D015215_0_0_10_Zidovudine_D056486_0_19_28_hepatitis	Zidovudine-induced hepatitis.
UN	15605432_C027576_6_1221_1225_4HNE_D028361_6_1289_1309_mitochondrial injury	Our data showed ADR induced 4HNE-protein adducts in mitochondria at the same time point as when mitochondrial injury initially appeared.
CID	15605432_D004317_0_46_56_adriamycin_D028361_0_73_93_mitochondrial injury	Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury.
UN	15605432_D004317_1_240_243_ADR_D066126_1_253_267_cardiotoxicity	The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.
UN	15605432_D009584_1_179_187_nitrogen_D066126_1_253_267_cardiotoxicity	The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.
UN	15605432_D010100_1_166_172_oxygen_D066126_1_253_267_cardiotoxicity	The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.
UN	15609701_C076259_2_335_359_nifekalant hydrochloride_D017180_2_371_373_VT	After the administration of nifekalant hydrochloride, sustained VT was terminated.
UN	15609701_D013015_0_0_7_Sotalol_D002311_0_49_71_dilated cardiomyopathy	Sotalol-induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia.
CID	15609701_D013015_0_0_7_Sotalol_D003329_0_16_30_coronary spasm	Sotalol-induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia.
UN	15609701_D013015_3_420_427_sotalol_D017180_3_470_472_VT	An alternate class III agent, sotalol, was also effective for the prevention of VT.
UN	15609701_D013015_0_0_7_Sotalol_D017180_0_98_121_ventricular tachycardia	Sotalol-induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia.
CID	15614572_D001058_8_1377_1388_apomorphine_D002375_8_1351_1360_catalepsy	Trazodone at 30, 40 and 50 mg/kg i.p. induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies.
CID	15614572_D001058_4_706_717_apomorphine_D002375_4_669_678_catalepsy	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.
UN	15614572_D001058_4_627_638_apomorphine_D009062_4_647_664_oral stereotypies	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.
UN	15614572_D003913_8_1393_1407_dexamphetamine_D002375_8_1351_1360_catalepsy	Trazodone at 30, 40 and 50 mg/kg i.p. induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies.
UN	15614572_D003913_11_1900_1914_dexamphetamine_D002375_11_1954_1963_catalepsy	We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.
UN	15614572_D003913_4_607_621_dexamphetamine_D009062_4_647_664_oral stereotypies	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.
UN	15614572_D004874_7_1231_1242_ergometrine_D002375_7_1220_1229_catalepsy	However, pretreatment with 5, 10 and 20 mg/kg i.p. trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.
UN	15614572_D004874_4_741_752_ergometrine_D009062_4_647_664_oral stereotypies	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.
UN	15614572_D005473_7_1268_1278_fluoxetine_D002375_7_1220_1229_catalepsy	However, pretreatment with 5, 10 and 20 mg/kg i.p. trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.
UN	15614572_D005473_4_794_804_fluoxetine_D009062_4_647_664_oral stereotypies	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.
CID	15614572_D006220_7_1208_1219_haloperidol_D002375_7_1220_1229_catalepsy	However, pretreatment with 5, 10 and 20 mg/kg i.p. trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.
CID	15614572_D006220_11_1942_1953_haloperidol_D002375_11_1954_1963_catalepsy	We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.
CID	15614572_D006220_4_690_701_haloperidol_D002375_4_669_678_catalepsy	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.
UN	15614572_D006220_4_690_701_haloperidol_D009062_4_647_664_oral stereotypies	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.
UN	15614572_D012701_11_1870_1874_5-HT_D002375_11_1954_1963_catalepsy	We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.
UN	15614572_D014196_5_880_889_trazodone_D002375_5_898_907_catalepsy	We also investigated whether trazodone induces catalepsy in rats.
UN	15614572_D014196_4_594_603_trazodone_D009062_4_647_664_oral stereotypies	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.
UN	15625689_D007980_11_1408_1416_levodopa_D003680_11_1467_1476_dysphagia	Our results suggest a role for levodopa in the oral phase of deglutition and confirm that dysphagia is not a good predictor of deglutition alterations in PD.
CID	15625689_D007980_2_352_360_levodopa_D004409_2_369_379_dyskinesia	The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without levodopa-induced dyskinesia.
UN	15625689_D007980_2_352_360_levodopa_D010300_2_323_325_PD	The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without levodopa-induced dyskinesia.
UN	15627798_D005839_1_143_153_gentamicin_D005355_1_194_202_fibrosis	BACKGROUND: Animals treated with gentamicin can show residual areas of interstitial fibrosis in the renal cortex.
CID	15627798_D005839_0_98_108_gentamicin_D009395_0_58_86_tubulointerstitial nephritis	Inhibition of nuclear factor-kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin.
CID	15627798_D005839_11_1557_1567_gentamicin_D009395_11_1517_1545_tubulointerstitial nephritis	CONCLUSIONS: These data show that inhibition of NF-kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin.
CID	15630069_C076029_13_2917_2927_olanzapine_D007333_13_2965_2983_insulin resistance	CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.
CID	15630069_C076029_14_3098_3108_olanzapine_D007333_14_3130_3148_insulin resistance	Patients taking clozapine and olanzapine must be examined for insulin resistance and its consequences.
CID	15630069_C076029_10_2119_2129_olanzapine_D007333_10_2153_2171_insulin resistance	There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
UN	15630069_C076029_6_1232_1242_olanzapine_D011618_6_1144_1168_schizoaffective disorder	Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.
UN	15630069_C076029_6_1232_1242_olanzapine_D012559_6_1127_1140_schizophrenia	Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.
CID	15630069_D003024_13_2902_2911_clozapine_D007333_13_2965_2983_insulin resistance	CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.
CID	15630069_D003024_14_3084_3093_clozapine_D007333_14_3130_3148_insulin resistance	Patients taking clozapine and olanzapine must be examined for insulin resistance and its consequences.
CID	15630069_D003024_10_2105_2114_clozapine_D007333_10_2153_2171_insulin resistance	There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
UN	15630069_D003024_6_1221_1230_clozapine_D011618_6_1144_1168_schizoaffective disorder	Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.
UN	15630069_D003024_6_1221_1230_clozapine_D012559_6_1127_1140_schizophrenia	Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.
UN	15630069_D005947_1_408_415_glucose_D003920_1_471_479_diabetes	BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.
UN	15630069_D005947_13_3002_3009_glucose_D007333_13_2965_2983_insulin resistance	CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.
UN	15630069_D005947_0_0_7_Glucose_D012559_0_36_49_schizophrenia	Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
UN	15630069_D005947_3_772_779_glucose_D012559_3_709_722_schizophrenia	DESIGN: A cross-sectional design in stable, treated patients with schizophrenia evaluated using a frequently sampled intravenous glucose tolerance test and the Bergman minimal model analysis.
UN	15630069_D018967_13_3038_3049_risperidone_D007333_13_2965_2983_insulin resistance	CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.
UN	15630069_D018967_10_2217_2228_risperidone_D007333_10_2153_2171_insulin resistance	There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
UN	15630069_D018967_6_1247_1258_risperidone_D011618_6_1144_1168_schizoaffective disorder	Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.
UN	15630069_D018967_6_1247_1258_risperidone_D012559_6_1127_1140_schizophrenia	Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.
CID	1563460_D014859_0_35_43_coumadin_D020758_0_0_21_Thoracic hematomyelia	Thoracic hematomyelia secondary to coumadin anticoagulant therapy: a case report.
UN	1564030_D005473_4_490_500_fluoxetine_D001289_4_560_600_attention-deficit hyperactivity disorder	Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.
CID	1564030_D005473_0_22_32_fluoxetine_D001714_0_0_5_Mania	Mania associated with fluoxetine treatment in adolescents.
CID	1564030_D005473_2_233_243_fluoxetine_D001714_2_272_277_mania	Generally safe and well tolerated by adults, fluoxetine has been reported to induce mania.
CID	1564030_D005473_3_388_398_fluoxetine_D001714_3_354_359_mania	The cases of five depressed adolescents, 14-16 years of age, who developed mania during pharmacotherapy with fluoxetine, are reported here.
CID	1564030_D005473_4_490_500_fluoxetine_D001714_4_473_482_hypomania	Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.
CID	1564030_D005473_5_903_913_fluoxetine_D001714_5_922_927_mania	Further study is needed to determine the optimal dosage and to identify risk factors that increase individual vulnerability to fluoxetine induced mania in adolescents.
UN	1564030_D005473_4_490_500_fluoxetine_D003866_4_634_644_depression	Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.
UN	1564030_D005473_3_388_398_fluoxetine_D003866_3_297_306_depressed	The cases of five depressed adolescents, 14-16 years of age, who developed mania during pharmacotherapy with fluoxetine, are reported here.
UN	1564030_D005473_1_59_69_Fluoxetine_D003866_1_176_186_depression	Fluoxetine, a selective serotonin reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent depression.
UN	1564030_D005473_4_490_500_fluoxetine_D011618_4_650_659_psychotic	Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.
UN	1564030_D005473_4_490_500_fluoxetine_D019964_4_690_708_affective disorder	Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.
UN	1564030_D012701_1_83_92_serotonin_D003866_1_176_186_depression	Fluoxetine, a selective serotonin reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent depression.
UN	15696449_D003404_7_878_888_creatinine_D058186_7_744_769_Acute renal insufficiency	Acute renal insufficiency (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum creatinine level that is greater than 50% of baseline immediately after conditioning.
UN	15696449_D008558_0_42_51_melphalan_C531616_0_69_97_primary systemic amyloidosis	Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.
CID	15696449_D008558_0_42_51_melphalan_D058186_0_0_25_Acute renal insufficiency	Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.
CID	15696449_D008558_14_1698_1707_melphalan_D058186_14_1682_1694_renal injury	Ongoing tubular injury may be a prerequisite for renal injury by melphalan as evidenced by the active urinary sediment.
CID	15696449_D008558_7_792_801_melphalan_D058186_7_771_774_ARI	Acute renal insufficiency (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum creatinine level that is greater than 50% of baseline immediately after conditioning.
CID	15696449_D008558_4_535_544_melphalan_D058186_4_491_516_acute renal insufficiency	The authors have noted the development of acute renal insufficiency immediately after melphalan conditioning.
CID	15696449_D008558_12_1445_1454_melphalan_D058186_12_1425_1428_ARI	Patients who had ARI after high-dose melphalan underwent dialysis more often (P = 0.007), and had a worse 1-year survival (P = 0.03).
CID	15696449_D008558_13_1599_1608_melphalan_D058186_13_1568_1580_renal injury	CONCLUSION: The timing of renal injury strongly suggests melphalan as the causative agent.
UN	15815446_C009591_3_780_815_2,3,5-triphenyltetrazolium chloride_D001930_3_728_740_brain injury	Part A, for eight rats in each group brain injury was evaluated by staining tissue using 2,3,5-triphenyltetrazolium chloride and edema was evaluated by microgravimetry.
UN	15815446_C009591_3_780_815_2,3,5-triphenyltetrazolium chloride_D004487_3_820_825_edema	Part A, for eight rats in each group brain injury was evaluated by staining tissue using 2,3,5-triphenyltetrazolium chloride and edema was evaluated by microgravimetry.
UN	15815446_D005070_7_1366_1376_Evans Blue_D006973_7_1425_1428_HTN	Evans Blue (mug g-1 of brain tissue) was greater in the 90/HTN group (24.4 +/- 6.0) versus the control group (12.3 +/- 4.1), which was in turn greater than the 15/HTN group (7.3 +/- 3.2).
UN	15815446_D010656_1_208_221_phenylephrine_D001930_1_246_267_ischemic brain injury	After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of phenylephrine-induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined.
UN	15815446_D010656_0_43_56_phenylephrine_D002545_0_6_23_cerebral ischemia	Focal cerebral ischemia in rats: effect of phenylephrine-induced hypertension during reperfusion.
CID	15815446_D010656_1_208_221_phenylephrine_D006973_1_230_242_hypertension	After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of phenylephrine-induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined.
CID	15815446_D010656_0_43_56_phenylephrine_D006973_0_65_77_hypertension	Focal cerebral ischemia in rats: effect of phenylephrine-induced hypertension during reperfusion.
UN	15815446_D010656_1_208_221_phenylephrine_D020244_1_125_157_middle cerebral artery occlusion	After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of phenylephrine-induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined.
UN	15817013_D014859_1_281_289_warfarin_D001281_1_244_263_atrial fibrillation	OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose warfarin who had been recently been admitted to hospital.
UN	15817013_D014859_0_46_54_warfarin_D001281_0_23_42_atrial fibrillation	People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.
UN	15817013_D014859_4_635_643_warfarin_D001281_4_612_631_atrial fibrillation	PARTICIPANTS: Two hundred thirty-five patients aged 76 and older admitted to a major healthcare network between July 1, 2001, and June 30, 2002, with atrial fibrillation on warfarin were enrolled.
CID	15817013_D014859_5_733_741_warfarin_D006470_5_701_709_bleeding	MEASUREMENTS: Information regarding major bleeding episodes, strokes, and warfarin use was obtained from patients, relatives, primary physicians, and medical records.
CID	15817013_D014859_1_281_289_warfarin_D006470_1_189_199_hemorrhage	OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose warfarin who had been recently been admitted to hospital.
CID	15817013_D014859_0_46_54_warfarin_D006470_0_74_84_hemorrhage	People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.
CID	15817013_D014859_10_1360_1368_warfarin_D006470_10_1230_1240_hemorrhage	CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective warfarin treatment is.
UN	15817013_D014859_10_1360_1368_warfarin_D020521_10_1345_1351_stroke	CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective warfarin treatment is.
UN	15817013_D014859_9_1181_1189_warfarin_D020521_9_1149_1155_stroke	The annual stroke rate after initiation of warfarin was 2.6%.
CID	15859361_C012655_0_95_105_nimesulide_D003875_0_45_59_skin reactions	Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
CID	15859361_C012655_5_704_705_N_D003875_5_675_694_cutaneous reactions	OBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.
CID	15859361_C012655_7_886_887_N_D003875_7_896_910_skin reactions	The diagnosis of P and N-induced skin reactions was based in vivo challenge.
UN	15859361_C012655_6_805_806_N_D004342_6_779_795_hypersensitivity	METHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs.
UN	15859361_C012655_15_1635_1636_N_D004342_15_1574_1590_hypersensitivity	CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients.
UN	15859361_C105934_0_10_19_celecoxib_D003875_0_45_59_skin reactions	Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
UN	15859361_C105934_15_1603_1605_CE_D004342_15_1574_1590_hypersensitivity	CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients.
CID	15859361_D000082_0_63_76_acetaminophen_D003875_0_45_59_skin reactions	Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
CID	15859361_D000082_7_880_881_P_D003875_7_896_910_skin reactions	The diagnosis of P and N-induced skin reactions was based in vivo challenge.
CID	15859361_D000082_5_698_699_P_D003875_5_675_694_cutaneous reactions	OBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.
UN	15859361_D000082_6_799_800_P_D004342_6_779_795_hypersensitivity	METHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs.
UN	15859361_D000082_15_1629_1630_P_D004342_15_1574_1590_hypersensitivity	CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients.
UN	15882284_D001241_10_1382_1389_aspirin_D007674_10_1517_1528_nephropathy	The risk of ESRD associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [2.35 (1.17-4.72)].
CID	15882284_D001241_10_1382_1389_aspirin_D007676_10_1361_1365_ESRD	The risk of ESRD associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [2.35 (1.17-4.72)].
CID	15882284_D001241_12_1739_1746_aspirin_D007676_12_1772_1776_ESRD	However, the chronic use of aspirin may increase the risk of ESRD.
CID	15953230_C012052_0_13_24_amisulpride_D008133_0_47_68_prolonged QT syndrome	Two cases of amisulpride overdose: a cause for prolonged QT syndrome.
UN	15953230_C012052_1_131_142_amisulpride_D011041_1_99_108_poisoning	Two cases of deliberate self-poisoning with 5 g and 3.6 g of amisulpride, respectively, are reported.
UN	15953230_C012052_0_13_24_amisulpride_D062787_0_25_33_overdose	Two cases of amisulpride overdose: a cause for prolonged QT syndrome.
UN	15953230_D002125_3_299_316_calcium gluconate_D008133_3_237_252_QT prolongation	The QT prolongation appeared to respond to administration of i.v. calcium gluconate.
UN	15987266_D003513_0_110_123_cycloheximide_D004827_0_82_91_epileptic	Growth-associated protein 43 expression in hippocampal molecular layer of chronic epileptic rats treated with cycloheximide.
UN	15987266_D003513_2_547_560_cycloheximide_D013226_2_465_483_status epilepticus	To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.
CID	15987266_D010862_2_495_506_pilocarpine_D013226_2_465_483_status epilepticus	To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.
CID	15991002_D002110_4_517_525_caffeine_D001008_4_498_505_anxiety	OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.
CID	15991002_D002110_12_1618_1626_caffeine_D001008_12_1635_1642_anxiety	CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on caffeine-induced anxiety is specific to caffeine, instead of a non-specific anxiolytic effect.
CID	15991002_D002110_10_1386_1394_caffeine_D001008_10_1431_1438_anxiety	Nicotine (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced anxiety.
UN	15991002_D009538_4_486_494_nicotine_D001008_4_498_505_anxiety	OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.
UN	15991002_D009538_12_1606_1614_nicotine_D001008_12_1635_1642_anxiety	CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on caffeine-induced anxiety is specific to caffeine, instead of a non-specific anxiolytic effect.
CID	15991002_D010433_10_1404_1422_pentylenetetrazole_D001008_10_1431_1438_anxiety	Nicotine (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced anxiety.
CID	16034922_D004967_13_1818_1827_oestrogen_D005705_13_1888_1907_gallbladder disease	Long-term oestrogen-only HT also significantly increased the risk of stroke and gallbladder disease.
CID	16034922_D004967_13_1818_1827_oestrogen_D020521_13_1877_1883_stroke	Long-term oestrogen-only HT also significantly increased the risk of stroke and gallbladder disease.
UN	16083708_D001663_9_1536_1545_bilirubin_D017114_9_1368_1393_fulminant hepatic failure	Factors associated with the development of fulminant hepatic failure were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), hepatocellular damage (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma bilirubin value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001).
CID	16083708_D019980_11_1721_1744_Amoxicillin-clavulanate_D056486_11_1791_1795_DILI	Amoxicillin-clavulanate stands out as the most common drug related to DILI.
CID	16092435_D004317_1_125_135_adriamycin_D009202_1_144_158_myocardiopathy	The influence of d-ribose on adriamycin-induced myocardiopathy in rats was studied.
UN	16092435_D004317_0_54_64_adriamycin_D066126_0_72_86_cardiotoxicity	Morphological evaluation of the effect of d-ribose on adriamycin-evoked cardiotoxicity in rats.
UN	16092435_D004317_3_329_332_ADR_D066126_3_333_347_cardiotoxicity	D-ribose in the multiple doses of 200 mg/kg did not influence ADR cardiotoxicity.
UN	16092435_D012266_1_113_121_d-ribose_D009202_1_144_158_myocardiopathy	The influence of d-ribose on adriamycin-induced myocardiopathy in rats was studied.
UN	16092435_D012266_0_42_50_d-ribose_D066126_0_72_86_cardiotoxicity	Morphological evaluation of the effect of d-ribose on adriamycin-evoked cardiotoxicity in rats.
UN	16112787_C048498_8_1389_1399_erdosteine_D001284_8_1294_1301_atrophy	There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups.
UN	16112787_C048498_10_1626_1636_erdosteine_D007674_10_1661_1674_kidney damage	It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM-induced kidney damage both at the biochemical and histological levels.
UN	16112787_C048498_7_1115_1125_Erdosteine_D007674_7_1182_1196_nephrotoxicity	Erdosteine showed histopathological protection against VCM-induced nephrotoxicity.
UN	16112787_C048498_8_1389_1399_erdosteine_D009336_8_1321_1329_necrosis	There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups.
UN	16112787_D008315_5_735_738_MDA_D007674_5_802_822_renal tubular injury	VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.
UN	16112787_D010100_1_256_262_oxygen_D007674_1_431_447_renal impairment	The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.
UN	16112787_D013481_5_848_858_superoxide_D007674_5_802_822_renal tubular injury	VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.
UN	16112787_D014640_8_1333_1336_VCM_D001284_8_1294_1301_atrophy	There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups.
CID	16112787_D014640_7_1170_1173_VCM_D007674_7_1182_1196_nephrotoxicity	Erdosteine showed histopathological protection against VCM-induced nephrotoxicity.
CID	16112787_D014640_10_1555_1558_VCM_D007674_10_1567_1581_nephrotoxicity	It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM-induced kidney damage both at the biochemical and histological levels.
CID	16112787_D014640_10_1649_1652_VCM_D007674_10_1661_1674_kidney damage	It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM-induced kidney damage both at the biochemical and histological levels.
CID	16112787_D014640_0_77_87_vancomycin_D007674_0_96_110_nephrotoxicity	In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine.
CID	16112787_D014640_1_419_422_VCM_D007674_1_431_447_renal impairment	The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.
UN	16112787_D014640_8_1333_1336_VCM_D009336_8_1321_1329_necrosis	There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups.
UN	1615846_D003401_7_1613_1621_creatine_D009212_7_1685_1698_myoglobinuria	Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria.(ABSTRACT TRUNCATED AT 250 WORDS)
UN	1615846_D003401_7_1613_1621_creatine_D009220_7_1465_1473_Myositis	Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria.(ABSTRACT TRUNCATED AT 250 WORDS)
UN	1615846_D003401_7_1613_1621_creatine_D012206_7_1667_1681_rhabdomyolysis	Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria.(ABSTRACT TRUNCATED AT 250 WORDS)
UN	1615846_D008148_1_218_228_lovastatin_D002340_1_305_337_atherosclerotic vascular disease	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had atherosclerotic vascular disease).
UN	1615846_D008148_1_218_228_lovastatin_D006949_1_273_287_hyperlipidemia	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had atherosclerotic vascular disease).
UN	1615846_D008148_0_12_22_lovastatin_D006951_0_43_64_hyperlipoproteinemias	Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias.
UN	1615846_D015248_1_206_217_gemfibrozil_D002340_1_305_337_atherosclerotic vascular disease	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had atherosclerotic vascular disease).
UN	1615846_D015248_1_206_217_gemfibrozil_D006949_1_273_287_hyperlipidemia	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had atherosclerotic vascular disease).
UN	1615846_D015248_0_0_11_Gemfibrozil_D006951_0_43_64_hyperlipoproteinemias	Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias.
UN	16309808_C035133_5_790_801_mirtazapine_D004415_5_743_765_postprandial dyspepsia	The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.
CID	16309808_C035133_0_28_39_mirtazapine_D012148_0_51_73_restless legs syndrome	Does domperidone potentiate mirtazapine-associated restless legs syndrome?
CID	16309808_C035133_5_790_801_mirtazapine_D012148_5_780_783_RLS	The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.
CID	16309808_C035133_6_925_936_mirtazapine_D012148_6_885_888_RLS	Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.
CID	16309808_C035133_6_1007_1018_mirtazapine_D012148_6_946_949_RLS	Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.
CID	16309808_C035133_7_1174_1185_mirtazapine_D012148_7_1197_1200_RLS	Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.
CID	16309808_C035133_8_1262_1273_mirtazapine_D012148_8_1297_1300_RLS	However, physicians should be aware of the possibility that mirtazapine can be associated with RLS in some individuals, especially those receiving concomitant dopamine D2 receptor antagonists.
UN	16309808_D004294_5_824_835_domperidone_D004415_5_743_765_postprandial dyspepsia	The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.
UN	16309808_D004294_0_5_16_domperidone_D012148_0_51_73_restless legs syndrome	Does domperidone potentiate mirtazapine-associated restless legs syndrome?
UN	16309808_D004294_5_824_835_domperidone_D012148_5_780_783_RLS	The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.
UN	16309808_D004294_7_1160_1170_domperione_D012148_7_1197_1200_RLS	Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.
UN	16309808_D004298_2_262_270_dopamine_D012148_2_213_216_RLS	For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.
UN	16309808_D004298_2_297_305_dopamine_D012148_2_354_357_RLS	For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.
UN	16309808_D007980_2_249_257_levodopa_D012148_2_213_216_RLS	For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.
UN	16323982_D002784_5_975_986_cholesterol_D003324_5_847_872_coronary arteriosclerosis	CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.
UN	16323982_D002784_2_246_258_cholesterols_D011471_2_411_426_prostate cancer	MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.
UN	16323982_D002784_5_975_986_cholesterol_D050171_5_1047_1071_hyperglyceridemic effect	CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.
UN	16323982_D004967_5_1082_1090_estrogen_D003324_5_847_872_coronary arteriosclerosis	CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.
UN	16323982_D004967_5_1082_1090_estrogen_D050171_5_1047_1071_hyperglyceridemic effect	CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.
UN	16323982_D014280_2_264_277_triglycerides_D011471_2_411_426_prostate cancer	MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.
CID	16323982_D017373_5_928_931_CPA_D003324_5_847_872_coronary arteriosclerosis	CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.
UN	16323982_D017373_4_723_726_CPA_D003327_4_800_822_coronary heart disease	After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease.
UN	16323982_D017373_2_486_505_cyproterone acetate_D011471_2_411_426_prostate cancer	MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.
CID	16323982_D017373_5_928_931_CPA_D050171_5_1047_1071_hyperglyceridemic effect	CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.
UN	16369751_C032348_4_700_704_FBAL_D002037_4_633_658_right bundle branch block	After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.
UN	16369751_C032348_4_700_704_FBAL_D002637_4_612_627_precordial pain	After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.
UN	16369751_C032348_11_1597_1601_FBAL_D066126_11_1629_1643_cardiotoxicity	The experience of this case, together with a review of the literature, suggests that FBAL is related to 5-FU-induced cardiotoxicity.
UN	16369751_C032348_0_41_66_alpha-fluoro-beta-alanine_D066126_0_15_29_cardiotoxicity	5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
CID	16369751_D005472_4_579_583_5-FU_D002037_4_633_658_right bundle branch block	After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.
CID	16369751_D005472_4_579_583_5-FU_D002637_4_612_627_precordial pain	After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.
CID	16369751_D005472_5_851_855_5-FU_D002637_5_743_758_precordial pain	Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5-FU.
CID	16369751_D005472_6_931_935_5-FU_D002637_6_864_879_precordial pain	As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned.
UN	16369751_D005472_1_139_143_5-FU_D009369_1_159_171_malignancies	Cardiotoxicity is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies.
UN	16369751_D005472_6_931_935_5-FU_D066126_6_944_958_cardiotoxicity	As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned.
UN	16369751_D005472_2_225_229_5-FU_D066126_2_238_252_cardiotoxicity	We herein report the case of a 70-year-old man with 5-FU-induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed.
UN	16369751_D005472_11_1616_1620_5-FU_D066126_11_1629_1643_cardiotoxicity	The experience of this case, together with a review of the literature, suggests that FBAL is related to 5-FU-induced cardiotoxicity.
UN	16369751_D005472_12_1693_1697_5-FU_D066126_12_1706_1720_cardiotoxicity	S-1 may be administered safely to patients with 5-FU-induced cardiotoxicity.
UN	16369751_D005472_0_0_14_5-Fluorouracil_D066126_0_15_29_cardiotoxicity	5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
UN	16369751_D005472_1_123_137_5-fluorouracil_D066126_1_68_82_Cardiotoxicity	Cardiotoxicity is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies.
UN	1655018_D000305_0_71_85_corticosteroid_D005199_0_28_44_Fanconi's anemia	Hepatocellular carcinoma in Fanconi's anemia treated with androgen and corticosteroid.
UN	1655018_D000305_4_707_721_corticosteroid_D005199_4_730_746_Fanconi's anemia	This case contributes to the previous observations that non-metastasizing hepatic neoplasms and peliosis can develop in patients with androgen- and corticosteroid-treated Fanconi's anemia.
CID	1655018_D000305_0_71_85_corticosteroid_D006528_0_0_24_Hepatocellular carcinoma	Hepatocellular carcinoma in Fanconi's anemia treated with androgen and corticosteroid.
UN	1655018_D000305_4_707_721_corticosteroid_D008113_4_633_650_hepatic neoplasms	This case contributes to the previous observations that non-metastasizing hepatic neoplasms and peliosis can develop in patients with androgen- and corticosteroid-treated Fanconi's anemia.
CID	1655018_D000305_4_707_721_corticosteroid_D010382_4_655_663_peliosis	This case contributes to the previous observations that non-metastasizing hepatic neoplasms and peliosis can develop in patients with androgen- and corticosteroid-treated Fanconi's anemia.
UN	1655018_D000728_4_693_701_androgen_D005199_4_730_746_Fanconi's anemia	This case contributes to the previous observations that non-metastasizing hepatic neoplasms and peliosis can develop in patients with androgen- and corticosteroid-treated Fanconi's anemia.
UN	1655018_D000728_1_202_211_androgens_D005199_1_152_168_Fanconi's anemia	The case of an 11-year-old boy is reported who was known to have Fanconi's anemia for 3 years and was treated with androgens, corticosteroids and transfusions.
UN	1655018_D000728_0_58_66_androgen_D005199_0_28_44_Fanconi's anemia	Hepatocellular carcinoma in Fanconi's anemia treated with androgen and corticosteroid.
CID	1655018_D000728_0_58_66_androgen_D006528_0_0_24_Hepatocellular carcinoma	Hepatocellular carcinoma in Fanconi's anemia treated with androgen and corticosteroid.
UN	1655018_D000728_4_693_701_androgen_D008113_4_633_650_hepatic neoplasms	This case contributes to the previous observations that non-metastasizing hepatic neoplasms and peliosis can develop in patients with androgen- and corticosteroid-treated Fanconi's anemia.
CID	1655018_D000728_4_693_701_androgen_D010382_4_655_663_peliosis	This case contributes to the previous observations that non-metastasizing hepatic neoplasms and peliosis can develop in patients with androgen- and corticosteroid-treated Fanconi's anemia.
UN	16565833_C522803_4_592_599_monoHER_D066126_4_645_659_cardiotoxicity	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties.
UN	16565833_D004317_2_304_307_DOX_D006331_2_316_330_cardiac damage	DOX-induced cardiac damage presumably results from the formation of free radicals by DOX.
UN	16565833_D004317_10_1503_1506_DOX_D006331_10_1533_1547_cardiac damage	Microscopic evaluation revealed that treatment with DOX alone induced significant cardiac damage in comparison to the saline control group (P<0.001).
UN	16565833_D004317_0_108_119_doxorubicin_D066126_0_128_142_cardiotoxicity	The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
UN	16565833_D004317_4_633_636_DOX_D066126_4_645_659_cardiotoxicity	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties.
UN	16565833_D005419_4_556_565_flavonoid_D066126_4_645_659_cardiotoxicity	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties.
UN	16565833_D007501_4_695_699_iron_D066126_4_645_659_cardiotoxicity	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties.
UN	16723784_D015764_1_143_146_Bpd_D001281_1_197_216_atrial fibrillation	BACKGROUND: Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL).
UN	16723784_D015764_0_46_54_bepridil_D001281_0_74_105_atrial fibrillation and flutter	Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.
UN	16723784_D015764_0_46_54_bepridil_D001282_0_74_105_atrial fibrillation and flutter	Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.
CID	16731636_D007545_0_9_22_isoproterenol_D006332_0_31_50_cardiac hypertrophy	Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen.
CID	16731636_D007545_5_703_706_Iso_D006332_5_677_691_LV hypertrophy	LV hypertrophy induced by Iso treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/- 0.004 vs. 0.24 +/- 0.004, respectively).
UN	16801510_D008691_10_1497_1506_methadone_D007008_10_1558_1569_hypokalemia	Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.
CID	16801510_D008691_13_1906_1915_methadone_D008133_13_1861_1877_Long QT syndrome	Long QT syndrome can occur with low doses of methadone.
CID	16801510_D008691_11_1640_1649_methadone_D008133_11_1612_1636_QT interval prolongation	CONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding.
CID	16801510_D008691_0_64_73_methadone_D008133_0_13_29_long QT syndrome	Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.
CID	16801510_D008691_3_356_365_methadone_D008133_3_326_350_QT interval prolongation	In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.
UN	16801510_D008691_8_1235_1244_methadone_D016171_8_1261_1280_torsades de pointes	Six patients (3.6%) in the methadone group presented torsades de pointes.
UN	16801510_D011188_12_1794_1803_potassium_D008133_12_1844_1859_QT prolongation	Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation.
CID	16810074_D009569_2_252_254_NO_D006973_2_213_225_hypertension	Experimental hypertension created by the removal of NO, however, involves mechanisms in addition to decreased arterial vasodilator activity.
CID	16810074_D009569_1_141_143_NO_D006973_1_148_160_hypertension	Loss of endothelial cell-derived nitric oxide (NO) in hypertension is a hallmark of arterial dysfunction.
CID	16810074_D009569_0_38_50_nitric oxide_D006973_0_14_26_hypertension	Mechanisms of hypertension induced by nitric oxide (NO) deficiency: focus on venous function.
UN	16810074_D009569_1_141_143_NO_D018754_1_178_198_arterial dysfunction	Loss of endothelial cell-derived nitric oxide (NO) in hypertension is a hallmark of arterial dysfunction.
UN	16810074_D018738_12_1641_1654_hexamethonium_D006973_12_1699_1711_hypertensive	Similarly, ganglionic blockade with hexamethonium caused a significantly greater fall in LNNA hypertensive rats (76 +/- 9 mm Hg) compared with control rats (35 +/- 10 mm Hg).
UN	16810074_D019335_12_1694_1698_LNNA_D006973_12_1699_1711_hypertensive	Similarly, ganglionic blockade with hexamethonium caused a significantly greater fall in LNNA hypertensive rats (76 +/- 9 mm Hg) compared with control rats (35 +/- 10 mm Hg).
UN	16810074_D019335_10_1342_1346_LNNA_D006973_10_1347_1359_hypertension	Mean circulatory filling pressure, an in vivo measure of venomotor tone, was not elevated in LNNA hypertension at 1 or 2 weeks after LNNA.
UN	16810074_D019335_4_589_593_LNNA_D006973_4_595_607_hypertension	We hypothesized that increased venous smooth muscle (venomotor) tone plays a role in Nomega-nitro-L-arginine (LNNA) hypertension through these mechanisms.
CID	16867246_D002746_3_576_590_chlorpromazine_D001480_3_599_602_EPS	In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients.
CID	16867246_D002746_0_38_52_chlorpromazine_D001480_0_61_84_extrapyramidal syndrome	Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients.
UN	16867246_D002746_0_38_52_chlorpromazine_D012559_0_96_109_schizophrenic	Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients.
UN	16867246_D002746_3_576_590_chlorpromazine_D012559_3_606_619_schizophrenic	In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients.
CID	16876986_D010862_4_501_512_pilocarpine_D012640_4_476_484_seizures	Thereafter, seizures were induced by pilocarpine injections in trained and non-trained control groups.
CID	16876986_D010862_0_57_68_pilocarpine_D012640_0_77_85_seizures	Physical training decreases susceptibility to subsequent pilocarpine-induced seizures in the rat.
UN	16880771_D004298_7_873_881_dopamine_D007859_7_904_932_impaired novel word learning	The dopamine agonist significantly impaired novel word learning compared to placebo.
UN	16880771_D004298_12_1436_1444_dopamine_D020521_12_1499_1505_stroke	Thus, phasic signaling seems to be the critical mechanism by which dopamine enhances associative learning in healthy subjects and stroke patients.
UN	16880771_D004298_2_192_200_dopamine_D020521_2_262_268_stroke	Administration of the dopamine precursor levodopa enhances learning in healthy subjects and stroke patients.
UN	16880771_D007980_2_211_219_levodopa_D020521_2_262_268_stroke	Administration of the dopamine precursor levodopa enhances learning in healthy subjects and stroke patients.
UN	16906379_D008911_1_118_129_minocycline_D005334_1_168_173_fever	A 47-year-old man who had been taking minocycline for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP).
CID	16906379_D008911_0_0_11_Minocycline_D010488_0_58_78_polyarteritis nodosa	Minocycline-induced vasculitis fulfilling the criteria of polyarteritis nodosa.
UN	16906379_D008911_1_118_129_minocycline_D011115_1_185_199_polyneuropathy	A 47-year-old man who had been taking minocycline for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP).
UN	16906379_D008911_1_118_129_minocycline_D011565_1_134_157_palmoplantar pustulosis	A 47-year-old man who had been taking minocycline for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP).
UN	16906379_D008911_1_118_129_minocycline_D013733_1_205_220_testicular pain	A 47-year-old man who had been taking minocycline for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP).
UN	16906379_D008911_0_0_11_Minocycline_D014657_0_20_30_vasculitis	Minocycline-induced vasculitis fulfilling the criteria of polyarteritis nodosa.
UN	16906379_D008911_5_608_619_minocycline_D014657_5_628_638_vasculitis	To our knowledge, this is the second case of minocycline-induced vasculitis satisfying the criteria.
UN	16906379_D008911_1_118_129_minocycline_D063806_1_175_183_myalgias	A 47-year-old man who had been taking minocycline for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP).
UN	16911931_D006514_1_326_331_HBsAg_D006509_1_243_254_hepatitis B	BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of HBsAg positive patients.
UN	16911931_D019259_0_56_66_lamivudine_D006509_0_84_95_hepatitis B	Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation.
UN	16911931_D019259_1_196_206_lamivudine_D006509_1_157_168_hepatitis B	BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of HBsAg positive patients.
UN	16911931_D019259_1_196_206_lamivudine_D006509_1_243_254_hepatitis B	BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of HBsAg positive patients.
UN	16920333_C416835_0_50_59_BIA 2-093_D012640_0_64_72_seizures	Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.
UN	16920333_C416835_2_526_549_eslicarbazepine acetate_D012640_2_591_599_seizures	We have studied the effects of oral treatment with eslicarbazepine acetate on a whole-animal model in which partial seizures can be elicited repeatedly on different days without changes in threshold or seizure patterns.
CID	16920333_D010852_3_894_904_picrotoxin_D012640_3_930_938_seizures	In the animals treated with threshold doses of picrotoxin, the average number of seizures was 2.3+/-1.2, and average seizure duration was 39.5+/-8.4s. Pre-treatment with a dose of 30 mg/kg 2h before picrotoxin microperfusion prevented seizures in the 75% of the rats.
CID	16920333_D010852_0_102_112_picrotoxin_D012640_0_64_72_seizures	Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.
UN	17028363_D000880_7_998_1011_anthraquinone_D007674_7_1112_1123_nephropathy	Although a causal relationship between the use of an anthraquinone-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained renal failure.
UN	17028363_D000880_7_998_1011_anthraquinone_D051437_7_1186_1199_renal failure	Although a causal relationship between the use of an anthraquinone-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained renal failure.
UN	17028363_D000880_7_998_1011_anthraquinone_D058186_7_1040_1052_renal injury	Although a causal relationship between the use of an anthraquinone-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained renal failure.
UN	17028363_D000880_0_82_96_anthraquinones_D058186_0_0_19_Acute renal failure	Acute renal failure associated with prolonged intake of slimming pills containing anthraquinones.
CID	17028363_D004008_4_695_705_diclofenac_D058186_4_589_601_renal injury	The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac.
UN	17028363_D004365_2_277_290_Chinese herbs_D007674_2_255_266_Nephropathy	Nephropathy caused by Chinese herbs has previously been reported, usually involving the use of aristolochic acids.
CID	17028363_D004365_3_475_489_Chinese herbal_D058186_3_414_433_acute renal failure	We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb).
UN	17028363_D034341_2_350_368_aristolochic acids_D007674_2_255_266_Nephropathy	Nephropathy caused by Chinese herbs has previously been reported, usually involving the use of aristolochic acids.
UN	17035713_C004656_1_105_123_Chloroacetaldehyde_D007674_1_218_230_renal damage	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.
UN	17035713_C004656_0_0_18_Chloroacetaldehyde_D007674_0_92_103_nephropathy	Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.
UN	17035713_C004656_10_1253_1256_CAA_D009336_10_1260_1268_necrosis	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and cysteine protease inhibition in living cells.
UN	17035713_C004656_1_105_123_Chloroacetaldehyde_D009369_1_246_251_tumor	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.
UN	17035713_D003545_10_1298_1306_cysteine_D009336_10_1260_1268_necrosis	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and cysteine protease inhibition in living cells.
CID	17035713_D007069_0_81_91_ifosfamide_D007674_0_92_103_nephropathy	Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.
CID	17035713_D007069_1_182_185_IFO_D007674_1_218_230_renal damage	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.
CID	17035713_D007069_13_1558_1561_IFO_D007674_13_1562_1573_nephropathy	Therefore, urinary acidification could be an option to prevent IFO nephropathy in patients.
UN	17035713_D007069_1_265_268_IFO_D009369_1_246_251_tumor	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.
UN	17035713_D013438_0_65_70_thiol_D007674_0_92_103_nephropathy	Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.
UN	17035713_D013438_6_741_747_thiols_D009336_6_767_775_necrosis	CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in necrosis markers.
CID	17042797_D010862_9_1607_1618_pilocarpine_D004833_9_1628_1650_temporal lobe epilepsy	The results provide new insight into the potential role of ectopic hilar granule cells in the pilocarpine model of temporal lobe epilepsy.
CID	17042797_D010862_0_96_107_pilocarpine_D013226_0_116_134_status epilepticus	Stereological methods reveal the robust size and stability of ectopic hilar granule cells after pilocarpine-induced status epilepticus in the adult rat.
CID	17042797_D010862_4_800_811_pilocarpine_D013226_4_820_838_status epilepticus	To quantify this population, the total number of ectopic hilar granule cells was estimated using unbiased stereology at different times after pilocarpine-induced status epilepticus.
UN	17069550_D005702_0_35_46_galantamine_D001321_0_50_67_autistic disorder	A prospective, open-label trial of galantamine in autistic disorder.
UN	17069550_D005702_9_1366_1377_galantamine_D001523_9_1508_1518_aggression	CONCLUSION: In this open trial, galantamine was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly aggression, behavioral dyscontrol, and inattention.
UN	17069550_D005702_9_1366_1377_galantamine_D002653_9_1520_1541_behavioral dyscontrol	CONCLUSION: In this open trial, galantamine was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly aggression, behavioral dyscontrol, and inattention.
CID	17069550_D005702_8_1229_1240_galantamine_D006261_8_1308_1317_headaches	Overall, galantamine was well-tolerated, with no significant adverse effects apart from headaches in one patient.
UN	17069550_D005702_9_1366_1377_galantamine_D019958_9_1547_1558_inattention	CONCLUSION: In this open trial, galantamine was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly aggression, behavioral dyscontrol, and inattention.
CID	17151160_C076029_6_1137_1147_olanzapine_D001480_6_1025_1047_Extrapyramidal symptom	Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with olanzapine.
UN	17151160_C076029_2_507_517_olanzapine_D011618_2_436_460_schizoaffective disorder	METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).
UN	17151160_C076029_1_186_196_olanzapine_D012559_1_247_260_schizophrenia	OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders.
UN	17151160_C076029_0_25_35_olanzapine_D012559_0_90_103_schizophrenia	Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
CID	17151160_C076029_7_1194_1204_olanzapine_D015430_7_1168_1179_weight gain	Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.
CID	17151160_C076029_11_1845_1855_olanzapine_D015430_11_1816_1827_weight gain	Both medications caused substantial rapid weight gain, but weight gain was greater with olanzapine.
CID	17151160_D018967_6_1095_1106_risperidone_D001480_6_1025_1047_Extrapyramidal symptom	Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with olanzapine.
UN	17151160_D018967_2_537_548_risperidone_D011618_2_436_460_schizoaffective disorder	METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).
UN	17151160_D018967_0_43_54_risperidone_D012559_0_90_103_schizophrenia	Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
UN	17151160_D018967_1_204_215_risperidone_D012559_1_247_260_schizophrenia	OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders.
CID	17151160_D018967_7_1215_1226_risperidone_D015430_7_1168_1179_weight gain	Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.
CID	17159032_D006886_0_55_73_hydroxychloroquine_D014786_0_18_35_visual field loss	Early paracentral visual field loss in patients taking hydroxychloroquine.
CID	17223814_D015251_0_71_81_epirubicin_D054537_0_15_37_atrioventricular block	Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel.
CID	17223814_D017239_0_86_96_paclitaxel_D054537_0_15_37_atrioventricular block	Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel.
UN	17255138_C105934_11_1720_1729_celecoxib_D009203_11_1701_1704_AMI	The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.
CID	17255138_C116926_11_1805_1814_rofecoxib_D009203_11_1701_1704_AMI	The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.
CID	17255138_C116926_8_1230_1239_rofecoxib_D009203_8_1172_1175_AMI	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
UN	17255138_D000082_3_506_519_acetaminophen_D006471_3_433_444_GI bleeding	We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.
UN	17255138_D000082_8_1186_1199_acetaminophen_D009203_8_1172_1175_AMI	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
CID	17255138_D000894_2_324_361_non-steroidal anti-inflammatory drugs_D009203_2_188_215_acute myocardial infarction	OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).
UN	17255138_D001241_10_1625_1632_aspirin_D006471_10_1684_1695_GI bleeding	CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.
UN	17255138_D001241_8_1209_1216_aspirin_D009203_8_1172_1175_AMI	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
UN	17255138_D004008_8_1316_1326_diclofenac_D009203_8_1172_1175_AMI	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
UN	17255138_D007052_8_1349_1358_ibuprofen_D009203_8_1172_1175_AMI	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
CID	17255138_D009288_10_1634_1642_naproxen_D006471_10_1684_1695_GI bleeding	CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.
CID	17255138_D009288_10_1634_1642_naproxen_D009203_10_1680_1683_AMI	CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.
UN	17255138_D052246_3_474_490_COX-2 inhibitors_D006471_3_433_444_GI bleeding	We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.
CID	17255138_D052246_3_474_490_COX-2 inhibitors_D009203_3_425_428_AMI	We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.
CID	17255138_D052246_2_227_243_COX-2 inhibitors_D009203_2_217_220_AMI	OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).
UN	17297207_D001663_4_583_592_bilirubin_D007565_4_671_679_jaundice	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
UN	17297207_D001663_4_583_592_bilirubin_D016778_4_651_665_severe malaria	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
UN	17297207_D005947_4_708_716_dextrose_D007565_4_671_679_jaundice	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
UN	17297207_D005947_4_708_716_dextrose_D016778_4_651_665_severe malaria	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
UN	17297207_D011188_4_605_614_potassium_D007565_4_671_679_jaundice	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
UN	17297207_D011188_4_605_614_potassium_D016778_4_651_665_severe malaria	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
UN	17297207_D011188_9_1378_1387_potassium_D018879_9_1311_1314_PVC	Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L.
UN	17297207_D011802_11_1472_1481_quinidine_D001145_11_1520_1530_arrhythmic	Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.
UN	17297207_D011802_11_1472_1481_quinidine_D018879_11_1654_1657_PVC	Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.
UN	17297207_D011803_1_219_226_quinine_D001145_1_158_168_arrhythmia	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.
UN	17297207_D011803_0_0_7_Quinine_D001145_0_16_26_arrhythmia	Quinine-induced arrhythmia in a patient with severe malaria.
UN	17297207_D011803_12_1688_1695_quinine_D003967_12_1935_1943_diarrhea	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
UN	17297207_D011803_12_1688_1695_quinine_D006331_12_1821_1835_heart diseases	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
UN	17297207_D011803_12_1688_1695_quinine_D007008_12_1875_1886_hypokalemia	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
UN	17297207_D011803_4_688_695_quinine_D007565_4_671_679_jaundice	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
UN	17297207_D011803_12_1688_1695_quinine_D008288_12_1947_1954_malaria	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
UN	17297207_D011803_6_833_840_quinine_D012848_6_1006_1022_sinoatrial block	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.
UN	17297207_D011803_12_1688_1695_quinine_D014839_12_1919_1927_vomiting	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
UN	17297207_D011803_12_1688_1695_quinine_D014883_12_1853_1873_electrolyte disorder	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
UN	17297207_D011803_0_0_7_Quinine_D016778_0_45_59_severe malaria	Quinine-induced arrhythmia in a patient with severe malaria.
UN	17297207_D011803_4_688_695_quinine_D016778_4_651_665_severe malaria	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
CID	17297207_D011803_1_219_226_quinine_D018879_1_170_203_premature ventricular contraction	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.
UN	17346443_D003300_1_256_262_copper_D001523_1_320_365_hepatic, neurologic and psychiatric disorders	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders.
UN	17346443_D003300_1_222_228_copper_D006527_1_159_175_Wilson's disease	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders.
UN	17346443_D003300_1_256_262_copper_D009422_1_320_365_hepatic, neurologic and psychiatric disorders	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders.
UN	17346443_D003300_1_256_262_copper_D056486_1_320_365_hepatic, neurologic and psychiatric disorders	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders.
UN	17346443_D010396_0_0_13_Penicillamine_D001008_0_126_133_anxiety	Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.
UN	17346443_D010396_4_963_976_penicillamine_D006527_4_929_945_Wilson's disease	In our case the therapy with zinc acetate represented an effective treatment for a Wilson's disease patient in which penicillamine-related side effects appeared.
UN	17346443_D010396_6_1251_1264_penicillamine_D006527_6_1234_1250_Wilson's disease	Since most of Wilson's disease penicillamine-treated patients do not seem to develop this skin lesion, it could be conceivable that a specific genetic factor is involved in drug response.
UN	17346443_D010396_6_1251_1264_penicillamine_D012871_6_1310_1321_skin lesion	Since most of Wilson's disease penicillamine-treated patients do not seem to develop this skin lesion, it could be conceivable that a specific genetic factor is involved in drug response.
CID	17346443_D010396_3_667_680_penicillamine_D017512_3_723_743_lichenoid dermatitis	During the follow-up of our patient, penicillamine was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects.
CID	17346443_D010396_0_0_13_Penicillamine_D017512_0_22_42_lichenoid dermatitis	Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.
UN	17346443_D019345_0_58_70_zinc acetate_D001008_0_126_133_anxiety	Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.
UN	17346443_D019345_4_875_887_zinc acetate_D006527_4_929_945_Wilson's disease	In our case the therapy with zinc acetate represented an effective treatment for a Wilson's disease patient in which penicillamine-related side effects appeared.
UN	17346443_D019345_0_58_70_zinc acetate_D006527_0_76_90_Wilson disease	Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.
UN	17346443_D019345_0_58_70_zinc acetate_D017512_0_22_42_lichenoid dermatitis	Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.
UN	17351238_D001285_4_475_492_atropine sulphate_D007022_4_414_436_drop in blood pressure	Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by atropine sulphate and a fluid challenge.
CID	17351238_D005996_4_377_380_GTN_D007022_4_414_436_drop in blood pressure	Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by atropine sulphate and a fluid challenge.
CID	17351238_D005996_0_56_59_GTN_D007022_0_11_33_drop in blood pressure	A dramatic drop in blood pressure following prehospital GTN administration.
UN	1735570_D014294_8_1079_1091_trimethaphan_D001919_8_1145_1156_bradycardia	The trimethaphan-induced hypotension was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion.
CID	1735570_D014294_8_1079_1091_trimethaphan_D007022_8_1100_1111_hypotension	The trimethaphan-induced hypotension was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion.
CID	1735570_D014294_8_1079_1091_trimethaphan_D013610_8_1210_1221_tachycardia	The trimethaphan-induced hypotension was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion.
CID	17356399_C042705_0_84_100_PEG-asparaginase_D020301_0_25_43_cerebral vasospasm	Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.
UN	17356399_C042705_0_84_100_PEG-asparaginase_D020803_0_0_20_Acute encephalopathy	Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.
UN	17356399_C042705_0_84_100_PEG-asparaginase_D054198_0_149_177_acute lymphoblastic leukemia	Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.
CID	17356399_D003561_2_571_581_cytarabine_D001037_2_394_401_aphasia	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.
CID	17356399_D003561_2_571_581_cytarabine_D006212_2_417_438_visual hallucinations	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.
CID	17356399_D003561_2_571_581_cytarabine_D014549_2_403_415_incontinence	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.
CID	17356399_D003561_2_571_581_cytarabine_D018908_2_456_464_weakness	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.
CID	17356399_D003561_0_117_127_cytarabine_D020301_0_25_43_cerebral vasospasm	Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.
CID	17356399_D003561_2_571_581_cytarabine_D020301_2_478_496_cerebral vasospasm	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.
UN	17356399_D003561_2_571_581_cytarabine_D020803_2_340_360_acute encephalopathy	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.
UN	17356399_D003561_0_117_127_cytarabine_D020803_0_0_20_Acute encephalopathy	Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.
UN	17356399_D003561_0_117_127_cytarabine_D054198_0_149_177_acute lymphoblastic leukemia	Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.
UN	17379047_C081489_5_1012_1015_VAL_C562386_5_878_900_essential hypertension	Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.
UN	17379047_C081489_3_602_611_valsartan_C562386_3_706_728_essential hypertension	OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension.
UN	17379047_C081489_0_14_23_valsartan_D006973_0_195_207_hypertensive	Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
UN	17379047_C081489_17_2636_2639_VAL_D007008_17_2609_2620_hypokalemia	The incidence of hypokalemia was lower with VAL/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%).
UN	17379047_D006852_3_621_640_hydrochlorothiazide_C562386_3_706_728_essential hypertension	OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension.
UN	17379047_D006852_5_1031_1035_HCTZ_C562386_5_878_900_essential hypertension	Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.
UN	17379047_D006852_0_24_43_hydrochlorothiazide_D006973_0_195_207_hypertensive	Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
CID	17379047_D006852_17_2640_2644_HCTZ_D007008_17_2609_2620_hypokalemia	The incidence of hypokalemia was lower with VAL/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%).
CID	17379047_D006852_20_3139_3143_HCTZ_D007008_20_3122_3133_hypokalemia	CONCLUSIONS: In this study population, combination therapies with VAL/HCTZ were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less hypokalemia than HCTZ alone.
CID	17384765_D004113_0_0_8_Succimer_D003072_0_114_134_cognitive impairment	Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure.
CID	17384765_D004113_6_1163_1171_succimer_D003072_6_1250_1285_cognitive and affective dysfunction	In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen.
UN	17384765_D004113_3_659_667_succimer_D007855_3_720_732_Pb poisoning	OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with succimer, a widely used chelating agent for the treatment of Pb poisoning.
UN	17384765_D004113_6_1163_1171_succimer_D019964_6_1250_1285_cognitive and affective dysfunction	In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen.
UN	17384765_D007854_6_1216_1218_Pb_D003072_6_1250_1285_cognitive and affective dysfunction	In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen.
UN	17384765_D007854_7_1507_1509_Pb_D003072_7_1481_1499_cognitive deficits	CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate cognitive deficits due to Pb exposure.
UN	17384765_D007854_0_153_157_lead_D003072_0_114_134_cognitive impairment	Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure.
UN	17384765_D007854_3_628_630_Pb_D007855_3_720_732_Pb poisoning	OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with succimer, a widely used chelating agent for the treatment of Pb poisoning.
CID	17384765_D007854_4_743_745_Pb_D007859_4_772_850_impairments in learning, attention, inhibitory control, and arousal regulation	RESULTS: Pb exposure produced lasting impairments in learning, attention, inhibitory control, and arousal regulation, paralleling the areas of dysfunction seen in Pb-exposed children.
CID	17384765_D007854_4_743_745_Pb_D019958_4_772_850_impairments in learning, attention, inhibitory control, and arousal regulation	RESULTS: Pb exposure produced lasting impairments in learning, attention, inhibitory control, and arousal regulation, paralleling the areas of dysfunction seen in Pb-exposed children.
UN	17384765_D007854_6_1216_1218_Pb_D019964_6_1250_1285_cognitive and affective dysfunction	In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen.
UN	17445520_D002110_4_677_685_caffeine_D001008_4_749_756_anxiety	In a randomized double-blind experiment performed in 2 occasions 7 days apart, 480 mg caffeine and a caffeine-free (placebo) solution were administered in a coffee form and anxiety scales were applied before and after each test.
UN	17445520_D002110_1_348_356_caffeine_D001523_1_235_251_Mental Disorders	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.
UN	17445520_D002110_6_1103_1111_caffeine_D003865_6_1076_1079_MDP	The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.
UN	17445520_D002110_6_1103_1111_caffeine_D003865_6_1136_1138_MD	The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.
UN	17445520_D002110_0_0_8_Caffeine_D003866_0_46_56_depression	Caffeine challenge test in panic disorder and depression with panic attacks.
CID	17445520_D002110_0_0_8_Caffeine_D016584_0_27_41_panic disorder	Caffeine challenge test in panic disorder and depression with panic attacks.
CID	17445520_D002110_1_348_356_caffeine_D016584_1_323_336_panic attacks	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.
CID	17445520_D002110_7_1202_1210_caffeine_D016584_7_1166_1178_panic attack	No panic attack was observed after the caffeine-free solution intake.
CID	17445520_D002110_5_996_1004_caffeine_D016584_5_966_978_panic attack	A total of 58.6% (n = 17) of patients with PD, 44.4% (n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).
CID	17445520_D002110_6_1103_1111_caffeine_D016584_6_1076_1079_MDP	The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.
CID	17484470_D011433_7_980_991_propranolol_D006333_7_951_964_heart failure	Acute heart failure was induced by propranolol and volume loading after weaning from cardiopulmonary bypass; an absence of MR was confirmed by echocardiography.
UN	17484470_D011433_7_980_991_propranolol_D008944_7_1068_1070_MR	Acute heart failure was induced by propranolol and volume loading after weaning from cardiopulmonary bypass; an absence of MR was confirmed by echocardiography.
UN	17496739_C085143_2_560_583_piperacillin/tazobactam_D001987_2_612_626_bronchiectasis	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.
CID	17496739_C085143_2_560_583_piperacillin/tazobactam_D003221_2_474_483_confusion	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.
CID	17496739_C085143_6_984_1007_piperacillin/tazobactam_D004830_6_938_942_GTCS	Despite the use of antiepileptic agents, another GTCS episode recurred after the sixth dose of piperacillin/tazobactam.
CID	17496739_C085143_2_560_583_piperacillin/tazobactam_D004830_2_537_541_GTCS	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.
UN	17496739_C085143_2_560_583_piperacillin/tazobactam_D007676_2_315_338_end-stage renal disease	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.
UN	17496739_C085143_0_0_23_Piperacillin/tazobactam_D012640_0_32_39_seizure	Piperacillin/tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.
CID	17496739_C085143_2_560_583_piperacillin/tazobactam_D014202_2_429_435_tremor	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.
UN	17496739_C085143_2_560_583_piperacillin/tazobactam_D060085_2_632_651_secondary infection	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.
UN	17496739_D000641_3_712_719_ammonia_D007964_3_731_743_leukocytosis	The laboratory data revealed normal plasma electrolyte and ammonia levels but leukocytosis.
UN	17496739_D010878_10_1419_1431_piperacillin_D001927_10_1440_1454_encephalopathy	CAPD is inefficient in removing piperacillin, whereas hemodialysis can rapidly terminate the piperacillin-induced encephalopathy.
UN	17496739_D010878_9_1200_1212_Piperacillin_D001927_9_1221_1235_encephalopathy	Piperacillin-induced encephalopathy should be considered in any uremic patients with unexplained neurological manifestations.
UN	17496739_D010878_9_1200_1212_Piperacillin_D006463_9_1264_1270_uremic	Piperacillin-induced encephalopathy should be considered in any uremic patients with unexplained neurological manifestations.
UN	17496739_D010878_1_196_208_piperacillin_D020258_1_166_179_neurotoxicity	Despite popular use of piperacillin, the dire neurotoxicity associated with piperacillin still goes unrecognized, leading to a delay in appropriate management.
CID	17554526_D003042_0_50_57_cocaine_D001925_0_0_25_Impaired fear recognition	Impaired fear recognition in regular recreational cocaine users.
UN	17554526_D018817_10_1573_1580_ecstasy_D001925_10_1450_1477_deficit in fear recognition	The selective deficit in fear recognition accuracy manifested by the RC group cannot be explained by the subacute effects of cocaine, or ecstasy, because recent and less recent users of these drugs within this group were similarly impaired.
UN	1756784_D002118_6_1021_1028_calcium_D009422_6_1076_1091_neuronal damage	Nissl-staining and antibodies against the neuron-specific calcium-binding protein, parvalbumin, served to detect neuronal damage in SNR.
CID	1756784_D010862_0_50_61_pilocarpine_D001930_0_0_42_Damage of substantia nigra pars reticulata	Damage of substantia nigra pars reticulata during pilocarpine-induced status epilepticus in the rat: immunohistochemical study of neurons, astrocytes and serum-protein extravasation.
CID	1756784_D010862_3_589_600_pilocarpine_D013226_3_533_551_status epilepticus	In this study, status epilepticus was induced by systemic injection of pilocarpine in rats.
CID	1756784_D010862_0_50_61_pilocarpine_D013226_0_70_88_status epilepticus	Damage of substantia nigra pars reticulata during pilocarpine-induced status epilepticus in the rat: immunohistochemical study of neurons, astrocytes and serum-protein extravasation.
CID	17572393_D002330_2_472_476_BCNU_D054220_2_485_503_cortical dysplasia	This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses.
CID	17572393_D002330_0_94_98_BCNU_D054220_0_107_125_cortical dysplasia	Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia.
CID	17572393_D002330_6_1117_1121_BCNU_D054220_6_1130_1148_cortical dysplasia	Histopathologically, typical findings were observed in the cerebella from the control groups, but the findings consistent with early embryonic development were noted in BCNU-exposed cortical dysplasia group.
UN	17572393_D008550_2_446_455_melatonin_D054220_2_485_503_cortical dysplasia	This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses.
UN	1760851_C032976_0_59_92_N-(2-hydroxypropyl)methacrylamide_D066126_0_8_22_cardiotoxicity	Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.
CID	1760851_D004317_0_26_37_doxorubicin_D066126_0_8_22_cardiotoxicity	Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.
CID	1760851_D004317_6_1366_1369_DOX_D066126_6_1378_1392_cardiotoxicity	Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity.
CID	1760851_D004317_1_239_250_doxorubicin_D066126_1_213_227_cardiotoxicity	A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.
CID	17721298_D016578_4_410_423_crack cocaine_D003320_4_379_393_corneal ulcers	RESULTS: Four patients with corneal ulcers associated with crack cocaine use were reviewed.
CID	17721298_D016578_0_43_56_crack cocaine_D003320_0_0_14_Corneal ulcers	Corneal ulcers associated with aerosolized crack cocaine use.
CID	17721298_D016578_10_927_940_crack cocaine_D003320_10_987_1001_corneal ulcers	CONCLUSIONS: Aerosolized crack cocaine use can be associated with the development of corneal ulcers.
CID	1779253_D002211_4_714_723_capsaicin_D008413_4_758_766_mastitis	Nineteen patients (48.7%) substantially improved after the 8-week trial; 5 (12.8%) discontinued therapy due to side-effects such as intolerable capsaicin-induced burning sensations (4) or mastitis (1); 15 (38.5%) reported no benefit.
UN	1779253_D002211_9_1424_1433_capsaicin_D051474_9_1437_1440_PHN	If confirmed in controlled trials, the long-term results of this open, non-randomized study might indicate that the analgesic effect of capsaicin in PHN is mediated by both interference with neuropeptide metabolism and morphological changes (perhaps degeneration) of nociceptive afferents.
UN	1779253_D002211_0_15_24_capsaicin_D051474_0_36_59_post-herpetic neuralgia	Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course.
UN	17828434_C002647_4_299_302_MIP_D012640_4_422_430_seizures	This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine-induced seizures model.
UN	17828434_D007294_4_383_391_inositol_D012640_4_422_430_seizures	This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine-induced seizures model.
UN	17828434_D008094_4_368_375_lithium_D012640_4_422_430_seizures	This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine-induced seizures model.
CID	17828434_D010862_4_402_413_pilocarpine_D012640_4_422_430_seizures	This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine-induced seizures model.
UN	17879100_D001241_4_643_650_aspirin_D005334_4_692_697_fever	He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation.
UN	17879100_D007052_4_678_687_ibuprofen_D005334_4_692_697_fever	He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation.
UN	17879217_D012293_0_0_10_Rifampicin_D004696_0_66_93_staphylococcal endocarditis	Rifampicin-associated segmental necrotizing glomerulonephritis in staphylococcal endocarditis.
CID	17879217_D012293_1_173_183_rifampicin_D005921_1_117_135_glomerulonephritis	Segmental necrotising glomerulonephritis has been reported as complication of rifampicin therapy in patients receiving treatment for tuberculosis.
CID	17879217_D012293_3_563_573_rifampicin_D005921_3_519_537_glomerulonephritis	We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.
CID	17879217_D012293_0_0_10_Rifampicin_D005921_0_44_62_glomerulonephritis	Rifampicin-associated segmental necrotizing glomerulonephritis in staphylococcal endocarditis.
UN	17879217_D012293_2_351_361_rifampicin_D007239_2_267_277_infections	Changing epidemiology of infections such as infective endocarditis (IE) has led to an increase in the use of rifampicin for Staphylococcal infections.
UN	17879217_D012293_2_351_361_rifampicin_D013203_2_366_391_Staphylococcal infections	Changing epidemiology of infections such as infective endocarditis (IE) has led to an increase in the use of rifampicin for Staphylococcal infections.
UN	17879217_D012293_0_0_10_Rifampicin_D013203_0_66_93_staphylococcal endocarditis	Rifampicin-associated segmental necrotizing glomerulonephritis in staphylococcal endocarditis.
UN	17879217_D012293_1_173_183_rifampicin_D014376_1_228_240_tuberculosis	Segmental necrotising glomerulonephritis has been reported as complication of rifampicin therapy in patients receiving treatment for tuberculosis.
CID	17879217_D012293_3_563_573_rifampicin_D058186_3_462_481_acute renal failure	We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.
UN	17954033_D019259_2_309_319_lamivudine_D006509_2_251_262_hepatitis B	Recent studies show that the YMDD motif mutants (resistant hepatitis B virus) occur as natural genome variability in lamivudine-untreated chronic hepatitis B patients.
UN	17954033_D019259_4_584_594_lamivudine_D019694_4_525_544_chronic hepatitis B	PATIENTS AND METHODS: A total of 77 chronic hepatitis B patients who had not been treated with lamivudine were included in the study.
UN	17954033_D019259_2_309_319_lamivudine_D019694_2_330_349_chronic hepatitis B	Recent studies show that the YMDD motif mutants (resistant hepatitis B virus) occur as natural genome variability in lamivudine-untreated chronic hepatitis B patients.
UN	17954033_D019259_3_430_440_lamivudine_D019694_3_451_470_chronic hepatitis B	In this study we aimed to determine the rate of YMDD motif mutants in lamivudine-untreated chronic hepatitis B patients in Iran.
UN	17954033_D019259_0_30_40_lamivudine_D019694_0_73_108_chronic hepatitis B virus infection	Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection.
UN	17954033_D019259_1_122_132_Lamivudine_D019694_1_162_181_chronic hepatitis B	BACKGROUND: Lamivudine is used for the treatment of chronic hepatitis B patients.
UN	17954033_D019259_12_1442_1452_lamivudine_D019694_12_1463_1482_chronic hepatitis B	CONCLUSION: Although the natural occurrence of YMDD motif mutants in lamivudine-untreated patients with chronic hepatitis B has been reported, these mutants were not detected in Iranian lamivudine-untreated chronic hepatitis B patients.
CID	18025637_D005473_1_102_112_fluoxetine_D006973_1_131_143_hypertension	A case of branch retinal vein occlusion associated with fluoxetine-induced secondary hypertension is described.
CID	18025637_D005473_0_34_44_fluoxetine_D012170_0_7_29_retinal vein occlusion	Branch retinal vein occlusion and fluoxetine.
CID	18025637_D005473_1_102_112_fluoxetine_D012170_1_63_85_retinal vein occlusion	A case of branch retinal vein occlusion associated with fluoxetine-induced secondary hypertension is described.
UN	18025637_D012701_2_207_216_serotonin_D006973_2_321_333_hypertension	Although an infrequent complication of selective serotonin reuptake inhibitor therapy, it is important that ophthalmologists are aware that these agents can cause hypertension because this class of drugs is widely prescribed.
UN	18165598_C116926_5_959_968_rofecoxib_D010146_5_1003_1007_pain	RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.
UN	18165598_D002045_5_947_958_bupivacaine_D010146_5_1003_1007_pain	RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.
UN	18165598_D002045_5_1127_1138_bupivacaine_D010146_5_1181_1185_pain	RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.
CID	18165598_D002045_2_357_368_bupivacaine_D010149_2_469_487_postoperative pain	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.
UN	18165598_D002045_8_1625_1636_bupivacaine_D017695_8_1676_1689_tissue injury	CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.
UN	18165598_D008012_0_44_53_lidocaine_D010146_0_118_122_pain	The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.
UN	18165598_D015232_8_1723_1727_PGE2_D010146_8_1743_1747_pain	CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.
UN	18165598_D015232_5_1198_1202_PGE2_D010146_5_1181_1185_pain	RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.
UN	18165598_D015232_2_378_394_prostaglandin E2_D010149_2_469_487_postoperative pain	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.
UN	18165598_D015232_8_1723_1727_PGE2_D017695_8_1676_1689_tissue injury	CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.
CID	18189308_D003520_3_586_602_cyclophosphamide_D003556_3_554_574_bladder inflammation	The present studies examine the expression and regulation of another receptor known to bind NGF, p75(NTR), after various durations of bladder inflammation induced by cyclophosphamide (CYP).
CID	18189308_D003520_0_78_94_cyclophosphamide_D003556_0_103_111_cystitis	p75NTR expression in rat urinary bladder sensory neurons and spinal cord with cyclophosphamide-induced cystitis.
CID	18189308_D003520_6_1112_1115_CYP_D003556_6_1124_1132_cystitis	Quantitative, real-time polymerase chain reaction also demonstrated significant increases (P < or = 0.01) in p75(NTR) mRNA in DRG with intermediate and chronic CYP-induced cystitis.
CID	18189308_D003520_4_610_613_CYP_D003556_4_622_630_cystitis	CYP-induced cystitis increased (P < or = 0.001) p75(NTR) expression in the superficial lateral and medial dorsal horn in L1-L2 and L6-S1 spinal segments.
CID	18189308_D003520_5_895_898_CYP_D003556_5_907_915_cystitis	The number of p75(NTR)-immunoreactive (-IR) cells in the lumbosacral dorsal root ganglia (DRG) also increased (P < or = 0.05) with CYP-induced cystitis (acute, intermediate, and chronic).
UN	18189308_D014443_2_328_336_tyrosine_D003556_2_390_418_urinary bladder inflammation	Previous studies have examined the expression and regulation of tyrosine kinase receptors (Trks) in micturition reflexes with urinary bladder inflammation.
CID	18340638_D001379_2_139_151_azathioprine_D000740_2_160_166_anemia	The side effects of azathioprine include anemia, which has been attributed to bone marrow suppression.
CID	18340638_D001379_9_1275_1287_azathioprine_D000740_9_1296_1302_anemia	CONCLUSIONS: Azathioprine triggers suicidal erythrocyte death, an effect presumably contributing to azathioprine-induced anemia.
UN	18340638_D010718_3_353_371_phosphatidylserine_D000740_3_237_243_anemia	Alternatively, anemia could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage.
UN	18341442_C026098_0_0_13_Levetiracetam_C562694_0_78_97_idiopathic epilepsy	Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy.
UN	18341442_C026098_1_173_186_levetiracetam_C562694_1_282_301_idiopathic epilepsy	OBJECTIVE: To assess pharmacokinetics, efficacy, and tolerability of oral levetiracetam administered as an adjunct to phenobarbital treatment in cats with poorly controlled suspected idiopathic epilepsy.
UN	18341442_C026098_10_1601_1614_levetiracetam_C562694_10_1713_1732_idiopathic epilepsy	CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that levetiracetam is well tolerated in cats and may be useful as an adjunct to phenobarbital treatment in cats with idiopathic epilepsy.
UN	18341442_C026098_8_1213_1226_levetiracetam_D012640_8_1232_1240_seizures	Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).
UN	18341442_C026098_8_1320_1333_levetiracetam_D012640_8_1282_1289_seizure	Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).
UN	18341442_C026098_6_896_909_levetiracetam_D012640_6_845_852_Seizure	Seizure frequencies before and after initiation of levetiracetam treatment were compared, and adverse effects were recorded.
UN	18341442_D010634_1_217_230_phenobarbital_C562694_1_282_301_idiopathic epilepsy	OBJECTIVE: To assess pharmacokinetics, efficacy, and tolerability of oral levetiracetam administered as an adjunct to phenobarbital treatment in cats with poorly controlled suspected idiopathic epilepsy.
UN	18341442_D010634_0_31_44_phenobarbital_C562694_0_78_97_idiopathic epilepsy	Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy.
UN	18341442_D010634_3_440_453_phenobarbital_C562694_3_388_407_idiopathic epilepsy	ANIMALS: 12 cats suspected to have idiopathic epilepsy that was poorly controlled with phenobarbital or that had unacceptable adverse effects when treated with phenobarbital.
UN	18341442_D010634_10_1676_1689_phenobarbital_C562694_10_1713_1732_idiopathic epilepsy	CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that levetiracetam is well tolerated in cats and may be useful as an adjunct to phenobarbital treatment in cats with idiopathic epilepsy.
CID	1837756_D000639_2_259_272_amitriptyline_D010259_2_183_191_paranoid	Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline are reported here.
UN	1837756_D004298_5_851_859_dopamine_D010259_5_773_781_paranoia	Although the pharmacology and neurobiology of paranoia remain cryptic, several mechanisms, including 5HT3 receptor-mediated dopamine release, beta-noradrenergic receptor downregulation, or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia (possibly in lateral orbitofrontal or anterior cingulate circuits), might apply to this phenomenon.
CID	1837756_D005473_2_244_254_fluoxetine_D010259_2_183_191_paranoid	Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline are reported here.
UN	1837756_D012701_4_696_705_serotonin_D003866_4_450_470_depressive disorders	Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors.
UN	1837756_D012701_2_214_223_serotonin_D010259_2_183_191_paranoid	Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline are reported here.
UN	1837756_D012701_4_696_705_serotonin_D010259_4_657_665_paranoid	Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors.
UN	1837756_D012701_6_1163_1172_serotonin_D010259_6_1135_1143_paranoid	These cases call attention to possible paranoid exacerbations with serotonin reuptake blockers in select patients and raise neurobiological considerations regarding paranoia.
UN	1837756_D012701_4_696_705_serotonin_D011605_4_606_615_psychosis	Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors.
UN	18399341_D004837_9_1387_1398_epinephrine_D007022_9_1417_1428_hypotension	Four (10.8%) patients in the conventional group and 1 (2.7%) in the unilateral group, P= 0.17 required epinephrine infusion to treat hypotension.
UN	18422462_D000409_4_974_981_alanine_D000740_4_851_857_anemia	Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).
UN	18422462_D000409_4_974_981_alanine_D007565_4_960_968_jaundice	Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).
UN	18422462_D000409_4_974_981_alanine_D056486_4_940_949_hepatitis	Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).
UN	18422462_D018119_6_1355_1358_d4T_D005076_6_1346_1350_rash	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05).
CID	18422462_D018119_6_1355_1358_d4T_D010523_6_1383_1404_peripheral neuropathy	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05).
CID	18422462_D019829_6_1289_1292_NVP_D005076_6_1346_1350_rash	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05).
UN	18422462_D019829_6_1289_1292_NVP_D010523_6_1383_1404_peripheral neuropathy	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05).
UN	18450790_D013792_3_665_676_thalidomide_D008178_3_639_642_CLE	PATIENTS AND METHODS: Clinical and electrophysiological data in 12 female patients with CLE during treatment with thalidomide and up to 47 months after discontinuation of treatment were analysed.
UN	18450790_D013792_2_384_395_thalidomide_D008178_2_366_369_CLE	The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.
CID	18450790_D013792_0_0_11_Thalidomide_D010523_0_16_37_sensory neurotoxicity	Thalidomide and sensory neurotoxicity: a neurophysiological study.
CID	18450790_D013792_1_194_205_thalidomide_D010523_1_124_149_sensory axonal neuropathy	BACKGROUND: Recent studies confirmed a high incidence of sensory axonal neuropathy in patients treated with different doses of thalidomide.
UN	18450790_D013792_2_459_470_thalidomide_D020258_2_435_445_neurotoxic	The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.
UN	18450790_D013792_12_1579_1590_thalidomide_D020258_12_1555_1565_neurotoxic	This electrophysiological parameter provides information about subclinical neurotoxic potential of thalidomide but is not helpful in predicting the appearance of sensory symptoms.
CID	1858969_D004049_0_60_78_diethylcarbamazine_D004660_0_14_26_encephalitis	Five cases of encephalitis during treatment of loiasis with diethylcarbamazine.
CID	1858969_D004049_1_132_150_diethylcarbamazine_D004660_1_94_106_encephalitis	Five cases of encephalitis following treatment with diethylcarbamazine (DEC) were observed in Congolese patients with Loa loa filariasis.
UN	1858969_D004049_1_152_155_DEC_D005368_1_206_216_filariasis	Five cases of encephalitis following treatment with diethylcarbamazine (DEC) were observed in Congolese patients with Loa loa filariasis.
UN	1858969_D004049_0_60_78_diethylcarbamazine_D008118_0_47_54_loiasis	Five cases of encephalitis during treatment of loiasis with diethylcarbamazine.
UN	18801087_D000638_1_154_164_Amiodarone_D001145_1_176_186_arrhythmic	Amiodarone is an anti-arrhythmic drug for life-threatening tachycardia, but various adverse effects have been reported.
UN	18801087_D000638_0_0_10_Amiodarone_D006349_0_93_115_valvular heart disease	Amiodarone-related pulmonary mass and unique membranous glomerulonephritis in a patient with valvular heart disease: Diagnostic pitfall and new findings.
UN	18801087_D000638_2_446_456_amiodarone_D006349_2_312_334_valvular heart disease	Reported herein is an autopsy case of valvular heart disease, in a patient who developed a lung mass (1.5 cm in diameter) and proteinuria (2.76 g/day) after treatment with amiodarone for a long time.
UN	18801087_D000638_3_784_794_amiodarone_D008175_3_515_526_lung cancer	The lung mass was highly suspected to be lung cancer on CT and positron emission tomography, but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra-alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies, indicating that it was an amiodarone-related lesion.
UN	18801087_D000638_7_1391_1401_amiodarone_D009369_7_1433_1441_neoplasm	The present case highlights the possibility that differential diagnosis between an amiodarone-related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment.
UN	18801087_D000638_2_446_456_amiodarone_D011507_2_400_411_proteinuria	Reported herein is an autopsy case of valvular heart disease, in a patient who developed a lung mass (1.5 cm in diameter) and proteinuria (2.76 g/day) after treatment with amiodarone for a long time.
UN	18801087_D000638_1_154_164_Amiodarone_D013610_1_213_224_tachycardia	Amiodarone is an anti-arrhythmic drug for life-threatening tachycardia, but various adverse effects have been reported.
CID	18801087_D000638_7_1570_1580_amiodarone_D015433_7_1498_1527_membranous glomerulonephritis	The present case highlights the possibility that differential diagnosis between an amiodarone-related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment.
CID	18801087_D000638_0_0_10_Amiodarone_D015433_0_45_74_membranous glomerulonephritis	Amiodarone-related pulmonary mass and unique membranous glomerulonephritis in a patient with valvular heart disease: Diagnostic pitfall and new findings.
CID	18801087_D000638_7_1391_1401_amiodarone_D055370_7_1410_1426_pulmonary lesion	The present case highlights the possibility that differential diagnosis between an amiodarone-related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment.
CID	18801087_D000638_0_0_10_Amiodarone_D055370_0_19_33_pulmonary mass	Amiodarone-related pulmonary mass and unique membranous glomerulonephritis in a patient with valvular heart disease: Diagnostic pitfall and new findings.
UN	18945509_C057619_7_1178_1189_glimepiride_D003324_7_1143_1146_CAD	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
UN	18945509_C057619_7_1178_1189_glimepiride_D003924_7_1058_1073_type 2 diabetes	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
CID	18945509_D005905_7_1079_1092_glibenclamide_D003324_7_1143_1146_CAD	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
UN	18945509_D005905_7_1079_1092_glibenclamide_D003924_7_1058_1073_type 2 diabetes	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
UN	18945509_D005907_7_1164_1174_gliclazide_D003324_7_1143_1146_CAD	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
UN	18945509_D005907_7_1164_1174_gliclazide_D003924_7_1058_1073_type 2 diabetes	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
UN	18945509_D005913_7_1096_1105_glipizide_D003324_7_1143_1146_CAD	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
UN	18945509_D005913_7_1096_1105_glipizide_D003924_7_1058_1073_type 2 diabetes	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
UN	18945509_D008687_5_854_863_metformin_D003324_5_640_643_CAD	The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin.
UN	18987260_D000804_1_186_200_angiotensin II_D006973_1_313_325_hypertensive	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.
UN	18987260_D000804_1_186_200_angiotensin II_D007674_1_270_283_renal disease	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.
UN	18987260_D004317_11_1613_1616_ADR_D001284_11_1562_1569_atrophy	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.
UN	18987260_D004317_11_1613_1616_ADR_D005355_11_1601_1609_fibrosis	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.
CID	18987260_D004317_12_1686_1689_ADR_D005923_12_1698_1732_focal segmental glomerulosclerosis	CONCLUSION: Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.
UN	18987260_D004317_0_23_33_adriamycin_D006973_0_63_75_hypertensive	Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.
UN	18987260_D004317_1_342_352_adriamycin_D006973_1_313_325_hypertensive	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.
UN	18987260_D004317_1_354_357_ADR_D007674_1_359_370_nephropathy	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.
UN	18987260_D004317_0_23_33_adriamycin_D007674_0_34_45_nephropathy	Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.
UN	18987260_D004317_11_1613_1616_ADR_D007674_11_1617_1628_nephropathy	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.
UN	18987260_D004317_10_1470_1473_ADR_D007674_10_1474_1485_nephropathy	Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.
UN	18987260_D004317_12_1686_1689_ADR_D007676_12_1736_1759_end-stage renal disease	CONCLUSION: Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.
CID	18987260_D004317_10_1470_1473_ADR_D014511_10_1421_1428_uraemia	Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.
UN	18987260_D014508_10_1443_1447_urea_D007674_10_1474_1485_nephropathy	Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.
UN	18987260_D014508_10_1443_1447_urea_D014511_10_1421_1428_uraemia	Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.
UN	18987260_D019808_11_1531_1539_losartan_D001284_11_1562_1569_atrophy	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.
UN	18987260_D019808_9_1205_1213_losartan_D005355_9_1320_1341_interstitial fibrosis	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.
UN	18987260_D019808_11_1531_1539_losartan_D005355_11_1601_1609_fibrosis	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.
UN	18987260_D019808_9_1205_1213_losartan_D005921_9_1242_1260_glomerulosclerosis	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.
UN	18987260_D019808_12_1642_1650_Losartan_D005923_12_1698_1732_focal segmental glomerulosclerosis	CONCLUSION: Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.
UN	18987260_D019808_0_92_100_losartan_D006973_0_63_75_hypertensive	Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.
UN	18987260_D019808_0_92_100_losartan_D007674_0_34_45_nephropathy	Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.
UN	18987260_D019808_10_1404_1412_Losartan_D007674_10_1474_1485_nephropathy	Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.
UN	18987260_D019808_12_1642_1650_Losartan_D007676_12_1736_1759_end-stage renal disease	CONCLUSION: Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.
UN	18987260_D019808_9_1205_1213_losartan_D007676_9_1381_1402_chronic renal failure	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.
UN	18987260_D019808_9_1205_1213_losartan_D011507_9_1365_1376_proteinuria	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.
UN	18987260_D019808_8_1020_1028_losartan_D011507_8_1167_1178_proteinuria	RESULTS: Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased proteinuria.
UN	18987260_D019808_10_1404_1412_Losartan_D014511_10_1421_1428_uraemia	Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.
CID	1905439_D016595_0_72_83_misoprostol_D003693_0_0_8_Delirium	Delirium in an elderly woman possibly associated with administration of misoprostol.
CID	1905439_D016595_5_553_564_misoprostol_D003693_5_515_523_delirium	Her delirium significantly improved after misoprostol was discontinued and her mental status returned to normal within a week.
CID	1905439_D016595_6_774_785_misoprostol_D003693_6_714_722_delirium	Because no other factors related to this patient changed significantly, the delirium experienced by this patient possibly resulted from misoprostol therapy.
UN	1905439_D016595_1_85_96_Misoprostol_D006261_1_204_212_headache	Misoprostol has been associated with adverse reactions, including gastrointestinal symptoms, gynecologic problems, and headache.
CID	19108278_D004837_8_1233_1243_adrenaline_D001145_8_1252_1271_cardiac arrhythmias	Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.
CID	19108278_D006221_8_1299_1308_halothane_D001145_8_1252_1271_cardiac arrhythmias	Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.
CID	19108278_D010042_11_1743_1750_ouabain_D017180_11_1709_1732_ventricular tachycardia	Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs.
UN	19108278_D011433_8_1194_1205_propranolol_D001145_8_1252_1271_cardiac arrhythmias	Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.
UN	19108278_D011433_0_52_63_propranolol_D001145_0_85_104_cardiac arrhythmias	The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. 1.
UN	19108278_D011433_11_1666_1677_propranolol_D017180_11_1709_1732_ventricular tachycardia	Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs.
UN	19139825_D019772_0_0_9_Topotecan_D005909_0_59_71_glioblastoma	Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study.
UN	19139825_D019772_2_185_194_Topotecan_D005910_2_261_267_glioma	Topotecan is an attractive option as it exhibits growth inhibition of human glioma as well as brain penetration.
CID	19154241_D008094_5_590_597_lithium_D006934_5_622_635_hypercalcemic	PRACTICAL IMPLICATIONS: As much as 15% of lithium-treated patients become hypercalcemic.
CID	19154241_D008094_2_253_260_lithium_D006934_2_295_308_hypercalcemia	We examined the case of a lithium-treated patient who had recurrent hypercalcemia to better understand the disease process.
CID	19154241_D008094_0_10_17_lithium_D006961_0_37_56_hyperparathyroidism	Long-term lithium therapy leading to hyperparathyroidism: a case report.
UN	19154241_D008094_3_459_466_lithium_D049950_3_363_390_Primary hyperparathyroidism	CONCLUSION: Primary hyperparathyroidism is a rare but potentially life-threatening side effect of long-term lithium therapy.
UN	19178808_C071741_1_466_478_remifentanil_D006470_1_209_217_bleeding	BACKGROUND: The purpose of this study was to compare surgical conditions, including the amount of intraoperative bleeding as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled hypotension anesthesia induced by propofol-remifentanil total i.v. anesthesia (TIVA).
CID	19178808_C071741_5_1318_1330_remifentanil_D007022_5_1288_1299_hypotension	CONCLUSION: In summary, our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of remifentanil during TIVA in patients undergoing FESS.
CID	19178808_C071741_2_670_682_remifentanil_D007022_2_628_639_hypotension	METHODS: Sixty normotensive American Society of Anesthesiologists I-II adult patients undergoing FESS under controlled hypotension anesthesia caused by propofol-remifentanil-TIVA were randomly assigned into two groups: group I, FRLMA; group II, ETT.
CID	19178808_C071741_1_466_478_remifentanil_D007022_1_423_434_hypotension	BACKGROUND: The purpose of this study was to compare surgical conditions, including the amount of intraoperative bleeding as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled hypotension anesthesia induced by propofol-remifentanil total i.v. anesthesia (TIVA).
UN	19178808_D015742_1_457_465_propofol_D006470_1_209_217_bleeding	BACKGROUND: The purpose of this study was to compare surgical conditions, including the amount of intraoperative bleeding as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled hypotension anesthesia induced by propofol-remifentanil total i.v. anesthesia (TIVA).
CID	19178808_D015742_2_661_669_propofol_D007022_2_628_639_hypotension	METHODS: Sixty normotensive American Society of Anesthesiologists I-II adult patients undergoing FESS under controlled hypotension anesthesia caused by propofol-remifentanil-TIVA were randomly assigned into two groups: group I, FRLMA; group II, ETT.
CID	19178808_D015742_1_457_465_propofol_D007022_1_423_434_hypotension	BACKGROUND: The purpose of this study was to compare surgical conditions, including the amount of intraoperative bleeding as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled hypotension anesthesia induced by propofol-remifentanil total i.v. anesthesia (TIVA).
UN	19184102_D014635_1_59_72_Valproic acid_D004827_1_127_135_epilepsy	Valproic acid (VPA) is effective for the treatment of many types of epilepsy, but its use can be associated with an increase in body weight.
CID	19184102_D014635_5_736_739_VPA_D006946_5_669_685_hyperinsulinemia	The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.
CID	19184102_D014635_5_736_739_VPA_D007333_5_687_705_insulin resistance	The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.
CID	19184102_D014635_2_309_312_VPA_D009765_2_294_301_obesity	We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed obesity during VPA treatment.
UN	19184102_D014635_4_415_418_VPA_D015431_4_461_472_weight loss	After the withdrawal of VPA therapy, our patient showed a significant weight loss, a decrease of body mass index, and normalization of metabolic and endocrine parameters; moreover, ultrasound measurements showed a complete normalization.
CID	19184102_D014635_0_40_49_valproate_D065626_0_0_32_Nonalcoholic fatty liver disease	Nonalcoholic fatty liver disease during valproate therapy.
CID	19184102_D014635_2_309_312_VPA_D065626_2_254_259_NAFLD	We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed obesity during VPA treatment.
CID	19184102_D014635_5_736_739_VPA_D065626_5_786_791_NAFLD	The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.
UN	19263707_D002231_4_451_462_carbimazole_D006111_4_407_422_Graves' disease	We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis.
UN	19263707_D002231_1_71_82_carbimazole_D006980_1_155_170_hyperthyroidism	Anti-thyroid drugs, like carbimazole and propylthiouracil (PTU) are commonly prescribed for the treatment of hyperthyroidism.
UN	19263707_D002231_8_952_963_carbimazole_D014657_8_972_982_vasculitis	To the best of our knowledge this is the first ANCA positive carbimazole induced vasculitis case reported from India.
UN	19263707_D002231_4_451_462_carbimazole_D014657_4_471_481_vasculitis	We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis.
CID	19263707_D002231_0_0_11_Carbimazole_D056648_0_20_44_ANCA positive vasculitis	Carbimazole induced ANCA positive vasculitis.
UN	19263707_D011441_1_105_108_PTU_D006980_1_155_170_hyperthyroidism	Anti-thyroid drugs, like carbimazole and propylthiouracil (PTU) are commonly prescribed for the treatment of hyperthyroidism.
UN	19263707_D013956_1_46_64_Anti-thyroid drugs_D006980_1_155_170_hyperthyroidism	Anti-thyroid drugs, like carbimazole and propylthiouracil (PTU) are commonly prescribed for the treatment of hyperthyroidism.
CID	19263707_D013956_3_358_380_antithyroidmedications_D056648_3_240_305_Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications.
UN	19293073_D001241_5_883_890_aspirin_D002318_5_936_958_cardiovascular disease	STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?
UN	19293073_D001241_10_1676_1683_Aspirin_D002318_10_1708_1711_CVD	Aspirin does not seem to affect CVD mortality or all-cause mortality in either men or women.
UN	19293073_D001241_8_1492_1499_aspirin_D002318_8_1526_1529_CVD	DATA SYNTHESIS: New evidence from 1 good-quality RCT, 1 good-quality meta-analysis, and 2 fair-quality subanalyses of RCTs demonstrates that aspirin use reduces the number of CVD events in patients without known CVD.
UN	19293073_D001241_14_2151_2158_aspirin_D002318_14_2189_2192_CVD	LIMITATIONS: New evidence on aspirin for the primary prevention of CVD is limited.
UN	19293073_D001241_2_348_355_aspirin_D003327_2_398_420_coronary heart disease	In 2002, the U.S. Preventive Services Task Force (USPSTF) strongly recommended that clinicians discuss aspirin with adults who are at increased risk for coronary heart disease.
UN	19293073_D001241_11_1780_1787_aspirin_D006470_11_1840_1848_bleeding	The use of aspirin for primary prevention increases the risk for major bleeding events, primarily gastrointestinal bleeding events, in both men and women.
UN	19293073_D001241_18_2548_2555_Aspirin_D006470_18_2591_2599_bleeding	Aspirin use increases the risk for serious bleeding events.
CID	19293073_D001241_6_1169_1176_aspirin_D006471_6_1186_1211_gastrointestinal bleeding	Does aspirin increase gastrointestinal bleeding or hemorrhagic strokes?
UN	19293073_D001241_17_2468_2475_Aspirin_D009203_17_2497_2518_myocardial infarction	CONCLUSION: Aspirin reduces the risk for myocardial infarction in men and strokes in women.
UN	19293073_D001241_3_477_484_aspirin_D009203_3_515_537_myocardial infarctions	PURPOSE: To determine the benefits and harms of taking aspirin for the primary prevention of myocardial infarctions, strokes, and death.
CID	19293073_D001241_12_1980_1987_aspirin_D020300_12_1955_1974_hemorrhagic strokes	Men have an increased risk for hemorrhagic strokes with aspirin use.
CID	19293073_D001241_6_1169_1176_aspirin_D020300_6_1215_1234_hemorrhagic strokes	Does aspirin increase gastrointestinal bleeding or hemorrhagic strokes?
CID	19293073_D001241_17_2468_2475_Aspirin_D020521_17_2530_2537_strokes	CONCLUSION: Aspirin reduces the risk for myocardial infarction in men and strokes in women.
CID	19293073_D001241_6_1169_1176_aspirin_D020521_6_1215_1234_hemorrhagic strokes	Does aspirin increase gastrointestinal bleeding or hemorrhagic strokes?
CID	19293073_D001241_12_1980_1987_aspirin_D020521_12_1955_1974_hemorrhagic strokes	Men have an increased risk for hemorrhagic strokes with aspirin use.
CID	19338378_C031942_9_1611_1621_argatroban_D006470_9_1597_1605_bleeding	Major bleeding with argatroban is 0-10% in the non-interventional setting and 0-5.8% periprocedurally.
UN	19338378_C031942_3_504_514_argatroban_D008107_3_572_590_hepatic impairment	The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds).
UN	19338378_C031942_7_1205_1215_argatroban_D009765_7_1345_1352_obesity	For PCI, argatroban has not been investigated in hepatically impaired patients; dose adjustment is unnecessary for adult age, sex, race/ethnicity or obesity, and lesser doses may be adequate with concurrent glycoprotein IIb/IIIa inhibition.
UN	19338378_C031942_0_75_85_argatroban_D013921_0_113_129_thrombocytopenia	Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.
UN	19338378_C031942_3_504_514_argatroban_D013921_3_523_526_HIT	The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds).
UN	19338378_C031942_11_1876_1886_argatroban_D013921_11_1898_1901_HIT	Improved familiarity of healthcare professionals with argatroban therapy in HIT, including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e.g. fewer thromboses) or its treatment (e.g. fewer argatroban medication errors).
UN	19338378_C031942_2_454_464_argatroban_D013921_2_476_479_HIT	The objective of this review is to summarize practical considerations of argatroban therapy in HIT.
UN	19338378_C031942_1_131_141_Argatroban_D013927_1_235_245_thrombosis	Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).
UN	19338378_D006493_1_249_256_heparin_D013921_1_265_281_thrombocytopenia	Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).
UN	19338378_D006493_0_97_104_heparin_D013921_0_113_129_thrombocytopenia	Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.
UN	19338378_D006493_1_249_256_heparin_D013927_1_235_245_thrombosis	Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).
UN	19392810_D003932_4_393_399_heroin_D002544_4_359_374_ischemic stroke	RESULTS: A 33-year-old man presented with rhabdomyolysis and cerebral ischemic stroke after intravenous heroin.
UN	19392810_D003932_0_46_52_heroin_D002544_0_25_40_ischemic stroke	Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male under methadone maintenance therapy.
UN	19392810_D003932_11_856_862_heroin_D002544_11_918_933_ischemic stroke	CONCLUSION: Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke.
CID	19392810_D003932_13_1051_1057_heroin_D012206_13_1066_1080_rhabdomyolysis	Hypotheses of heroin-related rhabdomyolysis and stroke in heroin abusers are discussed.
CID	19392810_D003932_11_856_862_heroin_D012206_11_899_913_rhabdomyolysis	CONCLUSION: Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke.
CID	19392810_D003932_0_46_52_heroin_D012206_0_0_14_Rhabdomyolysis	Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male under methadone maintenance therapy.
CID	19392810_D003932_4_393_399_heroin_D012206_4_331_345_rhabdomyolysis	RESULTS: A 33-year-old man presented with rhabdomyolysis and cerebral ischemic stroke after intravenous heroin.
CID	19392810_D003932_13_1095_1101_heroin_D020521_13_1085_1091_stroke	Hypotheses of heroin-related rhabdomyolysis and stroke in heroin abusers are discussed.
UN	19392810_D008691_11_842_851_methadone_D002544_11_918_933_ischemic stroke	CONCLUSION: Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke.
UN	19392810_D008691_0_74_83_methadone_D002544_0_25_40_ischemic stroke	Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male under methadone maintenance therapy.
CID	19392810_D008691_11_842_851_methadone_D012206_11_899_913_rhabdomyolysis	CONCLUSION: Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke.
UN	19419794_C005177_5_739_757_L-DOPA+benserazide_D004409_5_793_804_dyskinesias	Treatment with L-DOPA+benserazide (12 weeks) resulted in less severe dyskinesias in CB1 KO than in WT mice.
UN	19419794_D004298_6_943_945_DA_D004409_6_981_992_dyskinesias	The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and DA lesion, and reduced L-DOPA-induced dyskinesias.
CID	19419794_D007980_6_966_972_L-DOPA_D004409_6_981_992_dyskinesias	The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and DA lesion, and reduced L-DOPA-induced dyskinesias.
CID	19419794_D007980_7_1123_1129_L-DOPA_D004409_7_1138_1149_dyskinesias	These results suggest that activation of CB1 receptors offers neuroprotection against dopaminergic lesion and the development of L-DOPA-induced dyskinesias.
UN	19419794_D016627_0_27_44_6-hydroxydopamine_D004409_0_79_90_dyskinesias	Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors.
UN	1943082_D005978_6_771_782_glutathione_D007511_6_804_812_ischemia	There was no change in hepatic tissue total glutathione following intestinal ischemia-reperfusion injury.
UN	1943082_D005978_6_771_782_glutathione_D015427_6_813_831_reperfusion injury	There was no change in hepatic tissue total glutathione following intestinal ischemia-reperfusion injury.
CID	19447152_D010042_8_1327_1334_ouabain_D001714_8_1343_1348_mania	In conclusion, ouabain-induced mania-like behavior may provide a useful animal model to test the hypothesis of the involvement of oxidative stress in bipolar disorder.
CID	19447152_D010042_0_33_40_ouabain_D001714_0_16_21_mania	Animal model of mania induced by ouabain: Evidence of oxidative stress in submitochondrial particles of the rat brain.
UN	19447152_D010042_6_940_947_ouabain_D009069_6_978_993_hyperlocomotion	Our findings demonstrated that ouabain at 10(-2) and 10(-3)M induced hyperlocomotion in rats, and this response remained up to 7 days following a single ICV injection.
UN	19447152_D011188_1_188_189_K_D001714_1_270_283_bipolar mania	The intracerebroventricular (ICV) administration of ouabain (a Na(+)/K(+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human bipolar mania.
UN	19447152_D012964_1_182_184_Na_D001714_1_270_283_bipolar mania	The intracerebroventricular (ICV) administration of ouabain (a Na(+)/K(+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human bipolar mania.
CID	19515070_D000082_6_926_939_acetaminophen_D017114_6_948_971_fulminant liver failure	We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure.
CID	19515070_D000082_6_926_939_acetaminophen_D058186_6_988_991_AKI	We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure.
UN	19515070_D019343_6_1087_1094_citrate_D017114_6_948_971_fulminant liver failure	We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure.
UN	19515070_D019343_8_1290_1297_Citrate_D017114_8_1384_1407_fulminant liver failure	Citrate dialysate is a safe alternative for intradialytic support of liver transplantation in fulminant liver failure.
UN	19515070_D019343_6_1087_1094_citrate_D058186_6_988_991_AKI	We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure.
UN	19531695_D005424_4_625_635_Flecainide_D001281_4_671_690_atrial fibrillation	Flecainide had been started 2 weeks prior for atrial fibrillation.
CID	19531695_D005424_10_1436_1446_flecainide_D003693_10_1455_1463_delirium	A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.
CID	19531695_D005424_12_1733_1743_flecainide_D003693_12_1776_1784_delirium	CONCLUSIONS: Supratherapeutic flecainide plasma concentrations may cause delirium.
CID	19531695_D005424_11_1509_1519_flecainide_D003693_11_1560_1568_delirium	According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine.
CID	19531695_D005424_0_33_43_flecainide_D003693_0_0_8_Delirium	Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.
CID	19531695_D005424_1_164_174_flecainide_D003693_1_183_191_delirium	OBJECTIVE: To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with paroxetine.
UN	19531695_D012964_9_1172_1178_sodium_D003693_9_1198_1206_delirium	DISCUSSION: Flecainide and pharmacologically similar agents that interact with sodium channels may cause delirium in susceptible patients.
CID	19531695_D017374_1_248_258_paroxetine_D003693_1_183_191_delirium	OBJECTIVE: To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with paroxetine.
UN	19549709_C107135_14_1547_1553_RAD001_D002289_14_1591_1596_NSCLC	Evaluation of RAD001 plus standard therapy for metastatic NSCLC continues.
UN	19549709_C107135_0_24_30_RAD001_D002289_0_58_63_NSCLC	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.
UN	19549709_D010984_3_459_467_platinum_D002289_3_392_397_NSCLC	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.
UN	19549709_D014443_3_544_552_tyrosine_D002289_3_392_397_NSCLC	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.
UN	19549709_D020123_2_311_320_rapamycin_D002289_2_359_364_NSCLC	RAD001, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in NSCLC.
CID	19553912_D020123_5_544_553_sirolimus_D000740_5_521_527_anemia	This review considers anemia associated with sirolimus, including its presentation, mechanisms, and management.
CID	19655282_D003042_9_1450_1457_cocaine_D002637_9_1469_1479_chest pain	RESULTS: A total of 59 patients with cocaine-associated chest pain were evaluated.
CID	19655282_D003042_4_800_807_cocaine_D002637_4_819_829_chest pain	We studied whether a negative coronary CTA in patients with cocaine-associated chest pain could identify a subset safe for discharge.
CID	19655282_D003042_3_649_656_cocaine_D002637_3_668_678_chest pain	It is unclear whether a coronary CTA strategy would be efficacious in cocaine-associated chest pain, as coronary vasospasm may account for some of the ischemia.
CID	19655282_D003042_16_2216_2223_cocaine_D002637_16_2235_2245_chest pain	CONCLUSIONS: Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.
CID	19655282_D003042_1_195_202_cocaine_D002637_1_214_224_chest pain	BACKGROUND: Most patients presenting to emergency departments (EDs) with cocaine-associated chest pain are admitted for at least 12 hours and receive a "rule out acute coronary syndrome" protocol, often with noninvasive testing prior to discharge.
CID	19655282_D003042_0_91_98_cocaine_D002637_0_110_120_chest pain	Coronary computerized tomography angiography for rapid discharge of low-risk patients with cocaine-associated chest pain.
UN	19655282_D003042_3_649_656_cocaine_D003329_3_683_701_coronary vasospasm	It is unclear whether a coronary CTA strategy would be efficacious in cocaine-associated chest pain, as coronary vasospasm may account for some of the ischemia.
UN	19655282_D003042_16_2216_2223_cocaine_D007511_16_2253_2261_ischemic	CONCLUSIONS: Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.
CID	19655282_D003042_16_2120_2127_cocaine_D017202_16_2139_2158_myocardial ischemia	CONCLUSIONS: Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.
UN	19655282_D003042_1_195_202_cocaine_D054058_1_284_307_acute coronary syndrome	BACKGROUND: Most patients presenting to emergency departments (EDs) with cocaine-associated chest pain are admitted for at least 12 hours and receive a "rule out acute coronary syndrome" protocol, often with noninvasive testing prior to discharge.
UN	19681452_D000431_5_599_606_ethanol_D001145_5_527_545_cardiac arrhythmia	In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion.
UN	19681452_D000431_0_75_82_alcohol_D002543_0_10_56_haemorrhagic infarction of the globus pallidus	Bilateral haemorrhagic infarction of the globus pallidus after cocaine and alcohol intoxication.
UN	19681452_D000431_2_269_276_alcohol_D002545_2_221_252_ischemia of the globus pallidus	We present the case of a 31-year-old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use.
UN	19681452_D000431_5_599_606_ethanol_D012131_5_549_572_respiratory dysfunction	In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion.
UN	19681452_D000431_0_75_82_alcohol_D020520_0_10_56_haemorrhagic infarction of the globus pallidus	Bilateral haemorrhagic infarction of the globus pallidus after cocaine and alcohol intoxication.
UN	19681452_D003042_5_584_591_cocaine_D001145_5_527_545_cardiac arrhythmia	In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion.
UN	19681452_D003042_0_63_70_cocaine_D002543_0_10_56_haemorrhagic infarction of the globus pallidus	Bilateral haemorrhagic infarction of the globus pallidus after cocaine and alcohol intoxication.
UN	19681452_D003042_1_97_104_Cocaine_D002544_1_131_163_ischemic and haemorrhagic stroke	Cocaine is a risk factor for both ischemic and haemorrhagic stroke.
CID	19681452_D003042_2_292_299_cocaine_D002545_2_221_252_ischemia of the globus pallidus	We present the case of a 31-year-old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use.
UN	19681452_D003042_5_584_591_cocaine_D012131_5_549_572_respiratory dysfunction	In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion.
UN	19681452_D003042_4_435_442_cocaine_D020520_4_395_417_basal ganglia infarcts	Bilateral basal ganglia infarcts after the use of cocaine, without concurrent heroin use, have never been reported.
UN	19681452_D003042_0_63_70_cocaine_D020520_0_10_56_haemorrhagic infarction of the globus pallidus	Bilateral haemorrhagic infarction of the globus pallidus after cocaine and alcohol intoxication.
UN	19681452_D003042_1_97_104_Cocaine_D020521_1_131_163_ischemic and haemorrhagic stroke	Cocaine is a risk factor for both ischemic and haemorrhagic stroke.
CID	19681452_D003932_3_377_383_heroin_D020520_3_318_345_globus pallidus infarctions	Drug-related globus pallidus infarctions are most often associated with heroin.
CID	19728177_D000082_2_465_478_acetaminophen_D001929_2_493_507_cerebral edema	METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from acetaminophen and resultant cerebral edema.
CID	19728177_D000082_5_791_804_acetaminophen_D001929_5_809_823_cerebral edema	Initial evaluation confirmed FHF from acetaminophen and cerebral edema.
CID	19728177_D000082_11_1306_1319_acetaminophen_D001929_11_1286_1300_cerebral edema	CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.
UN	19728177_D000082_11_1306_1319_acetaminophen_D007035_11_1352_1363_hypothermia	CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.
CID	19728177_D000082_5_791_804_acetaminophen_D017114_5_782_785_FHF	Initial evaluation confirmed FHF from acetaminophen and cerebral edema.
CID	19728177_D000082_11_1306_1319_acetaminophen_D017114_11_1278_1281_FHF	CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.
CID	19728177_D000082_2_465_478_acetaminophen_D017114_2_456_459_FHF	METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from acetaminophen and resultant cerebral edema.
UN	19728177_D000082_11_1306_1319_acetaminophen_D062787_11_1320_1328_overdose	CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.
UN	19815465_D020888_2_293_296_VGB_D004827_2_190_198_epilepsy	Two hundred four people with epilepsy were grouped on the basis of antiepileptic drug therapy (current, previous, or no exposure to VGB).
CID	19815465_D020888_8_1166_1169_VGB_D012164_8_1133_1149_retinal toxicity	Assessment by conventional static perimetry may neither be sufficiently sensitive nor specific to reliably identify retinal toxicity associated with VGB.
CID	19815465_D020888_0_49_59_vigabatrin_D014786_0_0_28_Binasal visual field defects	Binasal visual field defects are not specific to vigabatrin.
CID	19815465_D020888_1_143_153_vigabatrin_D014786_1_89_103_visual defects	This study investigated the visual defects associated with the antiepileptic drug vigabatrin (VGB).
CID	19841052_D016578_9_1580_1593_crack cocaine_D006679_9_1641_1659_HIV seroconversion	INTERPRETATION: Smoking of crack cocaine was found to be an independent risk factor for HIV seroconversion among people who were injection drug users.
CID	19841052_D016578_8_1365_1378_crack cocaine_D006679_8_1301_1319_HIV seroconversion	After adjusting for potential confounders, we found that the risk of HIV seroconversion among participants who were daily smokers of crack cocaine increased over time (period 1: hazard ratio [HR] 1.03, 95% confidence interval [CI] 0.57-1.85; period 2: HR 1.68, 95% CI 1.01-2.80; and period 3: HR 2.74, 95% CI 1.06-7.11).
CID	19841052_D016578_4_726_739_crack cocaine_D006679_4_684_702_HIV seroconversion	To determine whether the risk of HIV seroconversion among daily smokers of crack cocaine changed over time, we used Cox proportional hazards regression and divided the study into 3 periods: May 1, 1996-Nov. 30, 1999 (period 1), Dec. 1, 1999-Nov. 30, 2002 (period 2), and Dec. 1, 2002-Dec. 30, 2005 (period 3).
UN	19841052_D016578_1_163_176_crack cocaine_D015658_1_201_214_HIV infection	BACKGROUND: Little is known about the possible role that smoking crack cocaine has on the incidence of HIV infection.
UN	19841052_D016578_0_11_24_crack cocaine_D015658_0_46_59_HIV infection	Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs.
CID	19914299_D005472_0_73_87_5-fluorouracil_D008569_0_24_39_memory deficits	Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil.
UN	19914299_D005473_0_0_10_Fluoxetine_D008569_0_24_39_memory deficits	Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil.
CID	19920070_D010634_0_134_147_phenobarbital_D006529_0_115_127_hepatomegaly	Liver-specific ablation of integrin-linked kinase in mice results in enhanced and prolonged cell proliferation and hepatomegaly after phenobarbital administration.
CID	19967075_D005839_9_999_1009_Gentamicin_D007674_9_1018_1029_nephropathy	Gentamicin-induced nephropathy may at least in part be causally related with a decreased expression of Na(+)/K(+)-ATPase, NHE3, NBC1, AQP1 and OAT.
CID	19967075_D005839_1_204_214_gentamicin_D007674_1_223_234_nephropathy	The present study was aimed to determine whether there is an altered regulation of tubular transporters in gentamicin-induced nephropathy.
CID	19967075_D005839_0_65_75_Gentamicin_D007674_0_84_95_Nephropathy	Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced Nephropathy.
UN	19967075_D011188_0_27_28_K_D007674_0_84_95_Nephropathy	Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced Nephropathy.
UN	19967075_D011188_9_1108_1109_K_D007674_9_1018_1029_nephropathy	Gentamicin-induced nephropathy may at least in part be causally related with a decreased expression of Na(+)/K(+)-ATPase, NHE3, NBC1, AQP1 and OAT.
UN	19967075_D012964_0_24_26_Na_D007674_0_84_95_Nephropathy	Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced Nephropathy.
UN	19967075_D012964_9_1102_1104_Na_D007674_9_1018_1029_nephropathy	Gentamicin-induced nephropathy may at least in part be causally related with a decreased expression of Na(+)/K(+)-ATPase, NHE3, NBC1, AQP1 and OAT.
UN	20009434_D008727_2_287_290_MTX_D001656_2_432_447_biliary atresia	We report a case of acute renal failure after HD-MTX therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for congenital biliary atresia.
UN	20009434_D008727_1_113_116_MTX_D002051_1_148_164_Burkitt lymphoma	High-dose methotrexate (HD-MTX) is an important treatment for Burkitt lymphoma, but can cause hepatic and renal toxicity when its clearance is delayed.
UN	20009434_D008727_1_96_108_methotrexate_D007674_1_180_206_hepatic and renal toxicity	High-dose methotrexate (HD-MTX) is an important treatment for Burkitt lymphoma, but can cause hepatic and renal toxicity when its clearance is delayed.
UN	20009434_D008727_1_96_108_methotrexate_D056486_1_180_206_hepatic and renal toxicity	High-dose methotrexate (HD-MTX) is an important treatment for Burkitt lymphoma, but can cause hepatic and renal toxicity when its clearance is delayed.
CID	20009434_D008727_2_287_290_MTX_D058186_2_258_277_acute renal failure	We report a case of acute renal failure after HD-MTX therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for congenital biliary atresia.
CID	20009434_D008727_0_36_48_methotrexate_D058186_0_0_19_Acute renal failure	Acute renal failure after high-dose methotrexate therapy in a patient with ileostomy.
CID	20009434_D008727_5_699_702_MTX_D058186_5_718_737_acute renal failure	Subsequent HD-MTX therapy caused acute renal failure that required continuous hemodialysis.
CID	20024739_D000431_7_1044_1051_alcohol_D003866_7_1068_1078_depression	The association between alcohol consumption and depression was significant (p<0.001).
CID	20024739_D000431_9_1232_1239_alcohol_D003866_9_1282_1292_depression	Our findings suggest that alcohol consumption has a direct association with depression.
CID	20024739_D000431_1_145_152_alcohol_D003866_1_169_179_depression	We evaluated the association of alcohol consumption and depression, and their effects on HIV disease progression among women with HIV.
UN	20024739_D000431_0_28_35_alcohol_D015658_0_45_56_HIV disease	Longitudinal association of alcohol use with HIV disease progression and psychological health of women with HIV.
CID	20034406_D010862_16_1556_1567_pilocarpine_D013226_16_1576_1578_SE	CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after pilocarpine-induced SE.
CID	20034406_D010862_0_80_91_pilocarpine_D013226_0_100_118_status epilepticus	Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus.
CID	20034406_D010862_3_473_484_pilocarpine_D013226_3_458_460_SE	In this work CCR2 and CCL2 expression were examined following status epilepticus (SE) induced by pilocarpine injection.
CID	20034406_D010862_4_523_534_pilocarpine_D013226_4_505_507_SE	METHODS: SE was induced by pilocarpine injection.
CID	20046642_D002330_3_426_430_BCNU_D003072_3_452_473_cognitive dysfunction	The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal cognitive dysfunction in rats.
CID	20046642_D002330_7_1077_1081_BCNU_D007859_7_1109_1156_deterioration of learning and short-term memory	The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content.
CID	20046642_D002330_7_1077_1081_BCNU_D008569_7_1109_1156_deterioration of learning and short-term memory	The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content.
UN	20046642_D002330_8_1328_1332_BCNU_D009336_8_1370_1378_necrosis	Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.
UN	20046642_D002330_8_1328_1332_BCNU_D009369_8_1364_1369_tumor	Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.
UN	20046642_D005978_7_1247_1258_glutathione_D007859_7_1109_1156_deterioration of learning and short-term memory	The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content.
UN	20046642_D005978_7_1247_1258_glutathione_D008569_7_1109_1156_deterioration of learning and short-term memory	The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content.
UN	20046642_D008315_8_1423_1438_malondialdehyde_D009336_8_1370_1378_necrosis	Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.
UN	20046642_D008315_8_1423_1438_malondialdehyde_D009369_8_1364_1369_tumor	Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.
UN	20046642_D008668_3_398_400_MT_D003072_3_452_473_cognitive dysfunction	The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal cognitive dysfunction in rats.
UN	20046642_D008668_8_1416_1418_MT_D009336_8_1370_1378_necrosis	Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.
UN	20046642_D008668_8_1416_1418_MT_D009369_8_1364_1369_tumor	Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.
CID	20129423_D002220_2_419_432_carbamazepine_D004342_2_462_478_hypersensitivity	A frequently fatal, although exceptionally rare side effect of carbamazepine is necrotizing eosinophilic (hypersensitivity) myocarditis.
CID	20129423_D002220_3_573_586_carbamazepine_D004342_3_513_529_hypersensitivity	We report a case of hypersensitivity myocarditis secondary to administration of carbamazepine.
CID	20129423_D002220_0_6_19_carbamazepine_D004342_0_52_68_hypersensitivity	Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.
CID	20129423_D002220_0_6_19_carbamazepine_D004802_0_28_50_fulminant eosinophilic	Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.
CID	20129423_D002220_7_909_922_carbamazepine_D009205_7_931_942_myocarditis	To best of our knowledge this is the second case of fatal carbamazepine induced myocarditis reported in English literature.
CID	20129423_D002220_0_6_19_carbamazepine_D009205_0_70_81_myocarditis	Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.
CID	20129423_D002220_3_573_586_carbamazepine_D009205_3_530_541_myocarditis	We report a case of hypersensitivity myocarditis secondary to administration of carbamazepine.
CID	20129423_D002220_2_419_432_carbamazepine_D009205_2_480_491_myocarditis	A frequently fatal, although exceptionally rare side effect of carbamazepine is necrotizing eosinophilic (hypersensitivity) myocarditis.
UN	20169779_D007980_4_492_500_levodopa_D001523_4_532_563_neuropsychiatric-like behaviors	Here we compare the time course of levodopa-induced motor fluctuations and neuropsychiatric-like behaviors to determine the relationship between duration of treatment and onset of symptoms.
UN	20169779_D007980_11_1791_1799_levodopa_D001523_11_1719_1745_neuropsychiatric disorders	CONCLUSIONS: The data suggest that neuropsychiatric disorders in PD are more likely an interaction between levodopa and the disease state than a consequence of sensitisation to repeated dopaminergic therapy.
UN	20169779_D007980_10_1526_1534_levodopa_D001523_10_1543_1574_neuropsychiatric-like behaviors	In contrast, levodopa-induced neuropsychiatric-like behaviors were present on Day 1 of levodopa treatment and their severity did not correlate with duration of treatment.
UN	20169779_D007980_7_1036_1044_levodopa_D001523_7_985_1016_neuropsychiatric-like behaviors	Animals were evaluated for parkinsonian disability, dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day.
CID	20169779_D007980_9_1393_1401_levodopa_D004409_9_1430_1440_dyskinesia	As anticipated, animals exhibited a progressive increase in levodopa-induced motor fluctuations, dyskinesia and wearing-off, that correlated with the duration of levodopa therapy.
UN	20169779_D007980_11_1791_1799_levodopa_D010302_11_1749_1751_PD	CONCLUSIONS: The data suggest that neuropsychiatric disorders in PD are more likely an interaction between levodopa and the disease state than a consequence of sensitisation to repeated dopaminergic therapy.
UN	20169779_D007980_7_1036_1044_levodopa_D020734_7_912_935_parkinsonian disability	Animals were evaluated for parkinsonian disability, dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day.
UN	20169779_D015632_3_369_373_MPTP_D001523_3_415_440_neuropsychiatric symptoms	The levodopa-treated MPTP-lesioned marmoset was used as a model of neuropsychiatric symptoms in PD patients.
UN	20169779_D015632_0_34_38_MPTP_D010302_0_57_76_Parkinson's disease	Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.
CID	20192893_D003287_2_333_335_CM_D007674_2_311_322_nephrotoxic	PURPOSE: To compare the susceptibility to nephrotoxic effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention (PCI).
CID	20192893_D003287_1_127_142_contrast medium_D007674_1_88_105_Renal dysfunction	BACKGROUND: Renal dysfunction induced by iodinated contrast medium (CM) administration can minimize the benefit of the interventional procedure in patients undergoing renal angioplasty (PTRA).
CID	20192893_D003287_0_0_15_Contrast medium_D007674_0_16_30_nephrotoxicity	Contrast medium nephrotoxicity after renal artery and coronary angioplasty.
CID	20192893_D003287_8_1446_1448_CM_D007674_8_1422_1434_renal damage	CONCLUSION: In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients.
CID	2021990_D002927_9_1105_1115_cimetidine_D007022_9_1080_1091_hypotension	We conclude that an H1 antagonist may be useful in preventing hypotension caused by iv cimetidine, since the vasodilating activity of cimetidine is mediated, in part, through the H1 receptor.
UN	20408947_D000082_8_1759_1772_acetaminophen_D008107_8_1804_1807_CLD	CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.
CID	20408947_D000082_5_1010_1023_acetaminophen_D017114_5_1032_1035_ALF	Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.
CID	20408947_D000082_5_1095_1108_acetaminophen_D017114_5_1117_1120_ALF	Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.
CID	20408947_D000082_6_1353_1366_acetaminophen_D017114_6_1375_1378_ALF	During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).
CID	20408947_D000082_6_1408_1421_acetaminophen_D017114_6_1430_1433_ALF	During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).
CID	20408947_D000082_7_1479_1492_acetaminophen_D017114_7_1501_1504_ALF	Two acetaminophen-induced ALF patients reattempted suicide post-LT (one died 8 years post-LT).
CID	20408947_D000082_8_1687_1700_acetaminophen_D017114_8_1709_1712_ALF	CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.
CID	20408947_D000082_8_1759_1772_acetaminophen_D017114_8_1781_1784_ALF	CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.
CID	20408947_D000082_1_140_153_Acetaminophen_D017114_1_205_224_acute liver failure	BACKGROUND: Acetaminophen-induced hepatotoxicity is the most common cause of acute liver failure (ALF) in the UK.
CID	20408947_D000082_3_564_577_acetaminophen_D017114_3_586_589_ALF	AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).
CID	20408947_D000082_3_663_676_acetaminophen_D017114_3_685_688_ALF	AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).
CID	20408947_D000082_4_760_773_Acetaminophen_D017114_4_782_785_ALF	RESULTS: Acetaminophen-induced ALF patients undergoing LT had a greater severity of pre-LT illness reflected by higher Acute Physiology and Chronic Health Evaluation II scores and requirement for organ support compared with the other two groups.
CID	20408947_D000082_0_63_76_acetaminophen_D017114_0_85_104_acute liver failure	Medical and psychiatric outcomes for patients transplanted for acetaminophen-induced acute liver failure: a case-control study.
CID	20408947_D000082_1_140_153_Acetaminophen_D056486_1_162_176_hepatotoxicity	BACKGROUND: Acetaminophen-induced hepatotoxicity is the most common cause of acute liver failure (ALF) in the UK.
CID	20431083_D014859_9_1912_1920_warfarin_D002543_9_1932_1935_ICH	CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH.
CID	20431083_D014859_9_1999_2007_warfarin_D002543_9_2019_2022_ICH	CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH.
CID	20431083_D014859_6_1293_1301_warfarin_D002543_6_1325_1328_ICH	There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).
UN	20431083_D014859_6_1377_1385_warfarin_D002544_6_1397_1399_IS	There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).
UN	20431083_D014859_6_1377_1385_warfarin_D002546_6_1400_1403_TIA	There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).
UN	20447294_C401121_2_424_431_CNSB002_D003929_2_669_688_diabetic neuropathy	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
UN	20447294_C401121_7_1455_1462_CNSB002_D006930_7_1514_1526_hyperalgesia	The antinociception after morphine (3.2 mg/kg) was increased by co-administration with CNSB002 from 28.0 and 31.7% to 114.6 and 56.9% reversal of hyperalgesia in the inflammatory and neuropathic models, respectively (P < 0.01; one-way analysis of variance-significantly greater than either drug given alone).
UN	20447294_C401121_4_1031_1038_CNSB002_D006930_4_880_892_hyperalgesia	The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
UN	20447294_C401121_2_424_431_CNSB002_D007249_2_623_635_inflammation	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
UN	20447294_C401121_4_1031_1038_CNSB002_D009422_4_1010_1020_neuropathy	The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
UN	20447294_C401121_0_72_79_CNSB002_D009437_0_115_131_neuropathic pain	Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
UN	20447294_C401121_2_424_431_CNSB002_D010146_2_586_590_pain	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
UN	20447294_D002351_2_599_610_carrageenan_D003929_2_669_688_diabetic neuropathy	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
CID	20447294_D002351_4_940_951_carrageenan_D006930_4_880_892_hyperalgesia	The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
CID	20447294_D002351_2_599_610_carrageenan_D007249_2_623_635_inflammation	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
UN	20447294_D002351_4_940_951_carrageenan_D009422_4_1010_1020_neuropathy	The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
UN	20447294_D002351_6_1290_1301_carrageenan_D009422_6_1331_1341_neuropathy	The ED50 values for morphine when given in combination with CNSB002 (5 mg/kg) were less than the maximum nonsedating dose: 0.56 (1.55) in the carrageenan model and 1.37 (1.23) in the neuropathy model (mg/kg; mean, SEM).
UN	20447294_D002351_2_599_610_carrageenan_D010146_2_586_590_pain	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
UN	20447294_D009020_2_411_419_morphine_D003929_2_669_688_diabetic neuropathy	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
UN	20447294_D009020_7_1394_1402_morphine_D006930_7_1514_1526_hyperalgesia	The antinociception after morphine (3.2 mg/kg) was increased by co-administration with CNSB002 from 28.0 and 31.7% to 114.6 and 56.9% reversal of hyperalgesia in the inflammatory and neuropathic models, respectively (P < 0.01; one-way analysis of variance-significantly greater than either drug given alone).
UN	20447294_D009020_4_1043_1051_morphine_D006930_4_880_892_hyperalgesia	The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
UN	20447294_D009020_2_411_419_morphine_D007249_2_623_635_inflammation	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
UN	20447294_D009020_4_1043_1051_morphine_D009422_4_1010_1020_neuropathy	The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
UN	20447294_D009020_1_296_304_morphine_D009437_1_339_355_neuropathic pain	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain.
UN	20447294_D009020_2_411_419_morphine_D010146_2_586_590_pain	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
UN	20447294_D012964_1_208_214_sodium_D009437_1_339_355_neuropathic pain	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain.
UN	20447294_D012964_0_48_54_sodium_D009437_0_115_131_neuropathic pain	Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
CID	20447294_D013311_2_656_659_STZ_D003929_2_669_688_diabetic neuropathy	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
CID	20447294_D013311_4_998_1001_STZ_D006930_4_880_892_hyperalgesia	The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
UN	20447294_D013311_2_640_654_streptozotocin_D007249_2_623_635_inflammation	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
UN	20447294_D013311_4_998_1001_STZ_D009422_4_1010_1020_neuropathy	The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
UN	20447294_D013311_2_640_654_streptozotocin_D010146_2_586_590_pain	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
UN	20495512_D000991_7_1070_1095_direct thrombin inhibitor_D013921_7_938_941_HIT	The treatment of HIT mandates an immediate cessation of all heparin exposure and the institution of an antithrombotic therapy, most commonly using a direct thrombin inhibitor.
UN	20495512_D000991_10_1390_1416_Direct thrombin inhibitors_D013921_10_1503_1506_HIT	Direct thrombin inhibitors are appropriate, evidence-based alternatives to heparin in patients with a history of HIT, who need to undergo percutaneous coronary intervention.
CID	20495512_D006493_10_1465_1472_heparin_D013921_10_1503_1506_HIT	Direct thrombin inhibitors are appropriate, evidence-based alternatives to heparin in patients with a history of HIT, who need to undergo percutaneous coronary intervention.
CID	20495512_D006493_11_1667_1674_heparin_D013921_11_1652_1655_HIT	As heparin remains one of the most frequently used medications today with potential for HIT with every heparin exposure, a close vigilance of platelet counts must be practiced whenever heparin is initiated.
CID	20495512_D006493_7_981_988_heparin_D013921_7_938_941_HIT	The treatment of HIT mandates an immediate cessation of all heparin exposure and the institution of an antithrombotic therapy, most commonly using a direct thrombin inhibitor.
CID	20495512_D006493_1_54_61_Heparin_D013921_1_70_86_thrombocytopenia	Heparin-induced thrombocytopenia (HIT) remains under-recognized despite its potentially devastating outcomes.
CID	20495512_D006493_0_0_7_Heparin_D013921_0_16_32_thrombocytopenia	Heparin-induced thrombocytopenia: a practical review.
CID	20495512_D006493_5_735_742_heparin_D013927_5_711_721_thrombosis	HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever thrombosis occurs after heparin exposure.
UN	20513036_C542870_14_1433_1438_Botox_D010243_14_1417_1426_paralysis	The incidence of abductor paralysis after Botox injection for ADSD was 0.34%.
UN	20513036_C542870_16_1663_1668_Botox_D010243_16_1637_1646_paralysis	The likely mechanism of paralysis is diffusion of Botox around the muscular process of the arytenoid to the posterior cricoarytenoid muscles.
UN	20513036_C542870_0_25_30_botox_D010243_0_9_18_paralysis	Abductor paralysis after botox injection for adductor spasmodic dysphonia.
UN	20513036_C542870_15_1537_1542_Botox_D010243_15_1501_1510_paralysis	CONCLUSIONS: Bilateral abductor paralysis is a rare complication of Botox injections for ADSD, causing difficulty with breathing upon exertion.
UN	20513036_C542870_3_422_427_Botox_D010243_3_402_411_paralysis	Here we report multiple cases of bilateral abductor paralysis following Botox injections for ADSD, a complication previously unreported.
CID	20513036_C542870_0_25_30_botox_D014826_0_45_73_adductor spasmodic dysphonia	Abductor paralysis after botox injection for adductor spasmodic dysphonia.
CID	20513036_C542870_3_422_427_Botox_D014826_3_443_447_ADSD	Here we report multiple cases of bilateral abductor paralysis following Botox injections for ADSD, a complication previously unreported.
CID	20513036_C542870_14_1433_1438_Botox_D014826_14_1453_1457_ADSD	The incidence of abductor paralysis after Botox injection for ADSD was 0.34%.
CID	20513036_C542870_15_1537_1542_Botox_D014826_15_1558_1562_ADSD	CONCLUSIONS: Bilateral abductor paralysis is a rare complication of Botox injections for ADSD, causing difficulty with breathing upon exertion.
UN	20513036_C542870_5_560_565_Botox_D055154_5_581_600_spasmodic dysphonia	METHODS: Patients that received Botox injections for spasmodic dysphonia between January 2000 and October 2009 were evaluated.
UN	20566328_C476756_0_116_121_MitoQ_D006331_0_56_75_cardiac dysfunction	Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.
UN	20566328_C476756_0_116_121_MitoQ_D028361_0_0_24_Mitochondrial impairment	Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.
UN	20566328_C476756_7_988_993_MitoQ_D028361_7_1071_1098_mitochondrial abnormalities	MitoQ, a mitochondrial-targeted antioxidant, was shown to completely prevent these mitochondrial abnormalities as well as cardiac dysfunction characterized here by a diastolic dysfunction studied with a conductance catheter to obtain pressure-volume data.
CID	20566328_D003042_8_1319_1326_cocaine_D006331_8_1335_1354_cardiac dysfunction	Taken together, these results extend previous studies and demonstrate that cocaine-induced cardiac dysfunction may be due to a mitochondrial defect.
CID	20566328_D003042_0_40_47_cocaine_D006331_0_56_75_cardiac dysfunction	Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.
CID	20566328_D003042_1_230_237_cocaine_D006331_1_246_265_cardiac dysfunction	The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction.
UN	20566328_D003042_8_1319_1326_cocaine_D028361_8_1371_1391_mitochondrial defect	Taken together, these results extend previous studies and demonstrate that cocaine-induced cardiac dysfunction may be due to a mitochondrial defect.
UN	20566328_D003042_0_40_47_cocaine_D028361_0_0_24_Mitochondrial impairment	Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.
CID	20589632_D014295_0_0_12_Trimethoprim_D000743_0_28_44_hemolytic anemia	Trimethoprim-induced immune hemolytic anemia in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction.
UN	20595935_D014700_0_0_9_Verapamil_D006966_0_30_48_hyperprolactinemia	Verapamil stimulation test in hyperprolactinemia: loss of prolactin response in anatomic or functional stalk effect.
UN	20595935_D014700_3_391_400_verapamil_D015175_3_443_461_macroprolactinemia	Here, we aimed to re-investigate the diagnostic value of verapamil in a population who were all screened for macroprolactinemia.
CID	20595935_D018967_8_1432_1443_risperidone_D006966_8_1452_1470_hyperprolactinemia	ROC curve analysis revealed that unresponsiveness to verapamil defined as PRL <7%, discriminated anatomical or functional stalk effect (sensitivity: 74%, specificity: 73%, AUC: 0.855+/-0.04, P <0.001, CI: 0.768-0.942) associated with pseudoprolactinoma or risperidone-induced hyperprolactinemia, respectively.
CID	20595935_D018967_7_1120_1131_risperidone_D006966_7_1140_1158_hyperprolactinemia	RESULTS: Verapamil significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced hyperprolactinemia (N. 7, PRL: 3%).
UN	20595935_D018967_7_1120_1131_risperidone_D015175_7_1028_1046_macroprolactinemia	RESULTS: Verapamil significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced hyperprolactinemia (N. 7, PRL: 3%).
UN	20682692_D000804_1_228_239_angiotensin_D003922_1_264_279_type 1 diabetes	OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-angiotensin system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy).
UN	20682692_D000804_1_228_239_angiotensin_D003928_1_425_445_diabetic nephropathy	OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-angiotensin system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy).
UN	20682692_D000804_1_228_239_angiotensin_D007674_1_335_346_nephropathy	OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-angiotensin system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy).
UN	20682692_D013311_2_682_685_STZ_D003920_2_695_703_diabetes	We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin (STZ)-induced diabetes.
CID	20682692_D013311_0_100_114_streptozotocin_D003928_0_123_143_diabetic nephropathy	Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy.
CID	20682692_D013311_6_1357_1360_STZ_D003928_6_1369_1389_diabetic nephropathy	Blocking studies using receptor for AGE siRNA and a specific inhibitor of Smad3 (SIS3) were performed in MMECs and in STZ-induced diabetic nephropathy in Tie2-Cre;Loxp-EGFP mice.
CID	20682692_D013311_8_1663_1666_STZ_D003928_8_1675_1695_diabetic nephropathy	Immunoprecipitation/Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in STZ-induced diabetic nephropathy.
UN	20682692_D013311_2_666_680_streptozotocin_D005355_2_610_618_fibrosis	We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin (STZ)-induced diabetes.
CID	20828385_C401859_7_1132_1144_temsirolimus_D009336_7_1083_1091_necrotic	Moreover, numerous patchy, well-limited fibrotic areas, compatible with post-necrotic tissue repair, were found after 6-month temsirolimus therapy.
UN	20828385_C401859_3_505_517_temsirolimus_D009369_3_471_476_tumor	However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.
UN	20828385_C401859_6_897_909_temsirolimus_D009369_6_956_961_tumor	Apart from this cytostatic effect, temsirolimus had an antiangiogenic effect with decrease of tumor microvessel density and of VEGF expression.
UN	20828385_C401859_5_717_729_temsirolimus_D009369_5_740_745_tumor	Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic tumor cells.
UN	20828385_C401859_8_1160_1172_temsirolimus_D009369_8_1181_1186_tumor	Thus, temsirolimus reduced tumor burden through associated cytostatic and anti-angiogenic effects.This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.
UN	20828385_C401859_8_1272_1284_temsirolimus_D009369_8_1288_1293_tumor	Thus, temsirolimus reduced tumor burden through associated cytostatic and anti-angiogenic effects.This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.
UN	20828385_C401859_0_42_54_temsirolimus_D020522_0_69_89_mantle cell lymphoma	Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.
UN	20828385_C401859_3_370_382_temsirolimus_D020522_3_353_356_MCL	However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.
UN	2083961_D012293_2_205_215_Rifampicin_D005334_2_346_351_fever	Rifampicin was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like nausea, vomiting and fever with chills and rigors.
UN	2083961_D012293_2_205_215_Rifampicin_D009325_2_325_331_nausea	Rifampicin was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like nausea, vomiting and fever with chills and rigors.
UN	2083961_D012293_2_205_215_Rifampicin_D014839_2_333_341_vomiting	Rifampicin was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like nausea, vomiting and fever with chills and rigors.
CID	2083961_D012293_0_27_37_rifampicin_D058186_0_0_19_Acute renal failure	Acute renal failure due to rifampicin.
UN	20859899_D000450_3_564_575_aldosterone_D006947_3_494_506_hyperkalemia	The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.
UN	20859899_D000809_0_73_84_angiotensin_D006947_0_18_30_hyperkalemia	Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
UN	20859899_D000809_0_73_84_angiotensin_D013575_0_0_7_Syncope	Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
UN	20859899_D011188_5_883_892_potassium_D006947_5_804_816_hyperkalemia	Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild renal disturbance.
UN	20859899_D011188_5_883_892_potassium_D007674_5_926_943_renal disturbance	Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild renal disturbance.
CID	20859899_D013148_3_545_559_spiranolactone_D006947_3_494_506_hyperkalemia	The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.
UN	20859899_D013148_0_117_131_spironolactone_D013575_0_0_7_Syncope	Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
CID	20859899_D017257_3_627_635_ramipril_D006947_3_494_506_hyperkalemia	The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.
UN	20927253_D004164_1_146_161_bisphosphonates_D010024_1_71_83_Osteoporosis	BACKGROUND: Osteoporosis is caused by bone resorption in excess of bone formation, and bisphosphonates, are used to inhibit bone resorption.
UN	20927253_D004164_6_677_691_bisphosphonate_D010024_6_643_655_osteoporosis	CONCLUSION: We conclude that patients with osteoporosis can report pain, and bisphosphonate-related pain should also be considered before ascribing this complaint to osteoporosis.
UN	20927253_D004164_6_677_691_bisphosphonate_D010146_6_700_704_pain	CONCLUSION: We conclude that patients with osteoporosis can report pain, and bisphosphonate-related pain should also be considered before ascribing this complaint to osteoporosis.
UN	20927253_D019386_2_200_211_Alendronate_D010024_2_284_296_osteoporosis	Alendronate, a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women.
CID	20927253_D019386_0_46_57_alendronate_D010146_0_17_21_pain	Diffuse skeletal pain after administration of alendronate.
CID	20927253_D019386_5_587_598_alendronate_D010146_5_540_544_pain	We presented a patient admitted to our out-patient clinic with diffuse skeletal pain after three consecutive administration of alendronate.
UN	20959502_D003404_6_788_798_creatinine_D058186_6_761_780_acute renal failure	On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission).
UN	20959502_D008712_1_134_145_methicillin_D008581_1_216_226_meningitis	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.
UN	20959502_D008712_1_134_145_methicillin_D016470_1_185_195_bacteremia	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.
UN	20959502_D009254_9_1178_1187_Nafcillin_D008581_9_1262_1272_meningitis	Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16.
CID	20959502_D009254_13_1705_1714_nafcillin_D009395_13_1729_1751_interstitial nephritis	DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing bacteremia.
UN	20959502_D009254_13_1705_1714_nafcillin_D016470_13_1766_1776_bacteremia	DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing bacteremia.
UN	20959502_D017576_0_45_55_daptomycin_D008581_0_91_101_meningitis	Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis.
UN	20959502_D017576_1_250_260_daptomycin_D008581_1_216_226_meningitis	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.
UN	20959502_D017576_9_1209_1219_daptomycin_D008581_9_1262_1272_meningitis	Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16.
UN	20959502_D017576_13_1643_1653_Daptomycin_D009395_13_1729_1751_interstitial nephritis	DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing bacteremia.
UN	20959502_D017576_15_1928_1938_daptomycin_D016470_15_1977_1987_bacteremia	CONCLUSIONS: High-dose daptomycin may be an alternative option for MSSA bacteremia with or without a CNS source in patients who have failed or cannot tolerate standard therapy.
UN	20959502_D017576_1_250_260_daptomycin_D016470_1_185_195_bacteremia	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.
UN	21195121_D001120_3_306_316_L-arginine_D004827_3_400_408_epilepsy	Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.
UN	21195121_D001120_5_601_611_L-arginine_D012640_5_693_703_convulsion	The administration of L-arginine (600, 800 and 1000 mg/kg, i.p.) in dose-dependent manner significantly increased convulsion incidence and severity and shortened latency time to first convulsion elicited by lower lindane dose (4 mg/kg, i.p.).
UN	21195121_D001556_4_526_533_lindane_D004827_4_542_550_epilepsy	The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of lindane-induced epilepsy in male Wistar albino rats.
CID	21195121_D001556_8_1332_1339_lindane_D012640_8_1340_1348_seizures	These results support the conclusion that NO plays a role of endogenous convulsant in rat model of lindane seizures.
CID	21195121_D001556_6_1026_1033_lindane_D012640_6_1007_1017_convulsive	On the contrary, pretreatment with L-NAME (500, 700 and 900 mg/kg, i.p.) decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane (8 mg/kg, i.p.).
CID	21195121_D001556_5_792_799_lindane_D012640_5_763_773_convulsion	The administration of L-arginine (600, 800 and 1000 mg/kg, i.p.) in dose-dependent manner significantly increased convulsion incidence and severity and shortened latency time to first convulsion elicited by lower lindane dose (4 mg/kg, i.p.).
CID	21195121_D001556_0_51_58_lindane_D012640_0_28_39_convulsions	The role of nitric oxide in convulsions induced by lindane in rats.
UN	21195121_D005680_2_174_178_GABA_D012640_2_132_143_convulsions	It evokes convulsions mainly trough the blockage of GABA(A) receptors.
UN	21195121_D009569_3_331_333_NO_D004827_3_400_408_epilepsy	Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.
UN	21195121_D009569_4_478_480_NO_D004827_4_542_550_epilepsy	The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of lindane-induced epilepsy in male Wistar albino rats.
UN	21195121_D009569_0_12_24_nitric oxide_D012640_0_28_39_convulsions	The role of nitric oxide in convulsions induced by lindane in rats.
UN	21195121_D019331_3_355_361_L-NAME_D004827_3_400_408_epilepsy	Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.
UN	21195121_D019331_6_857_863_L-NAME_D012640_6_905_915_convulsion	On the contrary, pretreatment with L-NAME (500, 700 and 900 mg/kg, i.p.) decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane (8 mg/kg, i.p.).
CID	2131034_D003561_5_730_735_ara-C_D020258_5_772_785_neurotoxicity	In spite of the fact that TSPA is a useful IT agent, its combination with MTX, ara-C and radiotherapy could cause severe neurotoxicity.
CID	2131034_D008727_3_473_485_methotrexate_D020258_3_423_444_Neurologic toxicities	Neurologic toxicities have been described with IT-methotrexate, IT-cytosine arabinoside and IT-TSPA.
CID	2131034_D013852_0_55_63_thiotepa_D011115_0_7_21_polyneuropathy	Severe polyneuropathy and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases.
CID	2131034_D013852_5_677_681_TSPA_D020258_5_772_785_neurotoxicity	In spite of the fact that TSPA is a useful IT agent, its combination with MTX, ara-C and radiotherapy could cause severe neurotoxicity.
CID	2131034_D013852_1_249_257_thiotepa_D020258_1_144_163_neurologic toxicity	Two cases of severe delayed neurologic toxicity related to the administration of intrathecal (IT) combination chemotherapy including thiotepa (TSPA) are presented.
CID	2131034_D013852_3_518_522_TSPA_D020258_3_423_444_Neurologic toxicities	Neurologic toxicities have been described with IT-methotrexate, IT-cytosine arabinoside and IT-TSPA.
UN	2173761_D000319_5_1095_1144_beta adrenergic and muscarinic receptors blockade_D007022_5_1011_1022_hypotension	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.
UN	2173761_D000319_5_1095_1144_beta adrenergic and muscarinic receptors blockade_D013610_5_1162_1173_tachycardia	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.
UN	2173761_D018727_5_1095_1144_beta adrenergic and muscarinic receptors blockade_D007022_5_1011_1022_hypotension	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.
UN	2173761_D018727_5_1095_1144_beta adrenergic and muscarinic receptors blockade_D013610_5_1162_1173_tachycardia	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.
CID	2173761_D019806_5_1034_1044_cromakalim_D007022_5_1011_1022_hypotension	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.
CID	2173761_D019806_5_1034_1044_cromakalim_D013610_5_1162_1173_tachycardia	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.
CID	2173761_D020110_5_1049_1058_pinacidil_D007022_5_1011_1022_hypotension	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.
CID	2173761_D020110_5_1049_1058_pinacidil_D013610_5_1162_1173_tachycardia	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.
UN	2217015_D008528_4_493_507_mefenamic acid_D007037_4_511_522_hypothyroid	However, it would seem prudent not to use mefenamic acid in hypothyroid patients until the hypothyroidism has been corrected.
CID	2217015_D008528_1_103_117_mefenamic acid_D009503_1_164_175_neutropenia	We report mefenamic acid-induced non-oliguric renal failure and severe neutropenia occurring simultaneously in two elderly females.
CID	2217015_D008528_0_0_14_Mefenamic acid_D009503_0_23_34_neutropenia	Mefenamic acid-induced neutropenia and renal failure in elderly females with hypothyroidism.
CID	2217015_D008528_1_103_117_mefenamic acid_D051437_1_139_152_renal failure	We report mefenamic acid-induced non-oliguric renal failure and severe neutropenia occurring simultaneously in two elderly females.
CID	2217015_D008528_0_0_14_Mefenamic acid_D051437_0_39_52_renal failure	Mefenamic acid-induced neutropenia and renal failure in elderly females with hypothyroidism.
UN	2239937_D002118_3_593_600_calcium_D006934_3_560_573_hypercalcemic	In addition to experiencing hypercalcemic episodes with peak calcium values of 2.7 to 3.8 mmol/L (10.7 to 15.0 mg/dL), patients in the hypercalcemic group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch, compared with the mean value obtained during the 7 months of observation after the switch (2.4 +/- 0.03 to 2.5 +/- 0.03 mmol/L [9.7 +/- 0.2 to 10.2 +/- 0.1 mg/dL], P = 0.006).
UN	2239937_D002118_2_333_340_calcium_D007674_2_517_530_renal disease	In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of renal disease.
CID	2239937_D002119_0_54_71_calcium carbonate_D006934_0_12_25_hypercalcemia	Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy.
CID	2239937_D002119_1_160_177_calcium carbonate_D006934_1_127_140_hypercalcemic	Fourteen of 39 dialysis patients (36%) became hypercalcemic after switching to calcium carbonate as their principal phosphate binder.
UN	2239937_D010710_1_197_206_phosphate_D006934_1_127_140_hypercalcemic	Fourteen of 39 dialysis patients (36%) became hypercalcemic after switching to calcium carbonate as their principal phosphate binder.
UN	22836123_D000305_4_536_551_corticosteroids_D007674_4_506_509_SRC	In this article, we report a patient with SRC induced by tacrolimus and corticosteroids.
UN	22836123_D000305_2_281_295_corticosteroid_D007674_2_341_344_SRC	Moderate to high dose corticosteroid use is recognized as a major risk factor for SRC.
UN	22836123_D011239_0_62_74_prednisolone_D007674_0_11_35_scleroderma renal crisis	Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report.
UN	22836123_D016559_0_47_57_tacrolimus_D007674_0_11_35_scleroderma renal crisis	Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report.
UN	22836123_D016559_4_521_531_tacrolimus_D007674_4_506_509_SRC	In this article, we report a patient with SRC induced by tacrolimus and corticosteroids.
CID	22836123_D016559_5_610_620_tacrolimus_D012595_5_642_645_SSc	The aim of this work is to call attention to the risk of tacrolimus use in patients with SSc.
UN	22836123_D016572_3_429_441_cyclosporine_D012595_3_459_462_SSc	Furthermore, there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with SSc.
CID	22836123_D016572_3_429_441_cyclosporine_D057049_3_386_412_thrombotic microangiopathy	Furthermore, there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with SSc.
CID	2320485_D008750_3_397_407_methyldopa_D000743_3_416_432_hemolytic anemia	We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the emergency department with near-syncope.
CID	2320485_D008750_0_0_10_Methyldopa_D000743_0_19_35_hemolytic anemia	Methyldopa-induced hemolytic anemia in a 15 year old presenting as near-syncope.
UN	2320485_D008750_2_275_285_Methyldopa_D000744_2_296_323_autoimmune hemolytic anemia	Methyldopa causes an autoimmune hemolytic anemia in a small percentage of patients who take the drug.
UN	2320485_D008750_3_397_407_methyldopa_D004630_3_475_495_emergency department	We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the emergency department with near-syncope.
UN	2320485_D008750_3_397_407_methyldopa_D013575_3_506_513_syncope	We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the emergency department with near-syncope.
UN	2320485_D008750_0_0_10_Methyldopa_D013575_0_72_79_syncope	Methyldopa-induced hemolytic anemia in a 15 year old presenting as near-syncope.
UN	2320485_D008750_4_557_567_methyldopa_D014947_4_577_583_trauma	The boy had been treated with intravenous methyldopa during a trauma admission seven weeks prior to presentation.
CID	23433219_D008694_10_1694_1709_methamphetamine_D000987_10_1660_1682_antisocial personality	It was associated with co-morbid affective disorder, antisocial personality, and heavy methamphetamine use.
UN	23433219_D008694_4_670_685_methamphetamine_D001523_4_721_742_psychiatric disorders	Patients with the diagnosis of methamphetamine based on DSM-IV were interviewed using the Mini International Neuropsychiatric Interview (M.I.N.I.) for methamphetamine-induced psychosis and other Axis I psychiatric disorders.
CID	23433219_D008694_7_1206_1221_methamphetamine_D001714_7_1082_1098_bipolar disorder	Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.
UN	23433219_D008694_7_1206_1221_methamphetamine_D003866_7_1031_1050_depressive disorder	Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.
CID	23433219_D008694_2_333_348_methamphetamine_D011605_2_357_366_psychosis	The association between psychiatric co-morbidity and methamphetamine-induced psychosis was also studied.
CID	23433219_D008694_0_35_50_methamphetamine_D011605_0_51_60_psychosis	The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia.
CID	23433219_D008694_1_201_216_methamphetamine_D011605_1_225_234_psychosis	OBJECTIVE: The objective of this study was to determine the risk of lifetime and current methamphetamine-induced psychosis in patients with methamphetamine dependence.
CID	23433219_D008694_7_1271_1286_methamphetamine_D011605_7_1295_1304_psychosis	Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.
CID	23433219_D008694_4_670_685_methamphetamine_D011605_4_694_703_psychosis	Patients with the diagnosis of methamphetamine based on DSM-IV were interviewed using the Mini International Neuropsychiatric Interview (M.I.N.I.) for methamphetamine-induced psychosis and other Axis I psychiatric disorders.
CID	23433219_D008694_11_1751_1766_methamphetamine_D011605_11_1801_1819_psychotic symptoms	It is recommended that all cases of methamphetamine dependence should be screened for psychotic symptoms.
CID	23433219_D008694_9_1579_1594_methamphetamine_D011605_9_1552_1561_psychosis	CONCLUSION: There was a high risk of psychosis in patients with methamphetamine dependence.
UN	23433219_D008694_10_1694_1709_methamphetamine_D019964_10_1640_1658_affective disorder	It was associated with co-morbid affective disorder, antisocial personality, and heavy methamphetamine use.
CID	23535177_D007980_1_221_229_levodopa_D004409_1_238_249_dyskinesias	The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and levodopa-induced dyskinesias (LIDs) is severely impaired.
UN	23535177_D007980_1_221_229_levodopa_D010300_1_213_215_PD	The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and levodopa-induced dyskinesias (LIDs) is severely impaired.
UN	2358093_D003613_0_24_31_danazol_D054179_0_46_67_hereditary angioedema	The long-term safety of danazol in women with hereditary angioedema.
UN	2358093_D003613_2_404_411_danazol_D054179_2_369_390_hereditary angioedema	We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with danazol for a continuous period of 6 months or longer.
CID	23666265_D003520_13_1776_1779_CYP_D003556_13_1788_1796_cystitis	CONCLUSIONS: In CYP-induced cystitis, the expression of P2X3 and NK1 receptors increased in urothelium and/or suburothelium.
CID	23666265_D003520_0_62_78_cyclophosphamide_D003556_0_87_95_cystitis	The function of P2X3 receptor and NK1 receptor antagonists on cyclophosphamide-induced cystitis in rats.
CID	23666265_D003520_1_225_228_CYP_D003556_1_238_246_cystitis	PURPOSE: The purpose of the study is to explore the function of P2X3 and NK1 receptors antagonists on cyclophosphamide (CYP)-induced cystitis in rats.
CID	23666265_D003520_4_739_742_CYP_D010146_4_692_696_pain	Spontaneous pain behaviors following the administration of CYP were observed.
CID	23666265_D003520_8_1053_1069_Cyclophosphamide_D010146_8_1106_1110_pain	RESULTS: Cyclophosphamide treatment increased the spontaneous pain behaviors scores.
UN	2383364_C048279_5_789_792_CHP_D002056_5_739_743_burn	One burn site was treated with each of four different CHP concentrations, from 0.25 per cent to 2 per cent, their vehicle, and 1 per cent silver sulphadiazine (AgSD) cream, an antimicrobial agent frequently used for topical treatment of burn wounds.
CID	2383364_C048279_7_1076_1079_CHP_D010146_7_1119_1123_pain	There was a direct relationship between CHP concentration and patients' ratings of pain on an analogue scale.
CID	2383364_C048279_8_1164_1167_CHP_D010146_8_1197_1201_pain	The 0.25 per cent CHP cream was closest to AgSD in pain tolerance; however, none of the treatments differed statistically from AgSD or from each other.
UN	2383364_D012837_5_873_893_silver sulphadiazine_D002056_5_972_976_burn	One burn site was treated with each of four different CHP concentrations, from 0.25 per cent to 2 per cent, their vehicle, and 1 per cent silver sulphadiazine (AgSD) cream, an antimicrobial agent frequently used for topical treatment of burn wounds.
UN	2383364_D012837_8_1189_1193_AgSD_D010146_8_1197_1201_pain	The 0.25 per cent CHP cream was closest to AgSD in pain tolerance; however, none of the treatments differed statistically from AgSD or from each other.
CID	23846525_C055162_5_607_618_clopidogrel_D056486_5_587_601_hepatic injury	In conclusion, we believe that physicians should carefully consider the risk of drug-induced hepatic injury when clopidogrel is prescribed.
CID	23846525_C055162_4_406_417_clopidogrel_D056486_4_384_398_hepatotoxicity	Reports about cases of hepatotoxicity due to clopidogrel are increasing in the last few years, after the increased use of this drug.
CID	23846525_C055162_2_239_250_clopidogrel_D056486_2_265_274_hepatitis	We describe a case of clopidogrel-related acute hepatitis.
CID	23846525_C055162_0_32_43_clopidogrel_D056486_0_6_15_hepatitis	Acute hepatitis associated with clopidogrel: a case report and review of the literature.
UN	23864035_C400082_11_1546_1550_Bort_D009101_11_1594_1596_MM	Bort-dex was an effective salvage treatment for MM patients, particularly for those in first relapse.
UN	23864035_D003907_11_1551_1554_dex_D009101_11_1594_1596_MM	Bort-dex was an effective salvage treatment for MM patients, particularly for those in first relapse.
UN	23864035_D003907_0_15_28_dexamethasone_D009101_0_85_101_multiple myeloma	Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
CID	23871786_C006780_0_21_32_Bisphenol A_D001008_0_43_50_anxiety	Pubertal exposure to Bisphenol A increases anxiety-like behavior and decreases acetylcholinesterase activity of hippocampus in adult male mice.
CID	23871786_C006780_9_1113_1116_BPA_D001008_9_1136_1143_anxiety	Our findings showed that pubertal BPA exposure increased anxiety-like behavior, which may be associated with decreased AChE activity of the hippocampus in adult male mice.
CID	23871786_C006780_7_883_886_BPA_D001008_7_828_835_anxiety	Results from our behavioral phenotyping indicated that anxiety-like behavior was increased in mice exposed to BPA.
CID	23872883_D007545_2_307_320_isoproterenol_D066126_2_329_343_cardiotoxicity	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats.
UN	23892921_C467567_2_569_571_RD_D009101_2_542_546_RRMM	We studied 212 RRMM patients who received RD in RW.
UN	23892921_C467567_0_48_60_lenalidomide_D009101_0_116_132_multiple myeloma	"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
UN	23892921_C467567_15_1799_1801_RD_D009101_15_1827_1831_RRMM	Our study confirms that RD is effective and safe in RRMM in the RW; it produces durable responses especially in patients who continue on treatment till progression and improves humoral immunity even in patients with stable disease.
UN	23892921_D003907_0_65_78_dexamethasone_D009101_0_116_132_multiple myeloma	"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
UN	23892921_D003907_15_1799_1801_RD_D009101_15_1827_1831_RRMM	Our study confirms that RD is effective and safe in RRMM in the RW; it produces durable responses especially in patients who continue on treatment till progression and improves humoral immunity even in patients with stable disease.
UN	23892921_D003907_2_569_571_RD_D009101_2_542_546_RRMM	We studied 212 RRMM patients who received RD in RW.
UN	23949582_D007069_8_1087_1090_IFO_D030342_8_1093_1105_genotoxicity	Mesna significantly reduces IFO's genotoxicity, while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug.
UN	23949582_D015080_8_1059_1064_Mesna_D030342_8_1093_1105_genotoxicity	Mesna significantly reduces IFO's genotoxicity, while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug.
CID	23952588_D007980_14_1421_1429_levodopa_D004409_14_1438_1448_dyskinesia	CONCLUSIONS: The prevalence of levodopa-induced dyskinesia in our patients was 44%.
CID	23952588_D007980_2_285_293_levodopa_D004409_2_302_312_dyskinesia	We studied the prevalence and predictors of levodopa-induced dyskinesia among multiethnic Malaysian patients with PD.
CID	23952588_D007980_13_1330_1338_levodopa_D004409_13_1302_1312_dyskinesia	The three significant predictors of dyskinesia were duration of levodopa therapy, onset age, and total daily levodopa dose.
CID	23952588_D007980_0_31_39_levodopa_D004409_0_48_58_dyskinesia	Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
UN	23952588_D007980_1_132_140_levodopa_D010300_1_153_172_Parkinson's disease	Chronic pulsatile levodopa therapy for Parkinson's disease (PD) leads to the development of motor fluctuations and dyskinesia.
UN	23952588_D007980_2_285_293_levodopa_D010300_2_355_357_PD	We studied the prevalence and predictors of levodopa-induced dyskinesia among multiethnic Malaysian patients with PD.
UN	23952588_D007980_3_447_455_levodopa_D010300_3_427_429_PD	METHODS: This is a cross-sectional study involving 95 patients with PD on uninterrupted levodopa therapy for at least 6 months.
UN	23952588_D007980_0_31_39_levodopa_D010300_0_93_112_Parkinson's disease	Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
UN	2400986_D002066_2_327_335_busulfan_D001932_2_424_436_brain tumors	We report here a retrospective study of 123 children (median age, 6.5 years) receiving high-dose busulfan in combined chemotherapy before bone marrow transplantation for malignant solid tumors, brain tumors excluded.
UN	2400986_D002066_9_1455_1463_busulfan_D002493_9_1408_1438_central nervous system disease	Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg/m2 busulfan with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1.39.
UN	2400986_D002066_2_327_335_busulfan_D009369_2_416_422_tumors	We report here a retrospective study of 123 children (median age, 6.5 years) receiving high-dose busulfan in combined chemotherapy before bone marrow transplantation for malignant solid tumors, brain tumors excluded.
UN	2400986_D002066_8_1168_1176_busulfan_D009461_8_1246_1267_neurological symptoms	Twenty-seven patients were given a 600-mg/m2 busulfan total dose with continuous i.v. infusion of clonazepam; none had any neurological symptoms.
CID	2400986_D002066_6_833_841_busulfan_D012640_6_799_807_seizures	Ninety-six patients were not given anticonvulsive prophylaxis; 7 (7.5%) developed seizures during the 4 days of the busulfan course or within 24 h after the last dosing.
UN	2400986_D002066_0_42_50_busulfan_D020258_0_15_28_neurotoxicity	Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.
UN	2400986_D002066_1_102_110_Busulfan_D020258_1_126_136_neurotoxic	Busulfan is known to be neurotoxic in animals and humans, but its acute neurotoxicity remains poorly characterized in children.
UN	2400986_D002066_11_1724_1732_busulfan_D020258_11_1733_1746_neurotoxicity	This study shows that busulfan neurotoxicity is dose-dependent in children and efficiently prevented by clonazepam.
UN	2400986_D002998_9_1469_1479_clonazepam_D002493_9_1408_1438_central nervous system disease	Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg/m2 busulfan with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1.39.
UN	2400986_D002998_8_1221_1231_clonazepam_D009461_8_1246_1267_neurological symptoms	Twenty-seven patients were given a 600-mg/m2 busulfan total dose with continuous i.v. infusion of clonazepam; none had any neurological symptoms.
UN	2400986_D002998_11_1806_1816_clonazepam_D020258_11_1733_1746_neurotoxicity	This study shows that busulfan neurotoxicity is dose-dependent in children and efficiently prevented by clonazepam.
CID	24040781_C107135_3_718_728_everolimus_D000686_3_543_554_amyloidosis	In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.
CID	24040781_C107135_0_84_94_everolimus_D000686_0_96_98_AL	An unexpected diagnosis in a renal-transplant patient with proteinuria treated with everolimus: AL amyloidosis.
CID	24040781_C107135_3_718_728_everolimus_D011507_3_670_681_proteinuria	In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.
CID	24040781_C107135_0_84_94_everolimus_D011507_0_59_70_proteinuria	An unexpected diagnosis in a renal-transplant patient with proteinuria treated with everolimus: AL amyloidosis.
UN	24040781_D016559_3_704_714_tacrolimus_D000686_3_543_554_amyloidosis	In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.
UN	24040781_D016559_3_704_714_tacrolimus_D011507_3_670_681_proteinuria	In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.
UN	24040781_D020123_1_208_217_rapamycin_D011507_1_112_123_Proteinuria	Proteinuria is an expected complication in transplant patients treated with mammalian target of rapamycin inhibitors (mTOR-i).
UN	24055495_D005690_9_1678_1687_galactose_D000544_9_1871_1873_AD	Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD.
CID	24055495_D005690_0_15_24_galactose_D003072_0_44_62_cognitive deficits	Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin.
UN	24055495_D005690_3_688_697_galactose_D008569_3_705_725_memory deterioration	Exclusively parenteral daily injections of galactose induce memory deterioration in rodents and are used to generate animal aging model, but the effects of oral galactose treatment on cognitive functions have never been tested.
UN	24055495_D005690_9_1678_1687_galactose_D018149_9_1845_1867_glucose hypometabolism	Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD.
CID	24055495_D005947_1_329_336_glucose_D000544_1_209_228_Alzheimer's disease	Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.
UN	24055495_D005947_1_329_336_glucose_D003704_1_188_196_dementia	Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.
CID	24055495_D013311_0_122_136_streptozotocin_D003072_0_44_62_cognitive deficits	Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin.
CID	24055495_D013311_4_992_1006_streptozotocin_D003072_4_970_988_cognitive deficits	We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.
CID	24055495_D013311_5_1249_1252_STZ_D003072_5_1265_1283_cognitive deficits	One month of oral galactose treatment initiated immediately after the STZ-icv administration, successfully prevented development of the STZ-icv-induced cognitive deficits.
CID	24067251_C418563_7_1167_1170_TDF_D005198_7_1251_1267_Fanconi syndrome	The incidence of hospitalisation for TDF kidney adverse effects was high, particularly amongst patients with features of Fanconi syndrome.
CID	24067251_C418563_5_874_877_TDF_D005198_5_1044_1060_Fanconi syndrome	Of the 407 Yellow Card records analysed, 106 satisfied criteria for TDF-related kidney disease, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had Fanconi syndrome.
UN	24067251_C418563_0_84_113_tenofovir disoproxil fumarate_D007674_0_35_48_kidney injury	An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database).
UN	24067251_C418563_5_874_877_TDF_D007674_5_886_900_kidney disease	Of the 407 Yellow Card records analysed, 106 satisfied criteria for TDF-related kidney disease, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had Fanconi syndrome.
CID	24068571_D013874_9_1226_1237_thiopentone_D003693_9_1302_1310_delirium	The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02).
UN	24068571_D015742_9_1323_1331_propofol_D003693_9_1302_1310_delirium	The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02).
UN	24072398_D004298_6_1072_1080_dopamine_D003866_6_885_895_depressive	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.
UN	24072398_D006719_6_1092_1095_HVA_D003866_6_885_895_depressive	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.
CID	24072398_D008694_8_1503_1507_METH_D003866_8_1529_1539_depressive	These findings demonstrate for the first time that a single high dose of METH induces long-lasting depressive-like behaviour in mice associated with a persistent disruption of frontostriatal dopaminergic and serotonergic homoeostasis.
CID	24072398_D008694_6_920_924_METH_D003866_6_885_895_depressive	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.
CID	24072398_D008694_0_28_43_methamphetamine_D003866_0_67_77_depressive	A single neurotoxic dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.
CID	24072398_D008694_1_179_183_METH_D003866_1_235_254_depressive symptoms	Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal.
CID	24072398_D008694_2_341_345_METH_D003866_2_373_383_depressive	However, it is currently unknown if the acute toxic dosage of METH also causes a long-lasting depressive phenotype and persistent monoaminergic deficits.
UN	24072398_D008694_0_28_43_methamphetamine_D020258_0_9_19_neurotoxic	A single neurotoxic dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.
UN	24072398_D012701_6_1122_1131_serotonin_D003866_6_885_895_depressive	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.
UN	24072398_D014443_6_1097_1105_tyrosine_D003866_6_885_895_depressive	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.
UN	24072398_D015102_6_1082_1087_DOPAC_D003866_6_885_895_depressive	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.
CID	24088636_C098010_0_0_9_Linezolid_D009901_0_18_34_optic neuropathy	Linezolid-induced optic neuropathy.
UN	24088636_C098010_3_301_310_linezolid_D014786_3_270_284_loss of vision	We describe a case of progressive loss of vision associated with linezolid therapy.
UN	24088636_C098010_4_427_436_linezolid_D054908_4_456_495_extensively drug-resistant tuberculosis	A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.
UN	24088636_D004977_6_666_676_Ethambutol_D009901_6_685_707_toxic optic neuropathy	Ethambutol-induced toxic optic neuropathy was suspected and tablet ethambutol was withdrawn.
UN	24088636_D004977_4_441_451_ethambutol_D014786_4_547_561_loss of vision	A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.
UN	24088636_D004977_7_814_824_ethambutol_D015354_7_759_782_Deterioration of vision	Deterioration of vision occurred despite withdrawal of ethambutol.
UN	24088636_D004977_4_441_451_ethambutol_D054908_4_456_495_extensively drug-resistant tuberculosis	A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.
CID	24091473_C476513_2_316_331_levobupivacaine_D002318_2_338_361_cardiovascular collapse	METHODS: Newborn piglets received levobupivacaine until cardiovascular collapse occurred.
UN	24091473_C476513_0_50_65_levobupivacaine_D066126_0_74_90_cardiac toxicity	Resuscitation with lipid, epinephrine, or both in levobupivacaine-induced cardiac toxicity in newborn piglets.
UN	24091473_D004837_0_26_37_epinephrine_D066126_0_74_90_cardiac toxicity	Resuscitation with lipid, epinephrine, or both in levobupivacaine-induced cardiac toxicity in newborn piglets.
CID	24100055_D006493_2_364_371_heparin_D013921_2_380_404_thrombocytopenia type II	The impact of immune-mediated heparin-induced thrombocytopenia type II (HIT type II) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results.
CID	24100055_D006493_0_13_20_heparin_D013921_0_29_53_thrombocytopenia type II	Incidence of heparin-induced thrombocytopenia type II and postoperative recovery of platelet count in liver graft recipients: a retrospective cohort analysis.
CID	24100257_C089750_7_1370_1382_zolmitriptan_D003329_7_1331_1356_coronary artery vasospasm	Extensive literature search revealed multiple cases of coronary artery vasospasm secondary to zolmitriptan, but none of the cases were associated with TS.
UN	24100257_C089750_3_896_908_zolmitriptan_D008881_3_937_946_migraines	Detailed history obtained retrospectively revealed that the patient took zolmitriptan sparingly only when she had migraines.
CID	24100257_C089750_0_64_76_Zolmitriptan_D054549_0_23_49_apical ballooning syndrome	Takotsubo syndrome (or apical ballooning syndrome) secondary to Zolmitriptan.
CID	24114426_D018817_0_83_116_3,4-methylenedioxymethamphetamine_D003866_0_0_10_Depression	Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
CID	24114426_D018817_9_1803_1810_ecstasy_D003866_9_1709_1719_depression	CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern.
UN	24114426_D018817_9_1803_1810_ecstasy_D008569_9_1656_1671_impaired memory	CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern.
CID	24114426_D018817_9_1803_1810_ecstasy_D010554_9_1721_1734_impulsiveness	CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern.
CID	24114426_D018817_0_83_116_3,4-methylenedioxymethamphetamine_D010554_0_12_25_impulsiveness	Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
CID	24114426_D018817_9_1803_1810_ecstasy_D020920_9_1740_1757_sleep disturbance	CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern.
CID	24126708_D007980_1_117_125_Levodopa_D004409_1_281_291_dyskinesia	Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations.
CID	24126708_D007980_1_117_125_Levodopa_D006212_1_296_317_visual hallucinations	Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations.
UN	24126708_D007980_1_117_125_Levodopa_D010300_1_172_191_Parkinson's disease	Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations.
UN	24126708_D007980_0_59_67_levodopa_D010300_0_87_106_Parkinson's disease	Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients.
UN	24132704_C029036_12_1530_1536_Crocin_D006949_12_1595_1607_hyperlipemia	Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript.
CID	24132704_D003976_13_1718_1726_diazinon_D006949_13_1735_1747_hyperlipemia	CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.
CID	24132704_D003976_12_1578_1586_diazinon_D006949_12_1595_1607_hyperlipemia	Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript.
UN	24158386_C056507_5_692_703_gemcitabine_D006689_5_676_678_HL	In this retrospective single-centre analysis, patients with relapsed or refractory HL treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; methylprednisolone 1,000 mg D1-5; and cisplatin 100 mg/m(2) D15, every 28 days (GEM-P) were included.
UN	24158386_C056507_4_439_450_Gemcitabine_D006689_4_482_484_HL	Gemcitabine and cisplatin have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting.
UN	24158386_D002945_4_455_464_cisplatin_D006689_4_482_484_HL	Gemcitabine and cisplatin have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting.
UN	24158386_D008775_5_740_758_methylprednisolone_D006689_5_676_678_HL	In this retrospective single-centre analysis, patients with relapsed or refractory HL treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; methylprednisolone 1,000 mg D1-5; and cisplatin 100 mg/m(2) D15, every 28 days (GEM-P) were included.
UN	24190587_D018817_10_1699_1706_ecstasy_D001008_10_1621_1628_anxiety	CONCLUSIONS: The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users.
CID	24190587_D018817_10_1699_1706_ecstasy_D003866_10_1633_1643_depression	CONCLUSIONS: The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users.
UN	24190587_D018817_1_145_152_Ecstasy_D008107_1_224_252_psychobiological dysfunction	RATIONALE: Ecstasy (MDMA) is a psychostimulant drug which is increasingly associated with psychobiological dysfunction.
UN	24209900_D007069_0_0_10_Ifosfamide_D001927_0_19_33_encephalopathy	Ifosfamide related encephalopathy: the need for a timely EEG evaluation.
UN	24209900_D007069_4_652_662_ifosfamide_D001927_4_677_691_encephalopathy	METHODS: Retrospective chart review including clinical data and EEG recordings was done on five patients, admitted to MD Anderson Cancer Center between years 2009 and 2012, who developed ifosfamide related acute encephalopathy.
UN	24209900_D007069_3_430_440_ifosfamide_D001927_3_449_463_encephalopathy	OBJECTIVE: To highlight the role of electroencephalogram (EEG) in the early detection and management of ifosfamide related encephalopathy.
UN	24209900_D007069_11_1477_1487_ifosfamide_D001927_11_1512_1526_encephalopathy	We suggest a timely EEG evaluation for patients receiving ifosfamide who develop features of encephalopathy.
UN	24209900_D007069_10_1356_1366_ifosfamide_D001927_10_1375_1389_encephalopathy	CONCLUSIONS: Severity of ifosfamide related encephalopathy correlates with EEG changes.
UN	24209900_D007069_1_85_95_Ifosfamide_D008223_1_190_198_lymphoma	BACKGROUND: Ifosfamide is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas, lymphoma, gynecologic and testicular cancers.
UN	24209900_D007069_4_652_662_ifosfamide_D009369_4_595_601_Cancer	METHODS: Retrospective chart review including clinical data and EEG recordings was done on five patients, admitted to MD Anderson Cancer Center between years 2009 and 2012, who developed ifosfamide related acute encephalopathy.
UN	24209900_D007069_1_85_95_Ifosfamide_D009369_1_162_169_cancers	BACKGROUND: Ifosfamide is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas, lymphoma, gynecologic and testicular cancers.
UN	24209900_D007069_1_85_95_Ifosfamide_D012509_1_180_188_sarcomas	BACKGROUND: Ifosfamide is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas, lymphoma, gynecologic and testicular cancers.
UN	24220752_C051890_13_1350_1360_irinotecan_D006973_13_1302_1314_Hypertension	Hypertension and the combination of bevacizumab/irinotecan may be additional risk factors for CIN development.
CID	24220752_D003287_0_13_21_contrast_D007674_0_30_41_nephropathy	Incidence of contrast-induced nephropathy in hospitalised patients with cancer.
CID	24220752_D003287_15_1427_1435_Contrast_D007674_15_1444_1455_nephropathy	Contrast-induced nephropathy (CIN) is a concern for oncological patients undergoing CT. .
CID	24220752_D003287_1_154_162_contrast_D007674_1_171_182_nephropathy	OBJECTIVES: To determine the frequency of and possible factors related to contrast-induced nephropathy (CIN) in hospitalised patients with cancer.
UN	24220752_D003287_0_13_21_contrast_D009369_0_72_78_cancer	Incidence of contrast-induced nephropathy in hospitalised patients with cancer.
CID	24234943_C086816_3_298_312_desvenlafaxine_D001008_3_344_351_anxiety	Her medications included desvenlafaxine, and symptoms included nausea, anxiety and confusion.
CID	24234943_C086816_3_298_312_desvenlafaxine_D003221_3_356_365_confusion	Her medications included desvenlafaxine, and symptoms included nausea, anxiety and confusion.
CID	24234943_C086816_9_926_940_desvenlafaxine_D007010_9_976_988_hyponatremia	This case report suggests that desvenlafaxine might cause clinically significant hyponatremia.
CID	24234943_C086816_0_73_87_desvenlafaxine_D007177_0_0_46_Syndrome of inappropriate antidiuretic hormone	Syndrome of inappropriate antidiuretic hormone secretion associated with desvenlafaxine.
CID	24234943_C086816_1_202_216_desvenlafaxine_D007177_1_169_174_SIADH	OBJECTIVE: To report a case of syndrome of inappropriate anti-diuretic hormone (SIADH) secretion associated with desvenlafaxine.
CID	24234943_C086816_3_298_312_desvenlafaxine_D009325_3_336_342_nausea	Her medications included desvenlafaxine, and symptoms included nausea, anxiety and confusion.
UN	24234943_D012964_4_490_496_sodium_D007177_4_539_544_SIADH	The serum sodium at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH.
UN	24275640_D004317_5_874_877_DOX_D006331_5_908_930_cardiac disarrangement	Single dose of DOX was associated with increased cardiac disarrangement, necrosis, and DNA damage (strand breaks (SBs) and oxidized pyrimidines) and decreased TAP.
CID	24275640_D004317_5_874_877_DOX_D009336_5_932_940_necrosis	Single dose of DOX was associated with increased cardiac disarrangement, necrosis, and DNA damage (strand breaks (SBs) and oxidized pyrimidines) and decreased TAP.
CID	24275640_D004317_8_1440_1443_DOX_D066126_8_1397_1411_cardiotoxicity	Our results suggest that oxidative damage is associated with acute cardiotoxicity induced by a single dose of DOX only.
CID	24275640_D004317_1_128_131_DOX_D066126_1_141_155_cardiotoxicity	The mechanism of doxorubicin (DOX)-induced cardiotoxicity remains controversial.
CID	24275640_D004317_0_85_96_doxorubicin_D066126_0_20_34_cardiotoxicity	Oxidative stress on cardiotoxicity after treatment with single and multiple doses of doxorubicin.
UN	24283660_D001663_6_881_890_bilirubin_D004830_6_614_635_tonic-clonic seizures	All exhibited generalized tonic-clonic seizures within the first two wk after LT. Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.
UN	24283660_D001663_6_881_890_bilirubin_D012640_6_735_743_seizures	All exhibited generalized tonic-clonic seizures within the first two wk after LT. Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.
UN	24283660_D001663_6_881_890_bilirubin_D058625_6_790_813_end-stage liver disease	All exhibited generalized tonic-clonic seizures within the first two wk after LT. Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.
UN	24283660_D016559_6_917_920_TAC_D004830_6_614_635_tonic-clonic seizures	All exhibited generalized tonic-clonic seizures within the first two wk after LT. Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.
CID	24283660_D016559_9_1472_1475_TAC_D012640_9_1484_1492_seizures	High trough TAC level was the predominant factor that contributed to seizures in the early post-operative period after pediatric LT. High PELD and Child-Pugh scores before LT and high post-operative serum Tbil may be contributory risk factors for TAC-related seizures.
CID	24283660_D016559_0_0_10_Tacrolimus_D012640_0_19_26_seizure	Tacrolimus-related seizure after pediatric liver transplantation--a single-center experience.
UN	24283660_D016559_6_917_920_TAC_D058625_6_790_813_end-stage liver disease	All exhibited generalized tonic-clonic seizures within the first two wk after LT. Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.
CID	24284476_D012601_3_504_515_scopolamine_D000647_3_485_492_amnesia	Furthermore, apigenin did not prevent the amnesia induced by scopolamine (1mg/kg, i.p., 30 min before the acquisition).
UN	24284476_D047310_3_456_464_apigenin_D000647_3_485_492_amnesia	Furthermore, apigenin did not prevent the amnesia induced by scopolamine (1mg/kg, i.p., 30 min before the acquisition).
UN	2429800_D006632_0_0_9_Histamine_D007022_0_49_60_hypotension	Histamine antagonists and d-tubocurarine-induced hypotension in cardiac surgical patients.
CID	2429800_D014403_0_26_40_d-tubocurarine_D007022_0_49_60_hypotension	Histamine antagonists and d-tubocurarine-induced hypotension in cardiac surgical patients.
CID	24309294_D009020_2_324_332_morphine_D000647_2_341_348_amnesia	We have previously reported that CCK-8 significantly alleviated morphine-induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.
UN	24309294_D009020_8_1409_1417_morphine_D008569_8_1426_1443_memory impairment	The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on morphine-induced memory impairment.
UN	24309294_D012844_2_293_298_CCK-8_D000647_2_341_348_amnesia	We have previously reported that CCK-8 significantly alleviated morphine-induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.
UN	24309294_D012844_8_1400_1405_CCK-8_D008569_8_1426_1443_memory impairment	The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on morphine-induced memory impairment.
UN	24333387_D007052_7_1114_1123_Ibuprofen_D020258_7_1233_1246_neurotoxicity	Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.
UN	24333387_D008559_7_1090_1099_Memantine_D020258_7_1233_1246_neurotoxicity	Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.
CID	24333387_D013311_3_401_404_STZ_D007249_3_490_507_neuroinflammation	STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and neuroinflammation.
CID	24333387_D013311_1_224_227_STZ_D008569_1_237_252_memory impaired	In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (STZ) induced memory impaired rats was explored.
CID	24333387_D013311_12_1808_1811_STZ_D008569_12_1820_1837_memory impairment	Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in STZ induced memory impairment and neuronal cell death.
CID	24333387_D013311_0_68_82_Streptozotocin_D008569_0_97_114_memory impairment	Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats.
UN	24333387_D013311_12_1808_1811_STZ_D020258_12_1771_1784_neurotoxicity	Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in STZ induced memory impairment and neuronal cell death.
UN	24341598_D003287_1_140_148_Contrast_D007674_1_157_168_nephropathy	INTRODUCTION AND OBJECTIVE: Contrast-induced nephropathy (CIN) significantly increases the morbidity and mortality of patients.
UN	24341598_D003287_0_82_90_contrast_D007674_0_99_110_nephropathy	Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast-induced nephropathy.
CID	24341598_D003287_9_1533_1541_contrast_D058186_9_1504_1507_ARF	Among a total of 60 patients included in the study, 16 patients developed acute renal failure (ARF) on the second day after contrast material was injected (26.6%).
UN	24341598_D004110_0_55_64_diltiazem_D007674_0_99_110_nephropathy	Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast-induced nephropathy.
UN	24341598_D012965_0_34_49_sodium chloride_D007674_0_99_110_nephropathy	Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast-induced nephropathy.
UN	24345882_D008727_2_334_337_MTX_D020258_2_339_352_neurotoxicity	Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.
UN	24345882_D008727_2_461_464_MTX_D054198_2_497_525_acute lymphoblastic leukemia	Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.
CID	24434397_D014148_5_488_491_TNA_D004830_5_527_551_tonic clonic convulsions	Two hours after the sixth dose of TNA, she had an episode of generalized tonic clonic convulsions.
UN	24434397_D014148_4_362_377_Tranexamic acid_D006470_4_432_440_bleeding	Tranexamic acid (TNA) 1 g 8-hourly was administered to her to control bleeding per vaginum.
UN	24434397_D014148_10_949_952_TNA_D012640_10_903_914_convulsions	Thus, the precipitating cause of convulsions was believed to be an overdose of TNA.
UN	24434397_D014148_0_0_15_Tranexamic acid_D012640_0_47_54_seizure	Tranexamic acid overdosage-induced generalized seizure in renal failure.
UN	24434397_D014148_0_0_15_Tranexamic acid_D051437_0_58_71_renal failure	Tranexamic acid overdosage-induced generalized seizure in renal failure.
UN	24434397_D014148_10_949_952_TNA_D062787_10_937_945_overdose	Thus, the precipitating cause of convulsions was believed to be an overdose of TNA.
UN	24438483_D002045_5_854_865_bupivacaine_D001145_5_696_707_dysrhythmia	We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption.
UN	24438483_D002045_0_17_28_bupivacaine_D002318_0_37_62_cardiovascular depression	Pre-treatment of bupivacaine-induced cardiovascular depression using different lipid formulations of propofol.
CID	24438483_D002045_5_854_865_bupivacaine_D006323_5_825_833_asystole	We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption.
CID	24438483_D002045_8_1504_1515_bupivacaine_D066126_8_1524_1535_cardiotoxic	The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.
CID	24438483_D002045_1_262_273_bupivacaine_D066126_1_282_296_cardiotoxicity	BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity.
CID	24438483_D002045_2_403_414_bupivacaine_D066126_2_423_437_cardiotoxicity	The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced cardiotoxicity.
UN	24438483_D015742_0_101_109_propofol_D002318_0_37_62_cardiovascular depression	Pre-treatment of bupivacaine-induced cardiovascular depression using different lipid formulations of propofol.
UN	24438483_D015742_1_239_247_propofol_D066126_1_282_296_cardiotoxicity	BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity.
UN	24438483_D015742_2_353_361_propofol_D066126_2_423_437_cardiotoxicity	The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced cardiotoxicity.
CID	24451297_C065180_0_54_65_Fluvastatin_D056486_0_0_31_Drug-Induced Acute Liver Injury	Drug-Induced Acute Liver Injury Within 12 Hours After Fluvastatin Therapy.
UN	24451297_D019161_1_84_91_statins_D056486_1_144_169_drug-induced liver injury	Although statins are generally well-tolerated drugs, recent cases of drug-induced liver injury associated with their use have been reported.
CID	24459006_D015725_1_96_107_fluconazole_D000380_1_119_134_agranulocytosis	CASE: We describe a second case of fluconazole associated agranulocytosis with thrombocytopenia and recovery upon discontinuation of therapy.
CID	24459006_D015725_0_0_11_Fluconazole_D000380_0_23_38_agranulocytosis	Fluconazole associated agranulocytosis and thrombocytopenia.
CID	24459006_D015725_4_673_684_fluconazole_D000380_4_599_614_agranulocytosis	CONCLUSION: According to Naranjo's algorithm the likelihood that our patient's agranulocytosis and thrombocytopenia occurred as a result of therapy with fluconazole is probable, with a total of six points.
UN	24459006_D015725_6_890_901_fluconazole_D001855_6_845_868_bone marrow suppression	In particular the temporal relationship of bone marrow suppression to the initiation of fluconazole and the abatement of symptoms that rapidly reversed immediately following discontinuation.
CID	24459006_D015725_4_673_684_fluconazole_D013921_4_619_635_thrombocytopenia	CONCLUSION: According to Naranjo's algorithm the likelihood that our patient's agranulocytosis and thrombocytopenia occurred as a result of therapy with fluconazole is probable, with a total of six points.
CID	24459006_D015725_0_0_11_Fluconazole_D013921_0_43_59_thrombocytopenia	Fluconazole associated agranulocytosis and thrombocytopenia.
CID	24459006_D015725_1_96_107_fluconazole_D013921_1_140_156_thrombocytopenia	CASE: We describe a second case of fluconazole associated agranulocytosis with thrombocytopenia and recovery upon discontinuation of therapy.
UN	24464946_D015251_1_355_365_epirubicin_D006331_1_317_336_cardiac dysfunction	AIMS: To investigate whether alterations of myocardial strain and high-sensitive cardiac troponin T (cTnT) could predict future cardiac dysfunction in patients after epirubicin exposure.
UN	24464946_D015251_2_446_456_epirubicin_D008228_2_412_432_non-Hodgkin lymphoma	METHODS: Seventy-five patients with non-Hodgkin lymphoma treated with epirubicin were studied.
UN	24464946_D015251_1_355_365_epirubicin_D009202_1_233_250_myocardial strain	AIMS: To investigate whether alterations of myocardial strain and high-sensitive cardiac troponin T (cTnT) could predict future cardiac dysfunction in patients after epirubicin exposure.
CID	24464946_D015251_0_157_168_epirubicine_D066126_0_135_149_cardiotoxicity	Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.
UN	24464946_D018943_12_1929_1942_anthracycline_D006331_12_1887_1906_cardiac dysfunction	CONCLUSIONS: GLS combined with cTnT may provide a reliable and non-invasive method to predict cardiac dysfunction in patients receiving anthracycline-based chemotherapy.
UN	24535067_D005045_6_1064_1073_etomidate_D009069_6_940_959_Myoclonic movements	Myoclonic movements are evaluated, which were observed and graded according to clinical severity during the 2 minutes after etomidate injection.
CID	24535067_D005045_9_1532_1541_etomidate_D009207_9_1550_1559_myoclonus	CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.
CID	24535067_D005045_2_306_315_etomidate_D009207_2_324_333_myoclonus	BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.
CID	24535067_D005045_0_14_23_etomidate_D009207_0_32_41_myoclonus	Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination?
UN	24535067_D005045_7_1113_1122_etomidate_D010146_7_1101_1105_pain	The severity of pain due to etomidate injection, mean arterial pressure, heart rate, and adverse effects were also evaluated.
UN	24535067_D005283_2_272_280_fentanyl_D009207_2_324_333_myoclonus	BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.
UN	24535067_D005283_9_1481_1489_fentanyl_D009207_9_1550_1559_myoclonus	CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.
UN	24535067_D008874_9_1494_1503_midazolam_D009207_9_1550_1559_myoclonus	CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.
UN	24535067_D008874_2_285_294_midazolam_D009207_2_324_333_myoclonus	BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.
CID	2453942_D001556_3_388_395_lindane_D012640_3_552_560_seizures	We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, dopamine and its metabolites in 7 brain areas at the onset of seizures.
CID	2453942_D001556_4_627_634_lindane_D012640_4_589_600_convulsions	All animals suffered tonic convulsions at 18.3 +/- 1.4 min after lindane administration.
UN	2453942_D001556_1_93_120_gamma-hexachlorocyclohexane_D020258_1_166_176_neurotoxic	Lindane (gamma-hexachlorocyclohexane) is an organochlorine insecticide with known neurotoxic effects.
UN	2453942_D004298_3_490_498_dopamine_D012640_3_552_560_seizures	We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, dopamine and its metabolites in 7 brain areas at the onset of seizures.
UN	2453942_D005680_3_484_488_GABA_D012640_3_552_560_seizures	We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, dopamine and its metabolites in 7 brain areas at the onset of seizures.
CID	24554916_D010758_3_522_532_phosphorus_D002779_3_465_476_cholestasis	We present a case of yellow phosphorus poisoning in which a patient presented with florid clinical features of cholestasis highlighting the fact that cholestasis can rarely be a presenting feature of yellow phosphorus hepatotoxicity.
CID	24554916_D010758_0_35_45_phosphorus_D002779_0_0_11_Cholestatic	Cholestatic presentation of yellow phosphorus poisoning.
CID	24554916_D010758_2_192_202_phosphorus_D006505_2_230_245_acute hepatitis	Poisoning with yellow phosphorus classically manifests with acute hepatitis leading to acute liver failure which may need liver transplantation.
UN	24554916_D010758_3_343_353_phosphorus_D011041_3_354_363_poisoning	We present a case of yellow phosphorus poisoning in which a patient presented with florid clinical features of cholestasis highlighting the fact that cholestasis can rarely be a presenting feature of yellow phosphorus hepatotoxicity.
UN	24554916_D010758_0_35_45_phosphorus_D011041_0_46_55_poisoning	Cholestatic presentation of yellow phosphorus poisoning.
UN	24554916_D010758_2_192_202_phosphorus_D011041_2_170_179_Poisoning	Poisoning with yellow phosphorus classically manifests with acute hepatitis leading to acute liver failure which may need liver transplantation.
CID	24554916_D010758_2_192_202_phosphorus_D017114_2_257_276_acute liver failure	Poisoning with yellow phosphorus classically manifests with acute hepatitis leading to acute liver failure which may need liver transplantation.
UN	24554916_D010758_3_522_532_phosphorus_D056486_3_533_547_hepatotoxicity	We present a case of yellow phosphorus poisoning in which a patient presented with florid clinical features of cholestasis highlighting the fact that cholestasis can rarely be a presenting feature of yellow phosphorus hepatotoxicity.
CID	24571687_D020927_0_62_77_dexmedetomidine_D001919_0_29_40_bradycardia	Vasovagal syncope and severe bradycardia following intranasal dexmedetomidine for pediatric procedural sedation.
UN	24571687_D020927_1_209_224_dexmedetomidine_D013575_1_123_130_syncope	We report syncope and bradycardia in an 11-year-old girl following administration of intranasal dexmedetomidine for sedation for a voiding cystourethrogram.
CID	24571687_D020927_0_62_77_dexmedetomidine_D019462_0_0_17_Vasovagal syncope	Vasovagal syncope and severe bradycardia following intranasal dexmedetomidine for pediatric procedural sedation.
UN	24582773_C069541_3_531_541_quetiapine_D010554_3_684_698_aggressiveness	Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder.
CID	24582773_C069541_5_951_961_quetiapine_D011595_5_925_934_agitation	The withdrawal and the gradual reintroduction of quetiapine 2 weeks later, which led to another severe agitation, enabled us to attribute the agitation specifically to quetiapine.
CID	24582773_C069541_0_58_68_quetiapine_D011595_0_19_28_agitation	Paradoxical severe agitation induced by add-on high-doses quetiapine in schizo-affective disorder.
UN	24582773_C069541_0_58_68_quetiapine_D011618_0_72_97_schizo-affective disorder	Paradoxical severe agitation induced by add-on high-doses quetiapine in schizo-affective disorder.
UN	24582773_D003006_1_272_286_zuclopenthixol_D011618_1_158_183_schizo-affective disorder	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum lithium=0.85 mEq/l).
UN	24582773_D008094_1_304_311_lithium_D011618_1_158_183_schizo-affective disorder	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum lithium=0.85 mEq/l).
CID	24587916_D003907_3_376_379_Dex_D006973_3_358_370_hypertension	In this study, we investigated the effect of chronic administration of LF on oxidative stress and hypertension upon Dex administration.
CID	24587916_D003907_13_1356_1359_Dex_D006973_13_1368_1380_hypertension	Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.
CID	24587916_D003907_0_45_58_dexamethasone_D006973_0_67_79_hypertension	Antioxidant effects of bovine lactoferrin on dexamethasone-induced hypertension in rat.
CID	24587916_D003907_1_104_107_Dex_D006973_1_118_130_hypertension	Dexamethasone- (Dex-) induced hypertension is associated with enhanced oxidative stress.
CID	24587916_D003907_11_1098_1101_Dex_D006973_11_1110_1122_hypertension	LF lowered (P < 0.01) and dose dependently prevented (P < 0.001) Dex-induced hypertension.
UN	24587916_D006861_12_1200_1204_H2O2_D015431_12_1142_1153_weight loss	LF prevented body weight loss and significantly reduced the elevated plasma H2O2 and increased FRAP values.
UN	24588023_D014148_8_1220_1235_tranexamic acid_D006333_8_1122_1146_congestive heart failure	Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.
UN	24588023_D014148_8_1220_1235_tranexamic acid_D007035_8_1153_1164_hypothermic	Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.
CID	24588023_D014148_9_1288_1303_tranexamic acid_D012640_9_1342_1350_seizures	When tested in a multivariate regression analysis, tranexamic acid was a strong independent predictor of seizures (OR 14.3, 95% CI 5.5-36.7; p < 0.001).
CID	24588023_D014148_0_24_39_tranexamic acid_D012640_0_44_54_convulsive	The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients.
CID	24595967_D018817_0_48_55_ecstasy_D008569_0_0_30_Dysfunctional overnight memory	Dysfunctional overnight memory consolidation in ecstasy users.
CID	24595967_D018817_8_1210_1217_ecstasy_D008569_8_1180_1198_memory impairments	We suggest that ecstasy-associated dysfunction in fronto-temporal circuitry may underlie overnight consolidation memory impairments in regular ecstasy users.
CID	24595967_D018817_6_692_699_Ecstasy_D008569_6_719_744_impaired overnight memory	Ecstasy users demonstrated impaired overnight memory consolidation, a finding that was more pronounced following associative interference.
CID	24595967_D018817_2_223_230_ecstasy_D012893_2_283_308_sleep-related impairments	Previous studies indicate that ecstasy users have marked and persistent neurocognitive and sleep-related impairments.
UN	24614773_D014635_6_822_831_valproate_D001927_6_840_854_encephalopathy	The possible aetiologies of valproate-induced encephalopathy and NMDA receptor-associated encephalitis present a diagnostic dilemma.
UN	24614773_D014635_6_822_831_valproate_D004660_6_884_896_encephalitis	The possible aetiologies of valproate-induced encephalopathy and NMDA receptor-associated encephalitis present a diagnostic dilemma.
UN	24614773_D014635_2_349_358_valproate_D010291_2_294_305_hemiparesis	In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed hemiplegic migraine.
UN	24614773_D014635_2_349_358_valproate_D020325_2_372_391_hemiplegic migraine	In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed hemiplegic migraine.
UN	24614773_D016202_6_859_863_NMDA_D001927_6_840_854_encephalopathy	The possible aetiologies of valproate-induced encephalopathy and NMDA receptor-associated encephalitis present a diagnostic dilemma.
UN	24614773_D016202_6_859_863_NMDA_D004660_6_884_896_encephalitis	The possible aetiologies of valproate-induced encephalopathy and NMDA receptor-associated encephalitis present a diagnostic dilemma.
UN	24618873_C002752_4_575_587_norpethidine_D001523_4_602_614_irritability	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.
UN	24618873_C002752_4_575_587_norpethidine_D010146_4_458_462_pain	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.
CID	24618873_C002752_4_575_587_norpethidine_D012640_4_619_626_seizure	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.
UN	24618873_C002752_4_575_587_norpethidine_D017093_4_394_427_impaired renal and liver function	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.
UN	24618873_C002752_4_575_587_norpethidine_D020258_4_552_562_neurotoxic	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.
UN	24618873_C002752_4_575_587_norpethidine_D051437_4_394_427_impaired renal and liver function	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.
UN	24618873_D008614_4_472_481_pethidine_D001523_4_602_614_irritability	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.
UN	24618873_D008614_0_67_76_pethidine_D002526_0_0_37_Cerebellar and oculomotor dysfunction	Cerebellar and oculomotor dysfunction induced by rapid infusion of pethidine.
UN	24618873_D008614_0_67_76_pethidine_D005128_0_0_37_Cerebellar and oculomotor dysfunction	Cerebellar and oculomotor dysfunction induced by rapid infusion of pethidine.
UN	24618873_D008614_4_472_481_pethidine_D010146_4_458_462_pain	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.
UN	24618873_D008614_1_78_87_Pethidine_D010146_1_145_149_pain	Pethidine is an opioid that gains its popularity for the effective pain control through acting on the opioid-receptors.
UN	24618873_D008614_4_472_481_pethidine_D012640_4_619_626_seizure	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.
UN	24618873_D008614_4_472_481_pethidine_D017093_4_394_427_impaired renal and liver function	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.
UN	24618873_D008614_4_472_481_pethidine_D020258_4_552_562_neurotoxic	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.
UN	24618873_D008614_4_472_481_pethidine_D051437_4_394_427_impaired renal and liver function	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.
CID	24641119_D007654_1_160_172_ketoconazole_D003875_1_85_107_maculopapular eruption	A 27-year-old male patient presented with a maculopapular eruption on the flexural areas and buttocks after using oral ketoconazole.
UN	24653743_C042288_5_823_835_pilsicainide_D001281_5_863_882_atrial fibrillation	Although the oral administration of class IC drugs, including pilsicainide, is effective to terminate atrial fibrillation, careful consideration must be taken before giving these drugs to octogenarians.
CID	24653743_C042288_0_38_50_Pilsicainide_D016171_0_59_78_Torsades de Pointes	A Case of Sudden Cardiac Death due to Pilsicainide-Induced Torsades de Pointes.
CID	24653743_C042288_0_38_50_Pilsicainide_D016757_0_10_30_Sudden Cardiac Death	A Case of Sudden Cardiac Death due to Pilsicainide-Induced Torsades de Pointes.
UN	24653743_D012964_1_135_141_sodium_D001281_1_213_232_atrial fibrillation	An 84-year-old male received oral pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed sudden cardiac death two days later.
UN	24653743_D012964_1_135_141_sodium_D016757_1_274_294_sudden cardiac death	An 84-year-old male received oral pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed sudden cardiac death two days later.
CID	24658375_D014212_0_0_23_All-trans retinoic acid_D009220_0_45_53_myositis	All-trans retinoic acid-induced inflammatory myositis in a patient with acute promyelocytic leukemia.
CID	24658375_D014212_2_380_384_ATRA_D009220_2_393_401_myositis	Only a handful of cases of ATRA-induced myositis in children have been reported, and none in the radiology literature.
UN	24658375_D014212_0_0_23_All-trans retinoic acid_D015473_0_72_100_acute promyelocytic leukemia	All-trans retinoic acid-induced inflammatory myositis in a patient with acute promyelocytic leukemia.
UN	24659727_D003520_0_46_62_cyclophosphamide_D008223_0_76_84_lymphoma	Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma.
UN	24659727_D003520_1_199_202_CTX_D008223_1_217_225_lymphoma	This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.
UN	24659727_D003520_9_1203_1206_CTX_D009369_9_1252_1257_tumor	On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs.
CID	24659727_D003520_4_657_660_CTX_D009503_4_611_622_neutropenia	Neutropenia was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of CCNU/CTX was 30% (95% confidence interval, 19-43%).
UN	24659727_D008130_1_171_175_CCNU_D008223_1_217_225_lymphoma	This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.
UN	24659727_D008130_0_16_25_lomustine_D008223_0_76_84_lymphoma	Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma.
UN	24659727_D008130_9_1169_1173_CCNU_D009369_9_1252_1257_tumor	On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs.
CID	24659727_D008130_4_652_656_CCNU_D009503_4_611_622_neutropenia	Neutropenia was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of CCNU/CTX was 30% (95% confidence interval, 19-43%).
UN	24664478_C104457_0_0_10_Nelarabine_D020258_0_11_24_neurotoxicity	Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature.
UN	24664478_C104457_1_112_122_nelarabine_D020258_1_123_136_neurotoxicity	Severe nelarabine neurotoxicity in a patient who received concurrent intrathecal (IT) chemotherapy is reported.
UN	24664478_C104457_15_1773_1783_nelarabine_D020258_15_1749_1762_neurotoxicity	To our knowledge, this is the first published case report of severe neurotoxicity caused by nelarabine in a patient who received concurrent IT chemotherapy.
UN	24665854_D014635_3_287_296_Valproate_D001927_3_320_334_encephalopathy	Valproate-induced hyperammonemic encephalopathy is an uncommon but serious effect of valproate treatment.
UN	24665854_D014635_0_0_9_Valproate_D001927_0_33_47_encephalopathy	Valproate-induced hyperammonemic encephalopathy in a renal transplanted patient.
CID	24665854_D014635_4_478_487_valproate_D003244_4_517_539_impaired consciousness	Here, we describe the case of a 15-year-old girl who was on a long-term therapy with valproate due to epilepsy and revealed impaired consciousness with hyperammonemia 12 days after renal transplantation.
UN	24665854_D014635_4_478_487_valproate_D004827_4_495_503_epilepsy	Here, we describe the case of a 15-year-old girl who was on a long-term therapy with valproate due to epilepsy and revealed impaired consciousness with hyperammonemia 12 days after renal transplantation.
CID	24665854_D014635_0_0_9_Valproate_D022124_0_18_32_hyperammonemic	Valproate-induced hyperammonemic encephalopathy in a renal transplanted patient.
CID	24665854_D014635_4_478_487_valproate_D022124_4_545_559_hyperammonemia	Here, we describe the case of a 15-year-old girl who was on a long-term therapy with valproate due to epilepsy and revealed impaired consciousness with hyperammonemia 12 days after renal transplantation.
CID	24665854_D014635_3_287_296_Valproate_D022124_3_305_319_hyperammonemic	Valproate-induced hyperammonemic encephalopathy is an uncommon but serious effect of valproate treatment.
UN	24671324_C400082_5_788_798_bortezomib_D001424_5_756_776_bacterial infections	Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation.
UN	24671324_C400082_3_564_574_bortezomib_D008258_3_441_471_Waldenstrom macroglobulinaemia	We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.
UN	24671324_C400082_0_28_38_bortezomib_D008258_0_101_131_Waldenstrom macroglobulinaemia	Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.
UN	24671324_C400082_1_133_143_Bortezomib_D009369_1_294_306_malignancies	Bortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies.
UN	24671324_C400082_3_564_574_bortezomib_D009503_3_515_526_neutropenia	We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.
CID	24671324_C400082_0_28_38_bortezomib_D019115_0_0_21_Necrotising fasciitis	Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.
CID	24671324_C400082_3_564_574_bortezomib_D019115_3_485_506_necrotising fasciitis	We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.
UN	24671324_D003907_5_814_827_dexamethasone_D001424_5_756_776_bacterial infections	Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation.
UN	24671324_D003907_0_43_56_dexamethasone_D008258_0_101_131_Waldenstrom macroglobulinaemia	Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.
UN	24671324_D003907_1_158_171_dexamethasone_D009369_1_294_306_malignancies	Bortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies.
UN	24671324_D003907_3_586_599_dexamethasone_D009503_3_515_526_neutropenia	We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.
CID	24671324_D003907_0_43_56_dexamethasone_D019115_0_0_21_Necrotising fasciitis	Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.
CID	24675088_D004317_2_380_383_DOX_D009202_2_393_407_cardiomyopathy	In this study, we have utilized a rat model of progressive doxorubicin (DOX)-induced cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this toxicity.
UN	24675088_D004317_0_86_97_doxorubicin_D066126_0_106_120_cardiotoxicity	An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity.
UN	24675088_D005682_9_1645_1655_gadolinium_D018754_9_1709_1730_diastolic dysfunction	Troponin I levels positively correlated with delayed and peak gadolinium contrast enhancement, histopathological grading, and diastolic dysfunction.
CID	24684312_D002211_13_1781_1790_capsaicin_D006930_13_1810_1822_hyperalgesic	In conclusion, glutamate and capsaicin yield reproducible hyperalgesic and allodynic responses, and the present model is well suited for basic research, as well as for assessing the modulation of central phenomena.
CID	24684312_D002211_11_1494_1503_Capsaicin_D006930_11_1535_1557_secondary hyperalgesia	Capsaicin injection was reproducible for secondary hyperalgesia (ICC > 0.70) and allodynia (ICC > 0.71).
UN	24684312_D002211_1_167_176_capsaicin_D010146_1_221_225_pain	Intradermal injections of glutamate and capsaicin are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders.
UN	24684312_D002211_1_167_176_capsaicin_D013001_1_303_317_pain disorders	Intradermal injections of glutamate and capsaicin are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders.
UN	24684312_D018698_13_1767_1776_glutamate_D006930_13_1810_1822_hyperalgesic	In conclusion, glutamate and capsaicin yield reproducible hyperalgesic and allodynic responses, and the present model is well suited for basic research, as well as for assessing the modulation of central phenomena.
UN	24684312_D018698_1_153_162_glutamate_D010146_1_221_225_pain	Intradermal injections of glutamate and capsaicin are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders.
UN	24684312_D018698_1_153_162_glutamate_D013001_1_303_317_pain disorders	Intradermal injections of glutamate and capsaicin are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders.
UN	24691439_C075773_9_1334_1357_sodium 4-phenylbutyrate_D009798_9_1390_1409_ocular hypertension	Furthermore, reduction of ER stress in the TM with sodium 4-phenylbutyrate prevented dexamethasone-induced ocular hypertension in WT mice.
CID	24691439_D003907_5_604_617_dexamethasone_D005901_5_783_791_glaucoma	Treatment of WT mice with topical ocular 0.1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients.
CID	24691439_D003907_5_604_617_dexamethasone_D009410_5_728_747_axonal degeneration	Treatment of WT mice with topical ocular 0.1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients.
CID	24691439_D003907_9_1368_1381_dexamethasone_D009798_9_1390_1409_ocular hypertension	Furthermore, reduction of ER stress in the TM with sodium 4-phenylbutyrate prevented dexamethasone-induced ocular hypertension in WT mice.
CID	24691439_D003907_8_1240_1253_dexamethasone_D009798_8_1262_1281_ocular hypertension	Dexamethasone induced the transcriptional factor CHOP, a marker for chronic ER stress, in the anterior segment tissues, and Chop deletion reduced ER stress in these tissues and prevented dexamethasone-induced ocular hypertension.
CID	24691439_D003907_6_824_837_dexamethasone_D009798_6_846_865_ocular hypertension	Furthermore, dexamethasone-induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork (TM).
UN	24691439_D003907_5_604_617_dexamethasone_D012173_5_700_716_retinal ganglion	Treatment of WT mice with topical ocular 0.1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients.
UN	24709919_C035054_9_963_966_Rg1_D006930_9_998_1001_OIH	Furthermore, Rg1 showed a tendency to aggravate OIH in the acetic acid-induced writhing test.
UN	24709919_C035054_8_887_911_Rg1 and Rb1 ginsenosides_D006930_8_930_933_OIH	However, the Rg1 and Rb1 ginsenosides failed to prevent OIH in either test.
UN	24709919_C049864_7_765_767_Re_D006930_7_790_793_OIH	Re (300 mg/kg) inhibited OIH in both the thermal sensitivity test and the acetic acid-induced writhing test.
UN	24709919_C442759_8_887_911_Rg1 and Rb1 ginsenosides_D006930_8_930_933_OIH	However, the Rg1 and Rb1 ginsenosides failed to prevent OIH in either test.
CID	24709919_D009020_4_476_484_morphine_D006930_4_414_417_OIH	OIH was achieved in mice after subcutaneous administration of morphine for 7 consecutive days three times per day.
UN	24709919_D019342_9_1009_1020_acetic acid_D006930_9_998_1001_OIH	Furthermore, Rg1 showed a tendency to aggravate OIH in the acetic acid-induced writhing test.
UN	24709919_D019342_7_839_850_acetic acid_D006930_7_790_793_OIH	Re (300 mg/kg) inhibited OIH in both the thermal sensitivity test and the acetic acid-induced writhing test.
UN	24709919_D036145_0_11_23_ginsenosides_D006930_0_42_54_hyperalgesia	Effects of ginsenosides on opioid-induced hyperalgesia in mice.
CID	24717468_D015742_12_1780_1788_propofol_D001919_12_1678_1689_bradycardia	CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol.
CID	24717468_D015742_12_1780_1788_propofol_D007022_12_1662_1673_hypotension	CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol.
CID	24717468_D020927_12_1761_1776_dexmedetomidine_D001919_12_1678_1689_bradycardia	CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol.
CID	24717468_D020927_12_1761_1776_dexmedetomidine_D007022_12_1662_1673_hypotension	CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol.
UN	24727461_C005975_3_578_592_hydroxytyrosol_D001943_3_606_619_breast cancer	Herein, we investigate whether doxorubicin-associated chronic cardiac toxicity can be ameliorated with the antioxidant hydroxytyrosol in rats with breast cancer.
UN	24727461_C005975_6_1014_1028_Hydroxytyrosol_D006331_6_1042_1062_cardiac disturbances	Hydroxytyrosol improved the cardiac disturbances enhanced by doxorubicin by significantly reducing the percentage of altered mitochondria and oxidative damage.
UN	24727461_C005975_8_1297_1311_hydroxytyrosol_D006331_8_1324_1336_heart damage	This study demonstrates that hydroxytyrosol protect rat heart damage provoked by doxorubicin decreasing oxidative damage and mitochondrial alterations.
UN	24727461_C005975_0_0_14_Hydroxytyrosol_D028361_0_48_73_mitochondrial dysfunction	Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.
UN	24727461_C005975_3_578_592_hydroxytyrosol_D066126_3_521_537_cardiac toxicity	Herein, we investigate whether doxorubicin-associated chronic cardiac toxicity can be ameliorated with the antioxidant hydroxytyrosol in rats with breast cancer.
UN	24727461_D004317_0_77_88_doxorubicin_D001943_0_125_138_breast cancer	Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.
UN	24727461_D004317_1_315_326_doxorubicin_D002318_1_218_240_cardiovascular disease	Oxidative stress is involved in several processes including cancer, aging and cardiovascular disease, and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin.
CID	24727461_D004317_8_1349_1360_doxorubicin_D006331_8_1324_1336_heart damage	This study demonstrates that hydroxytyrosol protect rat heart damage provoked by doxorubicin decreasing oxidative damage and mitochondrial alterations.
CID	24727461_D004317_6_1075_1086_doxorubicin_D006331_6_1042_1062_cardiac disturbances	Hydroxytyrosol improved the cardiac disturbances enhanced by doxorubicin by significantly reducing the percentage of altered mitochondria and oxidative damage.
UN	24727461_D004317_1_315_326_doxorubicin_D009369_1_200_206_cancer	Oxidative stress is involved in several processes including cancer, aging and cardiovascular disease, and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin.
UN	24727461_D004317_0_77_88_doxorubicin_D028361_0_48_73_mitochondrial dysfunction	Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.
UN	24727461_D004317_2_328_339_Doxorubicin_D066126_2_359_373_cardiotoxicity	Doxorubicin causes significant cardiotoxicity characterized by marked increases in oxidative stress and mitochondrial dysfunction.
UN	24727461_D004317_3_490_501_doxorubicin_D066126_3_521_537_cardiac toxicity	Herein, we investigate whether doxorubicin-associated chronic cardiac toxicity can be ameliorated with the antioxidant hydroxytyrosol in rats with breast cancer.
UN	24727461_D004317_0_77_88_doxorubicin_D066126_0_97_111_cardiotoxicity	Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.
UN	24729111_D000638_1_148_158_amiodarone_D001281_1_171_190_atrial fibrillation	A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation.
CID	24729111_D000638_1_148_158_amiodarone_D001919_1_71_82_bradycardia	A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation.
CID	24729111_D000638_9_944_954_amiodarone_D003128_9_963_977_myxoedema coma	The only two cases of amiodarone-induced myxoedema coma in the literature report patient death despite supportive therapy and thyroid hormone replacement.
CID	24729111_D000638_10_1139_1149_amiodarone_D003128_10_1158_1172_myxoedema coma	This case represents the most thoroughly investigated case of amiodarone-induced myxoedema coma with a history significant for subclinical thyroid disease.
CID	24729111_D000638_0_0_10_Amiodarone_D003128_0_19_33_myxoedema coma	Amiodarone-induced myxoedema coma.
CID	24729111_D000638_1_148_158_amiodarone_D007035_1_84_95_hypothermia	A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation.
CID	24729111_D000638_10_1139_1149_amiodarone_D007037_10_1158_1172_myxoedema coma	This case represents the most thoroughly investigated case of amiodarone-induced myxoedema coma with a history significant for subclinical thyroid disease.
CID	24729111_D000638_9_944_954_amiodarone_D007037_9_963_977_myxoedema coma	The only two cases of amiodarone-induced myxoedema coma in the literature report patient death despite supportive therapy and thyroid hormone replacement.
CID	24729111_D000638_0_0_10_Amiodarone_D007037_0_19_33_myxoedema coma	Amiodarone-induced myxoedema coma.
CID	24729111_D000638_1_148_158_amiodarone_D012131_1_100_119_respiratory failure	A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation.
UN	24729111_D000638_10_1139_1149_amiodarone_D013959_10_1216_1231_thyroid disease	This case represents the most thoroughly investigated case of amiodarone-induced myxoedema coma with a history significant for subclinical thyroid disease.
UN	24733133_C031942_11_1843_1853_argatroban_D000686_11_1766_1777_amyloidosis	CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with argatroban and CDT with alteplase.
UN	24733133_C031942_6_1114_1124_argatroban_D004844_6_1048_1057_epistaxis	The epistaxis resolved the next day, and the patient was restarted on argatroban.
UN	24733133_C031942_11_1843_1853_argatroban_D013479_11_1782_1794_SVC syndrome	CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with argatroban and CDT with alteplase.
UN	24733133_C031942_1_278_288_argatroban_D013921_1_251_255_HITT	PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.
UN	24733133_C031942_11_1843_1853_argatroban_D013921_11_1808_1812_HITT	CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with argatroban and CDT with alteplase.
UN	24733133_C031942_11_1843_1853_argatroban_D013927_11_1808_1812_HITT	CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with argatroban and CDT with alteplase.
UN	24733133_C031942_1_278_288_argatroban_D013927_1_251_255_HITT	PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.
UN	24733133_C031942_1_278_288_argatroban_D055499_1_312_324_thrombolysis	PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.
UN	24733133_C031942_0_7_17_argatroban_D055499_0_40_52_thrombolysis	Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis.
UN	24733133_D006493_2_619_626_heparin_D000686_2_408_419_amyloidosis	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.
CID	24733133_D006493_2_619_626_heparin_D011655_2_587_605_pulmonary embolism	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.
CID	24733133_D006493_0_96_103_heparin_D013921_0_112_128_thrombocytopenia	Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis.
CID	24733133_D006493_2_619_626_heparin_D013921_2_635_651_thrombocytopenia	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.
CID	24733133_D006493_1_201_208_heparin_D013921_1_217_233_thrombocytopenia	PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.
UN	24733133_D006493_1_201_208_heparin_D013927_1_239_249_thrombosis	PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.
UN	24733133_D006493_0_96_103_heparin_D013927_0_134_144_thrombosis	Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis.
CID	24733133_D006493_2_619_626_heparin_D020246_2_578_581_DVT	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.
UN	24733133_D006493_0_96_103_heparin_D055499_0_40_52_thrombolysis	Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis.
UN	24733133_D006493_2_619_626_heparin_D056824_2_538_576_upper-extremity deep venous thrombosis	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.
UN	24739405_D000661_4_395_406_Amphetamine_D002375_4_547_556_catalepsy	Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.
UN	24739405_D000661_4_395_406_Amphetamine_D006948_4_428_433_hyper	Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.
CID	24739405_D000661_0_37_48_amphetamine_D012559_0_57_70_schizophrenia	Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice.
UN	24739405_D001058_4_446_457_apomorphine_D002375_4_547_556_catalepsy	Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.
UN	24739405_D001058_4_446_457_apomorphine_D006948_4_428_433_hyper	Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.
CID	24739405_D001058_4_446_457_apomorphine_D012559_4_593_606_schizophrenia	Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.
UN	24739405_D003687_11_1486_1490_DHEA_D002375_11_1532_1541_catalepsy	CONCLUSION: We observed that DHEA reduced locomotor activity and increased catalepsy at both doses, while it had no effect on climbing behavior.
UN	24739405_D003687_0_11_33_dehydroepiandrosterone_D012559_0_57_70_schizophrenia	Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice.
UN	24739405_D003687_1_148_152_DHEA_D012559_1_174_187_schizophrenia	OBJECTIVE: To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia.
CID	24739405_D006220_9_1278_1289_haloperidol_D002375_9_1298_1307_catalepsy	There was a significant difference between groups in the haloperidol-induced catalepsy test (p<0.05).
UN	24739405_D006220_4_512_523_haloperidol_D006948_4_428_433_hyper	Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.
CID	24739405_D006220_4_512_523_haloperidol_D012559_4_593_606_schizophrenia	Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.
CID	24742750_D015283_6_1151_1161_Citalopram_D016171_6_1191_1209_Torsade de Pointes	Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause Torsade de Pointes (TdP) in clinical practice, produced early afterdepolarization (EAD). hiPS-CMs using MEA system and FPDc can predict the effects of drug candidates on QT interval.
CID	24742750_D016593_6_1135_1146_Terfenadine_D016171_6_1191_1209_Torsade de Pointes	Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause Torsade de Pointes (TdP) in clinical practice, produced early afterdepolarization (EAD). hiPS-CMs using MEA system and FPDc can predict the effects of drug candidates on QT interval.
CID	24753331_C083440_1_91_98_S-23121_D005317_1_228_246_growth retardation	BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.
CID	24753331_C083440_7_1069_1076_S-23121_D006345_7_1148_1173_ventricular septal defect	Dermal administration of S-23121 at 800 mg/kg resulted in an increased incidence of embryonic death and ventricular septal defect, but retarded fetal growth was not observed as it was following oral exposure to S-23121.
CID	24753331_C083440_1_91_98_S-23121_D020964_1_141_156_embryolethality	BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.
CID	24753331_C083440_8_1311_1318_S-23121_D064793_8_1324_1335_teratogenic	CONCLUSIONS: Based on the results, S-53482 and S-23121 were teratogenic when administered dermally to pregnant rats as were the compounds administered orally.
CID	24753331_C106487_1_79_86_S-53482_D005317_1_228_246_growth retardation	BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.
CID	24753331_C106487_1_79_86_S-53482_D006345_1_181_207_ventricular septal defects	BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.
CID	24753331_C106487_1_79_86_S-53482_D020964_1_141_156_embryolethality	BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.
CID	24753331_C106487_8_1299_1306_S-53482_D064793_8_1324_1335_teratogenic	CONCLUSIONS: Based on the results, S-53482 and S-23121 were teratogenic when administered dermally to pregnant rats as were the compounds administered orally.
UN	24778426_D002945_8_879_888_cisplatin_D006258_8_912_932_head and neck cancer	RESULTS: We evaluated 143 patients who received single-agent cisplatin; 97.2% of patients had head and neck cancer as their primary malignancy.
UN	24778426_D002945_12_1611_1620_cisplatin_D006973_12_1650_1662_hypertension	Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) cisplatin every 3 weeks and those with hypertension are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol.
UN	24778426_D002945_0_53_62_Cisplatin_D007674_0_9_23_Renal Toxicity	Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol.
UN	24778426_D002945_4_406_415_cisplatin_D007674_4_424_438_nephrotoxicity	OBJECTIVE: We aimed to evaluate the rates of cisplatin-induced nephrotoxicity in cancer patients receiving single-agent cisplatin with and without mannitol.
UN	24778426_D002945_2_179_188_cisplatin_D007674_2_210_224_nephrotoxicity	One of the major complications of cisplatin use is dose-limiting nephrotoxicity.
UN	24778426_D002945_0_53_62_Cisplatin_D009369_0_27_33_Cancer	Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol.
UN	24778426_D002945_6_703_712_cisplatin_D009369_6_664_670_cancer	Data were collected on adult cancer patients receiving single-agent cisplatin as an outpatient from January 2011 to September 2012.
UN	24778426_D002945_4_406_415_cisplatin_D009369_4_442_448_cancer	OBJECTIVE: We aimed to evaluate the rates of cisplatin-induced nephrotoxicity in cancer patients receiving single-agent cisplatin with and without mannitol.
UN	24778426_D008353_12_1745_1753_mannitol_D006973_12_1650_1662_hypertension	Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) cisplatin every 3 weeks and those with hypertension are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol.
UN	24778426_D008353_0_80_88_Mannitol_D007674_0_9_23_Renal Toxicity	Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol.
UN	24778426_D008353_12_1745_1753_mannitol_D007674_12_1691_1705_nephrotoxicity	Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) cisplatin every 3 weeks and those with hypertension are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol.
UN	24778426_D008353_9_991_999_mannitol_D007674_9_1028_1042_nephrotoxicity	Patients who did not receive mannitol were more likely to develop nephrotoxicity: odds ratio [OR] = 2.646 (95% CI = 1.008, 6.944; P = 0.048).
UN	24778426_D008353_0_80_88_Mannitol_D009369_0_27_33_Cancer	Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol.
UN	24778426_D008353_4_508_516_mannitol_D009369_4_442_448_cancer	OBJECTIVE: We aimed to evaluate the rates of cisplatin-induced nephrotoxicity in cancer patients receiving single-agent cisplatin with and without mannitol.
UN	24802403_D008687_9_1150_1159_metformin_D003072_9_1216_1236_cognitive impairment	We found that metformin suppressed the progression of kindling, ameliorated the cognitive impairment and decreased brain oxidative stress.
UN	24802403_D008687_6_775_784_metformin_D003072_6_798_818_cognitive impairment	This study was designed to evaluate the ameliorative effects of metformin on seizures, cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals.
UN	24802403_D008687_10_1313_1322_metformin_D003072_10_1419_1439_cognitive impairment	Thus the present study concluded that metformin may be a potential agent for the treatment of epilepsy as well as a protective medicine against cognitive impairment induced by seizures.
UN	24802403_D008687_10_1313_1322_metformin_D004827_10_1369_1377_epilepsy	Thus the present study concluded that metformin may be a potential agent for the treatment of epilepsy as well as a protective medicine against cognitive impairment induced by seizures.
UN	24802403_D008687_0_0_9_Metformin_D007859_0_37_68_learning and memory impairments	Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice.
UN	24802403_D008687_0_0_9_Metformin_D008569_0_37_68_learning and memory impairments	Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice.
UN	24802403_D008687_0_0_9_Metformin_D012640_0_27_35_seizures	Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice.
UN	24802403_D008687_6_775_784_metformin_D012640_6_788_796_seizures	This study was designed to evaluate the ameliorative effects of metformin on seizures, cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals.
CID	24802403_D010433_6_866_884_pentylenetetrazole_D003072_6_798_818_cognitive impairment	This study was designed to evaluate the ameliorative effects of metformin on seizures, cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals.
CID	24802403_D010433_0_101_119_pentylenetetrazole_D007859_0_37_68_learning and memory impairments	Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice.
CID	24802403_D010433_0_101_119_pentylenetetrazole_D008569_0_37_68_learning and memory impairments	Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice.
CID	24802403_D010433_0_101_119_pentylenetetrazole_D012640_0_27_35_seizures	Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice.
CID	24802403_D010433_6_866_884_pentylenetetrazole_D012640_6_788_796_seizures	This study was designed to evaluate the ameliorative effects of metformin on seizures, cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals.
CID	24812279_D004317_2_237_240_DOX_D006333_2_249_262_heart failure	Children are particularly sensitive to DOX-induced heart failure.
UN	24812279_D004317_1_87_90_DOX_D009369_1_113_119_cancer	AIMS: Doxorubicin (DOX) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage cardiotoxicity.
UN	24812279_D004317_3_323_326_DOX_D066126_3_327_341_cardiotoxicity	Here, the impact of p53 inhibition on acute vs. late-stage DOX cardiotoxicity was examined in a juvenile model.
UN	24812279_D018943_0_38_51_anthracycline_D066126_0_52_66_cardiotoxicity	P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.
CID	24816962_D008795_0_0_13_Metronidazole_D001927_0_22_36_encephalopathy	Metronidazole-induced encephalopathy: an uncommon scenario.
CID	24816962_D008795_2_242_255_metronidazole_D001927_2_207_221_encephalopathy	We present a case where a patient developed features of encephalopathy following prolonged metronidazole intake.
CID	24840785_D000157_0_0_9_Aconitine_D001145_0_39_49_arrhythmia	Aconitine-induced Ca2+ overload causes arrhythmia and triggers apoptosis through p38 MAPK signaling pathway in rats.
UN	24840785_D000157_6_725_734_aconitine_D009202_6_738_755_myocardial injury	To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.
UN	24840785_D000157_7_987_996_aconitine_D009202_7_1009_1026_myocardial injury	The results showed that aconitine resulted in myocardial injury and reduced NRVMs viability dose-dependently.
CID	24840785_D000157_3_404_413_aconitine_D011041_3_414_423_poisoning	However, no reports are available on the role of Ca(2+) in aconitine poisoning.
CID	24840785_D000157_4_503_512_aconitine_D011041_4_513_522_poisoning	In this study, we explored the importance of pathological Ca(2+) signaling in aconitine poisoning in vitro and in vivo.
CID	24840785_D000157_2_334_343_aconitine_D066126_2_316_330_cardiotoxicity	Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the cardiotoxicity of aconitine.
UN	24840785_D002118_0_18_20_Ca_D001145_0_39_49_arrhythmia	Aconitine-induced Ca2+ overload causes arrhythmia and triggers apoptosis through p38 MAPK signaling pathway in rats.
UN	24840785_D002118_13_1904_1906_Ca_D001145_13_1931_1941_arrhythmia	Hence, our results suggest that aconitine significantly aggravates Ca(2+) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.
UN	24840785_D002118_4_483_485_Ca_D011041_4_513_522_poisoning	In this study, we explored the importance of pathological Ca(2+) signaling in aconitine poisoning in vitro and in vivo.
UN	24840785_D002118_3_394_396_Ca_D011041_3_414_423_poisoning	However, no reports are available on the role of Ca(2+) in aconitine poisoning.
UN	24840785_D012964_2_275_277_Na_D066126_2_316_330_cardiotoxicity	Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the cardiotoxicity of aconitine.
UN	24840785_D019344_6_855_862_lactate_D009202_6_738_755_myocardial injury	To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.
UN	24842192_D000667_1_294_297_AMP_D009203_1_210_231_myocardial infarction	Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).
CID	24842192_D007545_4_760_773_Isoproterenol_D009203_4_849_876_acute myocardial infarction	Isoproterenol (100mg/kg) was injected subcutaneously on the 13th and 14th days to induce acute myocardial infarction.
UN	24842192_D007545_7_1150_1163_isoproterenol_D009336_7_1260_1268_necrosis	Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.
UN	24842192_D007545_7_1150_1163_isoproterenol_D009369_7_1254_1259_tumor	Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.
UN	24842192_D008687_2_394_403_metformin_D006331_2_407_426_cardiac dysfunction	In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.
UN	24842192_D008687_11_1655_1664_metformin_D009203_11_1678_1699_myocardial infarction	Chronic pre-treatment with metformin reduces post-myocardial infarction cardiac dysfunction and suppresses inflammatory responses, possibly through inhibition of TLR4 activities.
UN	24842192_D008687_1_173_182_metformin_D009203_1_210_231_myocardial infarction	Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).
UN	24842192_D008687_0_23_32_metformin_D018487_0_90_118_left ventricular dysfunction	Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction.
UN	2484903_D008713_1_171_182_methimazole_D008180_1_262_281_lupus-like syndrome	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.
CID	2484903_D008713_1_171_182_methimazole_D047508_1_194_217_hepatocellular necrosis	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.
UN	2484903_D008713_1_171_182_methimazole_D056486_1_142_151_hepatitis	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.
CID	2484903_D011441_1_234_250_propylthiouracil_D008180_1_262_281_lupus-like syndrome	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.
UN	2484903_D011441_1_234_250_propylthiouracil_D047508_1_194_217_hepatocellular necrosis	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.
CID	2484903_D011441_1_108_124_propylthiouracil_D056486_1_142_151_hepatitis	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.
UN	24881749_D013747_0_67_80_tetrabenazine_D001943_0_177_190_breast cancer	Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.
UN	24881749_D013747_0_67_80_tetrabenazine_D006816_0_121_141_Huntington's disease	Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.
UN	24881749_D013747_1_385_398_tetrabenazine_D006816_1_417_437_Huntington's disease	We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and tetrabenazine (12.5 mg/day) for Huntington's disease.
CID	24881749_D013747_0_67_80_tetrabenazine_D009459_0_0_30_Neuroleptic malignant syndrome	Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.
CID	24881749_D013747_4_778_791_tetrabenazine_D009459_4_715_745_neuroleptic malignant syndrome	To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported.
UN	24881749_D063325_0_85_93_tiapride_D001943_0_177_190_breast cancer	Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.
UN	24881749_D063325_0_85_93_tiapride_D006816_0_121_141_Huntington's disease	Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.
CID	24881749_D063325_0_85_93_tiapride_D009459_0_0_30_Neuroleptic malignant syndrome	Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.
CID	24881749_D063325_4_796_804_tiapride_D009459_4_715_745_neuroleptic malignant syndrome	To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported.
CID	24894748_C041359_0_13_24_terbinafine_D001919_0_45_56_bradycardia	A metoprolol-terbinafine combination induced bradycardia.
UN	24894748_C041359_3_356_367_terbinafine_D003221_3_458_467_confusion	On the 49th day of terbinafine therapy, he was brought to the emergency room for a decrease of his global health status, confusion and falls.
UN	24894748_C041359_2_295_306_terbinafine_D003324_2_232_255_coronary artery disease	A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis.
UN	24894748_C041359_1_114_125_terbinafine_D012804_1_70_87_sinus bradycardia	To report a sinus bradycardia induced by metoprolol and terbinafine drug-drug interaction and its management.
UN	24894748_C041359_5_734_745_terbinafine_D012804_5_668_685_sinus bradycardia	A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and terbinafine.
UN	24894748_C041359_2_295_306_terbinafine_D014009_2_322_335_onychomycosis	A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis.
CID	24894748_D008790_0_2_12_metoprolol_D001919_0_45_56_bradycardia	A metoprolol-terbinafine combination induced bradycardia.
UN	24894748_D008790_2_199_209_metoprolol_D003324_2_232_255_coronary artery disease	A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis.
UN	24894748_D008790_1_99_109_metoprolol_D012804_1_70_87_sinus bradycardia	To report a sinus bradycardia induced by metoprolol and terbinafine drug-drug interaction and its management.
UN	24894748_D008790_5_719_729_metoprolol_D012804_5_668_685_sinus bradycardia	A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and terbinafine.
UN	24894748_D008790_8_1001_1011_metoprolol_D012804_8_1070_1087_sinus bradycardia	By inhibiting the cytochrome P450 2D6, terbinafine had decreased metoprolol's clearance, leading in metoprolol accumulation which has resulted in clinically significant sinus bradycardia.
UN	24894748_D008790_2_199_209_metoprolol_D014009_2_322_335_onychomycosis	A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis.
CID	24897009_D004977_1_74_84_Ethambutol_D009901_1_103_119_optic neuropathy	Ethambutol is known to cause optic neuropathy and, more rarely, axonal polyneuropathy.
CID	24897009_D004977_2_358_368_ethambutol_D010292_2_288_300_paresthesias	We characterize the clinical, neurophysiological, and neuroimaging findings in a 72-year-old man who developed visual loss and paresthesias after 11 weeks of exposure to a supratherapeutic dose of ethambutol.
UN	24897009_D004977_0_48_58_ethambutol_D010523_0_19_40_peripheral neuropathy	Optochiasmatic and peripheral neuropathy due to ethambutol overtreatment.
CID	24897009_D004977_1_74_84_Ethambutol_D011115_1_145_159_polyneuropathy	Ethambutol is known to cause optic neuropathy and, more rarely, axonal polyneuropathy.
CID	24897009_D004977_2_358_368_ethambutol_D014786_2_272_283_visual loss	We characterize the clinical, neurophysiological, and neuroimaging findings in a 72-year-old man who developed visual loss and paresthesias after 11 weeks of exposure to a supratherapeutic dose of ethambutol.
CID	24902786_C067431_7_1128_1137_letrozole_D008569_7_1165_1184_impaired the memory	Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.
CID	24902786_D005485_7_1117_1126_flutamide_D008569_7_1165_1184_impaired the memory	Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.
CID	24902786_D013311_7_1272_1275_STZ_D008569_7_1300_1317_memory impairment	Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.
CID	24902786_D013311_8_1371_1374_STZ_D008569_8_1399_1416_memory impairment	CONCLUSION: Testosterone administration ameliorates STZ- and castration-induced memory impairment in male Wistar rats.
CID	24902786_D013311_0_25_39_streptozotocin_D008569_0_48_65_memory impairment	Testosterone ameliorates streptozotocin-induced memory impairment in male rats.
CID	24902786_D013311_1_141_144_STZ_D008569_1_154_171_memory impairment	AIM: To study the effects of testosterone on streptozotocin (STZ)-induced memory impairment in male rats.
CID	24902786_D013629_7_1141_1150_tamoxifen_D008569_7_1165_1184_impaired the memory	Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.
UN	24902786_D013739_1_109_121_testosterone_D008569_1_154_171_memory impairment	AIM: To study the effects of testosterone on streptozotocin (STZ)-induced memory impairment in male rats.
UN	24902786_D013739_0_0_12_Testosterone_D008569_0_48_65_memory impairment	Testosterone ameliorates streptozotocin-induced memory impairment in male rats.
UN	24902786_D013739_7_1234_1246_testosterone_D008569_7_1300_1317_memory impairment	Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.
UN	24902786_D013739_8_1331_1343_Testosterone_D008569_8_1399_1416_memory impairment	CONCLUSION: Testosterone administration ameliorates STZ- and castration-induced memory impairment in male Wistar rats.
UN	24911645_C573355_5_820_823_GFC_D012640_5_863_870_seizure	GFC produced an increased latency to first seizure, at doses 25mg/kg (20.12 + 2.20 min), 50mg/kg (20.95 + 2.21 min) or 75 mg/kg (23.43 + 1.99 min) when compared with seized mice.
UN	24911645_C573355_0_61_80_garcinielliptone FC_D012640_0_104_112_seizures	Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine-induced seizures.
UN	24911645_C573355_9_1472_1475_GFC_D013226_9_1574_1592_status epilepticus	The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced status epilepticus, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.
UN	24911645_D000596_4_648_658_amino acid_D012640_4_567_574_seizure	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
UN	24911645_D001224_4_699_708_aspartate_D012640_4_810_818_seizures	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
UN	24911645_D005680_4_660_679_r-aminobutyric acid_D012640_4_567_574_seizure	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
UN	24911645_D005978_4_713_724_glutathione_D012640_4_810_818_seizures	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
CID	24911645_D010862_0_84_95_pilocarpine_D012640_0_104_112_seizures	Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine-induced seizures.
CID	24911645_D010862_9_1554_1565_pilocarpine_D013226_9_1574_1592_status epilepticus	The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced status epilepticus, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.
UN	24911645_D018698_4_688_697_glutamine_D012640_4_810_818_seizures	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
UN	24927617_C417083_1_197_217_pegylated interferon_D006526_1_129_156_hepatitis C virus infection	A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.
UN	24927617_C486464_0_68_78_telaprevir_D006526_0_20_46_hepatitis C virus infected	Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.
CID	24927617_C486464_0_68_78_telaprevir_D012206_0_0_14_Rhabdomyolysis	Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.
UN	24927617_D012254_1_186_195_ribavirin_D006526_1_129_156_hepatitis C virus infection	A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.
UN	24927617_D019821_0_83_94_simvastatin_D006526_0_20_46_hepatitis C virus infected	Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.
CID	24927617_D019821_10_1091_1097_statin_D009135_10_1106_1121_muscle toxicity	Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.
CID	24927617_D019821_0_83_94_simvastatin_D012206_0_0_14_Rhabdomyolysis	Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.
UN	24928523_C400082_2_446_456_bortezomib_D009101_2_565_567_MM	In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed MM.
UN	24928523_C400082_0_15_25_bortezomib_D009101_0_150_166_multiple myeloma	Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
UN	24928523_D003907_0_44_57_dexamethasone_D009101_0_150_166_multiple myeloma	Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
UN	24928523_D003907_2_475_488_dexamethasone_D009101_2_565_567_MM	In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed MM.
UN	24928523_D013792_0_27_38_thalidomide_D009101_0_150_166_multiple myeloma	Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
UN	24928523_D013792_2_458_469_thalidomide_D009101_2_565_567_MM	In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed MM.
UN	24971338_D004801_5_798_803_eosin_D007674_5_751_764_Renal lesions	Renal lesions were analyzed in hematoxylin and eosin, periodic acid-Schiff, and Masson's trichrome stains.
UN	24971338_D006416_5_782_793_hematoxylin_D007674_5_751_764_Renal lesions	Renal lesions were analyzed in hematoxylin and eosin, periodic acid-Schiff, and Masson's trichrome stains.
CID	24971338_D016572_9_1339_1342_CsA_D007674_9_1351_1363_renal damage	Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.
CID	24971338_D016572_0_36_48_cyclosporine_D007674_0_57_68_nephropathy	Conversion to sirolimus ameliorates cyclosporine-induced nephropathy in the rat: focus on serum, urine, gene, and protein renal expression biomarkers.
CID	24971338_D016572_1_291_294_CsA_D007674_1_303_314_nephropathy	Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear.
CID	24971338_D016572_8_1135_1138_CsA_D007674_8_1159_1171_renal damage	Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, TBARs clearance, and kidney TGF-b and mTOR.
CID	24971338_D016572_7_973_976_CsA_D007674_7_1019_1033_kidney lesions	Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.
UN	24971338_D020123_9_1325_1328_SRL_D007674_9_1351_1363_renal damage	Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.
UN	24971338_D020123_0_14_23_sirolimus_D007674_0_57_68_nephropathy	Conversion to sirolimus ameliorates cyclosporine-induced nephropathy in the rat: focus on serum, urine, gene, and protein renal expression biomarkers.
CID	24971338_D020123_6_858_861_SRL_D011507_6_885_896_proteinuria	SRL-treated rats presented proteinuria and NGAL (serum and urinary) as the best markers of renal impairment.
UN	24975837_D002945_8_1563_1572_cisplatin_D007674_8_1537_1551_nephrotoxicity	These results highlight the kinin B2 receptor antagonist treatment in amelioration of nephrotoxicity induced by cisplatin therapy.
CID	24975837_D002945_1_90_99_Cisplatin_D007683_1_312_334_acute tubular necrosis	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).
UN	24975837_D002945_7_1290_1299_cisplatin_D009336_7_1345_1353_necrotic	Thus, our data suggest that the kinin B2 receptor is involved in cisplatin-induced acute kidney injury by mediating the necrotic process and the expression of inflammatory cytokines, thus resulting in declined renal function.
CID	24975837_D002945_7_1290_1299_cisplatin_D058186_7_1308_1327_acute kidney injury	Thus, our data suggest that the kinin B2 receptor is involved in cisplatin-induced acute kidney injury by mediating the necrotic process and the expression of inflammatory cytokines, thus resulting in declined renal function.
CID	24975837_D002945_3_643_652_cisplatin_D058186_3_661_680_acute kidney injury	To examine the role of the kinin B2 receptor in cisplatin-induced acute kidney injury, kinin B2 receptor knockout mice were challenged with cisplatin.
CID	24975837_D002945_0_52_61_cisplatin_D058186_0_70_88_acute renal injury	Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.
UN	24975837_D003404_1_278_288_creatinine_D007683_1_312_334_acute tubular necrosis	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).
UN	24975837_D003404_1_278_288_creatinine_D058186_1_181_200_acute kidney injury	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).
UN	24975837_D014508_1_293_297_urea_D007683_1_312_334_acute tubular necrosis	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).
UN	24975837_D014508_1_293_297_urea_D058186_1_181_200_acute kidney injury	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).
UN	24999722_D005446_0_23_45_fluocinolone acetonide_C537630_0_80_108_birdshot retinochoroidopathy	Safety and efficacy of fluocinolone acetonide intravitreal implant (0.59 mg) in birdshot retinochoroidopathy.
UN	24999722_D005446_13_1835_1857_fluocinolone acetonide_D007249_13_1893_1905_inflammation	CONCLUSION: The data suggest that fluocinolone acetonide implant (0.59 mg) helps to control inflammation in otherwise treatment-refractory cases of birdshot retinochoroidopathy.
UN	25006369_C061870_0_30_40_rocuronium_D005207_0_53_66_fasciculation	Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine administration.
UN	25006369_C061870_2_286_296_rocuronium_D005207_2_332_345_fasciculation	The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.
UN	25006369_C061870_0_30_40_rocuronium_D063806_0_71_78_myalgia	Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine administration.
UN	25006369_C061870_2_389_399_rocuronium_D063806_2_350_357_myalgia	The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.
CID	25006369_D013390_2_308_323_succinylcholine_D005207_2_332_345_fasciculation	The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.
CID	25006369_D013390_0_89_104_succinylcholine_D005207_0_53_66_fasciculation	Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine administration.
CID	25006369_D013390_2_308_323_succinylcholine_D063806_2_350_357_myalgia	The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.
CID	25006369_D013390_0_89_104_succinylcholine_D063806_0_71_78_myalgia	Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine administration.
CID	25006961_D008094_12_1679_1686_lithium_D011141_12_1654_1662_polyuria	Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe polyuria associated with lithium therapy.
CID	25006961_D008094_3_511_518_lithium_D011141_3_527_535_polyuria	Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating lithium-induced polyuria.
CID	25006961_D008094_0_32_39_lithium_D018500_0_48_78_nephrogenic diabetes insipidus	Absence of PKC-alpha attenuates lithium-induced nephrogenic diabetes insipidus.
CID	25006961_D008094_12_1590_1597_lithium_D018500_12_1606_1609_NDI	Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe polyuria associated with lithium therapy.
CID	25031906_D017311_5_387_397_amlodipine_D004408_5_408_417_dysguesia	We conclude that amlodipine can cause dysguesia.
CID	25031906_D017311_1_98_108_amlodipine_D004408_1_112_121_dysguesia	A very rare side-effect of amlodipine is dysguesia.
CID	25031906_D017311_6_501_511_amlodipine_D004408_6_516_525_dysguesia	Here, we describe the clinical presentation and review the relevant literature on amlodipine and dysguesia.
UN	25031906_D017311_3_257_267_amlodipine_D006973_3_221_233_hypertension	We report a case about a female with essential hypertension on drug treatment with amlodipine developed loss of taste sensation.
UN	25031906_D017311_3_257_267_amlodipine_D012678_3_278_301_loss of taste sensation	We report a case about a female with essential hypertension on drug treatment with amlodipine developed loss of taste sensation.
CID	25041770_D017291_2_315_329_clarithromycin_D012206_2_253_267_rhabdomyolysis	This particular case is of interest as rhabdomyolysis only occurred after an increase in the dose of clarithromycin.
CID	25041770_D017291_0_71_85_clarithromycin_D012206_0_0_14_Rhabdomyolysis	Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.
CID	25041770_D019821_6_788_794_statin_D012206_6_803_817_rhabdomyolysis	Our case suggests that troponin elevation could be associated with statin induced rhabdomyolysis, which may warrant further studies.
CID	25041770_D019821_0_35_46_simvastatin_D012206_0_0_14_Rhabdomyolysis	Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.
CID	25054547_C049430_1_264_274_mivacurium_C537417_1_143_175_Butyrylcholinesterase deficiency	Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.
CID	25054547_C049430_1_264_274_mivacurium_D001049_1_206_211_apnea	Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.
CID	25054547_D013390_1_247_260_suxamethonium_C537417_1_143_175_Butyrylcholinesterase deficiency	Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.
CID	25054547_D013390_1_247_260_suxamethonium_D001049_1_206_211_apnea	Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.
CID	25054547_D013390_0_128_141_suxamethonium_D001049_0_117_122_apnea	Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.
UN	25071004_C039726_0_47_57_artesunate_D000740_0_8_14_anemia	Delayed anemia after treatment with injectable artesunate in the Democratic Republic of the Congo: a manageable issue.
CID	25071004_C039726_1_205_215_artesunate_D000743_1_136_152_hemolytic anemia	Cases of delayed hemolytic anemia have been described after treatment with injectable artesunate, the current World Health Organization (WHO)-recommended first-line drug for the treatment of severe malaria.
UN	25071004_C039726_2_463_473_artesunate_D008288_2_485_492_malaria	A total of 350 patients (215 [61.4%] < 5 years of age and 135 [38.6%] > 5 years of age) were followed-up after treatment with injectable artesunate for severe malaria in hospitals and health centers of the Democratic Republic of the Congo.
UN	25080425_D001622_8_1344_1351_betaine_D009202_8_1355_1372_myocardial damage	The protective role of betaine on myocardial damage was further confirmed by histopathological examination.
UN	25080425_D001622_0_91_98_betaine_D009202_0_138_155_myocardial injury	Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats.
UN	25080425_D001622_1_243_250_betaine_D017202_1_260_279_myocardial ischemia	The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.
UN	25080425_D001622_9_1465_1472_betaine_D017202_9_1525_1544_myocardial ischemia	In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.
UN	25080425_D001622_5_833_840_betaine_D020257_5_950_972_ventricular remodeling	Oral administration of betaine (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left ventricular remodeling.
UN	25080425_D007545_0_110_123_isoproterenol_D009202_0_138_155_myocardial injury	Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats.
CID	25080425_D007545_3_653_666_isoproterenol_D017202_3_577_603_myocardial ischemic injury	Acute myocardial ischemic injury was induced in rats by subcutaneous injection of isoproterenol (85 mg/kg), for two consecutive days.
CID	25080425_D007545_9_1497_1510_isoproterenol_D017202_9_1525_1544_myocardial ischemia	In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.
UN	25084821_C069541_0_0_10_Quetiapine_D001714_0_36_43_bipolar	Quetiapine-induced neutropenia in a bipolar patient with hepatocellular carcinoma.
CID	25084821_C069541_8_1056_1066_quetiapine_D005334_8_999_1004_fever	Hepatic dysfunction may be one of the possible risk factors, and concomitant fever may be a diagnostic marker for adverse reaction to quetiapine.
UN	25084821_C069541_1_94_104_Quetiapine_D006402_1_200_216_blood dyscrasias	OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia.
UN	25084821_C069541_0_0_10_Quetiapine_D006528_0_57_81_hepatocellular carcinoma	Quetiapine-induced neutropenia in a bipolar patient with hepatocellular carcinoma.
UN	25084821_C069541_3_469_479_quetiapine_D006528_3_396_420_hepatocellular carcinoma	A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here.
CID	25084821_C069541_5_669_679_quetiapine_D007970_5_633_643_leucopenia	She developed leucopenia after being treated with quetiapine.
UN	25084821_C069541_8_1056_1066_quetiapine_D008107_8_922_941_Hepatic dysfunction	Hepatic dysfunction may be one of the possible risk factors, and concomitant fever may be a diagnostic marker for adverse reaction to quetiapine.
CID	25084821_C069541_0_0_10_Quetiapine_D009503_0_19_30_neutropenia	Quetiapine-induced neutropenia in a bipolar patient with hepatocellular carcinoma.
CID	25084821_C069541_3_469_479_quetiapine_D009503_3_436_447_neutropenia	A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here.
CID	25084821_C069541_7_828_838_quetiapine_D009503_7_785_796_neutropenia	CONCLUSIONS: Although neutropenia is not a common side effect of quetiapine, physicians should be cautious about its presentation and associated risk factors.
UN	25084821_D003024_1_151_160_clozapine_D006402_1_200_216_blood dyscrasias	OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia.
UN	25084821_D003024_1_151_160_clozapine_D009503_1_229_240_neutropenia	OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia.
UN	25096313_D013256_0_48_55_steroid_D009422_0_31_41_neuropathy	Lateral antebrachial cutaneous neuropathy after steroid injection at lateral epicondyle.
UN	25096313_D013256_1_227_234_steroid_D009422_1_186_196_neuropathy	BACKGROUND AND OBJECTIVES: This report aimed to present a case of lateral antebrachial cutaneous neuropathy (LACNP) that occurred after a steroid injection in the lateral epicondyle to treat lateral epicondylitis in a 40-year-old woman.
CID	25096313_D013256_2_487_494_steroid_D010292_2_454_465_paresthesia	MATERIAL AND METHOD: A 40-year-old woman presented with decreased sensation and paresthesia over her right lateral forearm; the paresthesia had occurred after a steroid injection in the right lateral epicondyle 3 months before.
UN	25096313_D013256_8_1238_1245_steroid_D013716_8_1277_1298_lateral epicondylitis	CONCLUSION: This report describes the case of a woman with LACNP that developed after a steroid injection for the treatment of lateral epicondylitis.
UN	25096313_D013256_1_227_234_steroid_D013716_1_280_301_lateral epicondylitis	BACKGROUND AND OBJECTIVES: This report aimed to present a case of lateral antebrachial cutaneous neuropathy (LACNP) that occurred after a steroid injection in the lateral epicondyle to treat lateral epicondylitis in a 40-year-old woman.
CID	25119790_C030272_9_1552_1559_maleate_D007674_9_1568_1579_nephropathy	It is concluded that curcumin is able to attenuate in vivo maleate-induced nephropathy and in vitro cell damage.
CID	25119790_C030272_3_439_446_Maleate_D007674_3_455_467_renal injury	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
CID	25119790_C030272_0_18_25_maleate_D007674_0_34_48_nephrotoxicity	Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.
CID	25119790_C030272_1_308_315_maleate_D007674_1_284_296_renal injury	The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.
CID	25119790_C030272_3_439_446_Maleate_D009336_3_782_790_necrosis	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
CID	25119790_C030272_2_410_417_maleate_D011507_2_339_350_proteinuria	Tubular proteinuria and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats.
UN	25119790_D003474_9_1514_1522_curcumin_D007674_9_1568_1579_nephropathy	It is concluded that curcumin is able to attenuate in vivo maleate-induced nephropathy and in vitro cell damage.
UN	25119790_D003474_0_0_8_Curcumin_D007674_0_34_48_nephrotoxicity	Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.
UN	25119790_D005947_3_562_569_glucose_D007674_3_455_467_renal injury	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
UN	25119790_D005947_3_562_569_glucose_D009336_3_782_790_necrosis	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
UN	25119790_D010100_0_119_125_oxygen_D007674_0_34_48_nephrotoxicity	Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.
UN	25119790_D012964_3_571_577_sodium_D007674_3_455_467_renal injury	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
UN	25119790_D012964_3_571_577_sodium_D009336_3_782_790_necrosis	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
UN	2553470_D008094_8_1556_1563_lithium_D001930_8_1536_1548_brain damage	These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium-pilocarpine model.
UN	2553470_D008094_4_695_702_lithium_D012640_4_760_767_seizure	Second, the anticonvulsant effect of MK-801 in the lithium-pilocarpine model only occurred after initial periods of seizure activity.
UN	2553470_D008094_6_1054_1061_lithium_D012640_6_1034_1042_seizures	Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.
CID	2553470_D008094_8_1556_1563_lithium_D013226_8_1513_1531_status epilepticus	These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium-pilocarpine model.
CID	2553470_D008094_0_40_47_lithium_D013226_0_69_87_status epilepticus	Anticonvulsant actions of MK-801 on the lithium-pilocarpine model of status epilepticus in rats.
UN	2553470_D010862_8_1564_1575_pilocarpine_D001930_8_1536_1548_brain damage	These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium-pilocarpine model.
UN	2553470_D010862_4_703_714_pilocarpine_D012640_4_760_767_seizure	Second, the anticonvulsant effect of MK-801 in the lithium-pilocarpine model only occurred after initial periods of seizure activity.
UN	2553470_D010862_6_1066_1077_pilocarpine_D012640_6_1034_1042_seizures	Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.
CID	2553470_D010862_0_48_59_pilocarpine_D013226_0_69_87_status epilepticus	Anticonvulsant actions of MK-801 on the lithium-pilocarpine model of status epilepticus in rats.
CID	2553470_D010862_8_1564_1575_pilocarpine_D013226_8_1513_1531_status epilepticus	These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium-pilocarpine model.
UN	2553470_D016202_8_1471_1475_NMDA_D001930_8_1536_1548_brain damage	These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium-pilocarpine model.
UN	2553470_D016202_1_122_142_N-methyl-D-aspartate_D012640_1_227_234_seizure	MK-801, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two seizure models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone.
UN	2553470_D016202_8_1471_1475_NMDA_D013226_8_1513_1531_status epilepticus	These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium-pilocarpine model.
UN	2553470_D016291_7_1257_1263_MK-801_D012640_7_1373_1380_seizure	Administration of MK-801 30 or 60 min after pilocarpine, i.e., during status epilepticus, gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate.
UN	2553470_D016291_1_97_103_MK-801_D012640_1_227_234_seizure	MK-801, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two seizure models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone.
UN	2553470_D016291_3_402_408_MK-801_D012640_3_614_622_seizures	First, pretreatment with MK-801 produced an effective and dose-dependent anticonvulsant action with the lithium-pilocarpine model but not with rats treated with pilocarpine alone, suggesting that different biochemical mechanisms control seizures in these two models.
UN	2553470_D016291_4_681_687_MK-801_D012640_4_760_767_seizure	Second, the anticonvulsant effect of MK-801 in the lithium-pilocarpine model only occurred after initial periods of seizure activity.
UN	2553470_D016291_0_26_32_MK-801_D013226_0_69_87_status epilepticus	Anticonvulsant actions of MK-801 on the lithium-pilocarpine model of status epilepticus in rats.
UN	256433_D002228_0_45_58_carbenicillin_D007239_0_63_73_infections	Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients.
UN	256433_D002228_0_45_58_carbenicillin_D009369_0_77_83_cancer	Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients.
UN	256433_D002228_3_435_448_carbenicillin_D009503_3_347_358_neutropenia	To overcome the adverse effects of neutropenia, tobramycin was given by continuous infusion and combined with intermittent carbenicillin.
UN	256433_D003404_13_1395_1405_creatinine_D053099_13_1379_1387_azotemia	Major azotemia (serum creatinine greater than 2.5 mg/dl or BUN greater than 50 mg/dl) occurred in only 2%.
UN	256433_D014031_0_20_30_tobramycin_D007239_0_63_73_infections	Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients.
UN	256433_D014031_0_20_30_tobramycin_D009369_0_77_83_cancer	Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients.
UN	256433_D014031_3_360_370_tobramycin_D009503_3_347_358_neutropenia	To overcome the adverse effects of neutropenia, tobramycin was given by continuous infusion and combined with intermittent carbenicillin.
CID	256433_D014031_14_1537_1547_tobramycin_D053099_14_1480_1488_Azotemia	Azotemia was not related to duration of therapy or serum tobramycin concentration.
CID	25907210_D003976_7_1566_1574_diazinon_D008175_7_1627_1638_lung cancer	CONCLUSIONS: Our updated evaluation of diazinon provides additional evidence of an association with lung cancer risk.
UN	25907210_D003976_1_389_397_diazinon_D009369_1_409_415_cancer	OBJECTIVE: Diazinon, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk.
UN	25907210_D003976_2_438_446_diazinon_D009369_2_460_466_cancer	We used updated diazinon exposure and cancer incidence information to evaluate solid tumour risk in the AHS.
UN	25907210_D003976_0_98_106_diazinon_D009369_0_19_26_tumours	Incidence of solid tumours among pesticide applicators exposed to the organophosphate insecticide diazinon in the Agricultural Health Study: an updated analysis.
UN	25907210_D010755_1_192_207_organophosphate_D008175_1_278_289_lung cancer	OBJECTIVE: Diazinon, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk.
UN	25907210_D010755_0_70_85_organophosphate_D009369_0_19_26_tumours	Incidence of solid tumours among pesticide applicators exposed to the organophosphate insecticide diazinon in the Agricultural Health Study: an updated analysis.
CID	25951420_D010126_1_173_178_ozone_D010300_1_212_231_Parkinson's disease	OBJECTIVE: This study describes associations of ozone and fine particulate matter with Parkinson's disease observed among farmers in North Carolina and Iowa.
CID	25951420_D010126_4_650_655_ozone_D010300_4_625_644_Parkinson's disease	RESULTS: We observed positive associations of Parkinson's disease with ozone (odds ratio = 1.39; 95% CI: 0.98 to 1.98) and fine particulate matter (odds ratio = 1.34; 95% CI: 0.93 to 1.93) in North Carolina but not in Iowa.
CID	25951420_D010126_0_16_21_Ozone_D010300_0_52_71_Parkinson's Disease	Associations of Ozone and PM2.5 Concentrations With Parkinson's Disease Among Participants in the Agricultural Health Study.
CID	25951420_D052638_1_188_206_particulate matter_D010300_1_212_231_Parkinson's disease	OBJECTIVE: This study describes associations of ozone and fine particulate matter with Parkinson's disease observed among farmers in North Carolina and Iowa.
CID	25986755_D002110_1_214_222_caffeine_D005317_1_251_282_intrauterine growth retardation	UNASSIGNED: Our previous study has indicated that prenatal caffeine exposure (PCE) could induce intrauterine growth retardation (IUGR) of offspring.
UN	25986755_D002110_0_136_144_caffeine_D005921_0_78_96_glomerulosclerosis	Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure.
UN	25986755_D003404_6_919_929_creatinine_D005355_6_856_877_interstitial fibrosis	The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein.
UN	25986755_D003404_6_919_929_creatinine_D005921_6_826_844_glomerulosclerosis	The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein.
UN	26002693_C031763_1_106_119_1,3-butadiene_D015464_1_178_202_chronic myeloid leukemia	UNASSIGNED: Epidemiological studies of 1,3-butadiene have suggest that exposures to humans are associated with chronic myeloid leukemia (CML).
CID	26033014_C051786_11_1533_1544_metolachlor_D008113_11_1549_1561_liver cancer	This suggestion of an association between metolachlor and liver cancer among pesticide applicators is a novel finding and echoes observation of increased liver neoplasms in some animal studies.
UN	26033014_C051786_10_1426_1437_metolachlor_D008175_10_1391_1402_lung cancer	An earlier suggestion of increased lung cancer risk at high levels of metolachlor use in this cohort was not confirmed in this update.
UN	26033014_C051786_12_1811_1822_metolachlor_D008223_12_1749_1757_lymphoma	However, our findings for both liver cancer and follicular cell lymphoma warrant follow-up to better differentiate effects of metolachlor use from other factors.
UN	26033014_C051786_6_835_846_metolachlor_D009369_6_872_879_cancers	We saw no association between metolachlor use and incidence of all cancers combined (n = 5,701 with a 5-year lag) or most site-specific cancers.
UN	26033014_C051786_0_21_32_metolachlor_D009369_0_0_6_Cancer	Cancer incidence and metolachlor use in the Agricultural Health Study: An update.
CID	26115410_D001152_6_1166_1169_iAs_D009369_6_1183_1189_cancer	CONCLUSIONS: Evidence is mounting that relates early-life iAs exposure and cancer development later in life.
UN	2614930_D009543_2_287_297_nifedipine_D001282_2_204_218_atrial flutter	He was found to have atrial flutter at a ventricular rate of 70/min which slowed down to 30-40/min when nifedipine (60 mg) in 3 divided doses, during which he was paced at a rate of 70/min.
CID	2614930_D009543_0_0_10_Nifedipine_D001919_0_19_30_bradycardia	Nifedipine induced bradycardia in a patient with autonomic neuropathy.
UN	2614930_D009543_0_0_10_Nifedipine_D009422_0_49_69_autonomic neuropathy	Nifedipine induced bradycardia in a patient with autonomic neuropathy.
CID	2614930_D009543_3_433_443_nifedipine_D013610_3_452_463_tachycardia	This is inconsistent with the well-established finding that nifedipine induces tachycardia in normally innervated hearts.
CID	2625524_D000661_3_395_406_amphetamine_D012640_3_415_423_seizures	Haloperidol failed to prevent amphetamine-induced seizures, but did lower the mortality rate at most doses tested.
CID	2625524_D000661_5_772_783_amphetamine_D012640_5_827_835_seizures	These data suggest a protective role for the central dopamine blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of seizures.
CID	2625524_D003042_6_896_903_cocaine_D012640_6_912_920_seizures	In contrast, haloperidol demonstrated an ability to reduce cocaine-induced seizures without significantly reducing mortality.
CID	2625524_D003042_4_519_526_cocaine_D012640_4_535_543_seizures	Haloperidol decreased the incidence of cocaine-induced seizures at the two highest doses, but the lowering of the mortality rate did not reach statistical significance at any dose.
UN	2625524_D004298_5_714_722_dopamine_D012640_5_827_835_seizures	These data suggest a protective role for the central dopamine blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of seizures.
UN	2625524_D006220_3_365_376_Haloperidol_D012640_3_415_423_seizures	Haloperidol failed to prevent amphetamine-induced seizures, but did lower the mortality rate at most doses tested.
UN	2625524_D006220_4_480_491_Haloperidol_D012640_4_535_543_seizures	Haloperidol decreased the incidence of cocaine-induced seizures at the two highest doses, but the lowering of the mortality rate did not reach statistical significance at any dose.
UN	2625524_D006220_6_850_861_haloperidol_D012640_6_912_920_seizures	In contrast, haloperidol demonstrated an ability to reduce cocaine-induced seizures without significantly reducing mortality.
CID	2650911_D004054_1_218_237_diethylstilbesterol_D002292_1_246_262_renal carcinomas	Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced renal carcinomas in three hamsters.
CID	2650911_D004054_0_65_84_diethylstilbesterol_D002292_0_101_117_renal carcinomas	Autoradiographic evidence of estrogen binding sites in nuclei of diethylstilbesterol induced hamster renal carcinomas.
UN	2650911_D004958_2_344_353_estradiol_D009369_2_393_398_tumor	Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of tumor cells; stereologic analysis revealed a 4.5- to 6.7-times higher concentration of reduced silver grains over nuclei than cytoplasm of these cells.
UN	2650911_D004967_4_787_795_estrogen_D002292_4_812_828_renal carcinomas	This is the first published report documenting the preferential in vivo binding of estrogen to nuclei of cells in estrogen induced hamster renal carcinomas.
UN	2650911_D004967_0_29_37_estrogen_D002292_0_101_117_renal carcinomas	Autoradiographic evidence of estrogen binding sites in nuclei of diethylstilbesterol induced hamster renal carcinomas.
UN	2650911_D012834_2_488_494_silver_D009369_2_393_398_tumor	Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of tumor cells; stereologic analysis revealed a 4.5- to 6.7-times higher concentration of reduced silver grains over nuclei than cytoplasm of these cells.
UN	2710809_C036432_1_152_169_biperiden lactate_D001919_1_243_254_bradycardia	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia.
UN	2710809_C036432_1_152_169_biperiden lactate_D003680_1_272_281_dysphagia	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia.
UN	2710809_C036432_1_152_169_biperiden lactate_D004401_1_256_266_dysarthria	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia.
UN	2710809_C036432_1_152_169_biperiden lactate_D006562_1_84_96_postzosteric	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia.
UN	2710809_C036432_1_152_169_biperiden lactate_D014277_1_97_117_trigeminal neuralgia	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia.
UN	2710809_D001285_3_532_540_atropine_D001919_3_422_433_Bradycardia	Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors.
CID	2710809_D001712_3_445_454_biperiden_D001919_3_422_433_Bradycardia	Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors.
CID	2710809_D001712_0_19_28_biperiden_D001919_0_0_11_Bradycardia	Bradycardia due to biperiden.
UN	2710809_D009116_3_555_564_muscarine_D001919_3_422_433_Bradycardia	Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors.
UN	2718706_D003404_8_1351_1361_creatinine_D007022_8_1328_1339_hypotension	During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group.
CID	2718706_D004737_0_60_69_enflurane_D007022_0_11_22_hypotension	Deliberate hypotension induced by labetalol with halothane, enflurane or isoflurane for middle-ear surgery.
CID	2718706_D004737_1_269_278_enflurane_D007022_1_195_206_hypotensive	The feasibility of using labetalol, an alpha- and beta-adrenergic blocking agent, as a hypotensive agent in combination with inhalation anaesthetics (halothane, enflurane or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery.
CID	2718706_D006221_1_258_267_halothane_D007022_1_195_206_hypotensive	The feasibility of using labetalol, an alpha- and beta-adrenergic blocking agent, as a hypotensive agent in combination with inhalation anaesthetics (halothane, enflurane or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery.
CID	2718706_D006221_0_49_58_halothane_D007022_0_11_22_hypotension	Deliberate hypotension induced by labetalol with halothane, enflurane or isoflurane for middle-ear surgery.
CID	2718706_D006221_3_765_766_H_D007022_3_788_799_hypotension	The mean H concentration during hypotension in the inspiratory gas was 0.7 +/- 0.1 vol%, the mean E concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%.
CID	2718706_D007530_0_73_83_isoflurane_D007022_0_11_22_hypotension	Deliberate hypotension induced by labetalol with halothane, enflurane or isoflurane for middle-ear surgery.
UN	2718706_D007741_10_1662_1671_labetalol_D006973_10_1755_1767_hypertension	These results indicate that labetalol induces easily adjustable hypotension without compensatory tachycardia and rebound hypertension.
CID	2718706_D007741_10_1662_1671_labetalol_D007022_10_1698_1709_hypotension	These results indicate that labetalol induces easily adjustable hypotension without compensatory tachycardia and rebound hypertension.
CID	2718706_D007741_0_34_43_labetalol_D007022_0_11_22_hypotension	Deliberate hypotension induced by labetalol with halothane, enflurane or isoflurane for middle-ear surgery.
UN	2718706_D007741_10_1662_1671_labetalol_D013610_10_1731_1742_tachycardia	These results indicate that labetalol induces easily adjustable hypotension without compensatory tachycardia and rebound hypertension.
CID	2765447_D019793_1_101_112_fluorescein_D004830_1_58_79_Tonic-clonic seizures	Tonic-clonic seizures followed intravenous fluorescein injection for fundus angiography in a 47-year-old male.
UN	2765447_D019793_0_33_44_fluorescein_D012640_0_0_10_Convulsion	Convulsion following intravenous fluorescein angiography.
UN	2767010_C043114_6_698_714_phenytoin sodium_D001145_6_740_750_arrhythmia	The total doses of ACC-9653 or phenytoin sodium necessary to convert the arrhythmia to a normal sinus rhythm were 24 +/- 6 and 14 +/- 3 mg/kg, respectively.
UN	2767010_C043114_7_829_845_phenytoin sodium_D001145_7_920_931_arrhythmias	Only phenytoin sodium displayed in vitro antiarrhythmic activity against strophanthidin-induced arrhythmias in guinea pig right atria.
UN	2767010_C043114_3_278_294_phenytoin sodium_D012640_3_343_351_seizures	ACC-9653 and phenytoin sodium have equivalent anticonvulsant activity against seizures induced by maximal electroshock (MES) in mice following i.p., oral, or i.v. administration.
UN	2767010_C043114_5_543_559_phenytoin sodium_D017180_5_621_644_ventricular tachycardia	ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ouabain-induced ventricular tachycardia in anesthetized dogs.
CID	2767010_D010042_5_605_612_ouabain_D017180_5_621_644_ventricular tachycardia	ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ouabain-induced ventricular tachycardia in anesthetized dogs.
CID	2767010_D013327_7_897_911_strophanthidin_D001145_7_920_931_arrhythmias	Only phenytoin sodium displayed in vitro antiarrhythmic activity against strophanthidin-induced arrhythmias in guinea pig right atria.
UN	2782734_D000420_1_150_160_salbutamol_D001249_1_230_236_asthma	High doses of inhaled salbutamol produce substantial improvements in airway response in patients with asthma, and are associated with dose-dependent systemic beta-adrenoceptor responses.
UN	2782734_D000420_0_102_112_salbutamol_D001249_0_116_126_asthmatics	Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics.
UN	2782734_D005947_5_1127_1130_Glu_D014202_5_1101_1107_tremor	At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms).
UN	2782734_D011188_5_1124_1125_K_D014202_5_1101_1107_tremor	At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms).
CID	2818777_D010672_1_99_108_phenytoin_D017093_1_77_92_hepatic failure	A 61 year old female developed fatal hepatic failure after phenytoin administration.
UN	2818777_D010672_0_0_9_Phenytoin_D056486_0_24_38_hepatic injury	Phenytoin induced fatal hepatic injury.
UN	2884595_D006632_4_457_466_histamine_D001927_4_535_549_encephalopathy	Blockade of histamine H1 receptors may reduce mortality in pertussis immunization-induced encephalopathy in mice.
UN	2884595_D006632_4_457_466_histamine_D014917_4_504_513_pertussis	Blockade of histamine H1 receptors may reduce mortality in pertussis immunization-induced encephalopathy in mice.
CID	2904523_D004837_0_12_22_adrenaline_D006973_0_23_35_hypertension	Support for adrenaline-hypertension hypothesis: 18 hour pressor effect after 6 hours adrenaline infusion.
CID	2904523_D004837_6_901_911_adrenaline_D006973_6_912_924_hypertension	These findings are strong support for the adrenaline-hypertension hypothesis in man.
UN	2907577_C028322_2_324_344_8-phenyltheophylline_D058186_2_410_429_acute renal failure	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1).
UN	2907577_C034347_2_363_375_enprofylline_D058186_2_410_429_acute renal failure	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1).
UN	2907577_D000241_1_79_88_Adenosine_D007511_1_153_162_ischaemic	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and nephrotoxic models of acute renal failure (ARF).
UN	2907577_D000241_1_79_88_Adenosine_D007674_1_167_178_nephrotoxic	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and nephrotoxic models of acute renal failure (ARF).
UN	2907577_D000241_6_1062_1071_adenosine_D058186_6_1140_1143_ARF	The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that adenosine plays little, if any, pathophysiological role in gentamicin-induced ARF.
UN	2907577_D000241_2_302_311_adenosine_D058186_2_410_429_acute renal failure	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1).
UN	2907577_D000241_1_79_88_Adenosine_D058186_1_189_208_acute renal failure	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and nephrotoxic models of acute renal failure (ARF).
UN	2907577_D003404_3_544_554_creatinine_D009336_3_670_678_necrosis	Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices.
CID	2907577_D005839_6_1121_1131_gentamicin_D058186_6_1140_1143_ARF	The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that adenosine plays little, if any, pathophysiological role in gentamicin-induced ARF.
CID	2907577_D005839_0_28_38_gentamicin_D058186_0_47_66_acute renal failure	Effect of alkylxanthines on gentamicin-induced acute renal failure in the rat.
CID	2907577_D005839_2_458_468_gentamicin_D058186_2_410_429_acute renal failure	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1).
UN	2907577_D010130_3_608_628_p-aminohippuric acid_D009336_3_670_678_necrosis	Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices.
UN	2907577_D013806_2_346_358_theophylline_D058186_2_410_429_acute renal failure	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1).
UN	2907577_D014508_3_535_539_urea_D009336_3_670_678_necrosis	Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices.
UN	2931989_D015474_5_624_636_Isotretinoin_C563492_5_796_818_optic nerve hypoplasia	Isotretinoin is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia).
UN	2931989_D015474_5_624_636_Isotretinoin_D000013_5_698_722_congenital abnormalities	Isotretinoin is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia).
UN	2931989_D015474_1_142_154_isotretinoin_D000152_1_211_215_acne	A total of 261 adverse ocular reactions occurred in 237 patients who received isotretinoin, a commonly used drug in the treatment of severe cystic acne.
UN	2931989_D015474_5_624_636_Isotretinoin_D006972_5_777_790_hypertelorism	Isotretinoin is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia).
UN	2931989_D015474_5_624_636_Isotretinoin_D008850_5_753_767_microphthalmos	Isotretinoin is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia).
UN	2933998_D013726_0_15_26_terbutaline_D001249_0_30_46_bronchial asthma	Procaterol and terbutaline in bronchial asthma.
UN	2933998_D017265_0_0_10_Procaterol_D001249_0_30_46_bronchial asthma	Procaterol and terbutaline in bronchial asthma.
UN	2933998_D017265_5_514_524_procaterol_D001249_5_477_486_asthmatic	Both anti-asthmatic and tremorgenic effects of procaterol were dose-related.
CID	2933998_D017265_5_514_524_procaterol_D014202_5_491_502_tremorgenic	Both anti-asthmatic and tremorgenic effects of procaterol were dose-related.
CID	2974281_D007545_7_1215_1228_isoproterenol_D006332_7_1244_1261_heart hypertrophy	Thus, the investigations did not provide any evidence that the beta-receptor blockers propranolol and B 24/76 have the potency to prevent isoproterenol from producing heart hypertrophy.
CID	2974281_D007545_0_47_60_isoproterenol_D006332_0_73_90_heart hypertrophy	Subacute effects of propranolol and B 24/76 on isoproterenol-induced rat heart hypertrophy in correlation with blood pressure.
CID	2974281_D007545_2_443_456_isoproterenol_D006332_2_465_482_heart hypertrophy	The studies were performed using an experimental model of isoproterenol-induced heart hypertrophy in rats.
UN	2974281_D009952_5_818_827_ornithine_D006332_5_878_898_hypertrophied hearts	It was possible to suppress the increased ornithine decarboxylase activity with both beta-blockers in hypertrophied hearts, but there was no effect on the heart mass.
UN	2974281_D011433_7_1163_1174_propranolol_D006332_7_1244_1261_heart hypertrophy	Thus, the investigations did not provide any evidence that the beta-receptor blockers propranolol and B 24/76 have the potency to prevent isoproterenol from producing heart hypertrophy.
UN	2974281_D011433_0_20_31_propranolol_D006332_0_73_90_heart hypertrophy	Subacute effects of propranolol and B 24/76 on isoproterenol-induced rat heart hypertrophy in correlation with blood pressure.
UN	2974281_D011433_6_951_962_propranolol_D006984_6_1052_1065_hypertrophied	Neither propranolol nor B 24/76 could stop the changes in the characteristic myosin isoenzyme pattern of the hypertrophied rat heart.
UN	2983630_D000241_7_1175_1184_adenosine_D009421_7_1131_1164_abnormalities in neuronal systems	Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine.
UN	2983630_D000241_7_1175_1184_adenosine_D016584_7_1098_1112_panic disorder	Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine.
UN	2983630_D002110_1_99_107_caffeine_D000379_1_338_349_agoraphobia	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.
CID	2983630_D002110_8_1242_1250_caffeine_D001008_8_1200_1217_anxiety disorders	Patients with anxiety disorders may benefit by avoiding caffeine-containing foods and beverages.
CID	2983630_D002110_2_388_396_Caffeine_D001008_2_455_462_anxiety	Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects.
CID	2983630_D002110_2_388_396_Caffeine_D009325_2_483_489_nausea	Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects.
UN	2983630_D002110_7_1020_1028_caffeine_D009421_7_1131_1164_abnormalities in neuronal systems	Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine.
UN	2983630_D002110_2_388_396_Caffeine_D011595_2_505_517_restlessness	Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects.
CID	2983630_D002110_2_388_396_Caffeine_D014202_2_523_530_tremors	Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects.
UN	2983630_D002110_0_32_40_caffeine_D016584_0_44_59_panic disorders	Increased anxiogenic effects of caffeine in panic disorders.
UN	2983630_D002110_4_776_784_caffeine_D016584_4_826_839_panic attacks	Seventy-one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks.
UN	2983630_D006854_1_245_253_cortisol_D000379_1_338_349_agoraphobia	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.
UN	2983630_D006854_1_245_253_cortisol_D016584_1_355_368_panic attacks	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.
UN	2983630_D008734_1_196_233_3-methoxy-4-hydroxyphenethyleneglycol_D000379_1_338_349_agoraphobia	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.
UN	2983630_D008734_1_196_233_3-methoxy-4-hydroxyphenethyleneglycol_D016584_1_355_368_panic attacks	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.
UN	3074291_C017590_0_28_46_oxitropium bromide_D001249_0_93_99_asthma	Comparison of the effect of oxitropium bromide and of slow-release theophylline on nocturnal asthma.
UN	3074291_C017590_4_854_864_oxitropium_D009325_4_906_912_nausea	No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline.
UN	3074291_C017590_4_854_864_oxitropium_D014202_4_927_934_tremors	No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline.
UN	3074291_C017590_4_854_864_oxitropium_D014839_4_914_922_vomiting	No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline.
UN	3074291_D013806_0_67_79_theophylline_D001249_0_93_99_asthma	Comparison of the effect of oxitropium bromide and of slow-release theophylline on nocturnal asthma.
UN	3074291_D013806_1_193_205_theophylline_D001249_1_233_239_asthma	The effects of a new inhaled antimuscarinic drug, oxitropium bromide, and of a slow-release theophylline preparation upon nocturnal asthma were compared in a placebo-controlled double-blind study.
UN	3074291_D013806_5_1005_1017_theophylline_D001249_5_1031_1037_asthma	Oxitropium proves to be a valuable alternative to theophylline in nocturnal asthma, since it is equally potent, safer and does not require the titration of dosage.
CID	3074291_D013806_4_941_953_theophylline_D009325_4_906_912_nausea	No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline.
CID	3074291_D013806_4_941_953_theophylline_D014202_4_927_934_tremors	No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline.
CID	3074291_D013806_4_941_953_theophylline_D014839_4_914_922_vomiting	No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline.
CID	3083835_D010406_2_248_258_penicillin_D000707_2_259_270_anaphylaxis	Emergency physicians should be aware of oral penicillin anaphylaxis in order to prevent its occurrence by prescribing the antibiotic judiciously and knowledgeably and to offer optimal medical therapy once this life-threatening reaction has begun.
CID	3083835_D010406_0_0_10_Penicillin_D000707_0_11_22_anaphylaxis	Penicillin anaphylaxis.
CID	3083835_D010406_1_39_49_penicillin_D000707_1_50_61_anaphylaxis	A case of oral penicillin anaphylaxis is described, and the terminology, occurrence, clinical manifestations, pathogenesis, prevention, and treatment of anaphylaxis are reviewed.
CID	3084231_D014635_0_11_24_valproic acid_D003704_0_33_41_dementia	Reversible valproic acid-induced dementia: a case report.
CID	3084231_D014635_1_69_82_valproic acid_D003704_1_91_99_dementia	Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.
UN	3084231_D014635_1_69_82_valproic acid_D004827_1_141_149_epilepsy	Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.
CID	3084231_D014635_3_766_779_valproic acid_D022124_3_788_802_hyperammonemia	Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.
UN	3088653_D009270_0_87_95_naloxone_D000647_0_32_39_amnesia	Reversal of scopolamine-induced amnesia of passive avoidance by pre- and post-training naloxone.
UN	3088653_D009270_5_691_699_naloxone_D000647_5_781_788_amnesia	Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the scopolamine-induced amnesia.
UN	3088653_D009270_1_153_161_naloxone_D008569_1_187_204_retention deficit	In a series of five experiments, the modulating role of naloxone on a scopolamine-induced retention deficit in a passive avoidance paradigm was investigated in mice.
UN	3088653_D009270_6_990_998_naloxone_D008569_6_1026_1043_retention deficit	Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.
UN	3088653_D009270_6_879_887_naloxone_D010146_6_848_852_pain	Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.
CID	3088653_D012601_0_12_23_scopolamine_D000647_0_32_39_amnesia	Reversal of scopolamine-induced amnesia of passive avoidance by pre- and post-training naloxone.
CID	3088653_D012601_5_761_772_scopolamine_D000647_5_781_788_amnesia	Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the scopolamine-induced amnesia.
UN	3088653_D012601_1_167_178_scopolamine_D008569_1_187_204_retention deficit	In a series of five experiments, the modulating role of naloxone on a scopolamine-induced retention deficit in a passive avoidance paradigm was investigated in mice.
UN	3088653_D012601_6_1006_1017_scopolamine_D008569_6_1026_1043_retention deficit	Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.
UN	3088653_D012601_6_1006_1017_scopolamine_D010146_6_848_852_pain	Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.
UN	3088653_D019832_2_284_302_methyl scopolamine_D000647_2_331_338_amnesia	Scopolamine, but not methyl scopolamine (1 and 3 mg/kg), induced an amnesia as measured by latency and duration parameters.
CID	3109094_D003520_0_43_59_cyclophosphamide_D001745_0_68_98_lesions of the urinary bladder	Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by mesna.
UN	3109094_D003520_1_157_173_cyclophosphamide_D003556_1_182_190_cystitis	Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses.
UN	3109094_D003520_1_157_173_cyclophosphamide_D004487_1_275_280_edema	Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses.
UN	3109094_D003520_1_157_173_cyclophosphamide_D009336_1_339_347_necroses	Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses.
UN	3109094_D015080_0_134_139_mesna_D001745_0_68_98_lesions of the urinary bladder	Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by mesna.
CID	3125850_D013390_0_41_54_suxamethonium_D005207_0_63_84_muscle fasciculations	Increase in intragastric pressure during suxamethonium-induced muscle fasciculations in children: inhibition by alfentanil.
CID	3125850_D013390_6_983_996_suxamethonium_D005207_6_951_972_muscle fasciculations	It is concluded that intragastric pressure increases significantly during muscle fasciculations caused by suxamethonium in healthy children.
CID	3125850_D013390_7_1100_1113_suxamethonium_D005207_7_1122_1143_muscle fasciculations	Alfentanil 50 micrograms kg-1 effectively inhibits the incidence and intensity of suxamethonium-induced muscle fasciculations; moreover, intragastric pressure remains at its control value.
CID	3125850_D013390_3_455_468_suxamethonium_D005207_3_423_444_muscle fasciculations	The incidence and intensity of muscle fasciculations caused by suxamethonium were significantly greater in the control than in the alfentanil group.
UN	3125850_D014867_4_663_666_H2O_D005207_4_574_595_muscle fasciculations	The intragastric pressure during muscle fasciculations was significantly higher in the control group (16 +/- 0.7 (SEM) cm H2O) than in the alfentanil group (7.7 +/- 1.5 (SEM) cm H2O).
UN	3125850_D015760_7_1018_1028_Alfentanil_D005207_7_1122_1143_muscle fasciculations	Alfentanil 50 micrograms kg-1 effectively inhibits the incidence and intensity of suxamethonium-induced muscle fasciculations; moreover, intragastric pressure remains at its control value.
UN	3125850_D015760_4_680_690_alfentanil_D005207_4_574_595_muscle fasciculations	The intragastric pressure during muscle fasciculations was significantly higher in the control group (16 +/- 0.7 (SEM) cm H2O) than in the alfentanil group (7.7 +/- 1.5 (SEM) cm H2O).
UN	3125850_D015760_3_523_533_alfentanil_D005207_3_423_444_muscle fasciculations	The incidence and intensity of muscle fasciculations caused by suxamethonium were significantly greater in the control than in the alfentanil group.
UN	3125850_D015760_0_112_122_alfentanil_D005207_0_63_84_muscle fasciculations	Increase in intragastric pressure during suxamethonium-induced muscle fasciculations in children: inhibition by alfentanil.
UN	3155884_D002395_7_1253_1266_catecholamine_D003920_7_1282_1290_diabetic	The rapid reversion after insulin treatment excludes the possibility that streptozotocin in itself causes the ISO resistance and points towards a direct insulin effect on myocardial catecholamine sensitivity in diabetic rats.
UN	3155884_D002395_4_736_750_catecholamines_D003920_4_780_788_diabetic	The myocardial content of catecholamines was estimated in these 8 day diabetic rats.
UN	3155884_D005947_3_668_675_glucose_D005355_3_506_514_fibrosis	Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared.
UN	3155884_D007545_0_79_92_isoproterenol_D003920_0_111_119_diabetic	Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in streptozotocin diabetic rats.
UN	3155884_D007545_2_348_361_isoproterenol_D003920_2_291_299_diabetes	The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.
CID	3155884_D007545_1_150_163_isoproterenol_D005355_1_183_191_fibrosis	A morphometric study of isoproterenol induced myocardial fibrosis.
CID	3155884_D007545_3_494_497_ISO_D005355_3_506_514_fibrosis	Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared.
UN	3155884_D007545_2_348_361_isoproterenol_D066126_2_312_323_cardiotoxic	The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.
UN	3155884_D007545_0_79_92_isoproterenol_D066126_0_57_68_cardiotoxic	Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in streptozotocin diabetic rats.
CID	3155884_D013311_0_96_110_streptozotocin_D003920_0_111_119_diabetic	Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in streptozotocin diabetic rats.
CID	3155884_D013311_2_276_290_streptozotocin_D003920_2_291_299_diabetes	The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.
UN	3155884_D013311_0_96_110_streptozotocin_D066126_0_57_68_cardiotoxic	Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in streptozotocin diabetic rats.
UN	3155884_D013311_2_276_290_streptozotocin_D066126_2_312_323_cardiotoxic	The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.
UN	3191389_D007052_2_400_409_ibuprofen_D012640_2_433_441_seizures	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine.
UN	3191389_D007213_2_386_398_indomethacin_D012640_2_433_441_seizures	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine.
UN	3191389_D008528_5_764_778_Mefenamic acid_D001930_5_857_869_brain damage	Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related brain damage induced by pilocarpine, 380 mg/kg.
UN	3191389_D008528_2_414_428_mefenamic acid_D012640_2_433_441_seizures	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine.
CID	3191389_D010653_2_370_384_phenylbutazone_D012640_2_433_441_seizures	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine.
UN	3191389_D010862_5_881_892_pilocarpine_D001930_5_857_869_brain damage	Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related brain damage induced by pilocarpine, 380 mg/kg.
CID	3191389_D010862_1_142_153_pilocarpine_D012640_1_170_178_seizures	The muscarinic cholinergic agonist pilocarpine induces in rats seizures and status epilepticus followed by widespread damage to the forebrain.
CID	3191389_D010862_2_454_465_pilocarpine_D012640_2_433_441_seizures	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine.
CID	3191389_D010862_0_86_97_pilocarpine_D012640_0_65_73_seizures	Differential effects of non-steroidal anti-inflammatory drugs on seizures produced by pilocarpine in rats.
CID	3191389_D010862_5_881_892_pilocarpine_D012640_5_841_848_seizure	Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related brain damage induced by pilocarpine, 380 mg/kg.
CID	3191389_D010862_6_1013_1024_pilocarpine_D012640_6_1033_1041_seizures	These results indicate that non-steroidal anti-inflammatory drugs differentially modulate the threshold for pilocarpine-induced seizures.
CID	3191389_D010862_4_751_762_pilocarpine_D012640_4_730_738_seizures	Indomethacin, 1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate seizures produced by pilocarpine.
CID	3191389_D010862_1_142_153_pilocarpine_D013226_1_183_201_status epilepticus	The muscarinic cholinergic agonist pilocarpine induces in rats seizures and status epilepticus followed by widespread damage to the forebrain.
CID	3191389_D012980_2_351_368_sodium salicylate_D012640_2_433_441_seizures	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine.
UN	3289726_D005047_8_1081_1090_etoposide_D005910_8_1103_1119_malignant glioma	This complication appears to represent a significant new toxicity of high-dose etoposide therapy for malignant glioma.
UN	3289726_D005047_0_45_54_etoposide_D005910_0_67_83_malignant glioma	Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma.
UN	3289726_D005047_1_85_94_Etoposide_D009369_1_152_158_tumors	Etoposide (VP-16-213) has been used in the treatment of many solid tumors and hematologic malignancies.
UN	3289726_D005047_0_45_54_etoposide_D009422_0_0_28_Acute neurologic dysfunction	Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma.
UN	3289726_D005047_1_85_94_Etoposide_D019337_1_163_187_hematologic malignancies	Etoposide (VP-16-213) has been used in the treatment of many solid tumors and hematologic malignancies.
UN	3297909_D013827_0_35_48_thiabendazole_D001649_0_12_28_bile duct injury	Progressive bile duct injury after thiabendazole administration.
UN	3297909_D013827_1_123_136_thiabendazole_D007565_1_91_99_jaundice	A 27-yr-old man developed jaundice 2 wk after exposure to thiabendazole.
UN	3323259_C038806_5_838_853_dihydropyridine_D000787_5_914_920_angina	As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function.
UN	3323259_C038806_10_1631_1646_dihydropyridine_D000855_10_1761_1769_anorexia	In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.
UN	3323259_C038806_10_1631_1646_dihydropyridine_D004244_10_1775_1784_dizziness	In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.
UN	3323259_C038806_10_1631_1646_dihydropyridine_D004487_10_1746_1751_edema	In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.
UN	3323259_C038806_10_1631_1646_dihydropyridine_D005483_10_1722_1730_flushing	In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.
UN	3323259_C038806_10_1631_1646_dihydropyridine_D006261_10_1705_1713_headache	In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.
UN	3323259_C038806_5_838_853_dihydropyridine_D006973_5_925_937_hypertension	As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function.
UN	3323259_C038806_10_1631_1646_dihydropyridine_D009325_10_1753_1759_nausea	In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.
UN	3323259_D002118_1_140_147_calcium_D002318_1_171_193_cardiovascular disease	Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases.
CID	3323259_D002121_10_1647_1671_calcium channel blockers_D000855_10_1761_1769_anorexia	In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.
UN	3323259_D002121_1_234_265_calcium channel blocking agents_D002318_1_296_319_cardiovascular diseases	Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases.
CID	3323259_D002121_10_1647_1671_calcium channel blockers_D004244_10_1775_1784_dizziness	In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.
CID	3323259_D002121_10_1647_1671_calcium channel blockers_D004487_10_1746_1751_edema	In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.
CID	3323259_D002121_10_1647_1671_calcium channel blockers_D005483_10_1722_1730_flushing	In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.
CID	3323259_D002121_10_1647_1671_calcium channel blockers_D006261_10_1705_1713_headache	In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.
CID	3323259_D002121_10_1647_1671_calcium channel blockers_D009325_10_1753_1759_nausea	In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.
UN	3323259_D009543_5_894_904_nifedipine_D000787_5_914_920_angina	As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function.
UN	3323259_D009543_5_894_904_nifedipine_D006973_5_925_937_hypertension	As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function.
UN	3323259_D009553_9_1499_1509_nimodipine_D003704_9_1593_1601_dementia	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke.
UN	3323259_D009553_9_1499_1509_nimodipine_D008881_9_1574_1591_migraine headache	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke.
UN	3323259_D009553_9_1499_1509_nimodipine_D013345_9_1549_1572_subarachnoid hemorrhage	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke.
UN	3323259_D009553_9_1499_1509_nimodipine_D020521_9_1607_1613_stroke	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke.
UN	3323259_D009568_7_1190_1202_nitrendipine_D006973_7_1324_1336_hypertension	Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension.
UN	3323259_D015737_8_1378_1389_nisoldipine_D000787_8_1445_1451_angina	The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina.
UN	3323259_D015737_7_1207_1218_nisoldipine_D006973_7_1324_1336_hypertension	Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension.
UN	3323599_D011479_9_1159_1161_PS_D005923_9_1243_1247_FSGS	Therefore, it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease.
UN	3323599_D011479_1_246_263_protamine sulfate_D005923_1_109_145_focal segmental glomerular sclerosis	An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (PS).
UN	3323599_D011479_9_1159_1161_PS_D007676_9_1273_1296_end-stage renal disease	Therefore, it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease.
CID	3323599_D011692_9_1187_1191_AMNS_D005923_9_1243_1247_FSGS	Therefore, it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease.
CID	3323599_D011692_9_1187_1191_AMNS_D007676_9_1273_1296_end-stage renal disease	Therefore, it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease.
UN	3323599_D011692_0_19_34_aminonucleoside_D009401_0_35_44_nephrosis	The enhancement of aminonucleoside nephrosis by the co-administration of protamine.
CID	3339945_D000628_2_289_302_aminophylline_D012640_2_326_334_seizures	Sprague-Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of aminophylline until onset of maximal seizures which occurred after 28 and 30 minutes respectively.
UN	3339945_D013806_6_909_921_theophylline_D020258_6_886_896_neurotoxic	It is concluded that advanced pregnancy has a negligible effect on the neurotoxic response to theophylline in rats.
UN	3339945_D013806_1_125_137_theophylline_D020258_1_108_121_neurotoxicity	The purpose of this investigation was to determine whether the neurotoxicity of theophylline is altered in advanced pregnancy.
UN	3339945_D013806_0_0_12_Theophylline_D020258_0_13_26_neurotoxicity	Theophylline neurotoxicity in pregnant rats.
UN	3375885_D005438_0_66_81_fludrocortisone_D006947_0_0_12_Hyperkalemia	Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone.
UN	3375885_D007213_1_265_277_indomethacin_D001172_1_123_143_rheumatoid arthritis	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.
CID	3375885_D007213_0_24_36_indomethacin_D006947_0_0_12_Hyperkalemia	Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone.
CID	3375885_D007213_3_628_640_indomethacin_D006947_3_602_614_hyperkalemia	Because he was unable to discontinue nonsteroidal anti-inflammatory drug therapy, fludrocortisone was added, correcting the hyperkalemia and allowing indomethacin therapy to be continued safely.
CID	3375885_D007213_1_265_277_indomethacin_D006947_1_196_208_hyperkalemia	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.
CID	3375885_D007213_1_265_277_indomethacin_D006994_1_227_244_hypoaldosteronism	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.
UN	3375885_D007213_1_265_277_indomethacin_D007674_1_176_187_nephropathy	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.
UN	3375885_D008528_1_161_175_mefenamic acid_D001172_1_123_143_rheumatoid arthritis	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.
UN	3375885_D008528_1_161_175_mefenamic acid_D006947_1_196_208_hyperkalemia	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.
UN	3375885_D008528_1_161_175_mefenamic acid_D006994_1_227_244_hypoaldosteronism	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.
CID	3375885_D008528_1_161_175_mefenamic acid_D007674_1_176_187_nephropathy	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.
UN	3375885_D009288_1_282_290_naproxen_D001172_1_123_143_rheumatoid arthritis	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.
CID	3375885_D009288_0_41_49_naproxen_D006947_0_0_12_Hyperkalemia	Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone.
CID	3375885_D009288_1_282_290_naproxen_D006947_1_196_208_hyperkalemia	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.
CID	3375885_D009288_1_282_290_naproxen_D006994_1_227_244_hypoaldosteronism	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.
UN	3375885_D009288_1_282_290_naproxen_D007674_1_176_187_nephropathy	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.
UN	3375885_D011453_2_441_454_prostaglandin_D006994_2_405_435_type IV renal tubular acidosis	It is likely that preexisting renal disease predisposed this patient to type IV renal tubular acidosis with prostaglandin synthetase inhibitors.
UN	3375885_D011453_2_441_454_prostaglandin_D007674_2_363_376_renal disease	It is likely that preexisting renal disease predisposed this patient to type IV renal tubular acidosis with prostaglandin synthetase inhibitors.
CID	3383127_D002945_0_77_86_cisplatin_D007022_0_0_11_Hypotension	Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.
UN	3383127_D002945_1_236_245_cisplatin_D015179_1_190_210_colorectal carcinoma	Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).
UN	3383127_D002945_5_691_695_CDDP_D066126_5_650_664_cardiotoxicity	The presentation and cardiac evaluation (hemodynamic, echocardiographic, and scintigraphic) of these patients suggest new manifestations of 5-FU cardiotoxicity that may be influenced by CDDP.
UN	3383127_D002945_0_77_86_cisplatin_D066126_0_34_48_cardiotoxicity	Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.
CID	3383127_D005472_0_91_105_5-fluorouracil_D007022_0_0_11_Hypotension	Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.
CID	3383127_D005472_1_257_271_5-fluorouracil_D007022_1_135_146_hypotension	Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).
UN	3383127_D005472_1_257_271_5-fluorouracil_D015179_1_190_210_colorectal carcinoma	Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).
UN	3383127_D005472_0_91_105_5-fluorouracil_D066126_0_34_48_cardiotoxicity	Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.
UN	3383127_D005472_5_645_649_5-FU_D066126_5_650_664_cardiotoxicity	The presentation and cardiac evaluation (hemodynamic, echocardiographic, and scintigraphic) of these patients suggest new manifestations of 5-FU cardiotoxicity that may be influenced by CDDP.
CID	3409843_D002220_0_48_61_carbamazepine_D000741_0_6_21_aplastic anemia	Fatal aplastic anemia in a patient treated with carbamazepine.
CID	3409843_D002220_1_102_115_carbamazepine_D000741_1_79_94_aplastic anemia	A case of fatal aplastic anemia due to carbamazepine treatment in an epileptic woman is reported.
UN	3409843_D002220_2_215_228_carbamazepine_D001855_2_187_207_bone marrow toxicity	Despite concerns of fatal bone marrow toxicity due to carbamazepine, this is only the fourth documented and published report.
UN	3409843_D002220_1_102_115_carbamazepine_D004827_1_132_141_epileptic	A case of fatal aplastic anemia due to carbamazepine treatment in an epileptic woman is reported.
CID	3423103_D003000_0_72_81_clonidine_D001919_0_106_117_bradycardia	Participation of a bulbospinal serotonergic pathway in the rat brain in clonidine-induced hypotension and bradycardia.
CID	3423103_D003000_5_939_948_clonidine_D001919_5_913_925_bradycardiac	Furthermore, selective destruction of the spinal 5-HT nerves, produced by bilateral spinal injection of 5,7-dihydroxytryptamine, reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats.
CID	3423103_D003000_4_631_640_clonidine_D001919_4_649_660_bradycardia	On the other hand, the clonidine-induced bradycardia was antagonized by prior bilateral vagotomy, but not spinal transection.
CID	3423103_D003000_6_1130_1139_clonidine_D001919_6_1164_1175_bradycardia	The data indicate that a bulbospinal serotonergic pathway is involved in development of clonidine-induced hypotension and bradycardia.
CID	3423103_D003000_6_1130_1139_clonidine_D007022_6_1148_1159_hypotension	The data indicate that a bulbospinal serotonergic pathway is involved in development of clonidine-induced hypotension and bradycardia.
CID	3423103_D003000_3_505_514_clonidine_D007022_3_523_534_hypotension	The clonidine-induced hypotension was antagonized by prior spinal transection, but not bilateral vagotomy.
CID	3423103_D003000_0_72_81_clonidine_D007022_0_90_101_hypotension	Participation of a bulbospinal serotonergic pathway in the rat brain in clonidine-induced hypotension and bradycardia.
UN	3423103_D012701_5_783_787_5-HT_D001919_5_913_925_bradycardiac	Furthermore, selective destruction of the spinal 5-HT nerves, produced by bilateral spinal injection of 5,7-dihydroxytryptamine, reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats.
UN	3423103_D015116_5_838_861_5,7-dihydroxytryptamine_D001919_5_913_925_bradycardiac	Furthermore, selective destruction of the spinal 5-HT nerves, produced by bilateral spinal injection of 5,7-dihydroxytryptamine, reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats.
UN	3439580_D007099_3_343_353_Imipramine_D002653_3_367_384_behavior disorder	We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given Imipramine to control a behavior disorder.
CID	3439580_D007099_0_41_51_imipramine_D006973_0_0_12_Hypertension	Hypertension in neuroblastoma induced by imipramine.
UN	3439580_D007099_3_343_353_Imipramine_D009447_3_315_328_neuroblastoma	We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given Imipramine to control a behavior disorder.
UN	3439580_D007099_0_41_51_imipramine_D009447_0_16_29_neuroblastoma	Hypertension in neuroblastoma induced by imipramine.
UN	3475563_D001507_1_156_170_beclomethasone_D001249_1_110_119_asthmatic	Of 158 asthmatic patients who were placed on inhaled beclomethasone, 15 (9.5%) developed either hoarseness (8), oral thrush (6), or both (1).
UN	3475563_D001507_7_803_817_beclomethasone_D002177_7_868_879_candidiasis	Concomitant use of oral prednisone and topical beclomethasone may increase the risk of developing hoarseness or candidiasis.
CID	3475563_D001507_0_74_101_beclomethasone dipropionate_D002180_0_38_54_oral candidiasis	Rechallenge of patients who developed oral candidiasis or hoarseness with beclomethasone dipropionate.
CID	3475563_D001507_7_803_817_beclomethasone_D006685_7_854_864_hoarseness	Concomitant use of oral prednisone and topical beclomethasone may increase the risk of developing hoarseness or candidiasis.
CID	3475563_D001507_0_74_101_beclomethasone dipropionate_D006685_0_58_68_hoarseness	Rechallenge of patients who developed oral candidiasis or hoarseness with beclomethasone dipropionate.
UN	3475563_D011241_7_780_790_prednisone_D002177_7_868_879_candidiasis	Concomitant use of oral prednisone and topical beclomethasone may increase the risk of developing hoarseness or candidiasis.
UN	3475563_D011241_7_780_790_prednisone_D006685_7_854_864_hoarseness	Concomitant use of oral prednisone and topical beclomethasone may increase the risk of developing hoarseness or candidiasis.
UN	3533179_D003520_4_731_734_CYA_D000741_4_835_850_aplastic anemia	Eighty patients who were to receive CYA 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, Wiskott-Aldrich syndrome, or severe combined immunodeficiency syndrome.
UN	3533179_D003520_11_1816_1819_CYA_D000741_11_1886_1901_aplastic anemia	We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.
UN	3533179_D003520_11_1983_1986_CYA_D000741_11_1886_1901_aplastic anemia	We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.
UN	3533179_D003520_11_1983_1986_CYA_D007153_11_1906_1924_immunodeficiencies	We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.
UN	3533179_D003520_4_731_734_CYA_D014923_4_852_876_Wiskott-Aldrich syndrome	Eighty patients who were to receive CYA 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, Wiskott-Aldrich syndrome, or severe combined immunodeficiency syndrome.
UN	3533179_D003520_4_731_734_CYA_D016511_4_881_922_severe combined immunodeficiency syndrome	Eighty patients who were to receive CYA 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, Wiskott-Aldrich syndrome, or severe combined immunodeficiency syndrome.
UN	3533179_D003520_0_0_16_Cyclophosphamide_D066126_0_17_31_cardiotoxicity	Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor.
UN	3533179_D003520_11_1781_1784_CYA_D066126_11_1785_1799_cardiotoxicity	We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.
UN	3533179_D003520_8_1398_1401_CYA_D066126_8_1349_1363_Cardiotoxicity	Cardiotoxicity that was thought to be related to CYA occurred in 1/32 (3%) of patients in Group 1 and in 13/52 (25%) patients in Group 2 (P less than 0.025).
UN	3533179_D003520_5_993_996_CYA_D066126_5_997_1011_cardiotoxicity	Fourteen of 84 (17%) patients had symptoms and signs consistent with CYA cardiotoxicity within ten days of receiving 1 to 4 doses of CYA.
UN	3533179_D003520_3_628_631_CYA_D066126_3_632_646_cardiotoxicity	Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of CYA cardiotoxicity correlated with the dose per body surface area.
CID	3538855_D000617_7_1068_1082_aminoglycoside_D007674_7_1091_1105_nephrotoxicity	These models may also be useful in developing insights into the pathophysiology of aminoglycoside-induced nephrotoxicity.
CID	3538855_D000617_0_28_42_aminoglycoside_D007674_0_43_57_nephrotoxicity	Studies of risk factors for aminoglycoside nephrotoxicity.
CID	3538855_D000617_1_79_93_aminoglycoside_D007674_1_102_116_nephrotoxicity	The epidemiology of aminoglycoside-induced nephrotoxicity is not fully understood.
UN	3538855_D000617_4_612_626_aminoglycoside_D008107_4_635_648_liver disease	Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity.
UN	3538855_D000617_3_345_360_aminoglycosides_D058186_3_434_453_acute renal failure	Clinical trials of aminoglycosides in seriously ill patients indicate that the relative risk for developing acute renal failure during therapy ranges from 8 to 10 and that the attributable risk is 70% to 80%.
UN	3538855_D003404_4_687_697_creatinine_D007674_4_763_777_nephrotoxicity	Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity.
UN	3538855_D003404_4_687_697_creatinine_D008107_4_635_648_liver disease	Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity.
CID	35781_C009695_6_727_741_xylometazoline_D002375_6_657_666_catalepsy	Codeine catalepsy was increased by clonidine and decreased by naphazoline and xylometazoline.
CID	35781_D003000_6_684_693_clonidine_D002375_6_657_666_catalepsy	Codeine catalepsy was increased by clonidine and decreased by naphazoline and xylometazoline.
CID	35781_D003061_6_649_656_Codeine_D002375_6_657_666_catalepsy	Codeine catalepsy was increased by clonidine and decreased by naphazoline and xylometazoline.
CID	35781_D005283_5_639_647_fentanyl_D002375_5_605_614_catalepsy	It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced catalepsy induced by morphine and fentanyl.
CID	35781_D009020_5_626_634_morphine_D002375_5_605_614_catalepsy	It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced catalepsy induced by morphine and fentanyl.
CID	35781_D009020_3_265_273_morphine_D002375_3_244_254_cataleptic	The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats.
CID	35781_D009278_6_711_722_naphazoline_D002375_6_657_666_catalepsy	Codeine catalepsy was increased by clonidine and decreased by naphazoline and xylometazoline.
UN	35781_D009638_5_508_510_NA_D002375_5_605_614_catalepsy	It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced catalepsy induced by morphine and fentanyl.
UN	35781_D010423_3_224_235_pentazocine_D002375_3_244_254_cataleptic	The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats.
UN	3685052_D004986_6_917_922_ether_D007035_6_932_943_hypothermia	Flurothyl ether produced hypothermia which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear.
UN	3685052_D004986_3_519_524_ether_D012640_3_525_532_seizure	A flurothyl ether seizure screening technique was used to evaluate seizure susceptibility in adult mice that received neonatal injections of MSG (4 mg/g and 1 mg/g).
CID	3685052_D005481_6_907_916_Flurothyl_D007035_6_932_943_hypothermia	Flurothyl ether produced hypothermia which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear.
UN	3685052_D005481_0_0_9_Flurothyl_D012640_0_10_17_seizure	Flurothyl seizure thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in flurothyl seizure testing.
UN	3685052_D005481_0_152_161_flurothyl_D012640_0_162_169_seizure	Flurothyl seizure thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in flurothyl seizure testing.
UN	3685052_D005481_3_509_518_flurothyl_D012640_3_525_532_seizure	A flurothyl ether seizure screening technique was used to evaluate seizure susceptibility in adult mice that received neonatal injections of MSG (4 mg/g and 1 mg/g).
UN	3685052_D005481_7_1081_1090_Flurothyl_D012640_7_1091_1098_seizure	Flurothyl seizure testing proved to be a rapid and reliable technique with which to evaluate seizure susceptibility.
UN	3685052_D009270_5_783_791_naloxone_D012640_5_849_856_seizure	A naloxone (5 mg/kg) challenge was also ineffective in altering the seizure thresholds of either control of MSG-treated mice.
UN	3685052_D012970_5_889_892_MSG_D012640_5_849_856_seizure	A naloxone (5 mg/kg) challenge was also ineffective in altering the seizure thresholds of either control of MSG-treated mice.
UN	3685052_D012970_1_201_204_MSG_D012640_1_250_261_convulsions	Monosodium glutamate (MSG) administration to neonatal rodents produces convulsions and results in numerous biochemical and behavioral deficits.
UN	3685052_D012970_3_648_651_MSG_D012640_3_574_581_seizure	A flurothyl ether seizure screening technique was used to evaluate seizure susceptibility in adult mice that received neonatal injections of MSG (4 mg/g and 1 mg/g).
UN	3685052_D012970_2_396_399_MSG_D012640_2_434_441_seizure	These studies were undertaken to determine if neonatal administration of MSG produced permanent alterations in seizure susceptibility, since previous investigations were inconclusive.
UN	3708328_D005680_10_2181_2185_GABA_D012640_10_2126_2134_seizures	The results demonstrate that the threshold for pilocarpine-induced seizures in rats is subjected to the regulation of the GABA-mediated synaptic inhibition within the substantia nigra.
UN	3708328_D005680_3_771_775_GABA_D013226_3_991_1009_status epilepticus	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus.
UN	3708328_D007538_0_83_92_isoniazid_D012640_0_18_26_seizures	Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra.
UN	3708328_D007538_6_1465_1474_isoniazid_D012640_6_1491_1499_seizures	Bilateral intrastriatal injections of isoniazid did not augment seizures produced by pilocarpine, 200 mg/kg.
UN	3708328_D007538_3_712_721_isoniazid_D013226_3_991_1009_status epilepticus	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus.
UN	3708328_D010862_1_140_151_Pilocarpine_D004833_1_231_253_temporal lobe epilepsy	Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of temporal lobe epilepsy and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain.
CID	3708328_D010862_0_39_50_pilocarpine_D012640_0_18_26_seizures	Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra.
CID	3708328_D010862_2_626_637_pilocarpine_D012640_2_605_613_seizures	In the present study, the effects of manipulating the activity of the gamma-aminobutyric acid (GABA)-mediated synaptic inhibition within the substantia nigra on seizures produced by pilocarpine in rats, were investigated.
CID	3708328_D010862_4_1112_1123_pilocarpine_D012640_4_1132_1143_convulsions	Electroencephalographic and behavioral monitoring revealed a profound reduction of the threshold for pilocarpine-induced convulsions.
CID	3708328_D010862_6_1512_1523_pilocarpine_D012640_6_1491_1499_seizures	Bilateral intrastriatal injections of isoniazid did not augment seizures produced by pilocarpine, 200 mg/kg.
CID	3708328_D010862_7_1769_1780_pilocarpine_D012640_7_1748_1756_seizures	Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg.
CID	3708328_D010862_9_2035_2046_pilocarpine_D012640_9_2011_2022_convulsions	Microinjections of gamma-vinyl-GABA, 5 micrograms, into the dorsal striatum, bilaterally, failed to prevent the development of convulsions produced by pilocarpine, 380 mg/kg.
CID	3708328_D010862_10_2106_2117_pilocarpine_D012640_10_2126_2134_seizures	The results demonstrate that the threshold for pilocarpine-induced seizures in rats is subjected to the regulation of the GABA-mediated synaptic inhibition within the substantia nigra.
UN	3708328_D010862_3_914_925_pilocarpine_D013226_3_991_1009_status epilepticus	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus.
UN	3708328_D018698_3_797_812_L-glutamic acid_D012640_3_978_986_seizures	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus.
UN	3708328_D018698_3_797_812_L-glutamic acid_D013226_3_991_1009_status epilepticus	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus.
UN	3708328_D020888_0_96_112_gamma-vinyl-GABA_D012640_0_18_26_seizures	Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra.
UN	3708328_D020888_9_1903_1919_gamma-vinyl-GABA_D012640_9_2011_2022_convulsions	Microinjections of gamma-vinyl-GABA, 5 micrograms, into the dorsal striatum, bilaterally, failed to prevent the development of convulsions produced by pilocarpine, 380 mg/kg.
UN	3708328_D020888_7_1599_1615_gamma-vinyl-GABA_D012640_7_1748_1756_seizures	Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg.
CID	3711722_D003035_3_341_347_cobalt_D009202_3_348_362_cardiomyopathy	In the first, cobalt cardiomyopathy was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0.05).
CID	3711722_D004317_4_531_542_doxorubicin_D006333_4_551_564_heart failure	In six dogs with doxorubicin-induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05).
UN	3746148_D004176_0_101_113_dipyridamole_D003324_0_26_49_coronary artery disease	Non-invasive detection of coronary artery disease by body surface electrocardiographic mapping after dipyridamole infusion.
UN	3746148_D004176_4_674_686_dipyridamole_D003866_4_708_718_depression	After dipyridamole, ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population.
UN	3746148_D004176_4_674_686_dipyridamole_D007511_4_688_696_ischemic	After dipyridamole, ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population.
UN	3746148_D004176_4_674_686_dipyridamole_D009203_4_768_770_MI	After dipyridamole, ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population.
CID	3746148_D004176_8_1279_1291_dipyridamole_D017202_8_1300_1319_myocardial ischemia	The data suggest that the dipyridamole-induced myocardial ischemia is caused by the inhomogenous distribution of myocardial blood flow.
UN	3746148_D004176_4_674_686_dipyridamole_D056988_4_789_795_ANT-MI	After dipyridamole, ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population.
UN	3746148_D004176_4_674_686_dipyridamole_D056989_4_814_820_INF-MI	After dipyridamole, ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population.
UN	3798047_D008775_1_155_173_methylprednisolone_D001172_1_99_119_rheumatoid arthritis	In 5 consecutive patients with rheumatoid arthritis who received intravenous high-dose methylprednisolone (MP) therapy (1 g daily for 2 or 3 consecutive days), a decline in pulse rate was observed, most pronounced on day 4.
CID	3798047_D008775_0_40_58_methylprednisolone_D001919_0_0_11_Bradycardia	Bradycardia after high-dose intravenous methylprednisolone therapy.
UN	3798047_D008775_7_669_671_MP_D006331_7_718_731_heart disease	High-dose MP may be contraindicated in patients with known heart disease.
UN	3812624_D002220_0_64_77_carbamazepine_D009759_0_13_31_downbeat nystagmus	Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine.
UN	3812624_D002220_3_457_470_carbamazepine_D009759_3_392_401_nystagmus	The nystagmus of both patients resolved after reduction of the serum carbamazepine levels.
UN	3812624_D002220_2_365_378_carbamazepine_D009759_2_335_353_downbeat nystagmus	We recorded the eye movements of two patients with reversible downbeat nystagmus related to carbamazepine therapy.
CID	3812624_D002220_0_64_77_carbamazepine_D015835_0_36_47_oscillopsia	Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine.
UN	3831029_C037293_4_766_776_denopamine_D001145_4_723_734_arrhythmias	No arrhythmias were induced by these doses of denopamine.
UN	3831029_C037293_5_817_827_denopamine_D006333_5_848_863_cardiac failure	The results warrant clinical trials of denopamine in the treatment of cardiac failure.
UN	3831029_C037293_0_27_33_TA-064_D006333_0_60_75_cardiac failure	Improvement by denopamine (TA-064) of pentobarbital-induced cardiac failure in the dog heart-lung preparation.
CID	3831029_D010424_0_38_51_pentobarbital_D006333_0_60_75_cardiac failure	Improvement by denopamine (TA-064) of pentobarbital-induced cardiac failure in the dog heart-lung preparation.
UN	3832950_D002998_1_168_178_clonazepam_D004827_1_119_127_epilepsy	Sixty patients (age-range one month to 14 years) with other types of epilepsy than infantile spasms were treated with clonazepam.
UN	3832950_D002998_0_0_10_Clonazepam_D004827_0_27_35_epilepsy	Clonazepam monotherapy for epilepsy in childhood.
UN	3832950_D002998_1_168_178_clonazepam_D013036_1_133_149_infantile spasms	Sixty patients (age-range one month to 14 years) with other types of epilepsy than infantile spasms were treated with clonazepam.
UN	3833372_D006852_1_241_260_hydrochlorothiazide_D006973_1_304_316_hypertensive	A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of timolol maleate and 25 mg of hydrochlorothiazide, administered twice daily for one month to hypertensive patients.
UN	3833372_D013999_1_212_227_timolol maleate_D006973_1_304_316_hypertensive	A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of timolol maleate and 25 mg of hydrochlorothiazide, administered twice daily for one month to hypertensive patients.
UN	3864191_D001241_12_1522_1529_aspirin_D006417_12_1610_1619_hematuria	The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).
CID	3864191_D001241_12_1522_1529_aspirin_D007674_12_1506_1518_renal damage	The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).
UN	3864191_D001663_2_320_329_bilirubin_D006932_2_237_255_hyperbilirubinemia	The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla.
UN	3864191_D003404_12_1656_1666_creatinine_D006417_12_1610_1619_hematuria	The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).
UN	3864191_D003404_12_1656_1666_creatinine_D007674_12_1506_1518_renal damage	The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).
UN	3864191_D011453_12_1450_1463_prostaglandin_D006417_12_1610_1619_hematuria	The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).
UN	3864191_D011453_12_1450_1463_prostaglandin_D007674_12_1506_1518_renal damage	The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).
UN	3864191_D011453_13_1978_1991_prostaglandin_D007674_13_2055_2086_deterioration of renal function	These results suggest that enhanced prostaglandin synthesis contributes to maintenance of renal function and morphological integrity, and that inhibition of prostaglandin synthesis may lead to pathological renal medullary lesions and deterioration of renal function.
UN	3864191_D011453_1_108_122_prostaglandins_D007674_1_155_166_nephropathy	We examined the potential role of prostaglandins in the development of analgesic nephropathy in the Gunn strain of rat.
UN	3864191_D011453_13_1978_1991_prostaglandin_D058186_13_2014_2050_pathological renal medullary lesions	These results suggest that enhanced prostaglandin synthesis contributes to maintenance of renal function and morphological integrity, and that inhibition of prostaglandin synthesis may lead to pathological renal medullary lesions and deterioration of renal function.
UN	3864191_D012459_0_0_10_Salicylate_D007674_0_11_22_nephropathy	Salicylate nephropathy in the Gunn rat: potential role of prostaglandins.
UN	3895875_D008012_3_735_744_lidocaine_D001145_3_669_680_arrhythmias	Lidocaine, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine (p less than 0.05).
UN	3895875_D008012_6_1285_1294_lidocaine_D006323_6_1324_1332_asystole	During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine.
UN	3895875_D008012_6_1356_1365_lidocaine_D006323_6_1324_1332_asystole	During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine.
CID	3895875_D008012_6_1205_1214_lidocaine_D007022_6_1222_1233_hypotension	During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine.
UN	3895875_D008012_4_784_793_lidocaine_D007238_4_939_949_infarction	The average plasma lidocaine level 10 minutes after administration for patients without a myocardial infarction was significantly higher than that for patients with an acute infarction.
UN	3895875_D008012_0_13_22_lidocaine_D009203_0_55_76_myocardial infarction	Prophylactic lidocaine in the early phase of suspected myocardial infarction.
UN	3895875_D008012_4_784_793_lidocaine_D009203_4_855_876_myocardial infarction	The average plasma lidocaine level 10 minutes after administration for patients without a myocardial infarction was significantly higher than that for patients with an acute infarction.
UN	3895875_D008012_7_1408_1417_lidocaine_D009203_7_1467_1488_myocardial infarction	We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.
UN	3895875_D008012_3_452_461_Lidocaine_D017180_3_562_585_ventricular tachycardia	Lidocaine, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine (p less than 0.05).
UN	3925479_D000109_5_640_653_acetylcholine_D002375_5_704_713_catalepsy	Intracranial injection of an acetylcholine-synthesis inhibitor, hemicholinium, prevented the catalepsy that is usually induced by haloperidol.
UN	3925479_D001285_4_560_568_atropine_D002375_4_600_609_catalepsy	A muscarinic receptor blocker, atropine, disrupted haloperidol-induced catalepsy.
CID	3925479_D006220_0_35_46_haloperidol_D002375_0_55_64_catalepsy	Evidence for a cholinergic role in haloperidol-induced catalepsy.
CID	3925479_D006220_6_852_863_haloperidol_D002375_6_801_810_catalepsy	These findings suggest the hypothesis that the catalepsy that is produced by neuroleptics such as haloperidol is actually mediated by intrinsic central cholinergic systems.
CID	3925479_D006220_5_741_752_haloperidol_D002375_5_704_713_catalepsy	Intracranial injection of an acetylcholine-synthesis inhibitor, hemicholinium, prevented the catalepsy that is usually induced by haloperidol.
CID	3925479_D006220_4_580_591_haloperidol_D002375_4_600_609_catalepsy	A muscarinic receptor blocker, atropine, disrupted haloperidol-induced catalepsy.
UN	3925479_D006426_5_675_688_hemicholinium_D002375_5_704_713_catalepsy	Intracranial injection of an acetylcholine-synthesis inhibitor, hemicholinium, prevented the catalepsy that is usually induced by haloperidol.
CID	3925479_D010862_3_409_420_pilocarpine_D002375_3_460_469_catalepsy	Low doses of pilocarpine caused a pronounced enhancement of the catalepsy that was induced by the dopaminergic blocker, haloperidol.
UN	3925479_D014150_6_831_843_neuroleptics_D002375_6_801_810_catalepsy	These findings suggest the hypothesis that the catalepsy that is produced by neuroleptics such as haloperidol is actually mediated by intrinsic central cholinergic systems.
UN	3925479_D014150_1_242_253_neuroleptic_D002375_1_262_271_catalepsy	Experiments in mice tested previous evidence that activation of cholinergic systems promotes catalepsy and that cholinergic mechanisms need to be intact for full expression of neuroleptic-induced catalepsy.
UN	3975902_C024986_0_91_106_barium chloride_D002318_0_0_26_Cardiovascular dysfunction	Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic barium chloride ingestion.
UN	3975902_C024986_0_91_106_barium chloride_D004342_0_31_47_hypersensitivity	Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic barium chloride ingestion.
UN	3975902_D001464_2_435_441_barium_D002318_2_450_495_disturbances within the cardiovascular system	Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant barium-induced disturbances within the cardiovascular system.
UN	3975902_D001464_3_532_538_barium_D004342_3_565_581_hypersensitivity	The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital.
UN	3975902_D001464_1_243_249_barium_D006973_1_196_208_hypertension	Barium-supplemented Long-Evans hooded rats were characterized by a persistent hypertension that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment.
UN	3975902_D001464_10_2064_2070_barium_D008659_10_1868_1890_metabolic disturbances	Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.
UN	3975902_D001464_10_2064_2070_barium_D009202_10_2020_2044_cardiomyopathic disorder	Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.
UN	3975902_D010424_0_51_71_sodium pentobarbital_D002318_0_0_26_Cardiovascular dysfunction	Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic barium chloride ingestion.
UN	3975902_D010424_10_1949_1969_sodium pentobarbital_D004342_10_1900_1916_hypersensitivity	Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.
UN	3975902_D010424_0_51_71_sodium pentobarbital_D004342_0_31_47_hypersensitivity	Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic barium chloride ingestion.
UN	3975902_D010424_3_614_634_sodium pentobarbital_D004342_3_565_581_hypersensitivity	The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital.
UN	3975902_D010424_10_1949_1969_sodium pentobarbital_D008659_10_1868_1890_metabolic disturbances	Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.
UN	3975902_D010424_10_1949_1969_sodium pentobarbital_D009202_10_2020_2044_cardiomyopathic disorder	Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.
UN	3987172_D010665_1_89_92_PPA_D002543_1_134_158_intracerebral hemorrhage	Phenylpropanolamine (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death.
CID	3987172_D010665_0_26_45_phenylpropanolamine_D006973_0_54_66_hypertension	Propranolol antagonism of phenylpropanolamine-induced hypertension.
CID	3987172_D010665_1_89_92_PPA_D006973_1_120_132_hypertension	Phenylpropanolamine (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death.
CID	3987172_D010665_2_241_244_PPA_D006973_2_253_265_hypertension	We studied the efficacy and safety of propranolol in the treatment of PPA-induced hypertension.
UN	3987172_D010665_6_723_726_PPA_D020521_6_741_747_stroke	Left ventricular function (assessed by echocardiography) showed that PPA increased the stroke volume 30% (from 62.5 +/- 20.9 to 80.8 +/- 22.4 ml), the ejection fraction 9% (from 64% +/- 10% to 70% +/- 7%), and cardiac output 14% (from 3.6 +/- 0.6 to 4.1 +/- 1.0 L/min).
UN	3987172_D010665_1_89_92_PPA_D062787_1_94_102_overdose	Phenylpropanolamine (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death.
UN	3987172_D011433_2_209_220_propranolol_D006973_2_253_265_hypertension	We studied the efficacy and safety of propranolol in the treatment of PPA-induced hypertension.
UN	3987172_D011433_0_0_11_Propranolol_D006973_0_54_66_hypertension	Propranolol antagonism of phenylpropanolamine-induced hypertension.
UN	3990093_D002244_3_453_459_carbon_D011507_3_384_395_proteinuric	After 4 weeks the PAN rats were severely proteinuric (190 +/- 80 mg/24 hr), and all rats were given colloidal carbon (CC) intravenously.
UN	3990093_D011692_1_199_224_puromycin aminonucleoside_D007674_1_159_179_glomerular sclerosis	The possible relationship between mesangial dysfunction and development of glomerular sclerosis was studied in the puromycin aminonucleoside (PAN) model.
UN	3990093_D011692_10_1390_1393_PAN_D007674_10_1423_1443_glomerular sclerosis	Similar to the remnant kidney model in PAN nephrosis the development of glomerular sclerosis may be related to "mesangial overloading."
UN	3990093_D011692_0_57_72_aminonucleoside_D007674_0_23_43_glomerular sclerosis	Mesangial function and glomerular sclerosis in rats with aminonucleoside nephrosis.
UN	3990093_D011692_0_57_72_aminonucleoside_D009401_0_73_82_nephrosis	Mesangial function and glomerular sclerosis in rats with aminonucleoside nephrosis.
UN	3990093_D011692_10_1390_1393_PAN_D009401_10_1394_1403_nephrosis	Similar to the remnant kidney model in PAN nephrosis the development of glomerular sclerosis may be related to "mesangial overloading."
CID	3990093_D011692_3_361_364_PAN_D011507_3_384_395_proteinuric	After 4 weeks the PAN rats were severely proteinuric (190 +/- 80 mg/24 hr), and all rats were given colloidal carbon (CC) intravenously.
UN	3990093_D011692_8_961_964_PAN_D012598_8_1141_1150_sclerosis	Since mesangial CC clearance from the mesangium did not change during chronic PAN treatment, we conclude that this preferential CC localization within the lesions is caused by an increased CC uptake shortly after injection in apparent vulnerable areas where sclerosis will develop subsequently.
UN	4010471_D004229_4_660_674_dithiothreitol_D012640_4_583_590_seizure	The binding sites from seizure sensitive and resistant mice were equally affected by treatment with dithiothreitol, trypsin or heat.
CID	4010471_D009538_0_21_29_nicotine_D012640_0_38_46_seizures	Relationship between nicotine-induced seizures and hippocampal nicotinic receptors.
CID	4010471_D009538_2_325_333_nicotine_D012640_2_342_350_seizures	Using mice derived from a classical F2 and backcross genetic design, a relationship between nicotine-induced seizures and alpha-bungarotoxin nicotinic receptor concentration was found.
UN	4082192_C002887_0_77_105_bis(p-nitrophenyl) phosphate_D007674_0_141_155_nephrotoxicity	The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.
UN	4082192_C002887_10_1404_1408_BNPP_D007674_10_1443_1457_nephrotoxicity	Therefore, the BNPP-induced reduction in APAP-induced nephrotoxicity appears to be due to inhibition of APAP deacetylation.
UN	4082192_C026729_0_127_140_p-aminophenol_D007674_0_141_155_nephrotoxicity	The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.
UN	4082192_C026729_4_603_606_PAP_D007674_4_607_621_nephrotoxicity	Therefore, the effect of bis(p-nitrophenyl) phosphate (BNPP), an acylamidase inhibitor, on APAP and PAP nephrotoxicity and metabolism was determined.
UN	4082192_C026729_3_437_440_PAP_D007674_3_487_501_nephrotoxicity	The purpose of this study was to determine if PAP formation is a requisite step in APAP-induced nephrotoxicity.
UN	4082192_C026729_6_932_935_PAP_D007674_6_936_950_nephrotoxicity	Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP nephrotoxicity.
CID	4082192_C026729_11_1534_1537_PAP_D007683_11_1603_1625_renal tubular necrosis	It is concluded that PAP formation, in vivo, accounts, at least in part, for APAP-induced renal tubular necrosis.
UN	4082192_D000082_4_594_598_APAP_D007674_4_607_621_nephrotoxicity	Therefore, the effect of bis(p-nitrophenyl) phosphate (BNPP), an acylamidase inhibitor, on APAP and PAP nephrotoxicity and metabolism was determined.
UN	4082192_D000082_3_474_478_APAP_D007674_3_487_501_nephrotoxicity	The purpose of this study was to determine if PAP formation is a requisite step in APAP-induced nephrotoxicity.
UN	4082192_D000082_0_29_42_acetaminophen_D007674_0_51_65_nephrotoxicity	The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.
UN	4082192_D000082_10_1430_1434_APAP_D007674_10_1443_1457_nephrotoxicity	Therefore, the BNPP-induced reduction in APAP-induced nephrotoxicity appears to be due to inhibition of APAP deacetylation.
UN	4082192_D000082_6_892_896_APAP_D007674_6_909_923_nephrotoxicity	Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP nephrotoxicity.
CID	4082192_D000082_11_1590_1594_APAP_D007683_11_1603_1625_renal tubular necrosis	It is concluded that PAP formation, in vivo, accounts, at least in part, for APAP-induced renal tubular necrosis.
CID	4082192_D000082_1_207_211_APAP_D007683_1_231_247_tubular necrosis	Acetaminophen (APAP) produces proximal tubular necrosis in Fischer 344 (F344) rats.
CID	4082466_D009020_0_0_8_Morphine_D012640_0_17_25_seizures	Morphine-induced seizures in newborn infants.
CID	4082466_D009020_1_127_143_morphine sulfate_D012640_1_85_93_seizures	Two neonates suffered from generalized seizures during the course of intravenous morphine sulfate for post-operative analgesia.
CID	4082466_D009020_4_536_544_morphine_D012640_4_485_496_convulsions	Other known reasons for seizures were ruled out and the convulsions stopped a few hours after cessation of morphine and did not reoccur in the subsequent 8 months.
CID	439781_D007213_0_0_12_Indomethacin_D007022_0_21_32_hypotension	Indomethacin induced hypotension in sodium and volume depleted rats.
UN	439781_D012964_0_36_42_sodium_D007022_0_21_32_hypotension	Indomethacin induced hypotension in sodium and volume depleted rats.
CID	44072_C024986_2_461_466_BaCl2_D001145_2_435_445_arrhythmia	Four types of experimental arrhythmia are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine.
CID	44072_D000157_2_525_534_aconitine_D001145_2_435_445_arrhythmia	Four types of experimental arrhythmia are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine.
CID	44072_D002725_4_785_795_chloroform_D001145_4_763_773_arrhythmia	The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the arrhythmia induced by chloroform-adrenaline (in 90 per cent) and with BaCl2 (in 84 per cent).
CID	44072_D004837_4_796_806_adrenaline_D001145_4_763_773_arrhythmia	The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the arrhythmia induced by chloroform-adrenaline (in 90 per cent) and with BaCl2 (in 84 per cent).
CID	44072_D010042_2_501_515_strophantine G_D001145_2_435_445_arrhythmia	Four types of experimental arrhythmia are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine.
UN	448423_D000614_0_50_67_aminocaproic acid_D007674_0_80_109_acute renal artery thrombosis	Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis.
UN	448423_D000614_0_50_67_aminocaproic acid_D013345_0_10_33_subarachnoid hemorrhage	Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis.
UN	448423_D015119_5_722_726_EACA_D004211_5_807_845_disseminated intravascular coagulation	Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other "consumption coagulopathies."
CID	448423_D015119_7_1015_1019_EACA_D013345_7_1046_1049_SAH	This occlusion occurred after EACA therapy in a patient with SAH and histopathological documentation of recurrent SAH.
UN	448423_D015119_4_586_590_EACA_D013923_4_601_625_thromboembolic phenomena	These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena.
CID	448423_D015119_5_722_726_EACA_D013927_5_782_789_thrombi	Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other "consumption coagulopathies."
CID	448423_D015119_3_363_367_EACA_D013927_3_335_345_thrombotic	Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy.
CID	448423_D015119_4_586_590_EACA_D013927_4_525_532_thrombi	These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena.
CID	448423_D015119_4_586_590_EACA_D020767_4_438_470_intracranial vascular thrombosis	These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena.
UN	4631913_D014750_4_604_623_vincristine sulfate_D007239_4_660_669_infection	Intravenous inoculation of 4.2 x 10(10) to 7.8 x 10(10) pyocin type 6 Pseudomonas organisms in monkeys given vincristine sulfate 4 days previously resulted in fatal infection in 11 of 14 monkeys, whereas none of four receiving Pseudomonas alone died.
CID	4631913_D014750_3_432_451_vincristine sulfate_D007970_3_468_478_leukopenia	Intravenous or intratracheal inoculation of 2.0 to 2.5 mg of vincristine sulfate was followed by leukopenia in 4 to 5 days.
CID	4631913_D014750_0_10_29_vincristine sulfate_D011552_0_33_55_Pseudomonas infections	Effect of vincristine sulfate on Pseudomonas infections in monkeys.
UN	48835_D011433_0_16_27_propranolol_D007003_0_65_78_hypoglycaemia	Modification by propranolol of cardiovascular effects of induced hypoglycaemia.
UN	573555_D011433_7_859_870_propranolol_D001049_7_756_770_neonatal apnea	We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.
UN	573555_D011433_7_859_870_propranolol_D001919_7_776_787_bradycardia	We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.
UN	573555_D011433_7_859_870_propranolol_D006932_7_722_740_hyperbilirubinemia	We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.
UN	573555_D011433_7_859_870_propranolol_D007003_7_708_720_hypoglycemia	We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.
UN	573555_D011433_7_859_870_propranolol_D011086_7_742_754_polycythemia	We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.
UN	6106951_D005479_10_1061_1064_FZP_D004827_10_1145_1153_epilepsy	These results may be relevant to the use of FZP in clinical situations in which there is increased neural excitability, such as epilepsy or sedative-hypnotic drug withdrawal.
CID	6106951_D005479_7_836_839_FZP_D012640_7_864_875_convulsions	As a function of dose, FZP first protected against convulsions and death.
CID	6106951_D005479_9_955_958_FZP_D012640_9_1004_1015_convulsions	These doses of FZP were lower than those that would alone cause convulsions.
UN	6106951_D005479_5_572_575_FZP_D012798_5_612_622_salivation	Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions.
UN	6106951_D005479_5_572_575_FZP_D014202_5_665_679_muscle tremors	Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions.
UN	611664_D002395_2_277_291_catecholamines_D004342_2_373_389_hypersensitivity	They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused norepinephrine.
UN	611664_D009638_2_424_438_norepinephrine_D004342_2_373_389_hypersensitivity	They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused norepinephrine.
UN	611664_D011433_9_1368_1379_propranolol_C544351_9_1430_1464_idiopathic orthostatic hypotension	The studies suggest that propranolol is a useful drug in selected patients with severe idiopathic orthostatic hypotension.
UN	611664_D011433_0_7_18_propranolol_C544351_0_39_73_idiopathic orthostatic hypotension	Use of propranolol in the treatment of idiopathic orthostatic hypotension.
CID	611664_D011433_5_854_865_propranolol_D006973_5_826_838_hypertension	In 1 patient, marked hypertension was induced by propranolol and the drug had to be withdrawn.
CID	612112_D005045_7_859_868_etomidate_D009207_7_999_1008_myoclonia	It is considered unlikely that etomidate will prove to be the hypnotic of choice for a totally intravenous anesthetic technique in adults because of the high incidence of myoclonia after prolonged administration.
UN	6299641_D001262_1_99_107_atenolol_D013610_1_217_228_tachycardia	We compared the effects of single doses of 50 mg atenolol (cardioselective), 40 mg propranolol (nonselective), and placebo on both exercise- and isoproterenol-induced tachycardia in two experiments involving nine normal subjects.
UN	6299641_D001285_3_546_554_atropine_D013610_3_501_512_tachycardia	The effects on isoproterenol tachycardia were determined before and after atropine (0.04 mg/kg IV).
CID	6299641_D007545_3_487_500_isoproterenol_D013610_3_501_512_tachycardia	The effects on isoproterenol tachycardia were determined before and after atropine (0.04 mg/kg IV).
CID	6299641_D007545_1_195_208_isoproterenol_D013610_1_217_228_tachycardia	We compared the effects of single doses of 50 mg atenolol (cardioselective), 40 mg propranolol (nonselective), and placebo on both exercise- and isoproterenol-induced tachycardia in two experiments involving nine normal subjects.
UN	6299641_D011433_1_133_144_propranolol_D013610_1_217_228_tachycardia	We compared the effects of single doses of 50 mg atenolol (cardioselective), 40 mg propranolol (nonselective), and placebo on both exercise- and isoproterenol-induced tachycardia in two experiments involving nine normal subjects.
CID	6310832_D001379_5_703_706_Aza_D007239_5_683_693_infections	Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients.
CID	6310832_D001379_4_444_447_Aza_D007239_4_474_484_infections	The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients.
UN	6310832_D001379_10_1298_1301_Aza_D009181_10_1427_1444_fungal infections	Aza patients had significantly more staphylococcal infections than all other transplant groups (P less than 0.005), and systemic fungal infections occurred only in the liver transplant group.
UN	6310832_D001379_10_1298_1301_Aza_D013203_10_1334_1359_staphylococcal infections	Aza patients had significantly more staphylococcal infections than all other transplant groups (P less than 0.005), and systemic fungal infections occurred only in the liver transplant group.
UN	6310832_D016572_12_1642_1654_cyclosporine_D003586_12_1693_1706_CMV infection	Of the cyclosporine patients, 15% had symptoms related to CMV infection.
CID	6310832_D016572_9_1213_1225_cyclosporine_D007239_9_1182_1192_infections	Pulmonary infections were less common in cyclosporine-treated renal patients than in Aza-treated patients (P less than 0.05).
CID	6310832_D016572_5_645_657_cyclosporine_D007239_5_629_639_infections	Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients.
UN	6310832_D016572_7_943_955_cyclosporine_D016470_7_971_982_bacteremias	Renal patients on cyclosporine had the fewest bacteremias.
UN	6310832_D016572_13_1785_1797_cyclosporine_D020031_13_1733_1761_Epstein Barr Virus infection	Serological evidence for Epstein Barr Virus infection was found in 20% of 65 cyclosporine patients studied.
UN	6316193_D002766_0_101_116_cholecystokinin_D012640_0_89_97_seizures	Structure-activity and dose-effect relationships of the antagonism of picrotoxin-induced seizures by cholecystokinin, fragments and analogues of cholecystokinin in mice.
UN	6316193_D003975_4_870_878_diazepam_D012640_4_917_925_seizures	The peptide CCK-5-8 had weak anticonvulsant activity in comparison to the octapeptides, 3.2 mumol/kg and larger doses of the reference drug, diazepam, totally prevented picrotoxin-induced seizures and mortality.
CID	6316193_D010852_4_898_908_picrotoxin_D012640_4_917_925_seizures	The peptide CCK-5-8 had weak anticonvulsant activity in comparison to the octapeptides, 3.2 mumol/kg and larger doses of the reference drug, diazepam, totally prevented picrotoxin-induced seizures and mortality.
CID	6316193_D010852_1_358_368_picrotoxin_D012640_1_338_346_seizures	Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of seizures induced by picrotoxin in mice.
CID	6316193_D010852_0_70_80_picrotoxin_D012640_0_89_97_seizures	Structure-activity and dose-effect relationships of the antagonism of picrotoxin-induced seizures by cholecystokinin, fragments and analogues of cholecystokinin in mice.
UN	6316193_D012844_1_304_309_CCK-8_D012640_1_338_346_seizures	Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of seizures induced by picrotoxin in mice.
UN	6321816_D003900_2_334_338_DOCA_D003919_2_309_327_diabetes insipidus	Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment.
CID	6321816_D003900_2_194_198_DOCA_D006973_2_204_216_hypertension	Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment.
CID	6321816_D008094_2_293_300_lithium_D003919_2_309_327_diabetes insipidus	Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment.
UN	6321816_D008094_2_293_300_lithium_D006973_2_204_216_hypertension	Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment.
UN	6321816_D014667_2_140_151_Vasopressin_D003919_2_309_327_diabetes insipidus	Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment.
UN	6321816_D014667_7_1130_1141_vasopressin_D006973_7_1186_1198_hypertension	However, the role of vasopressin remains to be determined in human essential hypertension.
UN	6321816_D014667_0_0_11_Vasopressin_D006973_0_41_53_hypertension	Vasopressin as a possible contributor to hypertension.
UN	6321816_D014667_1_67_78_vasopressin_D006973_1_105_117_hypertensive	The role of vasopressin as a pressor agent to the hypertensive process was examined.
CID	6453500_D004221_0_27_37_disulfiram_D056486_0_0_15_Toxic hepatitis	Toxic hepatitis induced by disulfiram in a non-alcoholic.
CID	6517710_D011796_0_62_86_quinacrine hydrochloride_D003328_0_0_17_Atrial thrombosis	Atrial thrombosis involving the heart of F-344 rats ingesting quinacrine hydrochloride.
UN	6517710_D011796_5_526_550_quinacrine hydrochloride_D013927_5_611_621_thrombosis	Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis.
UN	6517710_D012977_5_565_579_sodium nitrite_D003328_5_710_727_atrial thrombosis	Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis.
UN	6517710_D012977_5_565_579_sodium nitrite_D013927_5_611_621_thrombosis	Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis.
UN	6529939_D011433_1_223_234_propranolol_D000787_1_205_211_angina	Alternating sinus rhythm and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg propranolol daily.
CID	6529939_D011433_0_70_81_propranolol_D001146_0_0_24_Alternating sinus rhythm	Alternating sinus rhythm and intermittent sinoatrial block induced by propranolol.
CID	6529939_D011433_0_70_81_propranolol_D012848_0_42_58_sinoatrial block	Alternating sinus rhythm and intermittent sinoatrial block induced by propranolol.
UN	6529939_D011433_13_1661_1672_propranolol_D019955_13_1697_1716_conduction disorder	This was accepted as evidence for propranolol being the cause of this conduction disorder.
CID	6585590_D004317_6_813_824_doxorubicin_D000419_6_847_858_albuminuria	Light microscopic evidence of renal damage was seen above a dose of 0.5 mg doxorubicin/kg, which resulted in albuminuria and very low serum albumin levels.
UN	6585590_D004317_0_56_67_doxorubicin_D007674_0_38_52_nephrotoxicity	Antitumor effect, cardiotoxicity, and nephrotoxicity of doxorubicin in the IgM solid immunocytoma-bearing LOU/M/WSL rat.
UN	6585590_D004317_1_187_198_doxorubicin_D007674_1_161_175_nephrotoxicity	Antitumor activity, cardiotoxicity, and nephrotoxicity induced by doxorubicin were studied in LOU/M/WSL inbred rats each bearing a transplantable solid IgM immunocytoma.
UN	6585590_D004317_4_610_621_doxorubicin_D009369_4_580_585_tumor	Complete disappearance of the tumor was induced with 1.0 mg doxorubicin/kg.
UN	6585590_D004317_3_534_545_doxorubicin_D009369_3_492_497_Tumor	Tumor regression was observed with 0.5 mg doxorubicin/kg.
UN	6585590_D004317_1_187_198_doxorubicin_D066126_1_141_155_cardiotoxicity	Antitumor activity, cardiotoxicity, and nephrotoxicity induced by doxorubicin were studied in LOU/M/WSL inbred rats each bearing a transplantable solid IgM immunocytoma.
UN	6585590_D004317_0_56_67_doxorubicin_D066126_0_18_32_cardiotoxicity	Antitumor effect, cardiotoxicity, and nephrotoxicity of doxorubicin in the IgM solid immunocytoma-bearing LOU/M/WSL rat.
UN	6585590_D004317_5_722_733_doxorubicin_D066126_5_649_663_cardiotoxicity	Histologic evidence of cardiotoxicity scored as grade III was only observed at a dose of 1.0 mg doxorubicin/kg.
UN	6615679_D006221_4_627_636_halothane_D001919_4_664_675_bradycardia	It is postulated that this action may have been enhanced during halothane anaesthesia with resultant bradycardia and hypotension.
UN	6615679_D006221_1_256_265_halothane_D001919_1_214_225_bradycardia	A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became hypotensive during halothane anaesthesia.
UN	6615679_D006221_4_627_636_halothane_D007022_4_680_691_hypotension	It is postulated that this action may have been enhanced during halothane anaesthesia with resultant bradycardia and hypotension.
UN	6615679_D006221_1_256_265_halothane_D007022_1_237_248_hypotensive	A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became hypotensive during halothane anaesthesia.
CID	6615679_D010862_0_71_82_pilocarpine_D001919_0_15_26_bradycardia	Intraoperative bradycardia and hypotension associated with timolol and pilocarpine eye drops.
CID	6615679_D010862_0_71_82_pilocarpine_D007022_0_31_42_hypotension	Intraoperative bradycardia and hypotension associated with timolol and pilocarpine eye drops.
CID	6615679_D013999_0_59_66_timolol_D001919_0_15_26_bradycardia	Intraoperative bradycardia and hypotension associated with timolol and pilocarpine eye drops.
CID	6615679_D013999_0_59_66_timolol_D007022_0_31_42_hypotension	Intraoperative bradycardia and hypotension associated with timolol and pilocarpine eye drops.
CID	6627074_D013390_5_768_783_succinylcholine_D001049_5_784_790_apnoea	It is concluded that anticholinesterases are only partially effective in restoring neuromuscular function in succinylcholine apnoea despite muscle twitch activity typical of phase II block.
CID	6627074_D013390_0_0_15_Succinylcholine_D001049_0_16_22_apnoea	Succinylcholine apnoea: attempted reversal with anticholinesterases.
UN	6627074_D013390_1_200_215_succinylcholine_D020879_1_145_167_neuromuscular blockade	Anticholinesterases were administered in an attempt to antagonize prolonged neuromuscular blockade following the administration of succinylcholine in a patient later found to be homozygous for atypical plasma cholinesterase.
UN	6631522_C013102_6_957_965_I-131 HA_D066126_6_1011_1025_cardiotoxicity	Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with I-131 HA are not the initiating factor in doxorubicin cardiotoxicity.
CID	6631522_D004317_6_999_1010_doxorubicin_D066126_6_1011_1025_cardiotoxicity	Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with I-131 HA are not the initiating factor in doxorubicin cardiotoxicity.
CID	6673474_D009599_2_198_201_SNP_D007022_2_236_247_hypotension	Coronary blood flow, cardiac work and metabolism were studied in dogs under sodium nitroprusside (SNP) and trimetaphan (TMP) deliberate hypotension (20% and 40% mean pressure decrease from baseline).
CID	6673474_D009599_3_453_466_nitroprusside_D007022_3_467_478_hypotension	Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, trimetaphan hypotension to 20% mean blood pressure decrease.
CID	6673474_D009599_4_657_660_SNP_D007022_4_661_672_hypotension	Cardiac work was significantly reduced during SNP hypotension.
CID	6673474_D014294_3_550_561_trimetaphan_D007022_3_562_573_hypotension	Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, trimetaphan hypotension to 20% mean blood pressure decrease.
CID	6673474_D014294_2_220_223_TMP_D007022_2_236_247_hypotension	Coronary blood flow, cardiac work and metabolism were studied in dogs under sodium nitroprusside (SNP) and trimetaphan (TMP) deliberate hypotension (20% and 40% mean pressure decrease from baseline).
UN	6687006_C012102_4_528_532_DSP4_D006948_4_503_516_hyperactivity	The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.
UN	6687006_C012102_3_468_472_DSP4_D019956_3_417_429_stereotypies	However, the increased rearings and the amphetamine-induced stereotypies were not blocked by pretreatment with DSP4.
UN	6687006_C012102_4_660_664_DSP4_D020258_4_639_649_neurotoxic	The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.
UN	6687006_D000661_4_491_502_amphetamine_D006948_4_503_516_hyperactivity	The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.
UN	6687006_D000661_3_397_408_amphetamine_D019956_3_417_429_stereotypies	However, the increased rearings and the amphetamine-induced stereotypies were not blocked by pretreatment with DSP4.
UN	6687006_D000661_4_491_502_amphetamine_D020258_4_639_649_neurotoxic	The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.
UN	6687006_D003891_4_607_618_desipramine_D006948_4_503_516_hyperactivity	The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.
UN	6687006_D003891_4_607_618_desipramine_D020258_4_639_649_neurotoxic	The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.
CID	6687006_D003913_2_281_294_D-amphetamine_D006948_2_256_269_hyperactivity	The hyperactivity induced by D-amphetamine (10 mumol/kg) was significantly reduced by DSP4 pretreatment.
UN	6687006_D009638_4_570_583_noradrenaline_D006948_4_503_516_hyperactivity	The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.
UN	6687006_D009638_4_570_583_noradrenaline_D020258_4_639_649_neurotoxic	The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.
CID	6695685_D014700_1_199_208_verapamil_D001145_1_138_168_accelerated junctional rhythms	This study examined the frequency of atrioventricular (AV) dissociation and accelerated junctional rhythms in 59 patients receiving oral verapamil.
CID	6695685_D014700_0_43_52_verapamil_D001145_0_0_30_Accelerated junctional rhythms	Accelerated junctional rhythms during oral verapamil therapy.
UN	6695685_D014700_4_524_533_verapamil_D002637_4_502_512_chest pain	In patients with various chest pain syndromes, verapamil neither increased the frequency of junctional rhythms nor suppressed their role as escape rhythms under physiologically appropriate circumstances.
CID	6728873_D002110_3_574_582_caffeine_D012640_3_468_482_clonic seizure	Five phenotypic characteristics--locomotor activity, righting ability, clonic seizure induction, stress-induced lethality, death without external stress--were scored at various caffeine doses in drug-naive animals under empirically optimized, rigidly constant experimental conditions.
UN	6806735_C034868_1_226_230_CPDD_D010051_1_163_177_ovarian cancer	During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.
UN	6806735_D002945_1_213_224_cisplatinum_D010051_1_163_177_ovarian cancer	During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.
UN	6806735_D002945_0_50_62_cis-platinum_D010051_0_13_27_ovarian cancer	Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.
UN	6806735_D003520_1_265_281_cyclophosphamide_D010051_1_163_177_ovarian cancer	During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.
UN	6806735_D003520_0_76_92_cyclophosphamide_D010051_0_13_27_ovarian cancer	Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.
UN	6806735_D004317_0_64_74_adriamycin_D010051_0_13_27_ovarian cancer	Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.
UN	6806735_D006585_6_940_943_HMM_D005767_6_944_969_gastrointestinal toxicity	HMM gastrointestinal toxicity necessitated discontinuation of the drug in 5 patients.
UN	6806735_D006585_1_308_326_hexamethylmelamine_D010051_1_163_177_ovarian cancer	During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.
UN	6806735_D006585_0_97_115_hexamethylmelamine_D010051_0_13_27_ovarian cancer	Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.
CID	6884395_D003276_1_166_185_oral contraceptives_D000784_1_79_98_dissecting aneurysm	A case of nontraumatic dissecting aneurysm of the basilar artery in association with hypertension, smoke, and oral contraceptives is reported in a young female patient with a locked-in syndrome.
UN	6884395_D003276_1_166_185_oral contraceptives_D006973_1_141_153_hypertension	A case of nontraumatic dissecting aneurysm of the basilar artery in association with hypertension, smoke, and oral contraceptives is reported in a young female patient with a locked-in syndrome.
UN	6884395_D003276_1_166_185_oral contraceptives_D011782_1_231_249_locked-in syndrome	A case of nontraumatic dissecting aneurysm of the basilar artery in association with hypertension, smoke, and oral contraceptives is reported in a young female patient with a locked-in syndrome.
CID	689020_D005280_8_1067_1089_fenoterol-hydrobromide_D014202_8_1100_1106_tremor	After the end of fenoterol-hydrobromide infusion, tremor amplitudes decreased significantly faster than those following ritodrin-HCl infusion.
CID	689020_D012312_8_1170_1182_ritodrin-HCl_D014202_8_1100_1106_tremor	After the end of fenoterol-hydrobromide infusion, tremor amplitudes decreased significantly faster than those following ritodrin-HCl infusion.
CID	6893265_D011441_1_54_70_propylthiouracil_D056486_1_79_91_liver damage	Two cases of propylthiouracil-induced liver damage have been observed.
CID	6893265_D011441_0_0_16_Propylthiouracil_D056486_0_25_39_hepatic damage	Propylthiouracil-induced hepatic damage.
UN	6985297_D015764_1_48_56_Bepridil_D000787_1_112_127_anginal attacks	Bepridil, a novel active compound for prophylactic treatment of anginal attacks, induced persistent bradycardia and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo.
CID	6985297_D015764_0_38_46_bepridil_D001919_0_15_26_bradycardia	Studies on the bradycardia induced by bepridil.
UN	6985297_D015764_1_48_56_Bepridil_D013610_1_184_196_tachycardial	Bepridil, a novel active compound for prophylactic treatment of anginal attacks, induced persistent bradycardia and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo.
CID	6985498_D008733_1_132_146_methoxyflurane_D000141_1_221_243_renal tubular acidosis	A 69-year-old man operated for acute cholecystitis under methoxyflurane anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis.
CID	6985498_D008733_0_59_73_methoxyflurane_D000141_0_14_36_renal tubular acidosis	Hepatitis and renal tubular acidosis after anesthesia with methoxyflurane.
UN	6985498_D008733_1_132_146_methoxyflurane_D041881_1_106_125_acute cholecystitis	A 69-year-old man operated for acute cholecystitis under methoxyflurane anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis.
UN	6985498_D008733_1_132_146_methoxyflurane_D048550_1_186_216_hepatic insufficiency syndrome	A 69-year-old man operated for acute cholecystitis under methoxyflurane anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis.
CID	6985498_D008733_0_59_73_methoxyflurane_D056486_0_0_9_Hepatitis	Hepatitis and renal tubular acidosis after anesthesia with methoxyflurane.
CID	7018927_D006220_0_67_78_haloperidol_D006966_0_87_105_hyperprolactinemia	Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia.
CID	7121659_D012293_0_177_187_rifampicin_D006461_0_133_142_hemolysis	Antirifampicin antibodies in acute rifampicin-associated renal failure. 5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.
CID	7121659_D012293_0_177_187_rifampicin_D013921_0_116_128_thrombopenia	Antirifampicin antibodies in acute rifampicin-associated renal failure. 5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.
UN	7121659_D012293_0_35_45_rifampicin_D051437_0_57_70_renal failure	Antirifampicin antibodies in acute rifampicin-associated renal failure. 5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.
UN	7121659_D012293_0_35_45_rifampicin_D058186_0_88_107_acute renal failure	Antirifampicin antibodies in acute rifampicin-associated renal failure. 5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.
CID	7147232_D000255_6_748_751_ATP_D007022_6_725_736_Hypotension	Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0.001), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.001), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), total body oxygen consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after ATP was stopped.
CID	7147232_D000255_0_49_71_adenosine triphosphate_D007022_0_26_37_hypotension	Cardiovascular effects of hypotension induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts.
CID	7147232_D009599_1_184_187_SNP_D007022_1_240_251_hypotension	Adenosine triphosphate (ATP) and sodium nitroprusside (SNP) are administered to patients to induce and control hypotension during anesthesia.
CID	7147232_D009599_0_76_96_sodium nitroprusside_D007022_0_26_37_hypotension	Cardiovascular effects of hypotension induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts.
CID	7147232_D009599_8_1269_1272_SNP_D007022_8_1245_1256_hypotension	During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0.01), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.01), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), and oxygen content difference between arterial and mixed venous blood (p less than 0.05), while heart rate (p less than 0.001) and cardiac output (p less than 0.05) were increased.
UN	7147232_D010100_6_1059_1065_oxygen_D007022_6_725_736_Hypotension	Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0.001), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.001), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), total body oxygen consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after ATP was stopped.
UN	7147232_D010100_8_1562_1568_oxygen_D007022_8_1245_1256_hypotension	During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0.01), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.01), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), and oxygen content difference between arterial and mixed venous blood (p less than 0.05), while heart rate (p less than 0.001) and cardiac output (p less than 0.05) were increased.
CID	7173007_C006753_3_440_451_Endografine_D015746_3_484_498_abdominal pain	The Endografine group had a higher incidence of abdominal pain.
CID	7173007_C025504_2_374_381_Dimer-X_D004244_2_425_434_dizziness	The Dimer-X group had a higher incidence of nausea and dizziness.
CID	7173007_C025504_2_374_381_Dimer-X_D009325_2_414_420_nausea	The Dimer-X group had a higher incidence of nausea and dizziness.
UN	7176945_C084773_4_434_444_Fazadinium_D005207_4_396_410_fasciculations	The abolition of muscle fasciculations (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain.
UN	7176945_C084773_4_434_444_Fazadinium_D010146_4_490_494_pain	The abolition of muscle fasciculations (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain.
UN	7176945_D000530_5_533_541_Althesin_D010146_5_662_666_pain	Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain.
UN	7176945_D001965_5_618_625_bromide_D010146_5_662_666_pain	Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain.
UN	7176945_D002712_5_606_614_chloride_D010146_5_662_666_pain	Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain.
CID	7176945_D013390_4_482_489_scoline_D005207_4_396_410_fasciculations	The abolition of muscle fasciculations (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain.
CID	7176945_D013390_5_654_661_scoline_D010146_5_662_666_pain	Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain.
CID	7176945_D013390_4_482_489_scoline_D010146_4_490_494_pain	The abolition of muscle fasciculations (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain.
CID	7176945_D013390_3_309_316_scoline_D010146_3_317_321_pain	About 62% of the out-patients developed scoline pain as compared with about 26% among the in-patients.
CID	7176945_D013390_1_96_103_scoline_D010146_1_104_108_pain	Contrary to an earlier report by Coxon, scoline pain occurs in African negroes.
CID	7176945_D013390_0_5_18_suxamethonium_D010146_0_19_24_pains	Post-suxamethonium pains in Nigerian surgical patients.
UN	7176945_D013874_5_545_556_Thiopentone_D010146_5_662_666_pain	Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain.
CID	7248895_D003520_4_478_494_cyclophosphamide_D002277_4_593_602_carcinoma	Although the ability of cyclophosphamide to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract.
UN	7248895_D003520_4_478_494_cyclophosphamide_D003556_4_504_524_hemorrhagic cystitis	Although the ability of cyclophosphamide to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract.
CID	7248895_D003520_1_256_272_cyclophosphamide_D006417_1_206_215_hematuria	A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih cyclophosphamide for cerebral vasculitis.
UN	7248895_D003520_4_478_494_cyclophosphamide_D006470_4_504_524_hemorrhagic cystitis	Although the ability of cyclophosphamide to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract.
UN	7248895_D003520_1_256_272_cyclophosphamide_D006869_1_131_152_hydroureteronephrosis	A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih cyclophosphamide for cerebral vasculitis.
UN	7248895_D003520_8_1232_1248_cyclophosphamide_D006869_8_1117_1138_hydroureteronephrosis	The association of the tumor with preexisting hydroureteronephrosis suggests that stasis prolonged and intensified exposure of upper urinary tract epithelium to cyclophosphamide.
UN	7248895_D003520_8_1232_1248_cyclophosphamide_D009369_8_1094_1099_tumor	The association of the tumor with preexisting hydroureteronephrosis suggests that stasis prolonged and intensified exposure of upper urinary tract epithelium to cyclophosphamide.
UN	7248895_D003520_6_924_940_cyclophosphamide_D010386_6_865_894_carcinoma of the renal pelvis	The present case is the first carcinoma of the renal pelvis reported in association with cyclophosphamide treatment.
UN	7248895_D003520_0_49_65_cyclophosphamide_D010386_0_9_38_carcinoma of the renal pelvis	Invasive carcinoma of the renal pelvis following cyclophosphamide therapy for nonmalignant disease.
UN	7248895_D003520_7_1018_1034_cyclophosphamide_D014571_7_968_988_urinary tract cancer	It is the third urinary tract cancer reported in association with cyclophosphamide treatment for nonmalignant disease.
UN	7248895_D003520_1_256_272_cyclophosphamide_D020293_1_277_296_cerebral vasculitis	A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih cyclophosphamide for cerebral vasculitis.
UN	7315949_D009638_3_465_481_L-norepinephrine_D006547_3_509_516_hernias	In the media of the saphenous artery and its distal branch, vasoconstriction induced by L-norepinephrine produced many cell-to-cell hernias within 15 minutes.
CID	7315949_D009638_0_44_60_L-norepinephrine_D013035_0_27_32_spasm	Medial changes in arterial spasm induced by L-norepinephrine.
UN	733189_C000873_1_328_354_methylprednisolone acetate_D001766_1_267_276_blindness	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.
CID	733189_C000873_1_328_354_methylprednisolone acetate_D015356_1_215_261_retinal artery and choriocapillaris occlusions	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.
UN	733189_D000305_0_95_109_corticosteroid_D015356_0_10_55_retinal artery and choriocapillaris occlusion	Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting corticosteroid suspensions in combination with other drugs: I. Clinical studies.
UN	733189_D004837_1_386_397_epinephrine_D001766_1_267_276_blindness	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.
UN	733189_D004837_1_386_397_epinephrine_D015356_1_215_261_retinal artery and choriocapillaris occlusions	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.
UN	733189_D008012_1_375_384_lidocaine_D001766_1_267_276_blindness	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.
UN	733189_D008012_1_375_384_lidocaine_D015356_1_215_261_retinal artery and choriocapillaris occlusions	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.
UN	733189_D010406_1_402_412_penicillin_D001766_1_267_276_blindness	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.
UN	733189_D010406_1_402_412_penicillin_D015356_1_215_261_retinal artery and choriocapillaris occlusions	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.
CID	7369302_D011803_0_58_65_quinine_D000550_0_66_75_amblyopia	Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.
CID	7369302_D011803_1_252_267_quinine sulfate_D001766_1_83_92_blindness	Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.
UN	7369302_D011803_1_252_267_quinine sulfate_D009120_1_272_282_leg cramps	Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.
CID	7369302_D011803_3_434_441_quinine_D015845_3_337_352_tonic pupillary	A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.
CID	7369302_D011803_1_252_267_quinine sulfate_D015845_1_110_125_tonic pupillary	Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.
UN	7378868_D010197_6_755_766_pancuronium_D014313_6_623_645_prolonged jaw rigidity	The case shows that prolonged jaw rigidity and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium.
UN	7378868_D010197_6_755_766_pancuronium_D063806_6_650_657_myalgia	The case shows that prolonged jaw rigidity and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium.
CID	7378868_D013390_6_674_687_suxamethonium_D014313_6_623_645_prolonged jaw rigidity	The case shows that prolonged jaw rigidity and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium.
CID	7378868_D013390_0_0_13_Suxamethonium_D014313_0_22_35_jaw stiffness	Suxamethonium-induced jaw stiffness and myalgia associated with atypical cholinesterase: case report.
CID	7378868_D013390_6_674_687_suxamethonium_D063806_6_650_657_myalgia	The case shows that prolonged jaw rigidity and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium.
CID	7378868_D013390_0_0_13_Suxamethonium_D063806_0_40_47_myalgia	Suxamethonium-induced jaw stiffness and myalgia associated with atypical cholinesterase: case report.
UN	7411769_D007213_3_444_456_indomethacin_D003920_3_541_558_diabetes mellitus	Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication.
CID	7411769_D007213_0_0_12_Indomethacin_D006947_0_21_33_hyperkalemia	Indomethacin-induced hyperkalemia in three patients with gouty arthritis.
UN	7411769_D007213_3_444_456_indomethacin_D007674_3_574_587_renal disease	Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication.
UN	7411769_D007213_0_0_12_Indomethacin_D015210_0_57_72_gouty arthritis	Indomethacin-induced hyperkalemia in three patients with gouty arthritis.
UN	7411769_D007213_1_227_239_indomethacin_D015210_1_206_221_gouty arthritis	We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin.
CID	7411769_D007213_1_227_239_indomethacin_D051437_1_151_170_renal insufficiency	We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin.
UN	7411769_D011188_3_404_413_potassium_D003920_3_541_558_diabetes mellitus	Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication.
UN	7411769_D011188_3_404_413_potassium_D007674_3_574_587_renal disease	Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication.
UN	7411769_D011453_2_292_305_prostaglandin_D006994_2_331_362_hyporeninemic hypoaidosteronism	This complication may result from an inhibition of prostaglandin synthesis and consequent hyporeninemic hypoaidosteronism.
CID	7477981_D001058_2_426_437_apomorphine_D004409_2_446_457_dyskinesias	After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of parkinsonian motor disability.
UN	7477981_D001058_2_426_437_apomorphine_D009069_2_495_511_motor disability	After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of parkinsonian motor disability.
UN	7477981_D001058_2_426_437_apomorphine_D010300_2_482_494_parkinsonian	After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of parkinsonian motor disability.
UN	7477981_D004298_4_840_848_dopamine_D004409_4_865_876_dyskinesias	The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.
UN	7477981_D004298_4_840_848_dopamine_D009069_4_910_926_motor disability	The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.
UN	7477981_D004298_4_840_848_dopamine_D010300_4_897_909_parkinsonian	The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.
UN	7477981_D004298_1_222_230_dopamine_D010300_1_162_181_Parkinson's disease	We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days.
CID	7477981_D005473_0_45_55_fluoxetine_D004409_0_17_28_dyskinesias	Levodopa-induced dyskinesias are improved by fluoxetine.
CID	7477981_D005473_4_805_815_fluoxetine_D004409_4_865_876_dyskinesias	The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.
UN	7477981_D005473_4_805_815_fluoxetine_D009069_4_910_926_motor disability	The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.
UN	7477981_D005473_1_292_302_fluoxetine_D009069_1_86_102_motor disability	We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days.
UN	7477981_D005473_2_350_360_fluoxetine_D009069_2_495_511_motor disability	After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of parkinsonian motor disability.
UN	7477981_D005473_4_805_815_fluoxetine_D010300_4_897_909_parkinsonian	The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.
UN	7477981_D005473_1_292_302_fluoxetine_D010300_1_162_181_Parkinson's disease	We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days.
UN	7477981_D005473_2_350_360_fluoxetine_D010300_2_482_494_parkinsonian	After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of parkinsonian motor disability.
UN	7477981_D007980_0_0_8_Levodopa_D004409_0_17_28_dyskinesias	Levodopa-induced dyskinesias are improved by fluoxetine.
UN	7477981_D007980_1_128_136_levodopa_D004409_1_107_118_dyskinesias	We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days.
UN	7477981_D007980_4_827_835_levodopa_D004409_4_865_876_dyskinesias	The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.
UN	7477981_D007980_1_128_136_levodopa_D009069_1_86_102_motor disability	We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days.
UN	7477981_D007980_1_128_136_levodopa_D010300_1_162_181_Parkinson's disease	We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days.
UN	7477981_D007980_4_827_835_levodopa_D010300_4_897_909_parkinsonian	The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.
UN	7479194_D002506_1_336_346_cephalexin_D006402_1_380_419_liver, blood, skin, and renal disorders	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.
UN	7479194_D002506_1_336_346_cephalexin_D007674_1_380_419_liver, blood, skin, and renal disorders	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.
CID	7479194_D002506_1_336_346_cephalexin_D008107_1_380_419_liver, blood, skin, and renal disorders	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.
UN	7479194_D002506_1_336_346_cephalexin_D012871_1_380_419_liver, blood, skin, and renal disorders	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.
CID	7479194_D002506_6_1155_1165_cephalexin_D013262_6_1097_1123_toxic epidermal necrolysis	The one case of toxic epidermal necrolysis occurred in a patient who took cephalexin.
UN	7479194_D014295_1_293_305_trimethoprim_D006402_1_380_419_liver, blood, skin, and renal disorders	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.
UN	7479194_D014295_1_293_305_trimethoprim_D007674_1_380_419_liver, blood, skin, and renal disorders	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.
CID	7479194_D014295_3_794_806_trimethoprim_D008107_3_702_715_liver disease	The risk of clinically important idiopathic liver disease was similar for persons prescribed TMP-SMZ (5.2/100,000) and those prescribed trimethoprim alone (3.8/100,000).
CID	7479194_D014295_1_293_305_trimethoprim_D008107_1_380_419_liver, blood, skin, and renal disorders	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.
UN	7479194_D014295_1_293_305_trimethoprim_D012871_1_380_419_liver, blood, skin, and renal disorders	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.
UN	7479194_D015662_5_978_985_TMP-SMZ_D004892_5_1001_1020_erythema multiforme	Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to TMP-SMZ.
UN	7479194_D015662_1_233_262_trimethoprim-sulfamethoxazole_D006402_1_380_419_liver, blood, skin, and renal disorders	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.
UN	7479194_D015662_1_233_262_trimethoprim-sulfamethoxazole_D007674_1_380_419_liver, blood, skin, and renal disorders	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.
CID	7479194_D015662_3_751_758_TMP-SMZ_D008107_3_702_715_liver disease	The risk of clinically important idiopathic liver disease was similar for persons prescribed TMP-SMZ (5.2/100,000) and those prescribed trimethoprim alone (3.8/100,000).
UN	7479194_D015662_1_233_262_trimethoprim-sulfamethoxazole_D012871_1_380_419_liver, blood, skin, and renal disorders	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.
CID	7479194_D015662_5_1072_1079_TMP-SMZ_D013262_5_1025_1049_Stevens-Johnson syndrome	Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to TMP-SMZ.
UN	7492040_D003042_5_558_565_cocaine_D001919_5_608_625_bradydysrhythmias	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).
UN	7492040_D003042_6_901_908_cocaine_D002318_6_959_1008_cardiovascular or central nervous system toxicity	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.
UN	7492040_D003042_6_901_908_cocaine_D002493_6_959_1008_cardiovascular or central nervous system toxicity	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.
CID	7492040_D003042_4_419_426_cocaine_D009203_4_438_440_MI	PARTICIPANTS: Patients with cocaine-associated MI who received lidocaine in the emergency department.
CID	7492040_D003042_5_558_565_cocaine_D009203_5_577_579_MI	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).
CID	7492040_D003042_6_901_908_cocaine_D009203_6_920_922_MI	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.
CID	7492040_D003042_0_46_53_cocaine_D009203_0_65_86_myocardial infarction	Clinical safety of lidocaine in patients with cocaine-associated myocardial infarction.
CID	7492040_D003042_1_159_166_cocaine_D009203_1_175_196_myocardial infarction	STUDY OBJECTIVE: To evaluate the safety of lidocaine in the setting of cocaine-induced myocardial infarction (MI).
UN	7492040_D003042_5_558_565_cocaine_D012640_5_696_704_seizures	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).
UN	7492040_D003042_5_558_565_cocaine_D014693_5_655_679_ventricular fibrillation	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).
UN	7492040_D003042_5_558_565_cocaine_D017180_5_627_650_ventricular tachycardia	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).
UN	7492040_D008012_5_530_539_lidocaine_D001919_5_608_625_bradydysrhythmias	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).
UN	7492040_D008012_5_729_738_lidocaine_D001919_5_608_625_bradydysrhythmias	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).
UN	7492040_D008012_6_874_883_lidocaine_D002318_6_959_1008_cardiovascular or central nervous system toxicity	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.
UN	7492040_D008012_6_874_883_lidocaine_D002493_6_959_1008_cardiovascular or central nervous system toxicity	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.
UN	7492040_D008012_6_874_883_lidocaine_D009203_6_920_922_MI	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.
UN	7492040_D008012_4_454_463_lidocaine_D009203_4_438_440_MI	PARTICIPANTS: Patients with cocaine-associated MI who received lidocaine in the emergency department.
UN	7492040_D008012_5_530_539_lidocaine_D009203_5_577_579_MI	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).
UN	7492040_D008012_0_19_28_lidocaine_D009203_0_65_86_myocardial infarction	Clinical safety of lidocaine in patients with cocaine-associated myocardial infarction.
UN	7492040_D008012_1_131_140_lidocaine_D009203_1_175_196_myocardial infarction	STUDY OBJECTIVE: To evaluate the safety of lidocaine in the setting of cocaine-induced myocardial infarction (MI).
UN	7492040_D008012_5_729_738_lidocaine_D012640_5_696_704_seizures	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).
UN	7492040_D008012_5_729_738_lidocaine_D014693_5_655_679_ventricular fibrillation	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).
UN	7492040_D008012_5_729_738_lidocaine_D017180_5_627_650_ventricular tachycardia	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).
UN	753803_D008696_7_1274_1282_Dianabol_D009135_7_1321_1330_myopathic	The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E.
UN	753803_D013256_9_1823_1831_steroids_D009135_9_1848_1865_myopathic disease	The authors conclude by affirming the undoubted efficacy of the anabolizing steroids in experimental myopathic disease, but they have reservations as to the transfer of the results into the human field, where high dosage cannot be carried out continuously because of the effects of the drug on virility; because the tissue injury too often occurs at an irreversible stage vis-a-vis the "regeneration" of the muscle tissue; and finally because the dystrophic injurious agent is certainly not the lack of vitamin E but something as yet unknown.
UN	753803_D013256_7_1173_1181_steroids_D009135_7_1133_1142_myopathic	The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E.
UN	753803_D014810_3_443_452_vitamin E_D009135_3_457_465_myopathy	Myopathy due to lack of vitamin E and myopathy induced by certain viruses have much in common anatomically and pathologically with the human form.
UN	753803_D014810_7_1354_1363_vitamin E_D009135_7_1321_1330_myopathic	The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E.
CID	753803_D014810_4_641_650_vitamin E_D009136_4_586_598_myodystrophy	The authors induced myodystrophy in the rat by giving it a diet lacking in vitamin E.
UN	7644931_D016190_1_218_229_carboplatin_D002289_1_278_304_non-small cell lung cancer	Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with carboplatin in a phase I/II study directed to patients with non-small cell lung cancer.
UN	7644931_D016190_6_1006_1017_Carboplatin_D006402_6_1047_1069_hematologic toxicities	Carboplatin did not appear to add to the hematologic toxicities observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks.
UN	7644931_D017239_1_117_127_Paclitaxel_D002289_1_278_304_non-small cell lung cancer	Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with carboplatin in a phase I/II study directed to patients with non-small cell lung cancer.
CID	7644931_D017239_6_1088_1098_paclitaxel_D006402_6_1047_1069_hematologic toxicities	Carboplatin did not appear to add to the hematologic toxicities observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks.
UN	7661171_D007213_0_44_56_indomethacin_D005355_0_103_112_cirrhosis	The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated cirrhosis.
UN	7661171_D007213_1_184_196_indomethacin_D005355_1_243_252_cirrhotic	Misoprostol (200 micrograms) has been shown to acutely counteract the indomethacin-induced renal dysfunction in well compensated cirrhotic patients.
CID	7661171_D007213_0_44_56_indomethacin_D007674_0_65_82_renal dysfunction	The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated cirrhosis.
CID	7661171_D007213_1_184_196_indomethacin_D007674_1_205_222_renal dysfunction	Misoprostol (200 micrograms) has been shown to acutely counteract the indomethacin-induced renal dysfunction in well compensated cirrhotic patients.
UN	7661171_D012964_3_408_414_sodium_D005355_3_495_504_cirrhotic	Parameters of renal hemodynamics and tubular sodium and water handling were assessed by clearance techniques in 26 well compensated cirrhotic patients before and after an oral combination of 50 mg of indomethacin and various doses of misoprostol.
UN	7661171_D016595_0_29_40_misoprostol_D005355_0_103_112_cirrhosis	The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated cirrhosis.
UN	7661171_D016595_0_29_40_misoprostol_D007674_0_65_82_renal dysfunction	The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated cirrhosis.
CID	7671401_D000806_0_83_122_angiotensin-converting enzyme inhibitor_D000799_0_36_48_angio-oedema	Increased frequency and severity of angio-oedema related to long-term therapy with angiotensin-converting enzyme inhibitor in two patients.
UN	7671401_D000806_2_247_293_Angiotensin-converting enzyme (ACE) inhibitors_D006333_2_326_350_congestive heart failure	Angiotensin-converting enzyme (ACE) inhibitors, used to treat hypertension and congestive heart failure, were introduced in Europe in the middle of the eighties, and the use of these drugs has increased progressively.
UN	7671401_D000806_2_247_293_Angiotensin-converting enzyme (ACE) inhibitors_D006973_2_309_321_hypertension	Angiotensin-converting enzyme (ACE) inhibitors, used to treat hypertension and congestive heart failure, were introduced in Europe in the middle of the eighties, and the use of these drugs has increased progressively.
CID	7727612_D008140_0_26_35_lorazepam_D009207_0_0_9_Myoclonus	Myoclonus associated with lorazepam therapy in very-low-birth-weight infants.
CID	7727612_D008140_3_442_451_lorazepam_D009207_3_388_397_myoclonus	Three young infants, all of birth weight < 1,500 g, experienced myoclonus following the intravenous administration of lorazepam.
CID	7739955_D002220_2_320_333_carbamazepine_D004802_2_348_372_eosinophilic myocarditis	Three patients had acute viral myocarditis, one had a carbamazepine-induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock.
CID	7739955_D002220_2_320_333_carbamazepine_D009205_2_348_372_eosinophilic myocarditis	Three patients had acute viral myocarditis, one had a carbamazepine-induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock.
UN	7739955_D002220_2_320_333_carbamazepine_D012770_2_427_444_cardiogenic shock	Three patients had acute viral myocarditis, one had a carbamazepine-induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock.
CID	7931490_D002945_1_398_407_cisplatin_D009325_1_416_422_nausea	PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced nausea and vomiting.
CID	7931490_D002945_0_153_162_cisplatin_D009325_0_112_118_nausea	Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
CID	7931490_D002945_1_398_407_cisplatin_D014839_1_427_435_vomiting	PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced nausea and vomiting.
CID	7931490_D002945_0_153_162_cisplatin_D014839_0_123_131_vomiting	Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
UN	7931490_D012701_0_48_67_5-hydroxytryptamine_D009325_0_112_118_nausea	Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
UN	7931490_D012701_0_48_67_5-hydroxytryptamine_D014839_0_123_131_vomiting	Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
UN	7931490_D017829_1_252_263_granisetron_D009325_1_416_422_nausea	PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced nausea and vomiting.
UN	7931490_D017829_0_23_34_granisetron_D009325_0_112_118_nausea	Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
UN	7931490_D017829_9_1707_1718_granisetron_D014839_9_1748_1756_vomiting	CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of granisetron was effective in controlling vomiting in 57% to 60% of patients who received cisplatin at doses greater than 81 mg/m2 and totally prevented vomiting in 40% to 47% of patients.
CID	7949506_D003000_1_126_135_clonidine_D007022_1_219_230_hypotension	OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and verapamil resulting in atrioventricular (AV) block in both patients and severe hypotension in one patient.
CID	7949506_D003000_3_412_421_clonidine_D007022_3_480_491_hypotension	After the addition of a minimal dose of clonidine (0.15 mg bid), she developed complete AV block and severe hypotension, which resolved upon cessation of all medications.
CID	7949506_D003000_5_639_648_clonidine_D054537_5_684_692_AV block	After the addition of clonidine 0.15 mg bid she developed complete AV block, which resolved after all therapy was stopped.
CID	7949506_D003000_1_126_135_clonidine_D054537_1_163_190_atrioventricular (AV) block	OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and verapamil resulting in atrioventricular (AV) block in both patients and severe hypotension in one patient.
UN	7949506_D013148_2_347_361_spironolactone_D006929_2_288_306_hyperaldosteronism	CASE SUMMARIES: A 54-year-old woman with hyperaldosteronism was treated with verapamil 480 mg/d and spironolactone 100 mg/d.
UN	7949506_D014700_2_324_333_verapamil_D006929_2_288_306_hyperaldosteronism	CASE SUMMARIES: A 54-year-old woman with hyperaldosteronism was treated with verapamil 480 mg/d and spironolactone 100 mg/d.
CID	7949506_D014700_1_140_149_verapamil_D007022_1_219_230_hypotension	OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and verapamil resulting in atrioventricular (AV) block in both patients and severe hypotension in one patient.
CID	7949506_D014700_1_140_149_verapamil_D054537_1_163_190_atrioventricular (AV) block	OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and verapamil resulting in atrioventricular (AV) block in both patients and severe hypotension in one patient.
UN	7967231_C059447_2_757_764_S-312-d_D004827_2_820_828_epilepsy	S-312-d may be useful in the therapy of certain types of human epilepsy.
UN	7967231_C059447_1_492_499_S-312-d_D012640_1_549_560_convulsions	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
UN	7967231_C059447_1_142_149_S-312-d_D020195_1_241_269_audiogenic tonic convulsions	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
CID	7967231_D001534_1_611_620_bemegride_D012640_1_549_560_convulsions	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
UN	7967231_D001534_1_611_620_bemegride_D020195_1_241_269_audiogenic tonic convulsions	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
UN	7967231_D002118_1_175_182_calcium_D012640_1_549_560_convulsions	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
UN	7967231_D002118_1_175_182_calcium_D020195_1_241_269_audiogenic tonic convulsions	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
UN	7967231_D005444_1_403_414_flunarizine_D012640_1_549_560_convulsions	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
UN	7967231_D005444_1_403_414_flunarizine_D020195_1_241_269_audiogenic tonic convulsions	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
CID	7967231_D010433_1_572_590_pentylenetetrazole_D012640_1_549_560_convulsions	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
UN	7967231_D010433_1_572_590_pentylenetetrazole_D020195_1_241_269_audiogenic tonic convulsions	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
CID	7967231_D010852_1_712_722_picrotoxin_D012640_1_667_678_convulsions	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
UN	7967231_D010852_1_712_722_picrotoxin_D020195_1_241_269_audiogenic tonic convulsions	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
UN	7967231_D016202_1_690_710_N-methyl-D-aspartate_D012640_1_667_678_convulsions	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
UN	7967231_D016202_1_690_710_N-methyl-D-aspartate_D020195_1_241_269_audiogenic tonic convulsions	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
UN	8096565_D018170_2_250_261_sumatriptan_D003027_2_286_302_cluster headache	We describe a 47-year-old woman with an acute myocardial infarction after administration of sumatriptan 6 mg subcutaneously for cluster headache.
CID	8096565_D018170_2_250_261_sumatriptan_D009203_2_204_225_myocardial infarction	We describe a 47-year-old woman with an acute myocardial infarction after administration of sumatriptan 6 mg subcutaneously for cluster headache.
CID	8096565_D018170_0_38_49_sumatriptan_D009203_0_11_32_myocardial infarction	Transmural myocardial infarction with sumatriptan.
UN	8135424_D001569_1_119_133_benzodiazepine_D012640_1_167_175_seizures	STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask seizures in mixed cocaine-benzodiazepine intoxication.
UN	8135424_D001569_1_193_207_benzodiazepine_D012640_1_167_175_seizures	STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask seizures in mixed cocaine-benzodiazepine intoxication.
CID	8135424_D003042_1_185_192_cocaine_D012640_1_167_175_seizures	STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask seizures in mixed cocaine-benzodiazepine intoxication.
CID	8135424_D003042_0_47_54_cocaine_D012640_0_19_27_seizures	Flumazenil induces seizures and death in mixed cocaine-diazepam intoxications.
CID	8135424_D003975_0_55_63_diazepam_D012640_0_19_27_seizures	Flumazenil induces seizures and death in mixed cocaine-diazepam intoxications.
CID	8135424_D005442_18_1659_1669_Flumazenil_D012640_18_1681_1689_seizures	CONCLUSION: Flumazenil can unmask seizures and increase the incidence of death in a model of combined cocaine-diazepam intoxications.
CID	8135424_D005442_1_145_155_flumazenil_D012640_1_167_175_seizures	STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask seizures in mixed cocaine-benzodiazepine intoxication.
CID	8135424_D005442_0_0_10_Flumazenil_D012640_0_19_27_seizures	Flumazenil induces seizures and death in mixed cocaine-diazepam intoxications.
UN	8160791_C038983_9_1262_1266_DMTU_D007674_9_1306_1317_nephropathy	These results suggest that 1) both SOD and DMTU have protective effects on GM-mediated nephropathy, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction.
UN	8160791_C038983_7_1001_1005_DMTU_D007674_7_1032_1046_tubular damage	In contrast, DMTU significantly reduced the tubular damage and lipid peroxidation, but it did not affect renal hemodynamics and vasoactive substances.
CID	8160791_D005839_3_612_614_GM_D007674_3_624_635_nephropathy	A significant reduction in urinary guanosine 3',5'-cyclic monophosphate (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in GM-mediated nephropathy.
CID	8160791_D005839_1_223_225_GM_D007674_1_236_247_nephropathy	Studies were performed to examine the mechanisms for the protective effects of free radical scavengers on gentamicin (GM)-mediated nephropathy.
CID	8160791_D005839_0_64_74_gentamicin_D007674_0_84_95_nephropathy	Mechanisms for protective effects of free radical scavengers on gentamicin-mediated nephropathy in rats.
CID	8160791_D005839_9_1294_1296_GM_D007674_9_1306_1317_nephropathy	These results suggest that 1) both SOD and DMTU have protective effects on GM-mediated nephropathy, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction.
UN	8160791_D006152_3_459_495_guanosine 3',5'-cyclic monophosphate_D007674_3_624_635_nephropathy	A significant reduction in urinary guanosine 3',5'-cyclic monophosphate (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in GM-mediated nephropathy.
UN	8160791_D013481_9_1396_1406_superoxide_D007674_9_1306_1317_nephropathy	These results suggest that 1) both SOD and DMTU have protective effects on GM-mediated nephropathy, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction.
CID	816141_D002512_0_0_11_Cephalothin_D000743_0_27_43_hemolytic anemia	Cephalothin-induced immune hemolytic anemia.
CID	816141_D002512_1_133_144_cephalothin_D000743_1_100_116_hemolytic anemia	A patient with renal disease developed Coombs-positive hemolytic anemia while receiving cephalothin therapy.
UN	816141_D002512_1_133_144_cephalothin_D007674_1_60_73_renal disease	A patient with renal disease developed Coombs-positive hemolytic anemia while receiving cephalothin therapy.
CID	8184922_D007545_6_1090_1103_isoproterenol_D006332_6_1112_1131_cardiac hypertrophy	These data indicate that adult mouse atrial and ventricular cardiomyocytes do not synthesize DNA in response to isoproterenol-induced cardiac hypertrophy.
CID	8188982_D001127_0_34_37_AVP_D006973_0_80_92_hypertensive	Central cardiovascular effects of AVP and ANP in normotensive and spontaneously hypertensive rats.
UN	8188982_D001127_8_1379_1382_AVP_D007022_8_1401_1412_hypotension	CCB was reduced in WKY and SHR after LV administration of AVP during SN-induced hypotension.
UN	8188982_D009599_4_915_935_sodium nitroprusside_D006973_4_898_910_hypertension	Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (SN)-induced hypotension.
CID	8188982_D009599_4_937_939_SN_D007022_4_949_960_hypotension	Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (SN)-induced hypotension.
CID	8188982_D009599_8_1390_1392_SN_D007022_8_1401_1412_hypotension	CCB was reduced in WKY and SHR after LV administration of AVP during SN-induced hypotension.
CID	8188982_D010656_4_885_888_Phe_D006973_4_898_910_hypertension	Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (SN)-induced hypotension.
UN	8188982_D010656_4_870_883_phenylephrine_D007022_4_949_960_hypotension	Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (SN)-induced hypotension.
UN	8308951_D010894_4_527_536_piroxicam_D001778_4_592_604_coagulopathy	An adverse drug interaction with piroxicam, which she took occasionally, may have exacerbated the coagulopathy.
UN	8308951_D014859_1_142_150_warfarin_D001778_1_159_171_coagulopathy	A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.
UN	8308951_D014859_3_353_361_warfarin_D001778_3_370_382_coagulopathy	Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.
CID	8308951_D014859_0_22_30_warfarin_D002543_0_61_85_intracerebral hemorrhage	Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.
UN	8308951_D014859_1_142_150_warfarin_D006406_1_126_134_hematoma	A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.
UN	8312343_D004317_2_429_440_doxorubicin_D002311_2_239_264_idiopathic cardiomyopathy	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).
UN	8312343_D004317_2_429_440_doxorubicin_D002312_2_362_389_hypertrophic cardiomyopathy	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).
UN	8312343_D004317_2_429_440_doxorubicin_D006331_2_272_296_congenital heart disease	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).
UN	8312343_D004317_2_429_440_doxorubicin_D006349_2_396_418_valvular heart disease	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).
CID	8312343_D004317_2_429_440_doxorubicin_D009202_2_441_455_cardiomyopathy	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).
UN	8312343_D015774_14_1277_1288_ganciclovir_D003586_14_1219_1245_Cytomegalovirus infections	Cytomegalovirus infections were treated successfully with ganciclovir in 11 patients.
UN	8312983_C036139_6_771_790_desmethylfluoxetine_D003693_6_700_708_delirium	In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration.
UN	8312983_C036139_6_771_790_desmethylfluoxetine_D006948_6_687_699_hyperkinetic	In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration.
CID	8312983_D005473_6_743_753_fluoxetine_D003693_6_700_708_delirium	In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration.
CID	8312983_D005473_0_16_26_fluoxetine_D003693_0_0_8_Delirium	Delirium during fluoxetine treatment.
CID	8312983_D005473_6_743_753_fluoxetine_D006948_6_687_699_hyperkinetic	In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration.
UN	8312983_D015283_4_404_414_citalopram_D006970_4_485_495_somnolence	In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties.
UN	8312983_D015283_4_404_414_citalopram_D020820_4_500_521_movement difficulties	In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties.
UN	8318674_D003561_1_163_168_Ara-C_D008223_1_173_182_lymphomas	Four out of 23 consecutive patients treated with high-dose Ara-C for lymphomas in our institution developed a strikingly similar syndrome during the perfusion.
UN	8318674_D003561_0_42_53_aracytine-C_D008223_0_58_66_lymphoma	Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF.
CID	8318674_D003561_0_42_53_aracytine-C_D011654_0_0_15_Pulmonary edema	Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF.
UN	8318674_D003561_6_910_915_Ara-C_D012128_6_843_878_adult respiratory distress syndrome	As TNF and PAF are thought to be involved in the development of septic shock and adult respiratory distress syndrome, we hypothesize that high-dose Ara-C may be associated with cytokine release.
CID	8318674_D003561_0_42_53_aracytine-C_D012769_0_20_25_shock	Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF.
UN	8392553_C056595_5_684_694_clentiazem_D005355_5_794_802_fibrosis	Treatment with clentiazem prevented epinephrine-induced death (P < .05), and attenuated the ventricular ischemic lesions and fibrosis, in a dose-dependent manner.
UN	8392553_C056595_0_21_31_clentiazem_D006331_0_60_74_cardiac injury	Protective effect of clentiazem against epinephrine-induced cardiac injury in rats.
UN	8392553_C056595_10_1621_1631_clentiazem_D006331_10_1663_1677_cardiac injury	In conclusion, clentiazem attenuated epinephrine-induced cardiac injury, possibly through its effect on the adrenergic pathway.
UN	8392553_C056595_5_684_694_clentiazem_D007511_5_773_789_ischemic lesions	Treatment with clentiazem prevented epinephrine-induced death (P < .05), and attenuated the ventricular ischemic lesions and fibrosis, in a dose-dependent manner.
UN	8392553_C056595_1_115_125_clentiazem_D009202_1_192_206_cardiomyopathy	We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced cardiomyopathy in rats.
UN	8392553_C106746_1_129_148_1,5-benzothiazepine_D009202_1_192_206_cardiomyopathy	We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced cardiomyopathy in rats.
UN	8392553_D002118_1_149_156_calcium_D009202_1_192_206_cardiomyopathy	We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced cardiomyopathy in rats.
UN	8392553_D004837_5_705_716_epinephrine_D005355_5_794_802_fibrosis	Treatment with clentiazem prevented epinephrine-induced death (P < .05), and attenuated the ventricular ischemic lesions and fibrosis, in a dose-dependent manner.
UN	8392553_D004837_2_236_247_epinephrine_D005355_2_324_332_fibrosis	With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and fibrosis of the left ventricles were observed.
UN	8392553_D004837_10_1643_1654_epinephrine_D006331_10_1663_1677_cardiac injury	In conclusion, clentiazem attenuated epinephrine-induced cardiac injury, possibly through its effect on the adrenergic pathway.
UN	8392553_D004837_0_40_51_epinephrine_D006331_0_60_74_cardiac injury	Protective effect of clentiazem against epinephrine-induced cardiac injury in rats.
UN	8392553_D004837_5_705_716_epinephrine_D007511_5_773_789_ischemic lesions	Treatment with clentiazem prevented epinephrine-induced death (P < .05), and attenuated the ventricular ischemic lesions and fibrosis, in a dose-dependent manner.
UN	8392553_D004837_2_236_247_epinephrine_D007511_2_303_319_ischemic lesions	With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and fibrosis of the left ventricles were observed.
CID	8392553_D004837_1_172_183_epinephrine_D009202_1_192_206_cardiomyopathy	We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced cardiomyopathy in rats.
UN	851038_D000450_2_454_465_aldosterone_D007008_2_245_256_hypokalemia	The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.
CID	851038_D007980_2_171_177_L-dopa_D007008_2_245_256_hypokalemia	The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.
CID	851038_D007980_1_116_122_L-dopa_D007008_1_64_75_Hypokalemia	Hypokalemia, sometimes severe, was observed in some L-dopa-treated parkinsonian patients.
UN	851038_D007980_1_116_122_L-dopa_D010300_1_131_143_parkinsonian	Hypokalemia, sometimes severe, was observed in some L-dopa-treated parkinsonian patients.
UN	851038_D007980_0_21_27_L-dopa_D010300_0_41_53_parkinsonian	Kaliuretic effect of L-dopa treatment in parkinsonian patients.
UN	851038_D011188_2_204_213_potassium_D007008_2_245_256_hypokalemia	The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.
UN	851038_D012964_2_393_399_sodium_D007008_2_245_256_hypokalemia	The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.
UN	8511251_D002118_2_186_193_calcium_D003329_2_130_151_coronary artery spasm	The ischemia probably induced by coronary artery spasm was reversed by nitroglycerin and calcium blocking agents.
UN	8511251_D002118_2_186_193_calcium_D007511_2_101_109_ischemia	The ischemia probably induced by coronary artery spasm was reversed by nitroglycerin and calcium blocking agents.
CID	8511251_D003042_1_88_95_cocaine_D017202_1_57_76_myocardial ischemia	We report a case of myocardial ischemia induced by cocaine.
CID	8511251_D003042_0_0_7_Cocaine_D017202_0_16_35_myocardial ischemia	Cocaine induced myocardial ischemia.
UN	8511251_D005996_2_168_181_nitroglycerin_D003329_2_130_151_coronary artery spasm	The ischemia probably induced by coronary artery spasm was reversed by nitroglycerin and calcium blocking agents.
UN	8511251_D005996_2_168_181_nitroglycerin_D007511_2_101_109_ischemia	The ischemia probably induced by coronary artery spasm was reversed by nitroglycerin and calcium blocking agents.
UN	8603459_D004317_8_830_841_doxorubicin_D006984_8_891_903_hypertrophic	After sacrifice the hearts of doxorubicin-treated animals were enlarged and the atria were hypertrophic.
CID	8603459_D004317_0_0_11_Doxorubicin_D066126_0_20_34_cardiotoxicity	Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice.
CID	8603459_D004317_2_181_192_doxorubicin_D066126_2_201_215_cardiotoxicity	In laboratory animals, histology is most commonly used to study doxorubicin-induced cardiotoxicity.
CID	8603459_D004317_13_1572_1583_doxorubicin_D066126_13_1592_1606_cardiotoxicity	These findings result in a model that allows the testing of protectors against doxorubicin-induced cardiotoxicity as demonstrated by the protection provided by ICRF-187.
UN	8603459_D064730_13_1653_1661_ICRF-187_D066126_13_1592_1606_cardiotoxicity	These findings result in a model that allows the testing of protectors against doxorubicin-induced cardiotoxicity as demonstrated by the protection provided by ICRF-187.
UN	8659767_D002045_1_86_97_bupivacaine_D001145_1_135_147_dysrhythmias	Since bupivacaine and epinephrine may both precipitate dysrhythmias, circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine.
UN	8659767_D002045_2_287_298_bupivacaine_D009203_2_430_451_myocardial infarction	We therefore examined whether bupivacaine alters the dysrhythmogenicity of subsequent administration of epinephrine in conscious, healthy dogs and in anesthetized dogs with myocardial infarction.
UN	8659767_D002045_12_1395_1406_Bupivacaine_D017180_12_1483_1485_VT	Bupivacaine antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous postinfarct dysrhythmias.
UN	8659767_D004837_1_102_113_epinephrine_D001145_1_135_147_dysrhythmias	Since bupivacaine and epinephrine may both precipitate dysrhythmias, circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine.
UN	8659767_D004837_2_361_372_epinephrine_D009203_2_430_451_myocardial infarction	We therefore examined whether bupivacaine alters the dysrhythmogenicity of subsequent administration of epinephrine in conscious, healthy dogs and in anesthetized dogs with myocardial infarction.
UN	8659767_D004837_9_1147_1158_epinephrine_D009203_9_1048_1069_myocardial infarction	One day after experimental myocardial infarction, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared.
CID	8659767_D004837_9_1147_1158_epinephrine_D017180_9_1165_1167_VT	One day after experimental myocardial infarction, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared.
CID	8659767_D004837_12_1419_1430_epinephrine_D017180_12_1483_1485_VT	Bupivacaine antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous postinfarct dysrhythmias.
UN	8659767_D006221_9_1086_1095_halothane_D009203_9_1048_1069_myocardial infarction	One day after experimental myocardial infarction, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared.
UN	8659767_D006221_9_1086_1095_halothane_D017180_9_1165_1167_VT	One day after experimental myocardial infarction, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared.
UN	8667442_C019248_6_950_961_pamidronate_D006934_6_998_1018_milk-alkali syndrome	This illustrates intravenous pamidronate as a valuable therapeutic tool when milk-alkali syndrome presents as hypercalcemic emergency.
CID	8667442_D000468_1_225_231_alkali_D006934_1_81_101_Milk-alkali syndrome	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali.
UN	8667442_D000468_1_225_231_alkali_D010437_1_170_190_peptic ulcer disease	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali.
CID	8667442_D002117_4_712_722_calcitriol_D006934_4_771_791_milk-alkali syndrome	This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.
CID	8667442_D002117_0_32_42_1,25(OH)2D_D006934_0_0_20_Milk-alkali syndrome	Milk-alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism.
UN	8667442_D002117_0_32_42_1,25(OH)2D_D007011_0_61_79_hypoparathyroidism	Milk-alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism.
UN	8667442_D002117_4_712_722_calcitriol_D007011_4_650_668_hypoparathyroidism	This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.
CID	8667442_D002118_1_213_220_calcium_D006934_1_81_101_Milk-alkali syndrome	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali.
UN	8667442_D002118_1_213_220_calcium_D010437_1_170_190_peptic ulcer disease	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali.
CID	8667442_D002119_4_690_707_calcium carbonate_D006934_4_771_791_milk-alkali syndrome	This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.
UN	8667442_D002119_4_690_707_calcium carbonate_D007011_4_650_668_hypoparathyroidism	This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.
UN	8667442_D009853_2_284_294_omeprazole_D000471_2_416_425_alkalosis	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.
UN	8667442_D009853_2_284_294_omeprazole_D006934_2_330_350_milk-alkali syndrome	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.
UN	8667442_D009853_2_284_294_omeprazole_D014456_2_255_260_ulcer	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.
UN	8667442_D009853_2_284_294_omeprazole_D051437_2_431_447_renal impairment	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.
UN	8667442_D013392_2_300_310_sucralfate_D000471_2_416_425_alkalosis	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.
UN	8667442_D013392_2_300_310_sucralfate_D006934_2_330_350_milk-alkali syndrome	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.
UN	8667442_D013392_2_300_310_sucralfate_D014456_2_255_260_ulcer	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.
UN	8667442_D013392_2_300_310_sucralfate_D051437_2_431_447_renal impairment	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.
CID	8701013_D015738_0_0_10_Famotidine_D003693_0_22_30_delirium	Famotidine-associated delirium.
CID	8701013_D015738_4_442_452_famotidine_D003693_4_464_472_delirium	The authors report on six cases of famotidine-associated delirium in hospitalized patients who cleared completely upon removal of famotidine.
UN	8701013_D015738_2_55_65_Famotidine_D014456_2_156_162_ulcers	Famotidine is a histamine H2-receptor antagonist used in inpatient settings for prevention of stress ulcers and is showing increasing popularity because of its low cost.
CID	8748050_D000639_0_22_35_amitriptyline_D001927_0_0_14_Encephalopathy	Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?
CID	8748050_D000639_1_197_210_amitriptyline_D001927_1_155_169_encephalopathy	This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression.
UN	8748050_D000639_1_197_210_amitriptyline_D003866_1_242_261_unipolar depression	This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression.
UN	8748050_D000639_0_22_35_amitriptyline_D009459_0_49_79_neuroleptic malignant syndrome	Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?
UN	8748050_D000639_0_22_35_amitriptyline_D020230_0_84_102_serotonin syndrome	Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?
UN	8755612_D004054_7_1035_1038_DES_D006470_7_1114_1125_hemorrhagic	However, while DES-induced pituitary growth exhibited quantitative, additive inheritance, the hemorrhagic phenotype exhibited recessive, epistatic inheritance.
UN	8755612_D004054_2_225_243_diethylstilbestrol_D006470_2_415_426_hemorrhagic	Ten weeks of diethylstilbestrol (DES) treatment caused female F344 rat pituitaries to grow to an average of 109.2 +/- 6.3 mg (mean +/- SE) versus 11.3 +/- 1.4 mg for untreated rats, and to become highly hemorrhagic.
UN	8755612_D004967_0_68_76_estrogen_D006470_0_39_50_hemorrhagic	Genetic separation of tumor growth and hemorrhagic phenotypes in an estrogen-induced tumor.
UN	8755612_D004967_0_68_76_estrogen_D009369_0_85_90_tumor	Genetic separation of tumor growth and hemorrhagic phenotypes in an estrogen-induced tumor.
UN	8755612_D004967_1_118_126_estrogen_D010911_1_194_210_pituitary tumors	Chronic administration of estrogen to the Fischer 344 (F344) rat induces growth of large, hemorrhagic pituitary tumors.
UN	8808730_D000171_2_415_423_acrolein_D003556_2_344_352_cystitis	Chemical cystitis was induced by cyclophosphamide (CYP) which is metabolized to acrolein, an irritant eliminated in the urine.
CID	8808730_D003520_2_368_384_cyclophosphamide_D003556_2_344_352_cystitis	Chemical cystitis was induced by cyclophosphamide (CYP) which is metabolized to acrolein, an irritant eliminated in the urine.
UN	8808730_D009569_0_33_45_nitric oxide_D001745_0_102_120_bladder irritation	Increased expression of neuronal nitric oxide synthase in bladder afferent pathways following chronic bladder irritation.
UN	8808730_D009569_1_215_227_nitric oxide_D014570_1_291_322_irritation of the urinary tract	Immunocytochemical techniques were used to examine alterations in the expression of neuronal nitric oxide synthase (NOS) in bladder pathways following acute and chronic irritation of the urinary tract of the rat.
UN	8819482_C082828_7_1665_1671_CD-832_D003251_7_1726_1734_stenosis	These data show that CD-832 improves myocardial ischemia during ISO infusion with stenosis and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832.
UN	8819482_C082828_7_1665_1671_CD-832_D017202_7_1681_1700_myocardial ischemia	These data show that CD-832 improves myocardial ischemia during ISO infusion with stenosis and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832.
UN	8819482_C082828_1_141_147_CD-832_D017202_1_179_198_myocardial ischemia	Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.
UN	8819482_C082828_1_141_147_CD-832_D023921_1_233_250_coronary stenosis	Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.
UN	8819482_C082828_0_37_43_CD-832_D023921_0_111_128_coronary stenosis	Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.
UN	8819482_D002118_0_17_24_calcium_D017202_0_70_89_myocardial ischemia	Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.
UN	8819482_D002118_0_17_24_calcium_D023921_0_111_128_coronary stenosis	Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.
UN	8819482_D004110_3_838_847_diltiazem_D003251_3_696_704_stenosis	After the control ISO infusion with stenosis was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion.
UN	8819482_D004110_6_1371_1380_Diltiazem_D003251_6_1634_1642_stenosis	Diltiazem (30 micrograms/kg/min) also prevented the decrease in percentage segmental shortening from 34 +/- 14% to 63 +/- 18% of the control value (P < .05) and ST-segment elevation from 4.7 +/- 0.7 mV to 2.1 +/- 0.7 mV (P < .01) at 3 min after ISO infusion with stenosis.
UN	8819482_D004110_1_346_355_diltiazem_D017202_1_179_198_myocardial ischemia	Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.
UN	8819482_D004110_1_346_355_diltiazem_D023921_1_233_250_coronary stenosis	Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.
UN	8819482_D007545_7_1708_1711_ISO_D003251_7_1726_1734_stenosis	These data show that CD-832 improves myocardial ischemia during ISO infusion with stenosis and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832.
UN	8819482_D007545_3_678_681_ISO_D003251_3_696_704_stenosis	After the control ISO infusion with stenosis was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion.
UN	8819482_D007545_6_1616_1619_ISO_D003251_6_1634_1642_stenosis	Diltiazem (30 micrograms/kg/min) also prevented the decrease in percentage segmental shortening from 34 +/- 14% to 63 +/- 18% of the control value (P < .05) and ST-segment elevation from 4.7 +/- 0.7 mV to 2.1 +/- 0.7 mV (P < .01) at 3 min after ISO infusion with stenosis.
UN	8819482_D007545_5_1343_1346_ISO_D003251_5_1361_1369_stenosis	In contrast to nifedipine, CD-832 (10 micrograms/kg/min) prevented the decrease in percentage segmental shortening from 32 +/- 12% to 115 +/- 26% of the control value (P < .01) and ST-segment elevation from 5.6 +/- 1.0 mV to 1.6 +/- 1.3 mV (P < .01) at 3 min after ISO infusion with stenosis.
CID	8819482_D007545_1_166_169_ISO_D017202_1_179_198_myocardial ischemia	Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.
CID	8819482_D007545_0_48_61_isoproterenol_D017202_0_70_89_myocardial ischemia	Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.
CID	8819482_D007545_7_1708_1711_ISO_D017202_7_1681_1700_myocardial ischemia	These data show that CD-832 improves myocardial ischemia during ISO infusion with stenosis and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832.
UN	8819482_D007545_0_48_61_isoproterenol_D023921_0_111_128_coronary stenosis	Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.
UN	8819482_D009543_5_1093_1103_nifedipine_D003251_5_1361_1369_stenosis	In contrast to nifedipine, CD-832 (10 micrograms/kg/min) prevented the decrease in percentage segmental shortening from 32 +/- 12% to 115 +/- 26% of the control value (P < .01) and ST-segment elevation from 5.6 +/- 1.0 mV to 1.6 +/- 1.3 mV (P < .01) at 3 min after ISO infusion with stenosis.
UN	8819482_D009543_3_789_799_nifedipine_D003251_3_696_704_stenosis	After the control ISO infusion with stenosis was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion.
UN	8819482_D009543_1_332_342_nifedipine_D017202_1_179_198_myocardial ischemia	Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.
UN	8819482_D009543_1_332_342_nifedipine_D023921_1_233_250_coronary stenosis	Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.
UN	8825380_D008315_7_1236_1251_malondialdehyde_D005921_7_1171_1189_glomerulosclerosis	The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis, tubulointerstitial injury, or renal cortical malondialdehyde content.
UN	8825380_D008315_9_1597_1612_malondialdehyde_D007674_9_1639_1664_tubulointerstitial damage	In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter weight gain, blood pressure, proteinuria, GFR, glomerular planar area, renal cortical malondialdehyde content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4). rhIGF-I treatment reduced the steady state renal IGF-I mRNA level but did not modify gene expression of the IGF-I or GH receptors.
UN	8825380_D008315_9_1597_1612_malondialdehyde_D011507_9_1540_1551_proteinuria	In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter weight gain, blood pressure, proteinuria, GFR, glomerular planar area, renal cortical malondialdehyde content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4). rhIGF-I treatment reduced the steady state renal IGF-I mRNA level but did not modify gene expression of the IGF-I or GH receptors.
UN	8825380_D011692_2_457_460_PAN_D006130_2_421_435_growth failure	Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of growth failure in rats with chronic PAN nephropathy.
CID	8825380_D011692_8_1274_1277_PAN_D007674_8_1278_1289_nephropathy	In rats with PAN nephropathy, administration of rhIGF-I increased IGF-I and GH receptor gene expression, without altering the steady state level of IGF-I receptor mRNA.
CID	8825380_D011692_5_871_874_PAN_D007674_5_875_886_nephropathy	Urinary protein excretion was unaltered by rhIGF-I treatment in rats with chronic PAN nephropathy.
CID	8825380_D011692_10_1930_1933_PAN_D007674_10_1934_1945_nephropathy	We conclude that: 1) administration of rhIGF-I improves growth and GFR in rats with chronic PAN nephropathy and 2) unlike rhGH, long-term use of rhIGF-I does not worsen renal functional and structural injury in this disease model.
CID	8825380_D011692_6_1034_1037_PAN_D007674_6_1038_1049_nephropathy	After 12 wk, the inulin clearance was higher in rhIGF-I-treated rats, 0.48 +/- 0.08 versus 0.24 +/- 0.06 mL/min/100 g of body weight in untreated PAN nephropathy animals, p < 0.05.
CID	8825380_D011692_1_254_257_PAN_D007674_1_259_270_nephropathy	We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside (PAN) nephropathy, an experimental model of glomerular disease.
CID	8825380_D011692_0_72_97_puromycin aminonucleoside_D007674_0_98_109_nephropathy	The effect of recombinant human insulin-like growth factor-I on chronic puromycin aminonucleoside nephropathy in rats.
CID	8825380_D011692_3_535_538_PAN_D007674_3_478_492_glomerulopathy	The glomerulopathy was induced by seven serial injections of PAN over 12 wk.
CID	8825380_D011692_2_457_460_PAN_D007674_2_461_472_nephropathy	Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of growth failure in rats with chronic PAN nephropathy.
UN	8829135_C058876_2_437_448_nefiracetam_D000647_2_462_469_amnesia	Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism.
UN	8829135_C058876_0_13_20_DM-9384_D000647_0_51_58_amnesia	Nefiracetam (DM-9384) reverses apomorphine-induced amnesia of a passive avoidance response: delayed emergence of the memory retention effects.
UN	8829135_C058876_5_872_883_nefiracetam_D000647_5_924_931_amnesia	However, administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post-training time and the converse was also true.
UN	8829135_C058876_1_143_154_Nefiracetam_D007859_1_226_275_learning and post-training consolidation deficits	Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced learning and post-training consolidation deficits.
CID	8829135_D001058_0_31_42_apomorphine_D000647_0_51_58_amnesia	Nefiracetam (DM-9384) reverses apomorphine-induced amnesia of a passive avoidance response: delayed emergence of the memory retention effects.
CID	8829135_D001058_5_943_954_apomorphine_D000647_5_924_931_amnesia	However, administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post-training time and the converse was also true.
UN	8829135_D011760_1_166_177_pyrrolidone_D007859_1_226_275_learning and post-training consolidation deficits	Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced learning and post-training consolidation deficits.
CID	8829135_D012601_1_206_217_scopolamine_D007859_1_226_275_learning and post-training consolidation deficits	Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced learning and post-training consolidation deficits.
CID	891494_D010672_0_0_9_Phenytoin_D001927_0_10_24_encephalopathy	Phenytoin encephalopathy as probable idiosyncratic reaction: case report.
CID	891494_D010672_1_95_98_DPH_D001927_1_100_114_encephalopathy	A case of phenytoin (DPH) encephalopathy with increasing seizures and EEG and mental changes is described.
UN	891494_D010672_4_477_480_DPH_D005076_4_465_469_rash	In fact the concentration of free DPH was normal, the patient presented a retarded morbilliform rash during DPH treatment, the protidogram was normal, and an intradermic DPH injection had no local effect.
UN	891494_D010672_1_95_98_DPH_D012640_1_131_139_seizures	A case of phenytoin (DPH) encephalopathy with increasing seizures and EEG and mental changes is described.
UN	891494_D010672_5_622_625_DPH_D012640_5_662_670_seizures	The authors conclude that in a patient starting DPH treatment an unexpected increase in seizures, with EEG and mental changes occurring simultaneously, should alert the physician to the possible need for eliminating DPH from the therapeutic regimen, even if plasma concentrations are low.
UN	89511_D004967_4_719_728_oestrogen_D002277_4_833_842_carcinoma	Cyclical low-dose oestrogen therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma.
UN	89511_D004967_4_719_728_oestrogen_D004714_4_806_829_endometrial hyperplasia	Cyclical low-dose oestrogen therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma.
CID	89511_D004967_3_610_619_oestrogen_D006965_3_672_683_hyperplasia	Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy.
CID	89511_D004967_2_281_290_oestrogen_D006965_2_239_250_hyperplasia	Cystic hyperplasia was associated with unopposed oestrogen therapy without progestagen.
UN	89511_D004967_3_610_619_oestrogen_D009369_3_689_699_malignancy	Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy.
UN	89511_D004967_0_79_88_oestrogen_D014591_0_28_47_endometrial disease	Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy.
UN	89511_D004967_1_213_222_oestrogen_D014591_1_155_174_endometrial disease	The treatment regimens are described in 74 patients with endometrial disease among 850 climacteric women receiving oestrogen therapy.
UN	89511_D004967_3_610_619_oestrogen_D016889_3_494_515_endometrial carcinoma	Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy.
UN	89511_D009640_3_351_365_norethisterone_D006965_3_425_436_hyperplasia	Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy.
UN	89511_D009640_3_351_365_norethisterone_D009369_3_689_699_malignancy	Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy.
UN	89511_D009640_3_351_365_norethisterone_D016889_3_494_515_endometrial carcinoma	Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy.
UN	89511_D011372_4_756_767_progestagen_D002277_4_833_842_carcinoma	Cyclical low-dose oestrogen therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma.
UN	89511_D011372_4_756_767_progestagen_D004714_4_806_829_endometrial hyperplasia	Cyclical low-dose oestrogen therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma.
UN	89511_D011372_2_307_318_progestagen_D006965_2_239_250_hyperplasia	Cystic hyperplasia was associated with unopposed oestrogen therapy without progestagen.
UN	895432_D007545_9_1372_1385_isoproterenol_D007238_9_1424_1434_infarction	The results indicated that exercise reduced the mortality associated with the effects of large dosages of isoproterenol but had little on the severity of the infarction.
CID	895432_D007545_1_126_139_isoproterenol_D009203_1_148_169_myocardial infarction	The effect of exercise on the severity of isoproterenol-induced myocardial infarction was studied in male rats.
CID	895432_D007545_0_39_52_isoproterenol_D009203_0_61_82_myocardial infarction	Effects of exercise on the severity of isoproterenol-induced myocardial infarction.
UN	8957205_D000324_0_6_19_corticotropin_D006935_0_85_96_hypercapnic	Human corticotropin-releasing hormone and thyrotropin-releasing hormone modulate the hypercapnic ventilatory response in humans.
UN	8957205_D013972_0_42_53_thyrotropin_D006935_0_85_96_hypercapnic	Human corticotropin-releasing hormone and thyrotropin-releasing hormone modulate the hypercapnic ventilatory response in humans.
CID	8985298_D006514_0_72_99_hepatitis B surface antigen_D006509_0_39_50_hepatitis B	Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.
UN	8985298_D019259_0_0_10_Lamivudine_D006509_0_39_50_hepatitis B	Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.
UN	8985298_D019259_1_160_182_2',3'-dideoxy cytosine_D006509_1_230_241_hepatitis B	Lamivudine is a novel 2',3'-dideoxy cytosine analogue that has potent inhibitory effects on hepatitis B virus replication in vitro and in vivo.
UN	8985298_D019259_6_785_795_lamivudine_D006509_6_814_825_hepatitis B	All 36 patients receiving lamivudine had a decrease in hepatitis B virus (HBV) DNA values of >90% (P < .001 compared with placebo).
UN	8996419_C033273_15_2578_2587_gestodene_D054556_15_2494_2497_VTE	Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.
UN	8996419_C033273_1_319_328_gestodene_D054556_1_190_212_venous thromboembolism	BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.
UN	8996419_D003276_11_1859_1862_OCs_D013927_11_1922_1932_thrombosis	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified.
UN	8996419_D003276_11_1859_1862_OCs_D020246_11_1884_1904_deep-vein thrombosis	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified.
CID	8996419_D003276_7_1204_1206_OC_D054556_7_1179_1182_VTE	We did a cohort analysis to estimate and compare incidence of VTE in users of the main OC preparations, and a nested case-control study to calculate the odds ratios of VTE associated with use of different types of OC, after adjustment for potential confounding factors.
CID	8996419_D003276_3_580_582_OC_D054556_3_572_575_VTE	The aim of our study was to re-examine the association between risk of VTE and OC use with a different study design and analysis to avoid some of the bias and confounding of the earlier studies.
CID	8996419_D003276_0_81_100_oral contraceptives_D054556_0_34_56_venous thromboembolism	Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
CID	8996419_D003276_1_248_267_oral contraceptives_D054556_1_214_217_VTE	BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.
CID	8996419_D003276_11_1859_1862_OCs_D054556_11_1823_1826_VTE	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified.
UN	8996419_D004997_15_2543_2560_ethinyloestradiol_D054556_15_2494_2497_VTE	Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.
UN	8996419_D011372_10_1782_1793_progestagen_D054556_10_1751_1754_VTE	FINDINGS: 85 women met the inclusion criteria for VTE, two of whom were users of progestagen-only OCs.
UN	8996419_D011374_15_2468_2480_progestagens_D054556_15_2494_2497_VTE	Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.
UN	8996419_D011374_16_2824_2836_progestagens_D054556_16_2701_2704_VTE	With all second-generation OCs as the reference, the odds ratios for VTE were 3.49 (1.21-10.12) for desogestrel plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation progestagens.
UN	8996419_D011374_1_306_318_progestagens_D054556_1_190_212_venous thromboembolism	BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.
UN	8996419_D017135_15_2521_2532_desogestrel_D054556_15_2494_2497_VTE	Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.
UN	9061777_D010424_8_863_876_Pentobarbital_D001930_8_915_927_brain damage	Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.
UN	9061777_D010424_5_553_566_pentobarbital_D012640_5_614_621_seizure	Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine. 3.
UN	9061777_D010862_8_931_942_pilocarpine_D001930_8_915_927_brain damage	Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.
UN	9061777_D010862_0_16_27_pilocarpine_D001930_0_80_92_brain damage	MK-801 augments pilocarpine-induced electrographic seizure but protects against brain damage in rats. 1.
CID	9061777_D010862_7_776_787_Pilocarpine_D009410_7_797_811_neuronal death	Pilocarpine produced neuronal death in the hippocampus, which showed pyknotic changes.
CID	9061777_D010862_3_368_379_pilocarpine_D012640_3_399_406_seizure	Scopolamine (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of pilocarpine-induced behavioral seizure but MK-801 (0.5 mg/kg) did not. 2.
CID	9061777_D010862_2_234_245_pilocarpine_D012640_2_266_290_tonic and clonic seizure	Intraperitoneal injection of pilocarpine (400 mg/kg) induced tonic and clonic seizure.
CID	9061777_D010862_1_170_181_pilocarpine_D012640_1_190_197_seizure	The authors examined the anticonvulsant effects of MK-801 on the pilocarpine-induced seizure model.
CID	9061777_D010862_0_16_27_pilocarpine_D012640_0_51_58_seizure	MK-801 augments pilocarpine-induced electrographic seizure but protects against brain damage in rats. 1.
CID	9061777_D010862_5_688_699_pilocarpine_D012640_5_669_676_seizure	Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine. 3.
CID	9061777_D010862_4_510_521_pilocarpine_D012640_4_456_463_seizure	An electrical seizure measured with hippocampal EEG appeared in the pilocarpine-treated group.
CID	9061777_D010862_10_1178_1189_pilocarpine_D013226_10_1148_1166_status epilepticus	These results indicate that status epilepticus induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism.
UN	9061777_D012601_8_878_889_scopolamine_D001930_8_915_927_brain damage	Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.
UN	9061777_D012601_5_537_548_Scopolamine_D012640_5_614_621_seizure	Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine. 3.
UN	9061777_D016202_10_1348_1352_NMDA_D001930_10_1313_1325_brain damage	These results indicate that status epilepticus induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism.
UN	9061777_D016202_10_1348_1352_NMDA_D013226_10_1148_1166_status epilepticus	These results indicate that status epilepticus induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism.
UN	9061777_D016291_8_894_900_MK-801_D001930_8_915_927_brain damage	Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.
UN	9061777_D016291_0_0_6_MK-801_D001930_0_80_92_brain damage	MK-801 augments pilocarpine-induced electrographic seizure but protects against brain damage in rats. 1.
CID	9061777_D016291_0_0_6_MK-801_D012640_0_51_58_seizure	MK-801 augments pilocarpine-induced electrographic seizure but protects against brain damage in rats. 1.
CID	9061777_D016291_1_156_162_MK-801_D012640_1_190_197_seizure	The authors examined the anticonvulsant effects of MK-801 on the pilocarpine-induced seizure model.
CID	9061777_D016291_3_411_417_MK-801_D012640_3_399_406_seizure	Scopolamine (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of pilocarpine-induced behavioral seizure but MK-801 (0.5 mg/kg) did not. 2.
CID	9061777_D016291_5_623_629_MK-801_D012640_5_669_676_seizure	Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine. 3.
UN	9071336_D002955_0_32_44_folinic acid_D001943_0_59_72_breast cancer	Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. 5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients.
UN	9071336_D005472_0_12_26_5-fluorouracil_D001943_0_59_72_breast cancer	Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. 5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients.
UN	9071336_D005472_2_477_491_5-fluorouracil_D001943_2_562_575_breast cancer	We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer.
UN	9071336_D016179_3_823_860_granulocyte colony-stimulating factor_D009503_3_868_879_neutropenia	Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 neutropenia requiring hospitalization; seven (4%) cycles in two patients required granulocyte colony-stimulating factor due to neutropenia; no patient required platelet transfusions.
UN	9071336_D017239_2_383_393_paclitaxel_D001943_2_562_575_breast cancer	We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer.
UN	9071336_D017239_0_0_10_Paclitaxel_D001943_0_59_72_breast cancer	Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. 5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients.
UN	9125676_D013015_2_525_536_d,l-sotalol_D002311_2_410_432_dilated cardiomyopathy	Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.
UN	9125676_D013015_2_525_536_d,l-sotalol_D003324_2_373_396_coronary artery disease	Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.
UN	9125676_D013015_11_2025_2036_d,l-sotalol_D006331_11_1932_1947_cardiac disease	One female patient with stable cardiac disease had recurrent torsades de pointes after 2 years of successful treatment with d,l-sotalol.
UN	9125676_D013015_2_525_536_d,l-sotalol_D014693_2_486_510_ventricular fibrillation	Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.
UN	9125676_D013015_4_719_730_d,l-sotalol_D014693_4_781_805_ventricular fibrillation	Those patients in whom d,l-sotalol prevented induction of ventricular tachycardia or ventricular fibrillation were discharged with the drug and followed up on an outpatient basis for 21 +/- 18 months.
CID	9125676_D013015_8_1423_1434_d,l-sotalol_D016171_8_1476_1495_torsades de pointes	However, the oral dose of d,l-sotalol was significantly lower in patients with torsades de pointes (200 +/- 46 vs. 328 +/- 53 mg/day; p = 0.0017).
CID	9125676_D013015_11_2025_2036_d,l-sotalol_D016171_11_1962_1981_torsades de pointes	One female patient with stable cardiac disease had recurrent torsades de pointes after 2 years of successful treatment with d,l-sotalol.
CID	9125676_D013015_6_1237_1248_d,l-sotalol_D016171_6_1178_1197_torsades de pointes	Four (5%) patients had from torsades de pointes during the initial oral treatment with d,l-sotalol.
CID	9125676_D013015_14_2374_2385_d,l-sotalol_D016171_14_2434_2453_torsades de pointes	Other ECG parameters before the application of d,l-sotalol did not identify patients at increased risk for torsades de pointes.
CID	9125676_D013015_1_276_287_d,l-sotalol_D016171_1_231_250_torsades de pointes	This study prospectively evaluated the clinical efficacy, the incidence of torsades de pointes, and the presumable risk factors for torsades de pointes in patients treated with d,l-sotalol for sustained ventricular tachyarrhythmias.
UN	9125676_D013015_4_719_730_d,l-sotalol_D017180_4_754_777_ventricular tachycardia	Those patients in whom d,l-sotalol prevented induction of ventricular tachycardia or ventricular fibrillation were discharged with the drug and followed up on an outpatient basis for 21 +/- 18 months.
UN	9125676_D013015_5_964_975_d,l-sotalol_D017180_5_914_941_ventricular tachyarrhythmia	Induction of the ventricular tachyarrhythmia was prevented by oral d,l-sotalol in 35 (43%) patients; the ventricular tachyarrhythmia remained inducible in 40 (49%) patients; and two (2.5%) patients did not tolerate even 40 mg of d,l-sotalol once daily.
UN	9125676_D013015_0_43_54_d,l-sotalol_D017180_0_69_97_ventricular tachyarrhythmias	Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
UN	9125676_D013015_1_276_287_d,l-sotalol_D017180_1_302_330_ventricular tachyarrhythmias	This study prospectively evaluated the clinical efficacy, the incidence of torsades de pointes, and the presumable risk factors for torsades de pointes in patients treated with d,l-sotalol for sustained ventricular tachyarrhythmias.
UN	9125676_D013015_2_525_536_d,l-sotalol_D017180_2_459_482_ventricular tachycardia	Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.
UN	9125676_D013015_2_525_536_d,l-sotalol_D017180_2_565_592_ventricular tachyarrhythmia	Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.
UN	9128918_D004298_0_42_50_dopamine_D006966_0_8_26_hyperprolactinemia	Chronic hyperprolactinemia and changes in dopamine neurons.
UN	9128918_D004298_7_979_981_DA_D006966_7_933_951_hyperprolactinemia	Nine months of hyperprolactinemia produced a 50% increase in DA concentrations in the ME over the control group.
UN	9128918_D004298_9_1614_1616_DA_D006966_9_1576_1594_hyperprolactinemia	There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.
CID	9128918_D006220_8_1079_1090_haloperidol_D006966_8_1099_1117_hyperprolactinemia	However, DA response was lost if a 9-month long haloperidol-induced hyperprolactinemia was followed by a 1 1/2 month-long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule.
CID	9128918_D006220_5_554_565_haloperidol_D006966_5_505_523_Hyperprolactinemia	Hyperprolactinemia was induced by treatment with haloperidol, a dopamine receptor antagonist, and Palkovits' microdissection technique in combination with high-performance liquid chromatography was used to measure neurotransmitter concentrations in several areas of the brain.
UN	9128918_D006897_9_1540_1546_5-HIAA_D006966_9_1576_1594_hyperprolactinemia	There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.
UN	9128918_D009638_9_1302_1316_norepinephrine_D006966_9_1576_1594_hyperprolactinemia	There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.
UN	9128918_D012701_9_1323_1332_serotonin_D006966_9_1576_1594_hyperprolactinemia	There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.
UN	9132810_D008727_1_376_388_methotrexate_D054198_1_324_352_acute lymphoblastic leukemia	This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from acute lymphoblastic leukemia treated with high-dose methotrexate.
CID	9132810_D008727_1_376_388_methotrexate_D056784_1_282_301_leukoencephalopathy	This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from acute lymphoblastic leukemia treated with high-dose methotrexate.
UN	9158667_D006493_7_1005_1012_heparin_D013927_7_942_952_Thrombotic	Thrombotic events, however, could be avoided by using low-dose heparin.
UN	9158667_D014148_1_263_278_tranexamic acid_D015473_1_180_208_acute promyelocytic leukemia	A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.
UN	9158667_D014148_1_263_278_tranexamic acid_D058186_1_107_126_acute renal failure	A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.
UN	9158667_D014212_3_481_485_ATRA_D013923_3_436_450_thromboembolic	This case further supports the concern about thromboembolic complications associated with ATRA therapy in APL patients.
CID	9158667_D014212_0_64_87_all-trans-retinoic acid_D013927_0_0_10_Thrombotic	Thrombotic complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy.
UN	9158667_D014212_0_64_87_all-trans-retinoic acid_D015473_0_28_56_acute promyelocytic leukemia	Thrombotic complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy.
UN	9158667_D014212_2_379_383_ATRA_D015473_2_354_357_APL	We report a case of acute renal failure in an APL patient treated with ATRA alone.
UN	9158667_D014212_1_228_251_all-trans-retinoic acid_D015473_1_210_213_APL	A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.
UN	9158667_D014212_4_634_638_ATRA_D015473_4_584_587_APL	The patients, a 43-year-old man, presented all the signs and symptoms of APL and was included in a treatment protocol with ATRA.
UN	9158667_D014212_3_481_485_ATRA_D015473_3_497_500_APL	This case further supports the concern about thromboembolic complications associated with ATRA therapy in APL patients.
UN	9158667_D014212_6_820_824_ATRA_D015473_6_873_876_APL	We conclude that ATRA is a valid therapeutic choice for patients with APL, although the procoagulant tendency is not completely corrected.
CID	9158667_D014212_2_379_383_ATRA_D058186_2_328_347_acute renal failure	We report a case of acute renal failure in an APL patient treated with ATRA alone.
UN	9197951_D003042_1_107_114_cocaine_D001714_1_250_255_manic	A 30-year-old cocaine-dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion (DEP) became manic during his second week on the study drug.
CID	9197951_D004053_1_238_241_DEP_D001714_1_250_255_manic	A 30-year-old cocaine-dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion (DEP) became manic during his second week on the study drug.
UN	9197951_D004053_2_329_332_DEP_D011681_2_375_396_pupillary oscillation	Pupillometric changes while on DEP, especially changes in the total power of pupillary oscillation, were dramatically different than those observed in the eight other study subjects who did not become manic.
CID	920167_D014859_5_365_373_warfarin_D002806_5_420_438_stippled epiphyses	The baby showed warfarin-induced embryopathy with nasal hypoplasia and stippled epiphyses (chondrodysplasia punctata).
UN	920167_D014859_5_365_373_warfarin_D005315_5_382_393_embryopathy	The baby showed warfarin-induced embryopathy with nasal hypoplasia and stippled epiphyses (chondrodysplasia punctata).
UN	9272404_D002245_5_1174_1177_CO2_D010146_5_1136_1140_pain	Both CSSEPs as central and NMPs as peripheral correlates of pain were obtained in response to the CO2 stimuli.
UN	9272404_D002245_4_828_831_CO2_D010146_4_783_787_pain	Phasic pain was applied by means of short pulses of CO2 to the nasal mucosa (stimulus duration 500 ms, interval approximately 60 s), and tonic pain was induced in the nasal cavity by means of dry air of controlled temperature, humidity and flow rate (22 degrees C, 0% relative humidity, 145 ml.s-1).
CID	9272404_D007052_7_1498_1507_ibuprofen_D010146_7_1539_1543_pain	RESULTS: As described earlier, administration of ibuprofen was followed by a decrease in tonic pain but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions.
UN	931801_C038936_2_253_296_2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone_D051437_2_320_333_renal failure	Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran.
UN	931801_D000617_1_157_171_aminoglycoside_D003681_1_73_83_Dehydrated	Dehydrated rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only.
UN	931801_D000617_4_718_732_aminoglycoside_D007674_4_655_667_renal damage	D-Glucarates were effective against renal damage induced by peptide antibiotics as well as various aminoglycoside antibitocis.
CID	931801_D000617_1_157_171_aminoglycoside_D058186_1_107_126_acute renal failure	Dehydrated rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only.
UN	931801_D005937_9_1240_1252_D-glucarates_D007674_9_1261_1275_nephrotoxicity	The reduction effect of D-glucarates against nephrotoxicity of basic antibiotics was discussed.
UN	931801_D005937_0_10_22_D-Glucarates_D007674_0_51_63_renal damage	Effect of D-Glucarates on basic antibiotic-induced renal damage in rats.
UN	931801_D005937_4_619_631_D-Glucarates_D007674_4_655_667_renal damage	D-Glucarates were effective against renal damage induced by peptide antibiotics as well as various aminoglycoside antibitocis.
UN	931801_D005937_7_1055_1067_D-Glucarates_D007674_7_1095_1107_renal damage	D-Glucarates had the ability to prevent renal damage but not to cure it.
UN	931801_D007612_2_345_354_kanamycin_D051437_2_320_333_renal failure	Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran.
UN	931801_D009005_8_1199_1214_monosaccharides_D007674_8_1182_1195_renal lesions	Rats excreted acidic urine when they were spared from renal lesions by monosaccharides.
UN	9323412_D012701_2_384_393_serotonin_D003865_2_294_319_major depression disorder	She had developed a severe acute major depression disorder almost immediately thereafter, possibly related to the use of a serotonin antagonist.
UN	9323412_D012701_4_543_552_serotonin_D003866_4_637_656_depression disorder	Anaesthesia with a propofol infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder.
UN	9323412_D012701_4_543_552_serotonin_D009325_4_576_582_nausea	Anaesthesia with a propofol infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder.
UN	9323412_D015742_4_508_516_propofol_D003866_4_637_656_depression disorder	Anaesthesia with a propofol infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder.
UN	9323412_D015742_4_508_516_propofol_D009325_4_576_582_nausea	Anaesthesia with a propofol infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder.
UN	9323412_D017294_0_49_60_ondansetron_D003866_0_13_23_depression	Acute severe depression following peri-operative ondansetron.
UN	9323412_D017294_1_222_233_ondansetron_D020250_1_107_140_postoperative nausea and vomiting	A 41-year-old woman with a strong history of postoperative nausea and vomiting presented for abdominal hysterectomy 3 months after a previous anaesthetic where ondansetron prophylaxis had been used.
CID	9382023_D004280_0_29_39_dobutamine_D006973_0_0_12_Hypertensive	Hypertensive response during dobutamine stress echocardiography.
CID	9382023_D004280_2_397_407_dobutamine_D006973_2_328_340_hypertension	Patients with this response more often had a history of hypertension and had higher resting systolic and diastolic BP before dobutamine infusion.
UN	9428298_D000420_0_23_32_albuterol_D001249_0_60_66_asthma	Continuously nebulized albuterol in severe exacerbations of asthma in adults: a case-controlled study.
UN	9428298_D000420_1_278_287_albuterol_D001249_1_235_241_asthma	A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent albuterol (INA) treatments is reported.
UN	946593_D008727_4_916_928_methotrexate_C536409_4_949_966_folate deficiency	The role of methotrexate contaminants, local folate deficiency, and cranial irradiation in the pathogenesis of intrathecal methotrexate toxicity is unclear.
UN	946593_D008727_5_1135_1147_methotrexate_D002493_5_1167_1198_central nervous system leukemia	The incidence of neurotoxicity may be reduced by employing lower doses of methotrexate in the presence of central nervous system leukemia, in older children and adults, and in the presence of epidural leakage.
CID	946593_D008727_1_171_183_methotrexate_D010264_1_118_128_paraplegia	A patient who developed paraplegia following the intrathecal instillation of methotrexate is discribed.
CID	946593_D008727_0_33_45_methotrexate_D010264_0_0_10_Paraplegia	Paraplegia following intrathecal methotrexate: report of a case and review of the literature.
UN	946593_D008727_7_1465_1477_methotrexate_D020258_7_1533_1546_neurotoxicity	Periodic monitoring of cerebruspinal fluid methotrexate levels may be predictive of the development of serious neurotoxicity.
UN	946593_D008727_5_1135_1147_methotrexate_D020258_5_1078_1091_neurotoxicity	The incidence of neurotoxicity may be reduced by employing lower doses of methotrexate in the presence of central nervous system leukemia, in older children and adults, and in the presence of epidural leakage.
UN	946593_D008727_3_776_788_methotrexate_D020258_3_725_735_neurotoxic	The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.
UN	9538487_D005947_3_420_427_glucose_D011141_3_390_398_polyuric	After recovery from hyperglycaemia, he remained polyuric despite normal blood glucose concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be lithium-induced.
UN	9538487_D005947_3_420_427_glucose_D018500_3_480_510_nephrogenic diabetes insipidus	After recovery from hyperglycaemia, he remained polyuric despite normal blood glucose concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be lithium-induced.
UN	9538487_D005947_2_333_340_glucose_D059606_2_270_280_polydipsia	He gave a five-year history of polyuria and polydipsia, during which time urinalysis had been negative for glucose.
UN	9538487_D008094_1_168_175_lithium_D001714_1_138_154_manic depression	A 45-year-old man, with a 10-year history of manic depression treated with lithium, was admitted with hyperosmolar, nonketotic coma.
CID	9538487_D008094_0_45_52_lithium_D006944_0_0_28_Hyperosmolar nonketotic coma	Hyperosmolar nonketotic coma precipitated by lithium-induced nephrogenic diabetes insipidus.
CID	9538487_D008094_3_525_532_lithium_D011141_3_390_398_polyuric	After recovery from hyperglycaemia, he remained polyuric despite normal blood glucose concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be lithium-induced.
CID	9538487_D008094_0_45_52_lithium_D018500_0_61_91_nephrogenic diabetes insipidus	Hyperosmolar nonketotic coma precipitated by lithium-induced nephrogenic diabetes insipidus.
UN	9570197_D003042_3_833_854_cocaine hydrochloride_D002637_3_567_577_chest pain	METHODS AND RESULTS: In 20 patients (14 men and 6 women aged 39 to 72 years) referred for cardiac catheterization for the evaluation of chest pain, we measured heart rate, systemic arterial pressure, LV pressure and its first derivative (dP/dt), and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15-minute intracoronary infusion of saline (n=10, control subjects) or cocaine hydrochloride 1 mg/min (n=10).
CID	9570197_D003042_1_163_170_cocaine_D018487_1_189_245_deterioration of left ventricular (LV) systolic function	BACKGROUND: In dogs, a large amount of intravenous cocaine causes a profound deterioration of left ventricular (LV) systolic function and an increase in LV end-diastolic pressure.
CID	9646784_D006493_3_400_407_heparin_D000505_3_514_522_alopecia	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.
CID	9646784_D006493_3_400_407_heparin_D004342_3_463_481_allergic reactions	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.
CID	9646784_D006493_3_400_407_heparin_D004802_3_433_445_eosinophilia	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.
CID	9646784_D006493_3_400_407_heparin_D010024_3_419_431_osteoporosis	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.
CID	9646784_D006493_3_400_407_heparin_D012871_3_447_461_skin reactions	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.
CID	9646784_D006493_0_0_7_Heparin_D013921_0_16_32_thrombocytopenia	Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy.
CID	9646784_D006493_3_366_373_heparin_D013921_3_382_398_thrombocytopenia	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.
CID	9646784_D006493_0_0_7_Heparin_D013923_0_46_61_thromboembolism	Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy.
CID	9725303_D019469_4_738_747_indinavir_D014514_4_664_694_ureteric stones or obstruction	Images may need to be obtained using i.v. contrast material to enable diagnosis of ureteric stones or obstruction in patients with HIV infection who receive indinavir therapy.
CID	9725303_D019469_1_214_223_indinavir_D014514_1_158_174_ureteric calculi	OBJECTIVE: We describe the unique CT features of ureteric calculi in six HIV-infected patients receiving indinavir, the most commonly used HIV protease inhibitor, which is associated with an increased incidence of urolithiasis.
UN	9725303_D019469_4_738_747_indinavir_D014517_4_664_694_ureteric stones or obstruction	Images may need to be obtained using i.v. contrast material to enable diagnosis of ureteric stones or obstruction in patients with HIV infection who receive indinavir therapy.
UN	9725303_D019469_2_393_402_indinavir_D014517_2_349_369_Ureteric obstruction	CONCLUSION: Ureteric obstruction caused by precipitated indinavir crystals may be difficult to diagnose with unenhanced CT.
UN	9725303_D019469_0_90_99_indinavir_D014517_0_37_57_ureteric obstruction	Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy.
UN	9725303_D019469_4_738_747_indinavir_D015658_4_712_725_HIV infection	Images may need to be obtained using i.v. contrast material to enable diagnosis of ureteric stones or obstruction in patients with HIV infection who receive indinavir therapy.
UN	9725303_D019469_1_214_223_indinavir_D015658_1_182_194_HIV-infected	OBJECTIVE: We describe the unique CT features of ureteric calculi in six HIV-infected patients receiving indinavir, the most commonly used HIV protease inhibitor, which is associated with an increased incidence of urolithiasis.
UN	9725303_D019469_1_214_223_indinavir_D052878_1_323_335_urolithiasis	OBJECTIVE: We describe the unique CT features of ureteric calculi in six HIV-infected patients receiving indinavir, the most commonly used HIV protease inhibitor, which is associated with an increased incidence of urolithiasis.
UN	9759693_D018170_3_494_505_sumatriptan_D003329_3_411_429_coronary vasospasm	Cases have been published of coronary vasospasm, myocardial ischemia, and myocardial infarction occurring after sumatriptan use.
UN	9759693_D018170_4_618_629_sumatriptan_D008881_4_596_604_migraine	We report on the development of 8 serious cases of ischemic colitis in patients with migraine treated with sumatriptan.
UN	9759693_D018170_3_494_505_sumatriptan_D009203_3_456_477_myocardial infarction	Cases have been published of coronary vasospasm, myocardial ischemia, and myocardial infarction occurring after sumatriptan use.
CID	9759693_D018170_4_618_629_sumatriptan_D017091_4_562_578_ischemic colitis	We report on the development of 8 serious cases of ischemic colitis in patients with migraine treated with sumatriptan.
CID	9759693_D018170_0_21_32_sumatriptan_D017091_0_0_16_Ischemic colitis	Ischemic colitis and sumatriptan use.
UN	9759693_D018170_3_494_505_sumatriptan_D017202_3_431_450_myocardial ischemia	Cases have been published of coronary vasospasm, myocardial ischemia, and myocardial infarction occurring after sumatriptan use.
CID	9782254_D007980_0_247_253_L-DOPA_D004409_0_262_273_dyskinesias	Pallidotomy with the gamma knife: a positive experience. 51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and L-DOPA-induced dyskinesias.
UN	9782254_D007980_0_247_253_L-DOPA_D009127_0_233_241_rigidity	Pallidotomy with the gamma knife: a positive experience. 51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and L-DOPA-induced dyskinesias.
UN	9782254_D007980_0_247_253_L-DOPA_D010300_0_95_114_Parkinson's disease	Pallidotomy with the gamma knife: a positive experience. 51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and L-DOPA-induced dyskinesias.
UN	9782254_D007980_0_247_253_L-DOPA_D018476_0_219_231_bradykinesia	Pallidotomy with the gamma knife: a positive experience. 51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and L-DOPA-induced dyskinesias.
CID	978847_D002217_2_558_567_carbachol_D006973_2_493_522_enlargement of pulse pressure	This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c. carbachol (1 mug).
CID	978847_D002217_2_558_567_carbachol_D013610_2_531_542_tachycardia	This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c. carbachol (1 mug).
CID	978847_D003891_2_405_424_desmethylimipramine_D006973_2_493_522_enlargement of pulse pressure	This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c. carbachol (1 mug).
UN	978847_D003891_2_405_424_desmethylimipramine_D013610_2_531_542_tachycardia	This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c. carbachol (1 mug).
UN	978847_D006145_2_302_314_guanethidine_D006973_2_493_522_enlargement of pulse pressure	This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c. carbachol (1 mug).
UN	978847_D006145_2_302_314_guanethidine_D013610_2_531_542_tachycardia	This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c. carbachol (1 mug).
UN	978847_D010646_2_348_360_phentolamine_D006973_2_493_522_enlargement of pulse pressure	This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c. carbachol (1 mug).
UN	978847_D010646_2_348_360_phentolamine_D013610_2_531_542_tachycardia	This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c. carbachol (1 mug).
UN	978847_D011433_2_441_452_propranolol_D006973_2_493_522_enlargement of pulse pressure	This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c. carbachol (1 mug).
UN	978847_D011433_2_441_452_propranolol_D013610_2_531_542_tachycardia	This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c. carbachol (1 mug).
UN	978847_D018738_2_323_336_hexamethonium_D006973_2_493_522_enlargement of pulse pressure	This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c. carbachol (1 mug).
UN	978847_D018738_2_323_336_hexamethonium_D013610_2_531_542_tachycardia	This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c. carbachol (1 mug).
CID	9831002_D008774_6_1005_1020_methylphenidate_D009459_6_955_985_neuroleptic malignant syndrome	This is the first reported patient with neuroleptic malignant syndrome probably caused by methylphenidate.
CID	9831002_D008774_1_137_152_methylphenidate_D009459_1_87_117_neuroleptic malignant syndrome	A 1-year-old female presented with neuroleptic malignant syndrome probably caused by methylphenidate.
CID	9831002_D008774_0_35_50_methylphenidate_D009459_0_0_30_Neuroleptic malignant syndrome	Neuroleptic malignant syndrome and methylphenidate.
UN	9869655_D001647_10_1833_1842_bile salt_D002780_10_1734_1758_intrahepatic cholestasis	This study shows that 17alpha-ethinylestradiol (EE)-induced intrahepatic cholestasis in rats is associated with selective inhibition of the neutral pathway of bile salt (BS) synthesis.
CID	9869655_D004997_10_1722_1724_EE_D002780_10_1734_1758_intrahepatic cholestasis	This study shows that 17alpha-ethinylestradiol (EE)-induced intrahepatic cholestasis in rats is associated with selective inhibition of the neutral pathway of bile salt (BS) synthesis.
CID	9881641_C040442_6_900_910_helodermin_D007022_6_920_931_hypotension	These findings suggest that helodermin-produced hypotension is partly attributable to the activation of glibenclamide-sensitive K+ channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells.
CID	9881641_C040442_0_48_58_helodermin_D007022_0_24_35_hypotension	Glibenclamide-sensitive hypotension produced by helodermin assessed in the rat.
CID	9881641_C040442_5_761_771_helodermin_D007022_5_780_791_hypotension	Oxyhemoglobin did not affect helodermin-induced hypotension, whereas it shortened the duration of acetylcholine (ACh)-produced hypotension.
CID	9881641_C040442_3_455_465_Helodermin_D007022_3_475_486_hypotension	Helodermin produced hypotension in a dose-dependent manner with approximately similar potency and duration to VIP.
CID	9881641_D000109_5_845_848_ACh_D007022_5_859_870_hypotension	Oxyhemoglobin did not affect helodermin-induced hypotension, whereas it shortened the duration of acetylcholine (ACh)-produced hypotension.
UN	9881641_D000255_6_1015_1018_ATP_D007022_6_920_931_hypotension	These findings suggest that helodermin-produced hypotension is partly attributable to the activation of glibenclamide-sensitive K+ channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells.
UN	9881641_D005905_0_0_13_Glibenclamide_D007022_0_24_35_hypotension	Glibenclamide-sensitive hypotension produced by helodermin assessed in the rat.
UN	9881641_D005905_4_639_652_glibenclamide_D007022_4_570_581_Hypotension	Hypotension induced by both peptides was significantly attenuated by glibenclamide, which abolished a levcromakalim-produced decrease in arterial blood pressure.
UN	9881641_D005905_6_976_989_glibenclamide_D007022_6_920_931_hypotension	These findings suggest that helodermin-produced hypotension is partly attributable to the activation of glibenclamide-sensitive K+ channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells.
UN	9881641_D009569_7_1130_1142_nitric oxide_D007022_7_1207_1218_hypotension	EDRF (endothelium-derived relaxing factor)/nitric oxide does not seem to play an important role in the peptide-produced hypotension.
UN	9881641_D011188_6_1000_1001_K_D007022_6_920_931_hypotension	These findings suggest that helodermin-produced hypotension is partly attributable to the activation of glibenclamide-sensitive K+ channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells.
CID	9881641_D019806_4_672_685_levcromakalim_D007022_4_570_581_Hypotension	Hypotension induced by both peptides was significantly attenuated by glibenclamide, which abolished a levcromakalim-produced decrease in arterial blood pressure.
UN	9889429_D001806_4_840_859_blood urea nitrogen_D005885_4_910_930_gingival hyperplasia	The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients.
UN	9889429_D002118_1_267_274_calcium_D006973_1_177_189_hypertension	Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs.
UN	9889429_D002118_1_267_274_calcium_D011565_1_153_162_psoriatic	Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs.
CID	9889429_D009543_4_805_815_nifedipine_D005885_4_910_930_gingival hyperplasia	The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients.
CID	9889429_D009543_5_1001_1011_nifedipine_D005885_5_1152_1172_gingival hyperplasia	Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.
UN	9889429_D009543_5_1001_1011_nifedipine_D006973_5_1026_1038_hypertensive	Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.
UN	9889429_D009543_0_40_50_nifedipine_D006973_0_103_115_hypertension	Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.
UN	9889429_D009543_5_1001_1011_nifedipine_D011565_5_1039_1048_psoriatic	Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.
CID	9889429_D016572_4_787_800_cyclosporin A_D005885_4_910_930_gingival hyperplasia	The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients.
CID	9889429_D016572_5_1089_1102_cyclosporin A_D005885_5_1152_1172_gingival hyperplasia	Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.
CID	9889429_D016572_2_501_514_cyclosporin A_D006973_2_475_487_hypertensive	Seven of the 13 patients had exhibited a subclinical hypertensive state before cyclosporin A therapy.
CID	9889429_D016572_5_1089_1102_cyclosporin A_D006973_5_1026_1038_hypertensive	Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.
CID	9889429_D016572_1_211_224_cyclosporin A_D006973_1_177_189_hypertension	Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs.
CID	9889429_D016572_0_81_94_cyclosporin A_D006973_0_103_115_hypertension	Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.
UN	9889429_D016572_5_1089_1102_cyclosporin A_D011565_5_1039_1048_psoriatic	Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.
UN	9889429_D016572_0_81_94_cyclosporin A_D011565_0_133_142_psoriasis	Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.
UN	9889429_D016572_1_211_224_cyclosporin A_D011565_1_153_162_psoriatic	Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs.
